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ABSTRACT 
A genetic predisposition to Rhegmatogenous Retinal Detachment (RD) has been 
suggested for over 40 years. Ectopia Lentis (EL) is known to have a genetic aetiology as 
part of Marfan Syndrome, other ocular syndromes and when occurring in isolation. This 
work investigates the genetic aetiology to these conditions in Mendelian and non 
Mendelian inheritance.  
The work in this thesis establishes a clear genotype-phenotype correlation between 
isolated EL and its most important causative gene: ADAMTSL4. This suggests that 
mutations in this gene result in a more severe phenotype than other genes causing EL.  
In doing so, a novel clinical grading system for this condition has also been developed. 
The expression of ADAMTSL4 and distribution of its protein within ocular tissue has 
also been investigated and suggests further roles for this protein in ocular development. 
Modelling of the protein was undertaken and provides insights for future investigations. 
Traditional and novel next generation investigative tools have also been employed to 
examine families with Mendelian inherited phenotypes including RD and EL. The role 
of a deleted exon in ADAMTS17 has been identified as playing a role in Weill-
Marchesani Like syndrome. A novel ocular phenotype has also been defined in three 
families demonstrated to be caused by mutations in ADAMTS18. This gene has 
previously been described in few probands with ophthalmic phenotypes, and this work 
has further delineated the role of this gene. It is becoming clear that members of the 
ADAMTS family of proteins play a significant role in ocular development. 
Finally, over 1300 probands with non-Mendelian RD were recruited and closely 
phenotyped as part of this work. It has demonstrated novel racial differences in the 
phenotypes of those affected. This cohort contributed significantly towards the first 
genome wide association study (GWAS) into RD; and established for the first time the 
genetic contribution to this condition. Further funding has now been acquired to 
investigate this cohort further using a novel exome array. Preliminary quality control 
analysis has been performed; allowing a platform for further detailed analysis to 
identify putative functional variants associated with RD. 
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CHAPTER 1: INTRODUCTION 
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1.1. RHEGMATOGENOUS RETINAL DETACHMENT & ECTOPIA 
LENTIS: A BRIEF HISTORICAL INTRODUCTION 
A rhegmatogenous retinal detachment (RD) is the result of a full thickness break in the 
neurosensory retina resulting in the separation of this neurosensory retina from its 
underlying pigmented epithelium. The earliest histological observations of RD  in 
humans were described in the nineteenth century[31]. The understanding of this 
condition in the living human eye was not possible until the development of the 
ophthalmoscope in 1851[32]. The descriptions by Jules Gonin in 1904 of three cases of 
RD[33] was the beginning of his research and development of techniques to treat this 
condition over the next 12 years. Since then, our understanding of the aetiology and 
treatment of this blinding condition have progressed significantly[34]. 
The Austrian ophthalmologist Karl Stellwag[35] is credited with coining the term 
ectopia lentis (EL) in 1856. It describes abnormal movement of the crystalline lens from 
within its natural position. Inherited EL was first reported later that century by 
Williams[36], in 1875, by describing a family with EL in two generations. The daughter 
in that family subsequently developed a RD at the age of 28 years. Since then, the 
association between the two conditions has been maintained, but rarely studied. 
1.2. RHEGMATOGENOUS RETINAL DETACHMENT 
1.2.1. ANATOMICAL CONSIDERATIONS 
1.2.1.1. RETINA 
The retina is a transparent membrane, lining the inner layer of the eyeball. It is thinnest 
at the ora serrata (100µm) and thickest near the optic disc (560µm), with which it is 
continuous. Anteriorly, it becomes the epithelium of the iris and ciliary body. It is 
bounded on its outside by Bruch’s membrane of the choroid, and the vitreous body on 
its inside. The firmest attachments of the retina are at the optic disc and ora serrata.  
The retina consists of an outer pigmented and inner neurosensory retina (NSR) layer; 
derived from neuroectoderm.  
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1.2.1.1.1. RETINAL PIGMENTED EPITHELIUM 
This is a monolayer of hexagonal cells between the choriorcapillaris and the neural 
retina. These cells have a basal end, resting on the Bruch’s membrane and an apical end 
with microvilli (Figure 1.1). The retinal pigmented epithelium (RPE) is structurally and 
functionally asymmetric and has numerous functions. These include phagocytosis of the 
outer segment tips, formation of the blood-retinal barrier (via tight junctions between 
RPE cells) and secretion of extracellular matrix (ECM) molecules. These latter are 
secreted both basally (type IV collagen, and laminin) giving rise to Bruch’s membrane, 
and apically; contributing to the interphotoreceptor matrix (IPM)[34]. These cells 
therefore have a crucial role to play in the maintenance of normal visual function, and 
number between 4-6 million per human eye.  
The neural retina consists of nine layers (Figure 1.2). From most outer (adherent to the 
RPE) are; photoreceptors (rods and cones), outer limiting membrane (made of zonulae 
adherens between the radial processes of the Muller cells and the photoreceptors), the 
bipolar cells: which include the four layers of the outer nuclear layer, outer plexiform 
layer, inner nuclear layer and the inner plexiform layer. The outer nuclear layer contains 
the cell bodies of the rods and cones, whilst the inner nuclear layer those of the Muller, 
amacrine, bipolar and horizontal cells. The outer plexiform layer contains the synaptic 
connections between the horizontal, bipolar and Muller cells and the photoreceptors. 
The inner plexiform layer contains such connections between bipolar, amacrine and 
retinal ganglion cells (RGC).  Adjacent to this latter layer lays the retinal ganglion cell 
layer. This is lined by the nerve fibre layer, containing the nerve fibres of the RGC. The 
final layer is a basement membrane forming the retinal side of the vitreoretinal surface; 
known as the inner limiting membrane (ILM)[37].  
1.2.1.1.2. PHOTORECEPTORS 
These cells are separated into inner and outer segments. The former of these contain the 
majority of organelles for cell function. The latter contain discs which help these cells 
play a key role in phototransduction. There are two types of photoreceptors in the 
human eye; the rods (approximately 110 million per human retina) and the cones 
(approximately 6.5million per human retina)[34].   
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Figure 1.1: Retinal Pigment Epithelium cells intercellular integrity  
(adapted from [3]) 
A: Apical view of RPE cells demonstrating microvilli 
B: Transmission Electomicrograph showing tight and adherens junctions and 
microvilli (mv) 
C: Tight junctions demonstrated by high magnification 
NSR: neurosensory retina 
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Figure 1.2: The layers of the human retina 
Adapted from http://www.arthursclipart.org/medical/  
43 
 
1.2.2. NORMAL ADHESION BETWEEN THE PHOTORECEPTORS 
AND RETINAL PIGMENT EPITHELIUM 
The photoreceptor and RPE layer come together as a consequence of the invagination of 
the optic vesicle into the double walled optic cup during embryogenesis. The external 
layer forms the RPE, whilst the inner forms the photoreceptors. They remain continuous 
at the rim of the optic cup (the future ora serrata) and the stalk connecting the cup to the 
brain (future optic nerve). As the invagination continues, these layers are continually 
brought together. In between these two layers exists the IPM (Figure 1.3). This matrix is 
formed early in embryogenesis, soon after the invagination of the vesicle; certainly by 
day 45[38]. It has important roles to play in the interaction between the PR and RPE, 
and also acts as a “buffer” between the two layers.  Indeed separating the two layers in 
embryonic tissue prior to the development of the IPM is more challenging than in older 
embryos[34]. It is thought to be continually produced by the surrounding cells: the RPE, 
photoreceptors and Muller cells. It is composed of a hyaluronan (HA) scaffolding and 
large glycoproteins and proteoglycans. The former contributes towards the adhesion 
between the PR and RPE.  
The other mechanical forces which play a role in the adhesion of the PR and RPE 
include the hydrostatic and osmotic pressure exerted by aqueous production. Although 
the RPE has enormous capacity to actively transport fluid across it, there is limited 
passive posterior movement of this fluid through the NSR and RPE[39], resulting in the 
NSR pushed against the RPE.  The other mechanical forces involve the mechanical 
interdigitation of the RPE microvilli between the outer segments of the PR. This 
interaction may be secondary to electrostatic forces[40]; though the real effect of this is 
likely to be small. 
Finally, there are metabolic factors playing a role in maintaining the adhesion between 
the RPE and PR. It has been demonstrated that oxygenation and active metabolism of 
the RPE and PR helps maintain the adhesive strength between these two layers[41].  
This may play a role in influencing the structure and function of the IPM; thus indirectly 
affecting the mechanical adhesive properties.  
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Figure 1.3: Embryonic origin of the Interphotoreceptor Matrix  (IPM) 
This illustrates the outer eye wall from a 45-day post fertilisation human embryo 
before the development of photoreceptor cells (*). It is compared with the 
equivalent region from a 48 year old adult eye, with elongated photoreceptor cells 
(*); extending from the outer retinal surface.  The IPM is between these two layers.  
Adapted from http://glycoforum.gr.jp/science/  
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1.2.3. VITREORETINAL ADHESION 
The basement membrane of the Muller cells makes up the principal component of the 
ILM, with the remaining inner portion is made of vitreous fibrils. It consists of three 
layers. The innermost layer (lamina rara) is continuous with the vitreous[42]. The 
middle layer (lamina densa) varies in thickness; being greatest at the posterior pole. The 
outer layer (lamina rara) is immediately adjacent to the Muller cells, and is irregular in 
nature. The ILM varies with age, and is at its thickest most posteriorly (up to 
1900nm[34]). It ends abruptly at the margin of the optic nerve head; where it becomes 
continuous with the astrocytes which line the optic nerve head. It is very thin at the 
fovea (approximately 20nm) with reduced Muller cell processes[43]. The attachment of 
the vitreous collagen fibres to the ILM differs slightly at different regions of the NSR.  
At the vitreous base, the collagen fibres are perpendicular to the vitreous base, and 
therefore insert directly into the lamina rara of the ILM[44] and any crypts between 
cellular layers. This bond is therefore unbreakable. Elsewhere, however, the collagen 
fibres run parallel to the retina, and an extracellular “glue” acting as the adhesion[34]. 
This may be as a result of interactions between macromolecules on the inner surface of 
the ILM and components on the surface of the vitreous fibrils[5]. The further possible 
mechanism of an adhesion is the role of type XVIII collagen, which is present in the 
human ILM[45]. Type XVIII collagen is a heparan sulphate proteoglycan and opticin 
(see Section 1.2.4) which binds to heparan sulphate[46]. The opticin on vitreous 
collagen fibrils therefore may bind to the type XVIII collagen and act as a potential 
adhesive mechanism (Figure 1.4). Evidence for an important role of type XVIII 
collagen in vitreoretinal adhesions comes from the abnormal vitreoretinal adhesions 
seen in COL18A1 knockout mice[47]. 
1.2.4. BIOCHEMICAL STRUCTURE OF THE VITREOUS 
The vitreous is a highly specialised hydrated ECM and is the largest structure in the eye. 
It has a volume of approximately 4ml (weighing approximately 4g) (Figure 1.5), with a 
water content of over 98%. As with other ECM, it is composed of fibrillar proteins and 
charged carbohydrates (glycosamineglycans, GAGs). The main fibrillar component is 
collagen fibrils, and the major GAG is HA.  
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Figure 1.4: Postbasal vitreoretinal junction. Weakening of the adhesion at this 
interface predisposes to posterior vitreous detachment. Vitreoretinal adhesion may 
be dependent upon intermediary molecules acting as a ‘molecular 
glue’ and linking the corticol vitreous collagen fibrils to components of ILM. It is 
possible that opticin, because it binds 
to both vitreous collagen fibrils and HA in the ILM, contributes towards this 
‘molecular glue’. Adapted from [5] 
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Figure 1.5: 
Adherent vitreous (arrow) evident on dissection from human eye  
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1.2.4.1. COLLAGENS 
The human eye has a collagen concentration of approximately 300µg/ml [5], which is 
probably continually produced throughout life[48]. They are formed of three 
polypeptide chains, making a triple-helical shape. They consist of a highly conserved 
repeating triplet sequence, whereby glycine is every third amino acid. The collagen 
proteins also contain non-collagenous regions, usually at the end of the molecules. 
Within the vitreous, the collagen is of mixed composition, made of Type II, IX and 
V/XI collagen. 
1.2.4.1.1. Type II Collagen 
This is the most abundant of the collagen types in vitreous; accounting for 
approximately 75%[49]. The molecules undergo extracellular modification allowing 
them to form fibrils. It is known that alternative splicing of exon 2 results in two forms 
of procollagen; with type IIA predominating. This may explain the “ocular only” variant 
of Stickler’s, caused by mutation in exon 2 (see Section 1.2.10.4.1).  
1.2.4.1.2. Type IX Collagen 
This makes up approximately 25% of the vitreous collagen, and cannot form fibrils 
alone. It is a heterodimer of three distinct polypeptide chains, and is synthesised with a 
chondroitin sulphate chain attached[49]. 
1.2.4.1.3. Type V/XI Collagen 
These two types of collagen are found in most tissues independently. The vitreous 
however contains a hybrid molecule (thus termed type V/XI). This hybrid may play a 
role in initiation of collagen fibril formation in the vitreous[5]. Linkage to COLXIA1 
and A2 have been associated with Stickler’s syndrome[50]; although the latter of these 
does not have an abnormal ocular phenotype. 
1.2.4.1.4. Type VI Collagen 
This is found in very small concentrations in the vitreous, and may play a role in linking 
together collagen and HA[5].  
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1.2.4.2. NON-COLLAGENOUS PROTEINS 
1.2.4.2.1. Fibrillin 
Although fibrillin is found in the vitreous, the role of this protein is unclear in this 
tissue. This is discussed at further length in section 1.3.1. 
1.2.4.2.2. Opticin 
This is a member of the small leucine-rich repeat proteins family. It exists as a dimer in 
solution[51], and may play a role in binding GAGs.  
1.2.4.3. GLYCOSAMINOGLYCANS and PROTEOGLYCANS 
The predominant GAG in the vitreous is HA. It is a linear GAG, which is 
unsulphated[5]. It is at its highest concentration in the posterior cortex, and its 
concentration increases till the age of 20 years, after which is it stable[52]. It is a high 
molecular size polymer with electrostatic interactive properties. Its biophysic and 
hydrodynamic properties and size allow it to contribute to the structure and functional 
organisation of the vitreous[53]. It also acts as a template for the assembly of other 
vitreous macromolecules. 
Other GAGs in the vitreous are proteoglycans; they are attached to a protein core. These 
include chondroitin sulphate. The main Chondroitin Sulphates is versican. It is 
suggested that it may play a role in acting as a molecular bridge between cell surfaces 
and the ECM[53].  It may therefore play a part in vitreous adhesion to the ILM. 
Mutations in the encoding gene (previously known as CSPG2) have been shown to 
cause the vitreoretinopathy Wagner syndrome[54]. 
Finally heparan sulphate is a major proteoglycan component of basement membranes. 
This includes the ILM on the surface of the retina. Although it is found in vitreous 
development, it has very low concentrations in post natal vitreous. 
1.2.5. FUNCTION OF THE VITREOUS  
The vitreous body acts as a barrier against movement of solutes. Diffusion rates of low 
molecular weight solutes through the vitreous are slow[55], and unaffected by disease 
states[56]. Bulk flow of high molecular weight substances is even lower[57]. It is also 
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thought that the vitreous body may protect the retina, and may act to absorb external 
forces and reduce mechanical deformation of the globe[56]. However such mechanical 
functions are of limited importance; illustrated by the normal function of eyes which 
have undergone vitrectomy. 
1.2.6. MORPHOLOGY OF THE VITREOUS 
The vitreous is divided into three regions; the central vitreous, the vitreous base and the 
vitreous cortex. Within the central vitreous, collagen fibres are at their lowest 
concentration, and run in a posterior-anterior fashion. These fibres run into the vitreous 
base anteriorly and the cortex posteriorly. Collagen fibres run perpendicular to the 
vitreous base, and are interwoven closely. The cortex is a thin layer which surrounds the 
central vitreous, and has a high concentration of collagen. The fibres run parallel to the 
ILM. Anteriorly this layer runs across the vitreous base and along the posterior surface 
of the lens (anterior hyaloid).  
1.2.7. REGIONS OF FIRM VITREOUS ADHESIONS 
The vitreous is attached to adjacent structures, with varying strengths. It is most firmly 
attached to the 6mm circumferential band known as the vitreous base, where the 
collagen fibres of the vitreous attach perpendicularly (tangentially elsewhere) (Figure 
1.6). The vitreous fibres attach to the basement membrane of the non-pigmented 
epithelium of the posterior pars plana and the peripheral ILM[58].  
1.2.7.1. VITREOUS BASE ANOMALIES 
Within the vitreous base, there are several anatomical variations, which may have 
varying strengths of vitreous attachments; thus being regions with a tendency for retinal 
holes or breaks.  
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Figure 1.6:  
Orientation of collagen fibres attachment at different structures within the 
posterior segment of the human eye 
Adapted from [5] 
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1.2.7.1.1. Ora bays  
Ora bays are indentations which are either separated from the pars plana (enclosed bay) 
or partially separated (partially enclosed bay). It is reported that these bays may be 
present in less than 5% of eyes, with a very small rate of associated retinal tears being 
present[59]. 
1.2.7.1.2. Meridonal complexes and folds 
Meridonal folds are radial linear elevations of the peripheral retina, associated with 
dentate processes. Histologically, these are associated with thickened retina, hyperplasia 
or RPE and rarely retinal breaks[60]. Complexes are combinations of folds and ciliary 
processes and ora bays.  
1.2.7.1.3. Retinal tufts 
These are internal projections of retinal tissue associated with the vitreous base. They 
are either non cystic; which are fibroglial tissue in continuation with the vitreous, or 
cystic; which histologically consist of disorganised retinal layers and a loss of 
photoreceptors[61]. Both types have very low risks of developing tears.  
1.2.7.1.4. White with/without pressure 
These lesions were first described in 1952[62], and may represent tangential light upon 
dense collagen fibres[34]. Although some have suggested an increased risk of giant 
tears in fellow eyes with these lesions at the vitreous base[63], others afford no 
prognostic risk to these lesions[64].  
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1.2.7.2. LATTICE DEGENERATION 
The most important peripheral retinal degeneration associated with abnormal vitreous 
adhesion is lattice degeneration. First reported in 1920[65], it is usually described as 
demarcated, circumferentially orientated areas of retinal thinning with excessive 
vitreoretinal attachments at its edges and overlying vitreous liquefaction. There may be 
associated pigmentary changes, thinned punched out areas, overlying retinal vessels, 
fine white lines and retinal holes[66, 67]. It is present in up to 10% of the population, 
with a higher incidence in myopic patients[66, 67]. Retinal tears may occur on the 
posterior or lateral margins of these lesions, although reported in less than 2% of eyes 
followed for over 3 years[68]. It is suggested, nonetheless, that up to 30% of patients 
with acute RDs and retinal breaks had lattice degeneration[69]. Round holes, which 
frequently are associated with lattice degeneration may result in RD, although there is 
no evidence that eyes with these lesions are more likely to develop a RD after a 
posterior vitreous detachment[70]. Nevertheless, these degenerative features are 
important factors in the risk of developing RD.       
1.2.7.3. OPTIC NERVE & FOVEA  
Further regions of firm attachment include the optic nerve margin. This may be 
exacerbated by the cellular proliferation from the optic nerve head; and the formation of 
an epipapillary membrane.  An irregular 3-4mm diameter ring around the fovea is also a 
site of strong vitreoretinal adhesion[71], being a source of many vitreomacular 
disorders. 
1.2.7.4. BLOOD VESSELS 
Along the retinal blood vessels, vitreous appears to have strong attachments, and may 
be the cause of haemorrhage occasionally seen in the presence of posterior vitreous 
detachments[5]. Furthermore, the ILM thins and may be absent over major vessels[72], 
leading to potential incarceration of the vitreous, thus becoming continuous with the 
perivascular tissue. 
1.2.7.5. LENS 
The other regions of firm adhesion include most anteriorly; at the lens. The attachment 
to the lens (Wiegert’s ligament) is particularly strong (see Section 1.4). 
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1.2.8. AGEING VITREOUS 
1.2.8.1. BIOCHEMICAL CHANGES 
As the human vitreous ages, it undergoes a process of liquefaction. It occurs as pockets 
of fluid in the central vitreous cavity, which enlarge and eventually coalesce. There is a 
steady increase in this occurrence from the age of 40 years, with more than half of the 
vitreous liquid by the age of 80 years old[52]. The process involves aggregation of 
collagen fibrils; leaving areas of the vitreous without fibres, thus converted to liquid[73, 
74]. This is accompanied by the appearance of macroscopic fibres centrally. Bishop et 
al[74] showed that there was a loss of type IX collagen as the vitreous aged. The 
chondroitin sulphate side chains act as “spacers”, and their loss may precipitate 
aggregation of collagen fibres; in particular the type II fibres. Furthermore, HA acts to 
separate the collagen fibrils, and digestion of HA results in reduction of the collagen 
network[75]. It is suggested that free radicals may alter the HA and/or collagen 
structure; resulting in a dissociation between HA and collagen[76]. The results are 
thought to be collagen aggregation with HA pooling in liquefied lacunae.  
1.2.8.2. VITREOUS BASE CHANGES 
As the eye ages, the posterior border of the vitreous base extends. At birth, the posterior 
border is at the ora serrata. With age, the collagen fibres of the vitreous base intertwine 
with the internal limiting membrane. The extension is thought to be due to synthesis of 
new “vitreous” collagen, creating further unbreakable bonds. This progression in 
thought to be more prominent in men[77].If there are any abnormalities in this new 
border, there may be a predisposition towards break formation.  
1.2.8.3. POSTERIOR VITREOUS DETACHMENT 
Posterior vitreous detachment (PVD) is a process by which the cortical vitreous 
separates from the ILM, as far as the vitreous base, and may occur in up to 25% of the 
population in their lifetime[78]. It is a result of both the liquefaction and weakening of 
the interaction between vitreous and ILM. This is as a result of the dense posterior 
vitreous cortex rupturing, thus allowing liquefied vitreous from lacunae to pass into the 
subhyaloid space. Its prevalence increases with age, and has been shown to occur more 
frequently and at a younger age in myopia[79, 80]. 
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Sebag[81] first described the irregular PVD; whereby the liquefaction exceeded the 
weakening of the vitreoretinal adhesion. In this situation, during PVD, tears in the retina 
may occur, leading to subsequent RD.  
1.2.9. PATHOGENESIS OF RHEGMATOGENOUS RETINAL 
DETACHMENT 
A Rhegmatogenous Retinal Detachment has been defined as a full thickness break in 
the NSR associated with liquefied vitreous migrating through this break extending over 
two disc diameters[62]. The term rhegmatogenous retinal detachment is therefore 
actually a misnomer, as it describes the separation of the NSR from the underlying RPE; 
thus re-creating the potential space between the original layers of the embryonic optic 
cup.  
RD arises from a full thickness break in the NSR. A retinal break occurs when there is a 
misbalance between the level of vitreous liquefaction and the weakening of the 
vitreoretinal adhesion. Therefore, breaks tend to occur at areas of firmer vitreoretinal 
adhesion. This is usually around blood vessels, around vitreoretinal degenerations 
(particularly lattice degeneration) and at the posterior margin of the vitreous base. The 
resultant break is usually a horseshoe shape (always pointing towards the optic disc, and 
the vitreous attached to the anteriorly positioned operculum. However, with further 
traction, the operculum may avulse, leaving a round hole[82]. It has been reported from 
long term studies that retinal tears may occur in 22% of eyes with PVD[83]. Post 
mortem studies have suggested that the prevalence of retinal tears is between 3% to 
27%[84, 85]. However most eyes with a retinal break do not develop into a RD; as the 
metabolic pump of the RPE and the osmotic pressure of the choroid are usually 
sufficient to keep the RPE and NSR attached. 
Three factors need to be present for a primary RD to occur. There needs to be tractional 
forces, a retinal break, and liquefied vitreous gel to separate the NSR from the 
underlying RPE[34]. Gravitational forces[34], and even slight rotatory eye movements 
can have important tractional effects to propagate the RD.  
Beyond horseshoe tears and round holes, other notable retinal breaks include dialysis 
and giant retinal tears (GRT).  The former are circumferential tears along the ora serrata, 
with vitreous attached to the posterior margin. It has been suggested that most are 
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secondary to trauma[86], others postulate a potential genetic predisposition[87]. Giant 
retinal tears are circumferential tears extending more than 90°[88].They are responsible 
for approximately 0.5% of cases of RD[63]. They are more common in males, and may 
be associated with trauma, complicated intraocular surgeries or hereditary 
vitreoretinopathies (such as Stickler’s syndrome) [89], though most are idiopathic.  
1.2.9.1. RISK FACTORS IN THE AETIOLOGY OF 
RHEGMATOGENOUS RETINAL DETACHMENT 
The annual risk of RD is between 6.3 and 17.9 per 100,000[90]. There is growing 
evidence that the numbers of RD are increasing. Within England, the reported number 
of RD (based on Hospital Episode Statistics[91]: HES) grew from 3519 in 1998-9 to 
7,827 in 2011-12 (Figure 1.7).  Whether this is related to the increase in risk factors 
(such as the increase in myopia[92]) is uncertain. There are numerous such risk factors. 
1.2.9.1.1. Myopia 
The greatest risk factor for is myopia. It is suggested that eyes with a spherical error of 
between -1DS and -3DS have a fourfold lifetime risk of developing RD, with this risk 
increasing to over tenfold in those with a refractive error >10DS [93, 94]. Myopia 
predisposes to RD through increased vitreous liquefaction, earlier posterior vitreous 
detachment and a higher incidence of vitreo-retinal degeneration[82]. The biological 
explanation behind this phenomenon is unclear. It is suggested that altered Muller cell 
function may affect the vitreoretinal adhesions[79]. It is possible that myopia is 
associated with a developmental change to the vitreous structure itself[95]. 
1.2.9.1.2. Non Penetrating Trauma 
Non penetrating trauma is also a significant risk factor in the development of RD, being 
present in up to 12.2% of cases [96, 97]. Blunt trauma may cause compression in an 
antero-posterior direction; resulting in tractional forces on the retina; resulting in breaks 
in the NSR[82]. 
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Figure 1.7: Incidence of RD in the UK (data acquired from Hospital Episodes 
Statistics (HES) of England) 
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1.2.9.1.3. Previous Cataract Surgery 
Previous cataract surgery has been noted in up to 24% of cases of RD [97], with 17% of 
these having had vitreous loss during surgery. This may be secondary to increased rates 
of PVD after cataract surgery[98]. This may be associated with reduced concentrations 
of HA[82]. Recent data however suggests that this risk is reducing, with main operative 
risk factors being young age, male gender and peri-operative vitreous loss[99]. 
1.2.9.1.4. Socioeconomic Class 
Higher socioeconomic class [100], has been associated with increased rates of RD. 
Whether myopia, also known to aggregate with affluence, is a contributing effect is 
unclear.  
1.2.9.1.5. Gender  
Male gender seems to be associated with RD [101]. This is perhaps related to myopia 
and the posterior extension of the vitreous base; both of which are more common in 
men[77, 101]. 
1.2.9.1.6. Race 
Finally, there appears to be racial differences in RD. The incidence of RD in black 
patients is reported as being significantly lower than Caucasians [102] [103] [104]. This 
is not explained by predisposing risk factors, which are not thought to differ between 
races [85]. Indians appear to have a lower prevalence of RD compared to Chinese and 
Malay [105]. These differences have yet to be explained. 
1.2.10. GENETICS OF RHEGMATOGENOUS RETINAL 
DETACHMENT AND ASSOCIATED CONDITION 
There is evidence of a genetic predisposition to many of the risk factors and features of 
RD. These are discussed below. 
1.2.10.1. LATTICE DEGENERATION 
Lattice degeneration has a prevalence of between 6 to 9.5% [106] and is implicated in  
between 7 and 29% of RD cases[97, 107-109], being the most prevalent vitreoretinal 
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degeneration predisposing to RD [67]. A hereditary factor in the aetiology of lattice has 
been proposed for over four decades [66, 110-112]. Although autosomal dominant[110, 
111] and recessive[112] modes have been suggested, Mukarami[113] investigated 100 
patients with lattice without RD, and suggested that its inheritance was complex; with a 
three-fold higher prevalence of lattice degeneration in first degree relatives. In 2012, 
Meguro and colleagues [114] published a genome wide association study (GWAS) 
suggesting an association with COL4A4 in a Japanese population.  The role of this protein 
in the retina is unclear. 
1.2.10.2. GIANT RETINAL TEARS & RETINAL DIALYSIS 
Retinal dialysis and GRT account for approximately 6% and 1.3% of all RD cases [97]. 
Retina dialysis are suggested to be traumatic [115] with authors suggesting that a genetic 
predisposition is unlikely[86]. In a series of over 500 cases, Hagler found that less than 2% 
of cases had a relevant family history[116].  
GRT may be caused by trauma in some cases. However a recent review at Moorfields Eye 
Hospital (unpublished) suggests that trauma accounted for 22% of GRT over five years at 
this unit. It must be considered that hereditary vitreoretinopathies also have a high rate of 
GRT in presentation of RD[117]. 
Furthermore, the high prevalence of bilaterality in GRT[63] and dialysis[87], the 
concentration of cases in sibships [87]and evidence from twin studies [118, 119] do 
suggest a genetic aetiology to GRT and dialysis. 
1.2.10.3. MYOPIA 
The genetics of myopia is an extensive topic, and is briefly described below.  
Myopia is the most common ocular “disorder” [120], with an estimated 2.5billion 
people expected to be affected by 2030[121]. The main principal components, axial 
length and corneal curvature both shown to have high heritability; one study 
demonstrating this to be 0.95 for the former and 0.67 for the latter [122]. Guggenheim 
and colleagues [123] recently suggested that genetic components of these ocular 
endophenotypes were related, with a shared genetic scaling involved in ocular 
development. 
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Family aggregation studies have suggested a higher prevalence of myopia in children 
with myopic parents compared with those without[124]. Yap and colleagues[125] 
suggested that the prevalence of myopia in 7 year olds without myopic parents was 
7.3%, compared to 45% when both parents were so. Twin studies have estimated the 
monozygotic heritability as high as 0.9[126]. The increased risk to siblings of a person 
with high myopia (λs) has been reported between 4.9[127] to 20 [128] for high myopia. 
Wojciechowski et al. [129] described this to range between 1.9 and 2.52 for low 
myopia. 
To date there are at least 16 loci, distributed among 13 chromosomes, listed on the 
OMIM database (http:// www.ncbi.nlm.nih.gov/omim) (MYP2–MYP17) for non-
syndromic high myopia, common myopia or ocular refraction. At least seven loci for 
refractive phenotypes (MYP1, MYP3, MYP6, MYP11, MYP12, MYP14 and MYP17) 
have been successfully replicated in independent linkage datasets and identified as 
being associated with myopia. However, recent association studies have greatly 
advanced the understanding of the genetic aetiology of myopia.  
In a large twin based GWAS of refractive error in a European population, several 
polymorphisms at 15q25 near the RASGRF1 gene were found to be associated with 
ocular refraction[130].  In a companion paper, Solouki et al reported another European 
GWAS with a polymorphism (rs634990) at 15q14 significantly associated with 
refractive error [131]. More recent reports have replicated loci at 15q14 that underscore 
a risk for high myopia, in particular an association with axial length[132]  and a further 
GWAS for high myopia in a French population have refined a risk locus at MYP10 
implicating a role for microRNA variation in predisposition to high myopia[133].   
The recent expansion of collaborative GWAS have illustrated many novel loci and 
biological pathways involved in myopia aetiology, which are discussed further in 
section 4.1.9.1. 
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1.2.10.4. MONOGENIC CONDITIONS ASSOCIATED WITH 
RHEGMATOGENOUS RETINAL DETACHMENT: 
VITREORETINOPATHIES 
1.2.10.4.1. Stickler Syndrome 
The most common cause of inherited RD is Stickler syndrome[117]; first described in 
1965 as a connective tissue disorder comprising of articular, auditory, facial and ocular 
features[134]. It is now regarded as the most common manifestation of the spectrum of 
type II/XI collagenopathies; which include Kniest dysplasia, metatropic dysplasia, 
achondrogenesis type II and spondyloepiphyseal dysplasia congentia. Stickler syndrome 
is at the milder end of the spectrum regarding systemic manifestations[135]. 
The diagnostic criteria for Stickler syndrome is[50] a congenital vitreous anomaly with 
three of the following clinical features: 
1. Midline cleft palate 
2. Audiometrically confirmed sensorineural hearing loss 
3. Abnormal Beighton score[136] for joint hypermobility  
4. RD or paravascular pigmented lattice degeneration.  
Although myopia, characteristic lamellar corticol cataract, angle anomalies and 
megalophthalmos exist, the main clinical characteristic is the vitreous phenotype. It is 
believed that the vitreous phenotype is demonstrative of the underlying genetic 
mutation[117]. 
The most common subtype of Stickler syndrome is type 1; associated with skeletal, 
ocular and auditory features. The myopia is usually non-progressive, and congenital. 
These patients are at high risk of developing a GRT[117]. It is a highly penetrant 
autosomal dominant condition caused by mutations in COL2A1on chromosome 12q13. 
Frame shift, nonsense, missense and splice site mutations have been reported[137], 
though the former two are the most common; resulting in haploinsufficiency[117] . It is 
suggested that these patients have a membranous vitreous in the retrolenticular area 
extending to the periphery (Figure 1.8a). Interestingly, mutations in exon 2 of COL2A1  
gene have been reported to cause an ocular only phenotype[138], whilst it has also been  
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Figure 1.8: Vitreous phenotypes in Stickler’s syndrome 
(a) ‘Membranous’ congenital vitreous. Note vestigial gel occupying 
retrolental space and bordered by a distinct folded membrane (arrows).  
(b) ‘Beaded’ congenital vitreous anomaly seen in cases of COL11A1 
mutations. Note irregularly thickened fibre bundles giving ‘string of pearls or 
beaded’ appearance (arrow). 
Adapted from [28] 
63 
 
suggested that certain missense mutations may not lead to the characteristic vitreous 
phenotype[135]. There does perhaps therefore exist a genotype-phenotype correlation. 
Mechanisms such as alternatively spliced exons, alternative transcripts, effects of 
different amino acids or compound heterozygosity have been proposed as mechanisms 
for phenotypic variability[117] 
Stickler type 2 is also an autosomal dominant condition caused by mutations in 
COL11A1 on 1p21. Pedigrees with these mutations manifest a beaded congenital 
vitreous anomaly (Figure 1.8b) associated with arthropathy and cleft palate[139].  
This genotype- phenotype correlation based on vitreous phenotype is 
controversial[140], with conversion between vitreous phenotypes being described[141]. 
Type 3 Sticklers is caused by mutations in COL11A2, which is not present in the 
vitreous, and therefore does not manifest an ocular phenotype. Type 4 Sticklers is 
inherited recessively, by mutations in COL9A1[142] and COL9A2[143]. The vitreous 
phenotype is unclear from the few reports.  
Heterozygous splice site mutations in COL11A1 mutations have also been described to 
cause Marshall syndrome[144]. This condition has similar features to Sticklers; myopia, 
early cataracts, vitreous liquefaction and retinal breaks. However, these patients’ 
skeletal features are in stark contrast to Sticklers; characterised by short stature, 
hypoplastic nasal bones and round faces. Certain mutations have been reported to cause 
overlapping syndromes[145]; adding to controversy over the differentiation of the 
conditions.  
1.2.10.4.2. Chromosome 5q Retinopathies 
Wagner Syndrome was first described in 1938. It used to be considered allelic to 
Stickler syndrome and is characterised by an optically empty vitreous with pre-retinal 
condensations to the periphery, progressive chorioretinal degeneration, 
pseudostrabismus, and progressive reduction in the ERG; with b wave preservation[146, 
147]. Other clinical features include cataracts and anterior segment dysgenesis. RD is 
reported in up to 75% of patients[148]. In 2005 Miyamoto and colleagues[54] described 
a heterozygous mutation in CSPG2 on 5q13 causing Wagner syndrome in a 
consanguineous Japanese family. This gene encodes versican; a macromolecule in the 
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vitreous as described above. Mutations in this gene have since been described in 
European families[149]. 
Allelic to Wagner is a condition first described in 1994 by Stone[150]; Erosive 
vitreoretinopathy. The features in this family resembled Wagner syndrome; marked 
vitreous syneresis, tractional and RD, diffuse rod-cone dystrophy (with ensuing 
nyctalopia). The most marked feature was the progressive “erosion” of the RPE; 
resulting in visualisation of the choroidal vessels. High myopia was not evident. The 
same group subsequently illustrated the allelic nature of this condition with Wagner, by 
mapping two families to the similar region (on 5q13-14)[151]. This was confirmed 
when four families with Wagner and one with Erosive retinopathy were found to share 
the same causative mutation on Exon 7 of CSPG2 (c.4004-5T-->C). 
1.2.10.4.3. Snowflake Vitreoretinal Degeneration  
Snowflake Vitreoretinal Degeneration (SVD) was first described by Schepens in 
1974[152] and is characterised by a fibrillar vitreous degeneration; which may be so 
dense as to obscure the retina. Patients have an absent cup from the optic nerve and 
parapapillary sheathing with radial perivascular degeneration. The name of the 
condition comes from minute crystals that have been observed in the inner retina[152]. 
It is the only vitreoretinopathy associated with a corneal manifestation; guttatae similar 
to Fuch’s Endothelial dystrophy. Patients have been reported to have elevated dark 
adaptation and reduction of the scotopic b-wave in dim light[153]. Myopia is low, with 
no lattice degeneration reported. The rate of RD is reported to be 20% in those 
affected[154]. In 2008 a missense mutation in KCNJ13 was reported to cause snowflake 
retinopathy[155]. Although the mutation described has since been demonstrated to 
disrupt the function of the encoded potassium channel in toads[156], a confirmation of 
the role of this gene in SVD is awaited. The protein is found in the apical processes of 
the retinal pigment epithelium[157] and it is hard to explain all the phenotypes of SVD 
with mutations in this gene. Interestingly, a homozygous nonsense mutation in the same 
gene has since been described in two families with Leber congenital amaurosis[158]. 
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1.2.10.4.4. Goldmann-Favre  
Goldman-Favre (GV) is an autosomal recessive vitreoretinopathy caused by mutations 
in NR2E3 on 15q22[159]. It is allelic with enhanced S-cone syndrome; characterised by 
pigmentary clumps along the arcades, cystoid macular oedema, variable myopia and 
absent rod and enhanced S-cone function on ERG. If there is associated vitreoretinal 
degeneration; these are termed GV[160]. RD in this condition is rare.  
1.2.10.4.5. Autosomal Dominant Vitreoretinochoriodopathy  
Autosomal Dominant Vitreoretinochoriodopathy (ADVIRC) is a dominant condition 
cause by mutations in VMD2 on 11q13[161], the same gene in which mutations result in 
Best disease. It is characterised by an annular ring of chorioretinal hypopigmentation 
anterior to the vortex veins to the ora serrata; for 360°[162]. These patients have a 
depressed Arden ratio on ERG (as those with Best disease) and some have fibrillar 
degeneration. To date, one case has been reported to be associated with RD[163]. 
1.2.10.4.6. Familial Exudative Familial Vitreoretinopathy  
Familial Exudative Familial Vitreoretinopathy (FEVR) is a rare condition which is 
characterised by abnormal retinal vascularization during childhood, which may lead to 
retinal traction and detachment;  as well as exudative RD[164]. The X-linked form of 
the disorder has been linked to the Norrie disease gene in 1993[165]. Mutations in other 
genes, such as TSPAN12[166], FZD4 and LRP5 [167] have since been reported.  
1.2.10.4.7. Knobloch Syndrome 
Knobloch Syndrome (KNO) was first described in 1971[168] and is characterised by 
high myopia, vitreoretinal changes, occipital encephalocoeles and rhegmatogenous 
retinal detachment. It has been reported in at least 23 families since. It is a recessive 
condition caused by mutations in COL18A1; encoding type XVIII collagen. This is 
found in the ILM, and thought to play a role in vitreoretinal adhesion. KNO is discussed 
at length in section 3.5.2. 
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1.2.10.4.8. Marfan Syndrome  
Marfan Syndrome (MFS: OMIM 154700) is caused by mutations in Fibrillin-1 (FBN1) 
is associated with EL and an increased risk of RD. It is discussed at length in chapter 2. 
1.2.10.5. GENETIC PREDIPOSITION TO NON-SYNDROMIC RD 
Further to syndromic Mendelian vitreoretinopathies, a genetic predisposition for non-
syndromic, complex inherited RD was first proposed over 40 years ago[169]. Large 
population studies have suggested that a positive first degree relative family history of 
RD ranged between 1-8.2%[96, 170]. Go and colleagues reported autosomal dominant 
RD in two families with no features of sticklers with an R453T mutation in 
COL2A1[171]. More recently Edwards and colleagues describe a large family with 
autosomal dominant RD and no ocular or systemic features of Sticklers, with the 
pathogenic C192A mutation in exon 2 of COL2A1 [172]. Go and colleagues have also 
demonstrated that familial occurrence of RD was a risk factor in its development[173]. 
They suggested a risk ratio of 2.6 for cumulative lifetime risk of RD in first degree 
relatives of those with RD compared with those without. Siblings in particular had a 3-
fold risk; even when age, sex and myopia are controlled for. Very recently, Mitry and 
colleagues suggested that the sibling recurrence risk (λs) for RD was 2.1, and the 
parent-offspring risk as 2.9[174]. The precise genetic risk of non-syndromic RD is, 
however, not well defined.  
The common consideration in both syndromic and non syndromic conditions is the role 
of mutations affecting structural proteins, such as collagen. These proteins play in an 
integral part of the vitreous and retina, and abnormalities can therefore contribute to 
pathological vitreoretinal adhesions and thus breaks in the NSR. It is possible that such 
a common gene may play a role in Mendelian and non-Mendelian RD.  
1.3. ECTOPIA LENTIS 
1.3.1. ANATOMY AND AETIOLOGY OF ECTOPIA LENTIS 
The human crystalline lens develops around the 5th week of gestation as a product of 
and separating from the surface ectoderm. It is held in its natural position behind the iris 
by the zonular filaments (ZF). These form a circular structure between the equatorial 
lens and the ciliary body through a triangular shape (Figure 1.9) with the apex of the  
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Figure 1.9: Anterior view of the ciliary process with zonules attaching to the lens. 
Zonules form columns (a) on either side of the ciliary processes (b), which meet on 
a single site (c) as they attach to the lens. These two columns form a triangle 
having its base on the ciliary body and its apex on the lens. The zonules form a 
tent-like structure (d) as they become attached to the lens capsule. The equatorial 
surface of the lens is folded (e) by the attachment of 
the zonule. The iris is pulled upward, showing its posterior surface with the radial 
folds (f) and the circular furrows (g). Adapted from[14]  
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triangle on the equatorial margin of the lens covering an area of up to 55nm[175] which   
is rich in fibrillin fibres[176]. Their integrity is crucial to the maintenance of the lens’ 
position. They were first described as being part of the family of microfibrils in 
1971[177] and the most important macromolecular component of ZF are fibrillins.  
The three distinct fibrillins are fibrillin-1, -2 and -3, which are encoded by FBN1 
(OMIM 134797), FBN2 (OMIM 612570) and FBN3 (OMIM 608529) respectively. 
FBN1 is a 237kb gene consisting of 65 exons located at 15q21.1[178]. It encodes 
fibrillin-1, the most abundant macromolecule in ZF. This protein consists of 47 
epidermal growth factor domains (EGF), 43 of which are calcium binding (cbEGF) and 
two cysteine rich domains (Transforming growth factor binding protein-like (TB) 
domain)[179]. The latter of these are only found in LTBP/fibrillin family of proteins, 
and their specific function is unclear, although they may play a role in integrin 
binding[180] or TGF interaction[181]. cbEGF domains, in particular, form intradomain 
disulphide bonds and also contain a calcium binding consensus sequence. When 
calcium binds to these bonds, the molecule strengthens and is more resistant to 
degradation. It is these structures which are crucial to the ECM function of these 
proteins. It is proposed that fibrillin-1 provides force-bearing structural support, 
whereas fibrillin-2 acts mostly in the early process of fibre assembly[182]. 
The structure of the fibrillin microfibril is of a “beads on a string” (Figure 1.10) of 10-
15nm diameter with beads 50nm apart[23]. The bead like structures are mostly encoded 
for by exon 24 of FBN1[183]. Mutations in this exon lead to severe MFS. Other 
constituents of ZF include elastin, proteoglycans and GAGs. The most important 
associated glycoprotein is MAGP-1, which probably plays a role in cross linking the 
microfibrils[23]. 
Heterozygous mutations in FBN1 lead to haploinsufficiency of fibrillin-1. This results 
in disrupted microfibrillar architecture in the ECM[184]. Mutations in this gene result in 
classical MFS, neonatal MFS, autosomal dominant ascending aortic aneurysms, familial 
arachnodactyly, Shprintzen–Goldberg syndrome (OMIM 182212) and severe 
progressive kyphoscoliosis, the “MASS” phenotype (Myopia, Mitral valve prolapse, 
borderline Aortic root enlargement, Skin and Skeletal ﬁndings), mitral valve prolapse 
syndrome (MVPS) and autosomal dominant isolated EL. There may be significant 
overlap between these conditions.  
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Figure 1.10: Election microscopy image of ciliary zonules fibrillin-1.  
Adapted from  [23] 
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As fibrillin is a significant element of the ciliary zonules, it is unsurprising that EL 
manifest in up to 60% of MFS cases[185]. The diagnosis of MFS is based on the Ghent 
criteria[186], of which EL is a major feature.  
Although over 800 mutations in FBN1 have been described[187], analysis suggests that 
a significantly higher proportion of missense mutations involving cysteine residues 
(responsible for the disulphide bonds which are critical to the structural properties of 
fibrillin-1) and mutations at the 5’ end are causative in EL[187, 188], in particular 
within the first 15 exons. These exons encode the N-terminus of fibrillin-1. This portion 
of the protein is thought to be integral to homodimer formation of the fibrillin-1 
molecules, which eventually lead to polymers of fibrillin-1 and thus microfibrils[189], 
although most of this has been inferred from mutational analysis rather than direct 
proteonomics. 
The effect of mutations in FBN1 on lens structures is demonstrated by evidence of 
abnormal distribution and structure of microfibrillary bundles in the capsule of MFS 
patients, particularly at the site of zonule attachment[176, 190], conjunctiva[191] and 
zonules themselves[192].  
Fibrillin-1 is also found throughout other ocular tissue[193]. In the anterior segment, 
beyond the zonules and peripheral lens capsule, it is present in the ciliary body and 
processes, the connective tissues of the iris, the corneal epithelium and the endothelium 
of Schlemm’s canal. Disruption to fibrillin-1 (as seen in MFS) would unsurprisingly 
lead to clinical manifestations related to these structures. The cornea is thought to be 
less steep (“lower K values”), have thinner central thickness and reduced hysteresis in 
patients with MFS [194-197], leading to some authors suggesting that corneal 
phenotype being used as a minor criteria in the diagnosis of MFS[198]. It is probable 
that these features are secondary to corneal maldevelopment as a consequence of FBN1 
mutations.  
Furthermore, histological examination of the anterior chamber angle in eyes from 
patients with MFS have revealed structural abnormalities[199]. This may explain a 
mechanism behind raised intraocular pressure, and the higher prevalence of open angle 
glaucoma in MFS compared to the general population[200, 201]. However, it must be 
considered that although fibrillin-1 is not in the optic nerve tissue itself, it is present in 
the lamina cribrosa. This is known to act as a biomechanical structure in response to 
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intraocular pressure[202, 203]. The structure of the lamina cribrosa in MFS has not been 
investigated, but it is conceivable that there may be alterations in lamina cribrosa 
structure as a consequence of fibrillin-1 defects. This may result in an increased 
susceptibility of the optic nerve to intraocular pressure; as is seen in other forms of 
glaucoma[204]. Alternatively, a structural defect in the lamina cribrosa may result in 
more compliance of the optic nerve. Either theory is yet to be proven, and may be worth 
pursuing as a line of investigation in the future.  
Within the posterior segment, fibrillin-1 is known to be present in the lamina cribrosa, 
choroid, sclera and Bruch’s membrane[193]. The most common ocular manifestation of 
MFS is myopia. The cause of this is two-fold. It may be secondary to EL, specifically 
anterior movement of the lens, thus making the refractive index more myopic in that 
eye. Secondly, it is thought that those with MFS have a greater axial length[185]. It is 
possible that this is secondary to defects in the sclera, resulting in increased axial 
growth. It is likely to be the latter, as anterior displacement of the lens is not commonly 
found in MFS, and is more of a feature of homocystinuria[205], another condition 
associated with EL. Furthermore, it has recently been suggested that corneal flattening 
may counter the effect of axial growth, resulting in myopia not as extreme as would be 
expected with the axial lengths found in MFS[206]. 
1.4. RHEGMATOGENOUS RETINAL DETACHMENT & ECTOPIA 
LENTIS 
It is also proposed that retinal tears and RDs are more common in MFS[185, 207]. This 
data is not robustly replicated, and is therefore a subject of a national prospective 
epidemiological study through the British Ophthalmic Surveillance Unit (BOSU)[208], 
led by our research team at Moorfields Eye Hospital. The explanation behind these may 
be simply secondary to the increased prevalence of axial myopia seen in MFS. Certainly 
in a large series, those MFS patients with RD had greater axial length (AL) than those 
MFS patients without[185]. The relationship between axial myopia and retina tears and 
RD has been discussed previously in this thesis. Whether the increased incidence of RD 
in MFS is independent of axial myopia is as yet uncertain. A further risk factor in the 
development of RD includes lattice degeneration. Lattice degeneration has been 
described in 27.5% of eyes with EL and MFS in a report from Moorfields Eye 
Hospital[209]. Although this is greater than the general population[66], it is 
approximately the same prevalence seen within high myopes[210]. 
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Alternatively there may be changes in the vitreous predisposing to RD. Microfibrils are 
thought to be a constituent of vitreous[211]. Furthermore, fibrillin-1 is thought to exist 
in conjunction with other macromolecules in the vitreous body[212] and there is 
thought to be increased central and posterior vitreous liquefaction in MFS[213].  
Changes in vitreous structure, and particularly increased adhesions to the retina 
predispose to RDs in other vitreoretinopathies. This concept of MFS being a 
vitreoretinopathy is not certain, and it is not classically considered as one[160]. The role 
of an abnormal vitreous in MFS predisposing towards the development of RD is 
therefore controversial.   
The more probable cause of increased rates of RD may be related to the EL seen in 
MFS. Certainly it appears that RD is more common in MFS patients with EL[185, 214-
216]. The zonules themselves are regarded, embryonically, as tertiary vitreous; being 
attached to the pars plicata and plana. The posterior zonule insertion is in close relation 
to the anterior hyaloid’s attachment to the lens capsule. The anterior vitreous adheres to 
the capsule just centrally to the insertion of the posterior lens zonules (Figure 1.11 and 
1.12), though this distance varies with age. This attachment to the lens is called 
Wiegerts ligament[217] (Figure 1.13). This attachment is very close to the posterior 
zonules in children, and regresses as time proceeds (Figure 1.11). This attachment may 
be seen on the slit lamp; known as Egger’s line[218]. This ligament delineates Berger’s 
space; which is a potential space within the Wiegert’s ligament, and continuous with 
Cloquet’s canal (Figure 1.13).  
Disruption of the zonules, and therefore movement of the lens with Wiegerts ligament is 
therefore likely to induce vitreoretinal traction[73]. It is therefore unsurprising that this 
traction may lead to breaks in the neural retina and potential RD.  The relationship 
between the ectopic lens and the vitreous has been demonstrated with biomicroscopic 
studies[219]. 
A further role the zonules may play in traction is evidenced by zonular traction tufts. 
These were first described in 1969 as thickened zonules posteriorly displaced towards 
the anterior retina[220]. These were shown to consist of retinal thickening and 
degeneration at the base, glial tissue within the tuft, and attachment of the zonular tufts 
at the apex. They are found in up to 15% of autopsy cases, and are bilateral in 15% of  
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Figure 1.11: Posterior zonular bundles and the anterior hyaloid membrane 
(AHM). A. Irregular retraction of the AHM from the posterior zonular insertion 
in a 3-year-old patient. Note layering of posterior zonular bundles (SEM, × 
90). B. Complete retraction of the AHM to the end of the posterior zonular fibers 
(Z) in a 71-year-old patient (SEM, × 400). Adapted from 
http://www.oculist.net/downaton502/prof/ebook/duanes/pages/v7/v7c014.html 
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Figure 1.12: Anterior attachments of the vitreous 
Adapted from  http://www.oculist.net/ 
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Figure 1.13: Junction of the anterior hyaloid membrane and the lens capsule: 
site of Wieger's “ligament” (arrow) (haematoxylin and eosin, × 220). 
Adapted from http://www.oculist.net 
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the time. Tractional breaks associated with these are rare. However in the case of 
zonular loss, it is unknown whether the presence of these tufts increase the risk of RD.  
This relationship between RD and EL is further corroborated by considering other 
conditions associated with non-traumatic EL. These include homocystinuria, (OMIM 
236200)[221] (cystathionine beta-synthase gene), in which EL is the most common 
ocular feature. RD is a recognised complication of this metabolic disease, certainly if 
untreated[205, 222]. Furthermore, a more specific ocular phenotype includes Knobloch 
syndrome 1(OMIM 267750)[223] (COL18A1 gene) and Knobloch syndrome 2 (OMIM 
608454)[1] (ADAMTS18 gene). Both these conditions are classically characterised by 
EL and RD (amongst other ocular phenotypes and occipital bone defect[224]). The 
cause of the RD in this rare condition may be a distinct vitreoretinopathy, or related to 
the EL. Other rare conditions associated with EL include Weill-Marchesani syndrome 
(WMS) [225] (FBN1 and ADAMTS10 genes), Weill-Marchesani like syndrome (WML) 
(OMIM 613195)[226] (ADAMTS17 gene) and mutations in latent transforming growth 
factor-beta binding protein gene (LTBP2) (OMIM: 602091)[227]. These are discussed 
further in chapter 3. They are rare, and the incidence of RD in these conditions is 
inconclusive. 
These conditions are characterised by defects in extracellular proteins; resulting in 
disrupted ECM. There are similarities therefore with defects resulting in inherited RD. 
It is possible that a common gene or pathway may be involved in both, unifying the 
phenotypes.  
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1.5. AIMS OF THESIS 
The aims of this work are to investigate the genetic predisposition of Rhegmatogenous 
Retinal Detachment and Ectopia Lentis. These two closely related conditions have 
different genetic aetiologies. Working with numerous teams across four laboratories, 
three universities and one hospital, I have aimed in this thesis to investigate the genetic 
predisposition to these conditions. This involves techniques to investigate both 
Mendelian and non-Mendelian inheritance. Furthermore, I aimed to establish expression 
patterns within the eye of a gene and its protein which is common throughout this 
thesis. By furthering the understanding of both conditions independently; it may be 
possible to understand them in the context of each other.  
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2. CHAPTER 2: ECTOPIA LENTIS: GENOTYPE AND 
PHENOTYPE 
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2.1. INTRODUCTION 
The most common cause of inherited Ectopia Lentis (EL) is considered to be MFS. As 
discussed in the general introduction, this condition is thought to be associated with an 
increased risk of Rhegmatogenous Retinal Detachment (RD)[185, 207]. However, the 
current rate of these two related ocular manifestations (RD and EL) in MFS was not 
clear. To answer this, we undertook a questionnaire survey (Appendix I) of 567 
members of the Marfan Trust (UK) diagnosed with MFS.  
185 (32.6%) completed questionnaires were returned (Male: 49%, Female: 51%; 
P=0.22).  The mean age of this cohort was 47 years (M=48, F=47). 
28 (15.1%) of respondents reported having had a RD between 1965 and 2011 (M: 
17(61%), F: 11(39%)). The mean age of developing RD was 33 years, occurring earlier 
in women (25 years) than men (33 years) (P=0.019).  21% of those with RD had had 
previous lens surgery. 44% of those who had had RD surgery were affected bilaterally, 
whilst 13 (46%) had recurrence of RD. 
56 MFS patients (30.2%) reported having had EL between 1955 and 2011. The mean 
age for EL diagnosis was 32 years (range 4-64, male mean age: 32 years; female mean 
age: 16 years (P=0.549)).  75% of those who had had surgery had bilateral lens surgery.  
This survey lacked genetic data. It would be interesting to know if certain mutations in 
FBN1 predispose to RD or any other manifestations of MFS.  
It seems that  RD occurred later than previous large studies[185]. It is of interest that 
women seem to have developed this earlier than men, and is a novel finding not 
described in MFS, other syndromic nor non-syndromic RD. Further differences from 
non syndromic RD include the high rate of bilateral RD, and recurrent RD. These 
figures agree with previous reports, suggesting recurrence to occur in 30-42% of MFS 
cases[207]. It appears that management of RD in MFS is more complicated with lower 
success rates than non syndromic RD.  
21% of patients in our cohort who had had RD had previously had lens surgery, and it 
appears that EL surgery continues to be a risk for developing RD.  
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With regard to EL, we report it to have been bilateral in 75% of affected patients, 
perhaps because this questionnaire collected historical data; suggesting that over time, 
bilateral EL is more common. Although there is no statistical significance between the 
age of diagnosis of EL and gender, the trend of women being affected younger may 
need further confirmation. 
Although there are limitations to questionnaire studies, including whether this cohort is 
representative, I believe that this work does provide further valuable insights. Clearer 
data can only be ascertained from large prospective epidemiological studies.  
Beyond MFS, the most common inherited cause for EL, is isolated ectopia lentis (IEL). 
This condition describes, as the name implies, ectopia lentis with no other ocular or 
systemic features of other syndromes. These patients do not fulfil the Ghent criteria for 
MFS [186] (Appendix II) or resemble other syndromes. In many older series, this may 
represent misdiagnosis of these syndromes (MFS, Weill-Marchesani, Weill-Marchesani 
Like, Knobloch 1 & 2, Homocystinuria). Since the advent of modern molecular 
genetics, it is possible now to more definitely exclude most other causes.  
2.1.1. AUTOSOMAL DOMINANT ISOLATED ECTOPIA LENTIS 
Traditionally it is reported that IEL can be inherited in an autosomal dominant manner 
(OMIM 129600), most commonly caused by novel mutations in FBN1 not described in 
patients with classical MFS[228]. There are many reports of pedigrees in which the 
classical features of MFS are not reported, but EL segregates in an autosomal dominant 
fashion[188, 229, 230]. However, these patients are likely to represent part of a 
phenotypic spectrum of MFS[231], and the exclusion of MFS in these patients must be 
undertaken carefully and in view of the most recent Ghent criteria for MFS[186]. For 
example, Edwards and colleagues presented a family with autosomal dominant EL with 
some mild skeletal features but no cardiological features of MFS[232], hence 
diagnosing IEL. However, the mutation they found in FBN1 (R240C) was subsequently 
described in a family with classical MFS[233]. Because of the previous report of this 
mutation in MFS, the diagnosis would alter in this family to MFS, according to the most 
recent Ghent criteria[186]. Furthermore, it has been demonstrated with long term follow 
up that patients with IEL secondary to FBN1 mutations may progress to develop 
cardiovascular features of MFS[234, 235]. It is therefore recommended that these 
patients have long term cardiology follow up[186].  
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2.1.2. AUTOSOMAL RECESSIVE ISOLATED ECTOPIA LENTIS 
IEL can also be inherited in an autosomal recessive pattern (OMIM 225100). This has 
been established for over 70 years[236, 237]. Al Salem and colleagues[238], in 1990, 
were the first to describe detailed ocular phenotypes of two consanguineous families 
from Iraq and Jordan with recessive IEL. They were all diagnosed before the age of 10, 
and had no features of systemic syndromes. By a combination of linkage and fine 
mapping in the Jordanian family, Ahram and colleagues[2] 19 years later described a 
homozygous nonsense mutation in ADAMTSL4 on 1q21.2. This gene encodes 
ADAMTS-Like 4 (A Disintegrin And Metalloproteinase with ThromboSpondin motifs 
Like -4). This was the first report of a genetic cause for autosomal recessive IEL. A 
splice site mutation in this gene was subsequently confirmed in a consanguineous 
family from Turkey[10]. It has since been described in sporadic, unrelated patients 
throughout Europe[7, 9]. Of further interest, the most common mutation in this gene as 
well as two novel missense mutations also appear to cause autosomal recessive ectopia 
lentis et pupillae[8, 30]. This does suggest that this gene may perhaps be involved in 
ocular development. Finally, RD was documented as a complication of numerous 
patients in these cohorts[8, 30, 238]. 
2.1.2.1. ADAMTSL4 
The ADAMTSL4 gene (OMIM 610113) is a member of the ADAMTSL (A Disintegrin 
And Metalloproteinase with Thrombospondin motifs Like) gene family. It is found on 
chromosome 1q21 and encodes the 1074 amino acid ADAMTS-Like 4 protein 
(NP_061905). ADAMTSL4 consists of 17 coding exons and two untranslated exons, 
which span 11.5 kb of genomic sequence. ADAMTS-Like 4 is one of the family of 7 
ADAMTS-Like proteins, themselves part of the Thrombospondin type 1 repeat (TSR) 
(see Section 5.1) superfamily of proteins. These 7 proteins are divided into two distinct 
clades, of which ADAMTS-Like 4 and ADAMTS-Like 6 form part of one clade, 
differing from ADAMTS-Like 1, ADAMTS-Like 3 and ADAMTS-Like 7 by lacking 
immunoglobulin repeat regions[21]. The function and disease associations of these 
proteins are as yet unclear, and thus comparisons between structure and function remain 
challenging. ADAMTS proteins (A Disintegrin And Metalloproteinase with 
ThromboSpondin motifs) comprise a protease domain and an ancillary domain, the 
latter of which determines substrate recognition and function in tissue speciﬁcity. 
ADAMTS-Like proteins are structurally similar to the ADAMTS ancillary domain, 
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including at least one TSR module. Although the TSR repeats are very closely related, 
ADAMTS-Like proteins lack the proteolytic domains found in ADAMTS proteins. This 
homology with the ancillary domain may suggest an inhibitory or enhancer relationship 
between the ADAMTS-Like and ADAMTS proteins. Alternatively this relationship 
may be of a competitive nature, or represent the formation of complexes between these 
proteins. However, these roles have not yet been clearly deﬁned. ADAMTS-Like 4 
contains seven Thrombospondin type 1 repeat domains, six of which are clustered 
towards the C terminus. These domains are found in numerous mammalian proteins and 
are thought to have a role in anchoring ADAMTS-like proteins to the extracellular 
matrix (ECM)[239]. Other domains present in the full-length protein are an ADAMTS 
spacer 1 domain, an ADAMTS cysteine rich module and a PLAC (Protease and 
Lacunin) domain. 
The ADAMTS proteases are involved in maturation of procollagen (ADAMTS2, 
ADAMTS3, ADAMTS14) and von Willebrand factor (ADAMTS13). Additionally, 
they play a role in proteoglycanase activity as well as in ECM proteolysis relating to 
morphogenesis, angiogenesis, ovulation, cancer, and arthritis. ADAMTS-Like proteins 
lack the disintegrin-like domain thought to be essential in the protease domain and are 
therefore catalytically inactive. On this basis, it is suggested that they may have an 
architectural or regulatory role within the ECM, or a possible regulatory role of 
ADAMTS proteases.  
The ocular localisation of ADAMTS-Like 4 and its encoding mRNA in ocular tissue is 
discussed in Chapter 5. 
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2.2. AIMS 
The aim of this chapter is to investigate the genotype-phenotype relationship of the two 
most important genes causing isolated ectopia lentis (FBN1 and ADAMTSL4). It is 
hoped to further understanding of the role mutations in ADAMTS-Like 4 may play in 
ocular phenotype. Furthermore, a novel clinical grading system for ectopia lentis was 
devised and verified.  
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2.3. METHODS 
2.3.1. PHENOTYPING 
Consecutive patients diagnosed with IEL (present or previously operated upon), were 
identified and invited to participate in the study. IEL was diagnosed by exclusion of other 
systemic and ocular conditions associated with EL. In particular MFS was excluded by 
assessing against the current Ghent criteria[186]. 
Ophthalmic examination included visual acuity measurement, slit lamp examination, 
Goldmann applanation tonometry for intraocular pressure measurement, gonioscopy, 
dilated examination of lens and fundus, fundal photography, spectral domain optical 
coherence tomography, corneal pachymetry and topography analysis (Pentacam high-
resolution rotating Scheimpflug imaging system [Pentacam HR, Oculus, Wetzlar, 
Germany]), and axial length measurement (IOL Master [Carl Zeiss Meditex, Jena, 
Germany]). Statistical analysis (descriptive analysis and Mann–Whitney U test where 
appropriate) was performed by using SPSS for Windows version 19.0 (SPSS Inc., 
Chicago, IL). Systemic examination included measurement of arm span, upper and lower 
segment height, skeletal examination (palate, scoliosis, pectus deformity, and acromegaly), 
and Beighton score analysis of joint hypermobility[136] (Appendix III). 
If not previously done, echocardiography was performed by my colleague Dr Anne Child 
at the cardiological genetics department at St George’s Hospital, London. Two-
dimensional echocardiography was performed with either the Philips iE33 or Vivid 7 (GE 
Medical Systems, Milwaukee, WI). Standard cardiac views were obtained and analysed 
according to protocols specified by the European Society of Echocardiography[240] and 
the American Society of Echocardiography[241]. Left ventricular (LV) wall thickness, left 
atrial diameter, LV diameter, LV mass, transverse aortic root dimension, and diastolic 
function were measured. 
2.3.2. PHLEBOTOMY 
After informed consent, 10ml of venous blood was extracted from patients and stored at     
-300C until ready for transportation to the Sonalee Laboratory at St George’s University of 
London where the genetic analysis was performed on DNA from these samples, under the 
supervision of Dr Jose Aragon Martin and Dr Gavin Arno.  
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2.3.3. DNA EXTRACTION 
The FlexiGene DNA kit (Qiagen, Hilden, Germany) was used to extract DNA. Firstly, 
lypholised Qiagen protease was suspended with 50µl of hydration buffer (FG3). This was 
then divided into aliquots and stored at -200C.  
Blood was rapidly thawed in a 370C water bath before DNA extraction. During this 
process, denaturation buffer (FG2) was mixed with the reconstituted protease. For each 
DNA sample, 1ml of FG2 was mixed with 10µl of the protease solution.  
5ml of lysis buffer FG1was mixed with 2ml of whole blood, mixed and centrifuged for 5 
minutes at 2000 x g (Thermo Scientific Heraeus Multifuge X3R Centrifuge). This causes 
lysis of red blood cells. The supernatant was discarded leaving a small pellet of leucocytes. 
1ml of Protease/FG2 mixture was then added resulting in proteolysis. The mixture was 
vortexed till completely homogenised. This sample was then incubated at 650C for 10 
minutes in a water bath.  
1ml of 100% isopropanol was added and mixed with the sample. This leads to 
precipitation of DNA out of solution; which is at this stage visible. The mixture was then 
centrifuged for 3 minutes at 2000 x g. The supernatant was discarded, leaving a pellet of 
DNA. 1 ml of 70% ethanol was added to clean the sample. After vortex mixing, the 
mixture was centrifuged for 3 minutes at 2000 x g. The supernatant was discarded and the 
pellet of DNA was left to air dry, before 200µl of FG3 (hydration buffer) was added and 
the mixture then incubated in a water bath at 650C for 1 hour to aid hydration of the DNA.  
2.3.4. DNA QUANTIFICATION 
This DNA solution was then quantified; in terms of DNA concentrations and purity. 
Spectrophotometric analysis (Thermo Scientific NanoDrop 2000 – Thermo Fisher 
Scientific Inc.) was utilised. This method is based upon absorption of ultraviolet light 
(260nm) by nucleic acids. Using Beer-Lambert law for absorption of light, the 
spectrophotometer relates the light absorption to the concentration of nucleic acids. Purity 
is measured by comparing the absorption of 260nm and 280nm light (260:280). This ratio 
is used as the most common contaminants (proteins) absorb 280nm. The 260:280 has a 
high sensitivity for nucleic acids, and is little influenced by protein contamination; 
secondary to the higher extinction coefficient nucleic acids have at 360nm and 280nm 
87 
 
compared to proteins. Protein contamination therefore contributes little error to DNA 
quantity estimation.  
Based on the concentrations, an aliquot of nucleic acids at concentration 50ng/µl were 
prepared. This is calculated with the below equation:  
C1V1 = C2V2 
(C1 = Concentration of Stock DNA sample, V1 = Volume to be extracted from stock, C2 
= 50ng/µl (required concentrations for PCR), V2 = 50µl (final volume of working DNA 
solution)) 
2.3.5. PRIMER DESIGN 
Primers were designed using Primer3[242] software. Polymerase Chain Reaction (PCR) 
primers ideally had GC content between 50-60%, minimally self-complimentary, and 
between 18-28 nucleotides. PCR primers ideal annealing temperature were aimed to be 
similar (<50C difference). Primers with significant similarity to other nucleotide sequence 
through the genome were dismissed (checked on NCBI BLAST website: 
http://blast.ncbi.nlm.nih.gov/). Primers were designed to produce Amplimer lengths of up 
to 1000 nucleotides.  Optimisation included assessing optimal melting temperatures (Tm) 
and requirement of DMSO (Dimethyl sulphoxide). Primers did not produce secondary 
structures.  
2.3.6. ADAMTSL4 AMPLIFICATION METHODS 
In designing primers, ADAMTSL4 complimentary DNA (cDNA) sequence according to 
GenBank (RefSeq NM_019,032.4) was used, with the A of the ATG translation initiation 
codon as nucleotide 1. The initiation codon is identified as codon 1. 
Primers, product size and annealing temperatures for ADAMTSL4 sequencing are in 
Appendix IV: 
PCR is a method of amplifying small fragments of DNA [243]. PCR was performed using 
Platinum ® Taq DNA Polymerase (Invitrogen, USA).  
The reaction mix for each primer pair was prepared on ice. A master mix was prepared for 
the number of reactions to be undertaken. Per exon per DNA sample, 2µl of 10x PCR 
88 
 
buffer was added to 1.2µl of 25mM MgCl2., 2µl of 2mM Deoxyribonucleotide 
triphosphate (dNTP), 11.3µl H2O and 1.6µL Dimethyl sulfoxide 8% (DMSO). 0.4µl of 
forward and reverse primer (10mM) were then added. Finally 0.1µl Taq polymerase 
(5U/µl) was taken from the freezer and added. The protocol used for each primer is 
elaborated in Appendix V. 
This mixture was added to 1µl of DNA in the well of a 96 well plate. The samples were 
mixed thoroughly before PCR cycling. The cycles were as below: 
1. 950C initial denaturation (2 min)  
2. 950C denaturation (1 min), 
3. Annealing temperature (dependant on the primer set) 1 min  (570C) 
4. 720C elongation (1 min).  
5. 720C for 10 minutes for final elongation of the PCR products.  
6. 40C for 10 minutes for termination. 
2-4: Repeated 40 cycles 
At this juncture, a 2% agarose electrophoresis gel was prepared. This included 250ml of 
Tris Boric Acid EDTA solution mixed with 5g of Agarose. This solution was warmed in a 
microwave to melt the agarose, after which, 25µl of ethidium bromide was added to this 
liquid gel. Ethidium bromide is an intercalating agent which fluoresces brightly when 
exposed to ultraviolet light. This mixture was poured into an electrophoresis tray to cool.  
2.3.7. FBN 1 AMPLIFICATION METHOD 
FBN1 is a 65 exon gene covering approximately 237.4kb on 15q21.1.  In designing 
primers, FBN1 cDNA sequence according to GenBank (RefSeq NM_000,138.3, provided 
in the public domain by http://www.ncbi.nlm.nih.gov/gene) was used, with the A of the 
ATG translation initiation codon as nucleotide 1. The initiation codon is identified as 
codon 1.  
Primers used for PCR and sequencing this gene are in Appendix VI. The PCR mix for the 
different exons is documented in Appendix VII. The cycles used are in table 1. 
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PROTOCOL 1 PROTOCOL 2 
1 950C 5 mins 1 950C 5 mins 
2 950C 30Secs 2 950C 30Secs 
3 580C 30Secs 3 540C 30Secs 
4 560C 30Secs 4 520C 30Secs 
5 540C 30Secs 5 500C 30Secs 
6 720C 30Sec 6 720C 30Sec 
7 720C 5 mins 7 720C 5 mins 
       
  
  
Table 1 PCR cycle for amplification of FBN1 
Protocol 1, Steps 2-6 were repeated 35 times for Exons 1, 4, 6, 8-19, 22-26, 29-30, 32-
34, 36-37, 39-42, 44-46, 48, 50-51, 53-56, 58-65. 
Protocol 1, Steps 2-6 were repeated 40 times for Exons 2, 3, 5, 7, 15, 21, 27, 35, 38, 43, 
47, 49, 57 
Protocol 2, steps 2-6 were repeated 40 times for Exons 20, 28, 31, 52. 
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2.3.8. AGAROSE GEL ELECTROPHORESIS 
After PCR cycling for either gene, 2µl of PCR product was mixed with the loading dye. 
This consisted of 30% glycerol, 0.25% bromophenol blue and Xylene cyanol and dionised 
water. The mixture was then loaded into individual wells within the gel. Adjacent to each 
Exon PCR products was loaded a DNA size ladder (Bioline Hyperladder IV, London, 
UK). The electrophoresis was run for 20 minutes at 220V constant voltage. The separated 
fragments were visualised on a transilluminator (UV light of wavelength 210nm) (BioRad) 
and photographs were taken with an orange filtered camera.  
2.3.9. PURIFICATION OF PCR PRODUCTS 
After electrophoresis, and the correct sized fragments were verified by agarose gel 
electrophoresis, the products underwent enzymatic clean-up to eliminate unincorporated 
primers and dNTPs. This was done using Exonuclease-1 (EXO) and Shrimp Alkaline 
Phosphatase (SAP) (ThermoFisher Scientific, Walton, Massachusetts, USA). Exonuclease-
1 degrades single stranded DNA in a 3’ to 5’ direction, releasing deoxyribonucleoside 5’-
monophosphates in a stepwise manner. This releases dNTPs from the unincorporated 
primers. SAP catalyses the release of 5'- and 3'-phosphate groups from extra nucleotides. 
The mixture was as below: 
SAP (1U/µl) (240µl), Dilution Buffer (120µl), Exonuclease-1 (20U/µl: 6µl) were 
combined and 3.2µl of this mixture was added to each PCR product. The resultant mixture 
was incubated at 370C for 1 hour, followed by 800C for 15 minutes. The products were 
then stored at -200C.  
2.3.10. SEQUENCING 
The cleaned products were sequenced using Big Dye Terminator Cycle Sequencing Kit 
(containing Taq DNA Polymerase, dNTPs,  ddNTPs-Dye terminators, MgCl2 
buffer)(Applied Biosystems). The protocol used for the sequencing reaction is tabled 
below (Table 2): 
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Constituent Volume 
Big Dye 3.1 (1X) 1µl 
Primer (1µM) 1µl (Forward) or 1µl (Reverse) 
PCR Product 1µl 
dH2O 6µl 
TOTAL 10µl 
 
Temperature (0C) Time Number of cycles 
95 4m 1 
95 10s  
30 
57 15s 
60 4m 
4 10m 1 
 
  Table 2: BIG DYE mixture and Cycle for sequencing 
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The Qiagen DyeEx purification plates were centrifuged in order to remove the storage 
buffer from the sephadex gel column. The sequence reaction was then transferred to the 
column and centrifuged again (1000 x G at 3 mins – Thermo Scientific HEaeus Multifuge 
X3R Centrifuge). The elutant was the purified sequencing product. It was then incubated at 
850C for 20 minutes for evaporation. 12µl of Formamide was then added to resuspend the 
samples. The samples were heated for 4 minutes at 950C; to denature the samples. The 
samples were then sequenced employing an ABI 3130XL genetic analyser using standard 
protocols. 
The results were read using FinchTV (Version 4.0) (Geospiza, Inc.; Seattle, WA, USA; 
http://www.geospiza.com). 
Mutations were then verified. In silico websites were used to verify the pathogenicity of 
mutations. These included SIFT[244], Polyphen[245]. Furthermore, we confirmed absence 
of these mutations in 160 unrelated chromosome controls. We also confirmed their 
absence from population databases, such as the Exome Variant Server[246], Genebank 
dbSNP library[247] or 1000 Genome[248]. 
2.3.11. GRADING SYSTEM 
During the recruitment and analysis of this study, it became apparent that no unified 
clinical grading system existed for EL.  
A novel grading in ectopia lentis (GEL) classification system was thus created to 
encompass the full possibilities of lens movement. This was to be judged on 
pharmacologically dilated pupils. Primarily, subluxation (Sub) was defined as movement 
of the lens within the iris-lens diaphragm, whilst dislocation (D) was defined as complete 
movement either anteriorly (DA) into the anterior chamber or posteriorly (DP) into the 
vitreous cavity. Subluxation was categorised by direction and extent of lens movement as 
follows:  
Direction was described as such: superiorly (SubS), superonasally (SubSN), nasally 
(SubN), inferonasally (SubIN), inferiorly (SubI), inferotemporally (SubIT), temporally 
(SubT) and superotemporally (SubST).    
Extent was coded as to whether the lenticular edge had passed the central pupillary axis or 
not; graded as 2 or 1 respectively.  
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For example a left eye lens which has moved superotemporally beyond the pupillary axis 
is graded SubST2 (Figure 2.1) , a right eye lens which has moved inferonasally but not 
beyond the pupillary axis is graded SubIN1 (Figure 2.2). See Table 3.  
55 clinical images of EL were acquired from hospital databases, and 11% of these patients 
were clinically validated. Such a proportion has previously been used[249]. Two 
ophthalmologists assessed these images and patients independently at two separate time 
points 8 weeks apart. One non-ophthalmic physician also assessed the images. All 
involved used the GEL classification to grade the EL. Cohen’s Kappa coefficient was 
calculated for inter and intra observer reliability. 
2.4. RESULTS 
Eighteen unrelated consecutive patients diagnosed with IEL were recruited. One patient 
was found to have a FBN1 mutation which has been previously reported in classical 
MFS (see below). Although no cardiac and skeletal features of MFS were present, this 
patient was re-diagnosed as MFS according to the revised Ghent criteria[186]. A further 
patient, on ophthalmic examination, was clarified to have ectopia lentis et pupillae 
(ELetP). Detailed ocular phenotyping was therefore undertaken in 16 unrelated patients 
with IEL, and one patient with ELetP (Figure 2.3a). Two patients were bilaterally 
phakic (Figure 2.3b), and one patient was aphakic secondary to posterior lens 
dislocations. All other patients had had ocular surgery in the past for EL: two via an 
anterior segment approach, and the remainder via a posterior approach. 
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Figure 2.1: SubST2 (Left Eye) 
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Figure 2.2: SubIN1 (Right Eye) 
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MOVEMENT DIRECTION EXTENT CODE 
Dislocation Anterior - DA 
 Posterior - DP 
Subluxation Superiorly 1 SubS1 
  2 SubS2 
 Superior Nasal 1 SubSN1 
  2 SubSN2 
 Nasal 1 SubN1 
  2 SubN2 
 Inferonasal 1 SubIN1 
  2 SubIN2 
 Inferior 1 SubI1 
  2 SubI2 
 Inferior temporal 1 SubIT1 
  2 SubIT2 
 Temporal 1 SubT1 
  2 SubT2 
 Superotemporal 1 SubST1 
  2 SubST2 
 
 
 
 
  
Table 3: GEL Classification system  
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Figure 2.3: Clinical image of ectopia lentis.   
(A): Patient with Ectopia Lentis & Pupillae  
(B) Isolated ectopia lentis in a patient with a homozygous c.767_786del20 
(p.Gln256Profs*38) mutation in ADAMTSL4. 
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2.4.1. GENETICS 
2.4.1.1. FBN1 
Four patients (25%) were discovered to have heterozygous mutations in FBN1 (Table 4, 
Figure 2.4) which have not previously been reported in MFS. Three of these: 
c.2473C>T (p.Pro825Ser) (Figure 2.4a), c.3464A>G (p.Asp1155Gly) (Figure 2.4b), 
c.4259 G>A (p.Cys1420Tyr) (Figure 2.4c), are missense mutations. The first affects a 
consensus amino acid in a cbEGF-like domain whilst the second results in a change of a 
cysteine residue within a cbEGF-like domain. In silico analysis (SIFT[244], 
PolyPhen[245]) revealed these mutations to be pathogenic. The third affects a non-
consensus amino acid in a cbEGF-like domain of fibrillin-1, and has previously been 
reported in a patient with a fibrillinopathy not fulfilling the Ghent criteria[250]. The 
fourth is an intronic mutation (c.1327+1 G>A) (Figure 2.4d) in IVS10 predicted to 
abolish a splice donor site[251]. A further patient (a female diagnosed with IEL at 46 
years of age with no cardiovascular features of MFS), was found to have a missense 
mutation in FBN1 (c.3344A>G (p.Asp1115Gly)) (Figure 2.4e), which has previously 
been reported in classical MFS[252]. Her diagnosis was therefore altered to MFS and 
she was not included for analysis in this study. The final study group thus consisted of 
seventeen patients.  
2.4.1.2. ADAMTSL4  
Nine patients (53%) were found to have mutations in ADAMTSL4 which were thought 
to be causative. Six (66.7%) were homozygous for a nonsense 20 base pair deletion 
(c.767_786del20 (p.Gln256Profs*38)) (Figure 2.5). This mutation results in a frameshift 
leading to a premature termination codon (PTC) after 38 codons of altered reading 
frame.  
The remaining three patients were presumed compound heterozygotes for ADAMTSL4 
mutations. These included four novel mutations (Table 5 & 6) in exons 5 and 6 for IEL, 
and exon 14 for ELetP (Figure 2.6). The patient with ELetP was presumed compound 
heterozygous for two mutations; the 20 base pair deletion (above) and a novel mutation: 
c.2270dupG (p.Gly758Trpfs*59). Segregation analysis was not possible for the 
compound heterozygous mutations. The mutations were thus termed “presumed 
heterozygous”, as it was not possible to determine whether mutations were in cis- or 
trans-.  All mutations are nonsense, resulting in a PTC. One additional patient  
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Figure 2.4:FBN1 mutations in ectopia lentis.  
A-D: Mutations found in isolated ectopia lentis caused by FBN1 mutations. 
E: Mutation previously described in MFS, found in patient with apparent IEL. 
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Figure 2.6: Sequence chromatographs showing novel mutations in ADAMTSL4 
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(patient 8) was found to only have a heterozygous c.767_786del20 mutation. No other 
mutations were found in ADAMTSL4 or FBN1. This mutation does not cause EL in 
heterozygous carriers. This patient was thus placed in the “unknown cause” group. 
Unknown: Four patients (25%) were not found to have any causative mutations in FBN1 
or ADAMTSL4, including the patient described above with a heterozygous ADAMTSL4 
mutation. Two patients had affected family members. Case 5 (male) has reportedly 2 
affected brothers. Case 6 has an affected maternal aunt. These suggest non-autosomal 
dominant inheritance. Family members are not available for analysis. 
The FBN1 and ADAMTSL4 mutations described here were not observed in the control 
group. Furthermore, they are not reported in the Genbank dbSNP library[247], 1000 
Genomes[248] or in the Exome Variant Server[246]. 
2.4.2. CARDIOVASCULAR FINDINGS 
All patients were normotensive (<140/90mmHg) and none were found to have abnormal 
indices of left ventricular or atrial dimensions, aortic root dimension or left ventricular 
function. There were no differences between groups. 
2.4.3. MUSCULOSKELETAL FINDINGS 
Two patients had normal range Beighton joint hypermobility scores of 2/9. All others 
scored 0. No patients had any skeletal features of connective tissue disorder or MFS. 
2.4.4. OPHTHALMOLOGICAL PHENOTYPE 
16 patients with IEL and one with ELetP (Figure 3a) were examined. Ophthalmic 
parameters were measured for each individual eye, and a mean calculated per patient 
(Table 7). The mean values for all patients with were then used in statistical analysis. 
2.4.4.1. AGE OF DIAGNOSIS 
For the purpose of analysis, patients who reported the diagnosis of congenital EL were 
allocated the age of onset of 0.5 years. The median age of diagnosis of EL was 35 years 
old (range 15-46) in FBN1 group, 8.5 years (range 3-47) in the unknown group and 2 
years (range 0.5-46) in the ADAMTSL4 group. 9 out of the 10 in the ADAMTSL4 group 
were diagnosed in childhood. One patient (patient 13, Table 5) was diagnosed at 46 
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years old. Two explanations may account for this late diagnosis. Firstly the patient was 
found to have a novel mutation in exon 5, and it is possible that this mutation somehow 
protects from an early manifestation of EL. However, she admits to poor vision most of 
her life, and at diagnosis was found to have significant EL. It is more likely that her 
vision was affected by EL at an earlier age, which was not diagnosed. Excluding this 
outlier, the median age of diagnosis of EL in the ADAMTSL4 group was 2 years (range 
0.5-9). Comparing the mutation groups revealed that patients with ADAMTSL4 
mutations were affected by IEL at a significantly younger age than those with FBN1 
mutations (Figure 2.7a) (2 years v 35 years, P<0.01).  
2.4.4.2. AXIAL LENGTH 
Patients 16 and 17 (ELetP) were examined at 8 years and 11 years of age. All others 
were assessed as adults (>18years old). We excluded axial length of the children in the 
analysis, as AL in this age range is not comparable to adults[253]. Mean axial length 
was 22.74mm (95%CI: 21.3-24.2) for the FBN1 group, 27.54mm (95%CI: 24.2-30.9) in 
the ADAMTSL4 group and 24.55mm (95%CI: 18.8-30.3) for the unknown group. 
Comparing the two mutation groups (Figure 2.7b) revealed that patients with 
ADAMTSL4 mutations had significantly longer axial lengths (P<0.01). If the axial 
length of the children with IEL are included, analysis still reveals the difference to be 
significant (P=0.01). 
2.4.4.3. VISUAL ACUITY 
Mean ETDRS letters score was 59 (95%CI: 17-101) for the FBN1 group, 58 (95%CI: 
44-73) for the ADAMTSL4 group and 72 (95%CI: 60-83) for the unknown group. The 
differences were not significant.   
2.4.4.4. CORNEAL THICKNESS  
Mean corneal thickness was 410.2µm (95%CI: -26-846) for the FBN1 group, 566.1 
(95%CI: 515.3 – 616.8) for the ADAMTSL4 group and 561.1µm (95%CI: 552.4 – 
569.8) in the unknown group (Not significant).   
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Figure 2.7: Features of ectopia lentis.  
(A): Age of diagnosis (years) of isolated ectopia lentis in patients found to 
have FBN1 or ADAMTSL4 mutations.  
(B): Axial length (mm) in patients diagnosed with isolated ectopia lentis 
secondary to FBN1 or ADAMTSL4 mutations. 
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2.4.4.5. CORNEAL POWER 
Mean corneal refractive power was 40.9D (95%CI: 40.0-41.8) in the FBN1 group, 
41.5D (95%CI: 39.7-43.3) in the ADAMTSL4 group and 41.7D (95% CI: 39.6 -43.8) in 
the unknown group (Not significant).  
2.4.4.6. FOVEAL THICKNESS 
Mean foveal thickness was 352.5µm (95%CI: -73.2 – 778.2) for the FBN1 group, 
302.4µm (95%CI: 251.8 – 353.0) for the ADAMTSL4 group and 359.5µm (95%CI: 
306.5 – 412.5) in the unknown group (Not significant).  
2.4.4.7. INTRA OCULAR PRESSURE  
Mean intraocular pressure (IOP) was 16.9mmHg (95%CI: 13.7-20.1) in the FBN1 
group, 16.6mmHg (95%CI: 13.7-19.6) in the ADAMTSL4 group and 18mmHg (95%CI: 
12.9-23.1) in the unknown group (Not significant). 
2.4.4.8. OPTIC DISC FEATURES 
Mean cup: disc was 0.25 (95%CI: 0.02-0.48) in the FBN1 group, 0.2 (95%CI: 0.1-0.3) 
in the ADAMTSL4 group and 0.36 (95%CI: 0.16-0.56) in the unknown group (Not 
significant).  
No difference was observed in any features of the optic nerve head.  
2.4.4.9. OTHER OPHTHALMIC FEATURES 
No pattern was noted with regard to the direction of lens subluxation or dislocation. 
Furthermore, gonioscopy did not reveal any unusual anterior segment drainage strands. 
All angles were open (>450) at the time of examination. No significant pattern was 
observed for other associated ophthalmic conditions. A summary of the ophthalmic 
phenotype of this cohort is in table 7.        
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2.4.5. CRANIOSYNOSTOSIS and ECTOPIA LENTIS 
In addition to this cohort, DNA was analysed from a further patient referred to our 
group from another ophthalmic unit. Although this patient was not part of this initial 
study, the phenotype was recorded and genetic analysis was undertaken. 
2.4.5.1. PHENOTYPE 
The proband was one of non-identical triplets born at 30 weeks gestation by elective 
caesarean section due to maternal hypertension, after assisted pregnancy using parental 
ova and sperm. She weighed 2lb 10ozs at birth, and was healthy. She had a patent 
ductus arteriosus (PDA), which was closed using indomethacin. She was noted to have 
two haemangiomas. Her two sisters also had PDA and one had a haemangioma. 
At 10 weeks of age she was noted to have right coronal craniosynostosis (CS), with 
secondary facial asymmetry, requiring fronto-orbital advancement. Compared to her 
sisters, the proband’s early developmental milestones were slightly delayed, with 
speech at 18 months, and walking at 2 years. On examination at age 10 she had slight 
facial asymmetry with right eye higher than left. She has no other features to suggest 
MFS. Further examination revealed a normal echocardiogram. 
She presented with shimmering of the irides at 10 months of age, which was noted by 
her parents. Relevant family history included a blind grandfather, of unknown 
aetiology. Examination revealed high myopia (spherical equivalence: Right Eye -
12.5dioptres, Left eye -15dioptres). She had a right exotropia (>45 degrees) associated 
with hypertropia and a full range of ocular movement. Posterior segment examination 
revealed attached vitreous with no retinal degenerations or breaks. Both lenses were 
subluxed temporally, affecting visual acuity. She underwent a right lensectomy in 
October 2004, with a subsequent contralateral lensectomy in March 2005 both of which 
were uneventful. She is now bilaterally aphakic with a best corrected LogMAR visual 
acuity of 1.8 (right eye) and 0.1 (left eye). Most recent examination revealed intraocular 
pressures of 14mmHg (Right) and 16mmHg (Left). Retinal examination revealed no 
abnormalities. In particular there was no evidence of myopic fundal degeneration. 
Neither parents nor siblings exhibited any of these systemic or ophthalmic phenotypes.  
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2.4.5.2. GENETIC SCREENING 
Chromosomes: normal 46xx.  
The common genetic causes of craniosynostosis: FGFR2 exon 8 and exon 10 and 
FGFR3 exon 6 were ruled out by the North East Thames Regional Genetics Service 
(Great Ormond Street Hospital). FBN1 full gene analysis was undertaken by our 
laboratory. No mutation was identified in FBN1.  
ADAMTSL4 analysis was undertaken, which revealed the 20 base pair deletion 
(c.767_786del20, p.Gln256Profs*38) found in our larger cohort of IEL above (Figure 
2.5). 
2.4.6. GRADING ECTOPIA LENTIS CLASSIFICATION SYSTEM 
55 clinical images were obtained from Moorfields Eye Hospital databases. Inter 
ophthalmologist correlation was high on both occasions (κ=0.91 and 0.93, P<0.0001). 
Analysis between time points of the same ophthalmic observer revealed good 
correlation (κ =0.89, 0.82, P<0.0001). Interpretation of images by non-ophthalmic 
observer and ophthalmologists revealed κ = 0.77 (P<0.0001). 5 patients whose images 
had also been assessed (11%) were examined clinically and graded by two 
ophthalmologists. The grades of these clinical examination and photographical 
assessment were compared, and demonstrated complete correlation (κ = 1). 
2.5. DISCUSSIONS 
The incidence and aetiology of retinal detachment in MFS is unclear. Whether it is 
secondary to disruption of fibrillin-1 directly, thus causing a vitreoretinopathy is 
unlikely. It is most probable that it is related to the EL seen in MFS or the associated 
axial myopia. A method of investigating this is to examine a genotype-phenotype 
correlation between the two most important genetic causes of EL: FBN1 (causing a 
fibrillinopathy) and ADAMTSL4. In doing so, it is hoped to understand the risks of RD 
development in this condition and the closely related MFS. 
18 patients with EL were recruited. All patients underwent cardiovascular and skeletal 
examinations which excluded other associated conditions in 17 patients. We found five 
patients with causative FBN1 mutations, nine patients with causative mutations in 
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ADAMTSL4, three patients with no known mutations and one patient in whom a 
heterozygous mutation was found in ADAMTSL4 which could not fully explain the 
recessive inheritance of this condition. 
2.5.1. FBN1 MUTATIONS 
Four of the five mutations found in FBN1 all affected the calcium-binding epidermal 
growth factor –like ((cb) EGF-like) domains. One affected a consensus amino acid in a 
(cb) EGF-like domain, whilst the second resulted in a change of a cysteine residue 
within a cbEGF-like domain. Mutations affecting these residues are thought to result in 
EL at a younger age[187], and this particular individual was the youngest to be affected 
in our cohort. In silico analysis revealed these mutations to be pathogenic. The third 
affected a non-consensus amino acid in a cbEGF-like domain of fibrillin-1 and has 
previously been reported in a patient with a fibrillinopathy not fulfilling the Ghent 
criteria[186]. The fourth (c.3344A>G (p.Asp1115Gly) missense mutation results in a 
substitution of a glycine for an aspartic acid at codon 1115 in the cbEGF-like #13 
domain of the fibrillin-1 protein. This mutation has previously been reported in a patient 
affected by classic MFS and affects one of the conserved amino acids in this type of 
domain throughout the protein.  
The cbEGF domain is thought to be crucial towards the function of fibrillin-1 (Figure 
2.8). Most of the understandings of these domains have been based on mutational 
findings[187], though there has been some cellular work investigating these and closely 
related FBN1 domains[254]. It is hypothesised that disease causing mutations, 
particularly EL causing mutations, may lead to post-translational folding defects in the 
protein[255, 256]. Misfolded fibrillin-1 may accumulate in the endoplasmic 
reticulum[256]; thus leading to haploinsufficiency thought to be causative in MFS 
phenotype. In particular there is thought to be a predominance of mutations affecting 
cysteine residues in these domains[257], particularly missense mutations[187]. Four of 
our mutations affected these domains. Consistently, they were all found in the first 15 
exons (5’ end), confirming reports that these exons harbour more EL causing mutations, 
thus suggesting that the N-terminus of the protein (encoded by this end of the gene) is 
also particularly significant in the aetiology of EL[258]. It has even been suggested that 
there is an inverse relationship between mutations in the distal part of the gene (3’ end) 
and EL[250]. 
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Figure 2.8: Domain organisation of fibrillin-1. A schematic drawing of the 
structure of cbEGF32-36, modelled on the structure of cbEGF32-33 is indicated. 
Calcium ions are shown as red spheres. Adapted from [11] 
114 
 
The fifth FBN1 mutations found was intronic (c.1327þ1 G>A) in IVS10; predicted to 
abolish a splice donor site. The prevalence of splice site mutations in FBN1 is unclear. It 
has been shown that missense mutations of FBN1 are the most commonly found in 
patients with EL, followed by splice site mutations and in-frame mutations[187]. PTC 
mutations are thought to be significantly lower in proportion in those patients with 
EL[187]. Conversely, PTC mutations appear to have a striking correlation with skeletal 
features of MFS. This suggests different structural disruptions to fibrillin-1 have 
alternative effects on different organs.  
One female patient was found to have a heterozygous mutation in FBN1, which had 
previously been described in a patient with classical MFS[252], in particular the 
cardiovascular phenotype. The diagnosis of MFS depends on the Ghent criteria which 
were updated in 2010. This patient would be one of the 15% of patients who represent 
diagnostic differences between the previous and new Ghent criteria[259]. This patient, 
with no skeletal or cardiovascular features of MFS would previously have been 
diagnosed as IEL. There are previous reports of patients described as “isolated” EL 
caused by FBN1 mutations[228], whom would now be termed MFS because of their 
mutation profile.  Such diagnostic changes are important for patients, their families and 
those involved in their care. An up to date understanding and awareness of FBN1 
mutations causing disease[260] is therefore critical. 
Further to this we investigated all published reports of IEL or incomplete Marfan 
syndrome published between January 1993 and January 2013 to clarify whether the new 
Ghent criteria would alter published reports. The NCBI database was searched using the 
terms “FBN”, “Marfan”, “eye”, “Marfan related”, “Lens” and “ectopia lentis”.  Papers 
describing patients as having EL were highlighted. Within each paper, individuals with 
EL and a FBN1 mutation who did not fulfil the Ghent criteria for MFS appropriate for 
the era of the paper were analysed.  
There are 102 different mutations described in 181 individuals, representing 128 
probands, reported in 44 papers over this twenty year period. 16 of the patients reported 
did not have their ages published. 53 patients of the remaining were under the age of 20 
years. The 2010 Ghent criteria[186] state that true “isolated” EL cannot be diagnosed in 
individuals younger than 20 years, because of rapid cardiovascular development before 
this stage. Immediately this suggests that at least 29.3% of patients published with IEL 
were incorrectly so according to the modern Ghent criteria.  
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We investigated these mutations on the Universal Mutation Database (UMD)[260], 
Human Genome Mutation Database (HGMD)[261], NCBI, and an internal database of 
over 300 mutations in FBN1 at the Sonalee Laboratory at St George’s University of 
London. We searched for evidence that these mutations were reported in patients with 
MFS. This would immediately therefore change the diagnosis of a patient with such a 
mutation and EL to MFS. Our results therefore represent an absolute minimum 
proportion of mutations causing MFS, as complete clinical data is not available for all 
mutations. A mutation was ascribed the title “MFS mutation” only if there was absolute 
certainty from available literature that this was true.  
Out of 181patients described as having EL caused by FBN1 mutations, 64 (35%) would 
now have their diagnosis altered to MFS based on Ghent criteria[186]. However, when 
concentrating on probands alone, 70 (54.7%) would now have their diagnosis altered.  
Analysing the mutations themselves, 51 out of 102 (50%) have been described in 
patients with MFS. The different types of mutations described are in table 8. 
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MUTATION TYPE Number (%) 
Missense 75 (73.5%) 
Splice site 
11 (10.8%) 
(2 proven to cause exon skipping) 
Insertion/ Deletion 
10 (.8%) 
(1 causing PTC) 
Nonsense 6 (5.9%) 
 
Table 8: Mutations in FBN1 causing EL reported in literature (1993-2013) 
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When analysing the most common type of mutations (missense), 69.3% (52 out of 75) 
involved a cysteine (39 replacing and 13 creating a cysteine). This is comparable to the 
61% suggested in the largest study of pathogenic FBN1 mutations[187], which 
suggested that missense mutations involving cysteine residues were significantly 
associated with EL. Of their cohort, 81.6% of the cysteine involving missense mutations 
replaced this residue, with the rest creating it. Comparison of those mutations creating 
or replacing cysteine residues in our findings amongst the MFS mutations and “non 
MFS mutations” is of interest. In the MFS mutations, 60.7% of the cysteine involving 
missense mutations resulted in this residue being replaced. In the “non MFS” mutations, 
this was 92% (P=0.0385). PTC mutations, which Faivre et al[187] described as being 
significantly less common in EL, accounted for only 6.9% (7 mutations) of the 
mutations.  
The most widely reported mutations are demonstrated in the Figure 2.9: 
These data present interesting findings. The most widely reported mutations are all 
missense, with 60% involving cysteine residues.  
Of these, the four most reported have all been described in MFS. This illustrates again 
the predominance of MFS mutations in EL. The mutations in blue (R62C, C2017R, 
E2447K, Y63C, G1594V, N164S, S634P, C652Y, E2250G) may be considered “EL” 
mutations of FBN1. This must be interpreted with caution, as these reports include up to 
only 2 independent probands.  
This work describes the major changes that have occurred as a consequence of the 2010 
Ghent criteria. Over 50% of probands not fulfilling the criteria for MFS now would be, 
based on their FBN1 mutation. It is worrying that the guidelines are still occasionally 
being ignored since the 2010 watershed of the new Ghent criteria; with patients being 
described as isolated EL with FBN1 mutations already shown to cause MFS[262, 263]. 
A further point of interest is those papers which describe patients with MFS, with truly 
novel FBN1 mutations and not enough clinical criteria to fulfil this diagnosis[264]. 
Clearly the Ghent criteria of 2010 need to be more widely publicised and clarified.   
These findings suggest that EL caused by mutations in FBN1 is actually part of a 
spectrum of fibrillinopathies with MFS. This also demonstrates the importance of 
having an up to date database of FBN1 mutations known to cause MFS.  
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Figure 2.9: FBN1 mutations causing ectopia lentis reported in the literature in  
>1 proband (1993-2013).     :  Mutations described also in MFS. 
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The only such database to date is the UMD database [252]. This was however last 
updated in 2003.  
To highlight that those with FBN1 mutations causing EL are in a spectrum with MFS, it 
can be argued that the term “FBN1 associated isolated ectopia lentis” or “Autosomal 
dominant isolated ectopia lentis” (OMIM 129600) should be dismissed. Loeys et al 
[186] suggest the phrase “Ectopia Lentis Syndrome” be used, to illustrate that other 
systems may become involved. However, this is somewhat inaccurate, as not all of 
these patients will develop other complications. Alternative phrases, such as 
“incomplete Marfan Syndrome”, “Lenticular fibrillinopathy” or simply “dominant 
ectopia lentis” should be used to demonstrate that these patients are not necessary 
“isolated”. Truly “Isolated Ectopia Lentis” should be reserved for those with autosomal 
recessive EL. To date, ADAMTSL4 is the only gene that has been shown to cause this 
condition.  
It must be acknowledged that some of the work in this thesis contradicts this theory, in 
that current terminology is used. Four patients with FBN1 related EL were termed 
“isolated” in this work[27]. Furthermore, one of our cohort with a FBN1 mutation was 
18 years of age at the time of analysis (Patient 3). Although her mutation was not 
described in classical MFS, technically MFS cannot be excluded. However, since this 
work, she has become 20 years old, and still has no cardiovascular signs of MFS. She 
will however receive lifelong cardiovascular follow up, as will all patients with a FBN1 
mutation. 
2.5.2. ADAMTSL4 MUTATIONS 
We found 9 patients with IEL and recessive mutations in ADAMTSL4 which were 
thought to be causative.  Six of these were the same homozygous 20 base pair deletion 
(termed a “micro-deletion”[265]) in exon 6. This mutation was first described 
simultaneously by our group in the UK[7], in Germany[9] and in Norway[8]. Neuhann 
and colleagues[9] described 8 individuals from 7 families originating from the south of 
Germany. The location for the mutation is notable for the “deduplication” of the octamer 
CAGAGCCC (Figure 2.10).  One can see that after the deletion, the same octamer 
(separated in the wild type sequence by 12 bp AGGCCTCTGGCA) as at the beginning of 
the mutation continues. These are thought to have a potential causative role in  
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the occurrence of microdeletions. Viguera et al. [266] suggest that during DNA replication, 
DNA polymerase pauses. During this pause, disassociation between the primer and 
template strands may occur. The primer strand may then “slip” along to the adjacent direct 
repeat sequence, thus deleting the intermediary nucleotides. Such deduplications occur in 
up to 66% of microdeletions [267]. However, the frequency of these are thought to be 
inversely related to the size of the microdeletion, occurring in less than 3% of deletions 
>6bp [265]. In this gene, the size of the microdeletion would suggest that the occurrence of 
this deduplication would be therefore particularly unusual. In an analysis of 8399 
microdeletions, Ball and colleagues[265] discovered certain repetitive motifs were more 
significantly associated +/- 2base pair of the deletions. Interestingly, the motif sequence 
ACCCC (termed the “Immunoglobulin heavy chain class switch repeat”) was one of the 
more significantly associated repeat (P=2.24x10-6). This is present 7 base pairs upstream of 
this micro deletion (Figure 2.10). This particular dataset investigated microdeletions of up 
to 20bp; however, the vast majority of the deletions studied were less than 6 base pairs. 
The inference of their data to this mutation is therefore limited.  Furthermore, the 
frequency of deletions of greater than 6 base pairs are thought to represent less than 3% of 
all microdeletions[261, 265].  
Nonsense mutations represent at least 11% of all described gene lesions causing human 
inherited disease[261].  Therefore homozygous large micro deletions (</=20bp) resulting 
in PTC are very rare. For this mutation to be frequently found throughout Europe suggest a 
Founder mutation, with a moderate allele frequency. Discovering it in 3 heterozygotes out 
of 190 controls, Christensen suggested an allele frequency of 0.0079 with a homozygous 
individual in approximately 1 in 16000 individuals[8]. Extrapolating this to the UK, one 
would expect over 3500 individuals with this mutation.  
With regard to a founder effect, all patients with the 20bp deletion described by Neuhann 
shared the identical SNP haplotype “C-A-T-ins4” (SNPs rs41317515, rs9659061, 
rs12124948, rs66703603). The marker TSL4CA “209 allele” (CA is repeated 14 times) 
was found in all their cases, and 37% of the control cohort. This, they therefore suggest, 
implies a founder effect. The next nearest marker ((D1S498, 770kb distance to 
ADAMTSL4) showed some variation amongst the ADAMTSL4 cases –suggesting that the 
original founder mutation is at least 150 generations old. This mutation has been found in 
15 unrelated families across Europe, adding further evidence that this mutation has this 
ancient founder effect.  
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This microdeletion results in a PTC, after 110 nucleotides, in exon 6. The result of this 
would be either protein truncation or nonsense mediated decay (NMD) as a consequence 
of mRNA being read as erroneous. Christensen and colleagues[8] investigated ADAMTSL4 
mRNA from patients with the 20bp deletion, and suggested a truncated product was 
produced. They however did not show their original data demonstrating this, and it has not 
been since replicated. It is also been suggested that nonsense mutations which result in 
PTC more than 55 nucleotides from the Exon-Exon boundary are more likely to result in 
NMD[268]. This mutation results in a PTC which is 232 nucleotides from the end of exon 
6. We believe that, at present, it is difficult to determine which (NMD or protein 
truncation) would be the case in this 20 base pair deletion[269].  
Most other mutations published in ADAMTSL4 with EL would result in the loss of the C-
terminal six TSR-1 domains which may suggest an important role for these in the protein’s 
function. Our group at St George’s had previously described a mutation in exon 19[7] 
which only affect the PLAC domain. If this transcript would survive NMD, it would 
suggest that this domain is critical for ADAMTS-Like function.  
Four novel nonsense mutations were discovered in exons 5, 6 and 14. The mutations in 
the first were both deletions. One (c.237delC) had the same motif as the 20bp deletion 
(ACCCC) preceding it (Figure 2.11a). The second exon 5 deletion (c.293delG) had the 
oligonucleotide C5G two base pairs upstream form the deletion (Figure 2.11b). The 
insertion in exon 14 (c.2270dupG) had the oligonucleotide G6 immediately upstream to 
it (Figure 2.11d). Both of these sequences have been shown to be most frequently in the 
vicinity of micro deletions and insertions respectively[265]. The final mutation was a 
substitution resulting in a nonsense mutation.  
The effect of these mutations is again unclear. c.237delC(p.Pro80Argfs*53 ) results in a 
frameshift and a PTC after 53 codons. The resultant PTC is 19 nucleotides from the end 
of the exon. c.293delG results in a frameshift and a PTC after 34 codons. This is then 34 
nucleotides from the exon-exon boundary and suggests that the mRNA is less likely to 
undergo NMD[268], thus resulting in a truncated protein. The insertion mutation 
(c.2270dupG) produces a PTC after 59 codons; 108 nucleotides from the end of the 
exon.  The final mutation, a substitution in Exon 6 (.925C>T) changes an arginine to a 
PTC immediately. This PTC is 108 nucleotides from the end of the exon. These final 
two mutations may therefore result in NMD. This uncertainty in understanding the 
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effect on the protein of mutations in this gene, add further controversy to the role of this 
protein in the eye, manifesting in EL.  
To date, there have therefore been two missense mutations and 12 nonsense mutations 
described in the literature in ADAMTSL4 (Table 6). It is thought that these nonsense 
mutations which are more likely to result in NMD as described above) tend to result in 
recessive disorders[270].  
The phenotype analysis was enlightening. It is useful to put these findings in the context 
of the phenotype of MFS. We analysed the corneal features. It is suggested that in MFS, 
the cornea is thinner and of lower curvature [194, 198]. It is unclear why this is the case. 
The majority of the corneal microstructure is stroma. The stroma, of neural crest origin, 
consists of collagen I, with some collagen V and proteoglycans[271]. Fibrillin-1 is 
thought to be present in the corneal epithelium[193], but evidence from other parts of 
the cornea is lacking. The contribution of corneal epithelium to corneal pathology is 
limited. The only direct evidence of fibrillin-1 modulating corneal phenotype comes 
from an association study, which suggested that FBN1 may contribute to central corneal 
thickness[272]. Nonetheless differences between the corneal phenotype of MFS and 
controls continue to be described. Iordanidou and colleagues[195] described highly 
reflective ECM of the stroma and brightly reflective particles among the endothelial 
cells in patients with MFS, though this finding is yet to be replicated or explained 
further. It would be interesting to understand if the EL seen in MFS relates to corneal 
features. Kara and colleagues[197] recently suggested that corneal hysteresis and 
corneal resistance factors were significantly lower in MFS patients with EL than 
without. Konradsen[196], in addition to confirming that MFS patients had lower K 
values and central corneal thickness, also suggested that within MFS; those with EL 
demonstrated greater astigmatism. Finally, there have also been reports that corneal 
guttata are present more commonly in MFS patients with zonular deficiencies[273]. 
We investigated corneal curvature and central corneal thickness in our cohort.  It is 
particularly interesting that all patients (by definition with EL) had corneal curvature 
(K) values of <42D, a suggested cut off for MFS[198]. Some may caution in 
interpreting this data as most of the patients in this series had had lens surgery by 
vitrectomy. The effect on corneal curvature of this is unclear[274, 275]. Most data 
however suggests that any induced astigmatism after this surgery resolves to 
baseline[276, 277], suggesting that our data is likely to be a true reflection of the 
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patients’ true curvature. Our data therefore suggests that EL itself may influence corneal 
curvature.   
When comparing central corneal thickness (CCT), we found no differences between the 
two groups. It is suggested that peripheral corneal thinning (due to altered fibrillin-1 
between the corneal epithelium and Bowmans layer) combined with ocular elongation, 
may lead to central corneal thinning[194] in MFS. Sultan and colleagues[194] also 
suggest that this feature is correlated with EL. These findings are however not 
consistently described. Indeed, although these two corneal features (curvature and CCT) 
were in the 1993 Ghent criteria[278], they were removed from the most recent 
version[186]. The effect in IEL is even less well understood, with Zhao and 
colleagues[230] finding normal CCT in a family with dominant EL secondary to a 
FBN1 mutation. Our findings add more controversy to the debate of the effect of FBN1 
mutations and EL on CCT. 
The further findings were of particular interest. The age of onset of EL is important not 
only for understanding the aetiology, but also of clinical relevance for patients. It has 
been long established, in MFS, that missense mutations affecting cysteine residues 
resulted in a younger age of onset of EL than other missense mutations[187]. This is 
thought to be because of the important role that cysteine residues and disulphide bonds 
play in the structural integrity of the suspensory zonules[14]. The youngest patient in 
our FBN1 cohort (Patient 3) was the only one to have a mutation affecting such a 
residue (p.Cys1420Tyr), in line with the cysteine residue theory.  
However, the cohort with ADAMTSL4 mutations was affected at a significantly younger 
age, compared to those with FBN1 mutations. This is significant, as we believe that this 
demonstrates that ADAMTS-Like 4 may play an independent role in ocular 
development, unrelated to fibrillin-1 function. It is becoming apparent that mutations in 
other genes in the ADAMTS family are resulting in early onset ocular malformations. 
There is evidence for a possible interactive role between many of the ADAMTS 
proteins and fibrillin-1[279], and this remains a likely possibility in view of the very 
similar ocular phenotypes seen from mutations in these genes and FBN1. However, 
unlike ocular manifestations secondary to FBN1 mutations, all those with mutations in 
genes of the ADAMTS family who have been published to date and with relevant 
information available are affected before the age of 20[1, 2, 7, 9, 10, 22, 27, 226, 280, 
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281]. The young age of onset of these ocular phenotypes suggests a developmental role 
for these proteins.  
The data suggests that children affected with IEL, thought to be recessively inherited, 
should have ADAMTSL4 mutation analysis as the primary candidate.  
Investigating the axial length data in this cohort was highly relevant. As discussed in the 
introduction, patients with MFS are thought to have increased axial lengths. One would 
therefore imagine a similar finding in patients with EL secondary to FBN1 mutations. 
However, our data suggests that the axial lengths are greater in those patients with 
ADAMTSL4 mutations than FBN1 mutations.  This may be related to the age of onset of 
the EL. It is established that the rate of AL growth is greatest before the age of 10 
years[282]. The molecular basis of axial length growth in humans and animals have 
been the subject of studies for over 3 decades (see Brown et al.[283] and Meng et al 
[284]). Highly relevant is the finding in 15 Japanese children that axial length growth 
increases in the presence of non-traumatic EL[285]. This study showed that even after 
lens extraction, AL continues to grow at a greater rate and for longer than normal. 
Interestingly, they found no difference in their cohort of 15 patients between those with 
IEL (n=5) and MFS (n=10). There are no definite theories as to why AL grows more 
rapidly in EL at a young age. It is possible that this may be secondary to two significant 
mechanisms: Form deprivation myopia (FDM) and lens induced myopia (LIM); both 
which are closely related. Animal models have shown that blurring vision during critical 
periods in globe growth have important effects on the axial length[286, 287]. It is 
probable that any of the signalling molecules, including dopamine, acetylcholine, 
vasoactive intestinal peptide, glucagon, retinoic acid, crystallin, seratonin and 
melatonin, nitric oxide or other growth factors may be influential; be this at the neural 
retina, RPE, choroid or sclera[286, 288-290]. It is clear, that this mechanism plays an 
important role in human development as well, whichever the cause of FDM[291]. It has 
been shown that severing the optic nerve in chicks does not inhibit axial length 
elongation by FDM, and if only part of the field is deprived, axial elongation occurs 
only in the corresponding retina[292]. These features strongly suggest that FDM is 
controlled by local retinal mechanisms.  
The aetiology is different between FDM and LIM[293]. LIM is controlled by visual 
pathway signals; illustrated by the findings that optic nerve severing in chicks limits the 
effect of negative lenses on the induced myopia[294]. The effect of the parasympathetic 
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innervation to axial growth has also been investigated. Nickla and colleagues showed 
that lesions to the parasympathetic innervation via the VII cranial nerve, to the ciliary 
and the cervical ganglion disrupted axial elongation in response to occlusion, but had no 
effect on lens induced myopia[293]. The underlying implications of this are not fully 
understood, but does emphasise the fact that different mechanisms control these 
phenomenon.  
In the clinical setting, FDM is more commonly found in cases of corneal scarring or lid 
obstruction. LIM is more commonly found in the instances of anisometropia. What 
effect an ectopic lens may have has not been demonstrated. It is more likely that 
blurring from ectopic lens edge, cataractous lens or effective aphakia from significant 
subluxation, would lead to LIM rather than FDM. It is interesting to consider that in the 
papers describing phenotype data in ectopia lentis et pupillae, axial myopia is a 
prominent feature[295-297]. It is possible to envisage that ectopia pupillae (EP) would 
result in more FDM over the fovea than lens effect. Conversely, recent animal[298] and 
clinical studies[299] have suggested that peripheral rather than foveal blurring may have 
more impact on axial myopia development. The importance of LIM may still be greater 
than FDM in these cases.  
It has been suggested that FDM in one eye may affect the contralateral AL[300]. 
However, this study examined guinea pigs which had pre-existing anisometropia prior 
to form deprivation. Drawing conclusions from this paper is thus challenging. 
Our results indicating long axial length in patients with ADAMTSL4 mutations suggest 
that these patients may be more susceptible to RD than those with FBN1 mutations. 
Indeed, there are reports of RD in the few papers describing ADAMTSL4 mutations[2, 8, 
30]. Whether this is secondary to the early onset EL, the apparent increased axial 
myopia or secondary to an effect of ADAMTS-Like 4 itself is unclear. Whichever the 
underlying cause, it is our suspicion that patients with ADAMTSL4 mutations are more 
predisposed to RD than those with FBN1 mutations. 
Finally, one should consider what effect mutations in ADAMTSL4 might have on other 
organs. The protein is thought to be expressed widely[2]. We found one patient who had 
had EL and a coronal craniosynostosis [301] with the 20bp deletion (c.767_786del 20). 
It is worth considering this case in particular. 
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Craniosynostosis (CS) can be classified according to the sutures involved (in order of 
frequency sagittal, coronal, metoptic and lambdoidal). Although it can be inherited as 
part of over 180 syndromes, 85% of cases are nonsydromic with no identifiable 
mutation[302]. Coronal CS has an incidence of approximately 1 in 10,000 live births, 
with up to 75% of cases being female and approximately 10% of cases reporting a 
positive family history[303]. The most common mutations associated with CS are found 
in fibroblast growth factor receptor genes 1-3 (FGFR 1-3)[304] and the transcription 
factor TWIST1[305]. FGFR has been shown to be involved in modulating osteoblast 
activity in bone ossification[306], and disruptions to this are thought to be the molecular 
basis for CS[302]. Other genetic mutations described have been MSX2, EFNB1, RAB23, 
POR, GLI3, RECQL4 and FBN1.  
Sprintzen-Goldberg Syndrome (SGS) (OMIM 182212), also known as marfanoid 
craniosynostosis syndrome, has been described over 40 times and is characterised by 
craniosynostosis, distinctive craniofacial features, marfanoid skeletal changes, and 
neurologic and brain anomalies. Marfanoid cardiovascular features include valve 
incompetence, but not aortic root dilatation. Mutations in FBN1 have been identified in 
SGS[307, 308]. Sood and colleagues[307] first reported a patient with typical features 
of MFS, including EL, associated with features of SGS with a heterozygous missense 
mutation in exon 29 (p.Cys1223Ty) of FBN1. They first proposed that the elastin-
microfibrillar pathway may affect early patterning events in the cranium. Ades and 
colleagues[308] subsequently described two patients with CS and EL, one of whom 
fulfilled the Ghent criteria, who had FBN1 mutations in exon 26. Hiraki[309] presented 
a 19 month child with CS who had a deletion of FBN1. In spite of these reports, the role 
of FBN1 in CS is still to be clearly defined. 
Loeys-Dietz Syndrome (LDS) causes ascending aortic aneurysm with associated 
abnormalities in the cardiovascular, skeletal, craniofacial and neurocognitive systems. 
CS is known to be a feature. Mutations in the genes which encode the transmembrane 
receptor of TGFβ (TGFBR1 & TGFBR2) cause LDS. This enforces the hypothesis that 
abnormal transforming growth factor beta (TGFβ) signalling pathway may cause 
vascular and craniofacial phenotypes. Mutations in TGFBR2 have also been found in 
patients fulfilling the Ghent criteria for MFS[310]. LDS, SGS and MFS therefore are 
considered related conditions, part of a spectrum. 
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Craniosynostosis and EL have been described in sporadic cases with an unknown mode 
of inheritance (OMIM 603595)[311-315]. None of the most common mutation hotspots 
for craniosynostosis yielded a mutation in our patient: (FGFR2 & FGFR3). In addition, 
no mutation was identified in FBN1 or TGFBR2 known to cause MFS or EL and LDS 
respectively. We therefore investigated other genes associated with EL, and discovered 
the deletion mutation in ADAMTSL4. Christensen et al[8] mention a patient with ectopia 
lentis et pupillae who had craniosynostosis corrected caused by the same mutation. Our 
patient did not have pupil involvement. Taken together, these findings raise interesting 
questions. The first explanation is that these patients represent identification of a 
mutation causing EL and craniosynostosis syndrome. This case may be the first 
example of pleiotropic effects of ADAMTSL4 with regulatory or environmental 
influences affecting different phenotypes; our patient was one of non-identical triplets 
conceived by in vitro fertilisation of parental ova and sperm, who were delivered at 30 
weeks. It has been suggested that infertility treatment may itself be associated with 
craniosynostosis[316]. However, that study was based on only 10 affected patients, and 
must be interpreted with caution. Furthermore, a subsequent multi-national study found 
no association between maternal subfertility, or treatments for infertility and infantile 
craniosynostosis[317]. Such an association is therefore controversial. Furthermore, the 
report by Christensen and colleagues[8] did not mention infertility.   
Alternatively, one must consider that this nonsense mutation is the most commonly 
reported in ADAMTSL4, with no other patients presenting with CS. It may be therefore 
that this patient manifested two rare conditions, only one of which (EL) which we have 
discovered the causative mutation. It is difficult to be certain without further reports 
being published. 
2.5.3. GRADING IN ECTOPIA LENTIS (GEL) 
Our novel grading system (GEL) revealed very high correlation between both 
ophthalmic and non-ophthalmic observers. The correlation between inter and intra 
ophthalmologists are excellent[318, 319]. Although the correlation between 
ophthalmologists and non-ophthalmic physician is lower, this level may still be 
regarded as excellent[318] or substantial[319].  
The number of cases used in our validity testing compares favourably with other novel 
ophthalmic clinical assessment tools[320], and our levels of inter observer correlation 
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equally compared favourably with previous ophthalmic systems[321]. The system also 
was highly repeatable at different time points.  
Previous grading systems have been suggested[322, 323] but their reproducibility has 
not been validated. Waiswol and Kasahara[323] described a four point grading system 
for EL and reported a correlation between visual outcomes after surgery for EL with 
less severe subluxation.  Furthermore they suggest fewer complications in patients with 
less complex subluxations. Their grading system was based on undilated pupils; which 
may differ from the appearance preoperatively. GEL is undertaken under 
pharmacological dilatation, which may help standardise the assessment. The GEL 
system allows more detailed description of lens movement; for which maximal 
pupillary dilation would be optimal.  
It must be acknowledged that the GEL system does not account for subluxation where 
the lens is rotated. In practice, to confirm that this is the plane of movement, the 
observer requires a detailed slit lamp examination. Therefore by excluding rotation from 
the classification system simplifies its use, and does not limit GEL to ophthalmic 
specialists. 
This system was devised during the recruitment of cohort for the genotype-phenotype 
work. It was therefore not employed in that work. It would be of interest to validate it in 
further cohorts, and perhaps further delineate any genotype-phenotype correlation.  
In summary work presented in this chapter has defined for the first time a genotype-
phenotype relationship between the two most important genes in IEL; highlighting the 
importance of ADAMTSL4. The role of FBN1 in this condition is likely to be less 
important than previously considered. A novel clinical grading system has been 
suggested, and may provide the basis for clearer phenotyping of this condition in the 
future.  
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GENE OCULAR 
PHENOTYPE 
REFERENCE 
ADAMTSL4 Isolated Ectopia Lentis 
(OMIM 225100) 
Ahram (2009)[2] 
Greene (2010)[10] 
Aragon Martin(2010)[7] 
Neuhann(2010)[9] 
Chandra (2012)[27] 
Ectopia lentis et pupillae 
(OMIM 225200) 
Christensen(2010)[8] 
Chandra (2012)[27] 
Sharifi (2013)[30]  
Ectopia Lentis and 
craniosynostosis 
(OMIM 603595) 
Chandra (2012)[27] 
ADAMTS10 Weill-Marchesani  
(OMIM 277600) 
Dagoneau (2004)[280] 
Kutz (2008)[281] 
Morales(2009)[226] 
ADAMTS17 
 
Weill-Marcahasni-Like 
(microsherophakia and 
short stature) 
(OMIM 613915) 
Morales (2009)[226] 
Khan (2012)[324] 
ADAMTS18 Knobloch 2 syndrome 
(OMIM 608454) 
Aldahmesh (2011) [1] 
Early onset retinal 
dystrophy 
Peluso (2013)[22] 
 
Table 9: Ocular manifestations of recessive mutations in the ADAMTS genes 
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3. CHAPTER 3: FAMILIAL INVESTIGATIONS OF 
RHEGMATOGENOUS RETINAL DETACHMENT AND 
ECTOPIA LENTIS 
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Publications arising from work related to this chapter: 
(i) Chandra A., Arno G., Williamson K., Sergionotis PI., Preising MN., 
Charteris DG., Thompson DA., Holder G., Borman AD., Davangnanam I., 
Webster AR., Lorenz B., Fitzpatrick DR., Moore AT.  
Extension of the ocular phenotype features caused by mutations in 
ADAMTS18 
JAMA Ophthalmology [In Press]  
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3.1. INTRODUCTION 
Investigating families with Mendelian traits not only informs us about the pathogenesis 
within the family, and in potentially other families with similar monogenic conditions; it 
also is believed to help reveal genes in multifactorial diseases. For example autosomal 
dominant mutations in MAPT lead to frontotemporal dementia[325], and yet normal 
variation in this gene can alter mRNA levels resulting in sporadic progressive 
supranuclear palsy[326]. As Jonathan Cohen suggested in 2010, these “Goldilocks 
alleles” can offer direct insights into the mechanisms of complex diseases[327].  
Furthermore, the traditional distinction of Mendelian and complex inheritance for 
inherited diseases has for a long time now been blurred[328]. However such 
compartmentalisation of conditions does help with focussing methods of investigation.  
Towards this, families were sought in whom RD or EL were inherited. As previously 
discussed, both of these conditions are thought to be related[185, 214-216], though 
rarely investigated in conjunction. For such families, those in whom a clear diagnosis 
was not made were highlighted and recruited. Attention was particularly drawn to 
families with RD and EL. 
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3.2. AIMS 
The aims of this chapter are to investigate families in whom RD and/or its associated 
condition, EL, are inherited. Those families in whom a formal clinical and genetic 
diagnosis had not been made were recruited in order to undertake genetic investigations.  
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3.3. METHODS 
Methods employed in this work include PCR, Sanger Sequencing, SNP genotyping with 
homozygosity mapping, next generation sequencing, RNA extraction, and reverse 
transcriptase PCR.  
Phenotype examination, phlebotomy, DNA extraction and quantification, primer design 
were completed as described in section 2.3. PCR was performed also as described in 
chapter 2.  Platinum ® Taq DNA Polymerase (Invitrogen, USA), BioTaq (Bioline) 
DNA polymerase or MyTaq DNA Polymerase (Biolabo) were used.  DMSO was 
occasionally added to increase reaction efficiency. MgCL2  concentration was altered on 
occasion to improve the reaction.  
The sequence of the PCR products was read using Sanger’s chain termination 
method[329]. BigDye terminator v3.1 (ABI, California, USA) was used as described in 
section 2.3.10. 
Genes sequenced in these studies included FBN1 and ADAMTSL4 which have been 
described in chapter 2. The sequencing of the 26 exons ADAMTS10 was undertaken by 
our collaborators; Professor Valérie Cormier-Daire, Department of Genetics, INSERM 
U781, Hôpital Necker, Université Paris Descartes, Sorbonne Paris Cité, France.  
Genes amplified as part of this chapter included:  
23 exons of ADAMTS18, 26 exons of PAPLN, 35 exons of LTBP2 and 22 exons of 
ADAMTS17. Primers are given in the appendices VII-XI and reaction conditions are as 
follows. 
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For ADAMTS18 
 STEP Temp (0C) 
1. Denaturation (180s) 95 
2. Denaturation (30s) 95 
3. Annealing (60s) 60 
4. Elongation  (90s) 72 
5. Final elongation  (5min) 72 
6. Termination (>10min) 4 
Repeat Cycle of steps 2-4: 40 times. 
 
For PAPILIN and LTBP2 
STEP Temp (0C) 
1. Denaturation (180s) 95 
2. Denaturation (30s) 95 
3. Annealing (60s) 65 (except Exon 19 of PAPILIN (66.50C)  
4. Elongation  (60s) 72 
5. Final elongation  (5min) 75 
6. Termination (>10min) 4 
Repeat cycle of steps 2-4 40 times 
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For ADAMTS17 
For Exons 1, 3-14, 16-22: 
STEP Temp (0C) 
1. Denaturation (180s) 95 
2. Denaturation (30s) 95 
3. Annealing (30s) 56 (except Exon 21: 640C) 
4. Elongation  (30s) 72 
5. Final elongation  (5min) 72 
6. Termination (>10min) 4 
Repeat cycle of steps 2-4 40 times 
3.3.1. EXOME SEQUENCING 
Although traditional methods of gene discovery for Mendelian conditions, including 
linkage and candidate gene screening  are thought to have identified loci for up to a half 
of all known such disorders[330], the recent revolution of next generation sequencing 
(NGS) has changed the genetic landscape. Since 2005, the availability of NGS has 
become widespread. Combining this technology with highly targeted capture has 
allowed an exponential growth of sequencing the coding region; the “Exome”. Since the 
first report of this combination being fruitful in investigation of human disease in 
2009[331], and the first discovery of a causative mutation in Mendelian disease in 
2010[332], this has led to over 600 papers describing the success of exome sequencing 
between Jan 2010 and Dec 2012[18].The steps involved in whole exome sequencing are 
illustrated in the Figure 3.1. 
In summary, DNA is randomly sheared (into sizes 100-300bp), typically using 
ultrasound (Step A).  Adapter ligation then occurs which are complimentary to primers 
in the hybridisation step (B). After washing, NGS is undertaken. Amplification occurs 
by primers bound to a surface of a “flow cell”.  The termination method uses 
fluorescently modified nucleotides used for sequencing. This dye labelled  
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Figure 3.1: Schematic diagram illustrating the steps of next generation 
sequencing (Adapted from  [18] and [29]) 
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nucleotide (complementary to the base) leads to termination of DNA synthesis. This is 
then imaged, before removal of this incorporated base for a repeat cycle. 
After calling the bases, the data is read and aligned to a reference genome. A major 
challenge in interpreting the data from these experiments involves shortlisting candidate 
variants from the background vast number of variants which are seen. On average there 
would be 20,000 single nucleotide variants (SNV) identified from the exome of a 
European individual[333]. The model used for filtering out those variants is dependent 
on mode of inheritance, population structure, and whether the search is for de novo 
mutations. An initial step would involve using online databases, such as dbSNP[247], 
exome variant server[246] or 1000 genomes project[248], or internal databases of 
unaffected controls. Minor allele frequencies of 1% and 0.1% are thought to provide 
power for autosomal recessive and dominant traits respectively[333]. Subsequently 
filtering on predicted deleterious nature of the mutation is often utilised; therefore 
focussing on frameshift, nonsense, splice site and non-synonymous missense mutations. 
Subsequent exclusion techniques included biological effect of genes and distribution 
within ocular tissue. 
3.3.2. HOMOZYGOSITY MAPPING 
Although as mentioned previously linkage analysis may seem less favourable in the 
new era of NGS, a very productive method of this was used in this chapter. In 
consanguineous families, exploiting large runs of homozygosity has been the 
cornerstone of understanding recessive disorders.   
Homozygosity refers to both alleles of a genetic sequence being identical.  Long regions 
of apparent homozygosity may represent deletion polymorphisms, loss of 
heterozygosity (LOH), segmental uniparental disomy, or autozygosity[334, 335]. It is 
this latter cause which is exploited when investigating genetic causes of autosomal 
recessive conditions in consanguineous families. Autozygosity mapping is based on the 
assumption that regions either side of a disease allele are likely to be identical by 
descent in a consanguineous family[336]. This is demonstrated in Figure 3.2. Although 
regions of homozygosity (sometimes termed loss of heterozygosity) can be found in 
outbred populations (usually up to 1.5Mb)[337, 338], long continuous stretches of 
homozygosity (LCSH – usually over 2Mb) on multiple chromosomes are regarded as 
indicative of parental blood  
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Figure 3.2: Homozygous region around a mutation in a consanguineous family. 
This region is autozygous, as it is identical by descent (IBD). 
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relationship[338-340]. A very conservative threshold of 5mb has been suggested for the 
term of LCSH[338] to suggest parental consanguinity. See Figure 3.2. 
Consanguinity increases the probability of IBD (as demonstrated in Figure 3.2), thus the 
risk of autosomal recessive diseases. It is estimated that an offspring of first cousin 
parents have up to a 2% increased risk, compared to non-consanguineous parents, of 
having an autosomal recessive disorder; an approximately 1.1% increased risk of 
infantile mortality and up to 4% risk of pre-reproductive age mortality[341]. Ocular 
disease is particularly common amongst consanguineous families, as these conditions 
do not tend to be lethal.  
Investigating regions on the genome, for linkage or for regions of homozygosity, 
involves genotyping markers on DNA throughout the genome. Traditional 
polymorphism based markers involved blood group analysis, electrophoretic mobility of 
variants of serum proteins and HLA tissue types[342]. From approximately 1975, the 
use of restriction fragment length polymorphisms (RFLP) became widespread, initially 
viewed by Southern blotting. From the 1990’s the use of short tandem repeats 
(microsatellites) become particularly powerful for linkage, as numerous alleles may be 
present in a family. Some of the early examples of these being used to determine 
aetiology of human disease include ophthalmic conditions [343, 344]. The advent of the 
Human Genome Project[345] (see Section 4.1.3) enabled the mapping of the more 
common polymorphisms; SNPs. Assessing for linkage with SNPs became common in 
the early part of this century. Further details of SNPs and their importance are discussed 
in chapter 3. Their use in assessing for regions of homozygosity grew as SNP 
genotyping array technologies improved.  
3.3.3. GENOTYPING 
Microarray hybridisation technology was developed in the 1990s, allowing many 
hybridisation assays to occur simultaneously. Microarrays consist of many thousands of 
probes (oligonucleotides) fixed to a glass or other surface. Fluorescently labelled 
denatured DNA (from the test sample) is then hybridized to the probe molecules on the 
microarray. The bound fluorescence is then viewed with a scanner, and the signal 
emitted is then analysed according to intensity. Genome-wide SNP microarrays are 
available from two large companies; Affymetrix and Illumina. Affymetrix chip 
technology involves synthesis of oligonucleotide probes on the glass microarray, in situ. 
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For some cases in this study, Affymetrix SNP 6.0 was used. This incorporates 1.8 
million markers, which includes 906600 SNPs and 946000 oligonucleotide probes 
designed to detect copy number variants. The distance between each marker is 
approximately1.6kb 
(http://ubioinfo.cicancer.org/TUTORIAL_3_CFontanillo_EuGESMA.pdf). 
Illumina use pre-synthesized oligonucleotides. These are more than 70 nucleotides long, 
with a 50nucleotide gene-specific probe and approximately 22-25 nucleotide “address” 
code. These are coupled to silica microspheres (beads) which are 3µm diameter. Each of 
these beads acts as the array, and houses more than 100,000 identical oligonucleotides. 
The beads are spread across a microarray and immobilised within wells.  After whole 
genome replication and fragmentation of target DNA, hybridisation to the probes 
occurs. Scanning of the fluorescent labels thus allow interpretation of the genotypes of 
interest.  See Figure 3.3.  
During this work, the Illumina CytoSNP-12 v2.1 was used in three families at St 
George’s University of London. This chip incorporates over 250,000 SNPs across the 
genome.  
For either chip, 500ng of DNA from each individual was sent for genotyping (St 
George’s University of London: Illumina CytoSNP12, St Mary’s Hospital Academic 
Medicine Department, University of Manchester: Affymetrix SNP 6.0). Excel sheets of 
SNP genotypes indicating regions of homozygosity were received from either 
department.  
3.3.3.1. ANALYSIS OF GENOTYPE DATA 
Illumina Genotype data is called using Illumina GenomeStudio, before being exported 
onto Excel ©. On Excel ©, a macro formula function was created to search for 
homozygous calls. Runs of consecutive homozygous calls were presumed to represent 
regions of loss of heterozygosity. If multiple affected members of one family were 
investigated, the macro would search for regions which were shared amongst them, and 
these were annotated.  
Regions of homozygosity were then annotated on www. http://genome.ucsc.edu/cgi-
bin/hgGateway to identify genes within these regions.  
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Figure 3.3: Schematic diagram illustrating the steps of bead technology.  
1: Bead with oligonucleotide attached.  
2-3: Hybridisation and single base extension along probe.  
4-5: Staining of nucleotide of interest and imaging of fluorescent labels.  
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3.3.4. RNA EXTRACTION AND cDNA AMPLIFICATION 
DNA sequencing was revolutionised by Sanger’s “chain terminating” method in 
1977[329]. However, even with the great strides that have been made in the interval 35 
years, confirming that variations found by this method are pathogenic require definitive 
segregation analysis and/ or investigation of downstream cellular effects of such 
variations. It has been noted that up to 50% of point mutations which cause human 
disease affect the process of splicing[346]. Genomic DNA sequencing cannot inform us 
about the effect on the mRNA sequence, and thus impacts on splicing; such as the 
creation of pseudoexons or exonic deletion. Although there are bioinformatics methods 
of analysing mutations affecting the spliceosome[347] and experimental studies using in 
vitro or in vivo minigene approaches, the most accurate method involves investigating 
the mRNA itself. Handling RNA comes with significant challenges; due to the continual 
state of flux that RNA is in, the short half-life and differential rate of expression in 
different tissues. However, in cases where a certain genomic mutation cannot be found, 
one has to consider mutations elsewhere, perhaps in the intron or co-transcription 
factors; affecting the transcriptome. In this work, such techniques were used to amplify 
ADAMTS17 in investigating family 6. 
3.3.4.1. RNA EXTRACTION 
RNA is unstable, therefore extracting and using this nuclear material involves more 
precautions than with DNA. The QIAamp RNA Blood Mini Kit (Qiagen ®) protocol 
was employed. 
Prior to starting; all surfaces are cleaned with RNAse AWAY (Cole-Parmer©, USA). 
Buffer RPE was diluted in 4 volumes of 100% ethanol. 10µl of β-Mercaptoethanol, a 
potent reducing agent, was added to 1ml of Buffer RLT.  
1ml of freshly extracted blood was mixed with 5mls of buffer EL. This was then 
incubated for 15 minutes on ice, with intermittent vortexing. The mixture was then 
centrifuged at 400xg for 10 mins at 4°C.  The supernatant was discarded. 2mls of Buffer 
EL was added to the cell pellet, and vortexed. This was again centrifuged at 400xg for 
10 minutes at 4°C before discarding the supernatant. 600µl of buffer RLT was then 
added to the leucocyte pellet and vortexed. This lysate was then added to the 
QIAshredder spin column and centrifuged at maximum speed (14,000xg) for 2 minutes. 
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The spin column was discarded, and the homogenised lysate was retained. 600µL of 
70% ethanol was then added to this lysate and mixed. This mixture was added to a fresh 
QIAamp spin column and centrifuged into a 2ml collection tube for 15s at maximum 
speed (>8000 x g). This residue then underwent on-column DNase digestion with RNas-
free DNase as such: 350µl of buffer RW1 was added to the QIAamp spin column with 
the residue in place. This was centrigfuged for 15s at maximum speed (>8000 x g). 80µl 
of buffer RDD and DNase solution (70µl RDD with 10µl DNase) was added directly to 
the QIAmp spin column, and allowed to work for 15 minutes at room temperature. 
350µl of buffer RW1 was then added to the spin column and centrifuged for 15s at 
>8000 x g. The QIAamp spin column was placed in a fresh 2ml collection tube and 
500µl of buffer RPE was added, before centrifuge at maximum speed for 15s. The flow 
through was discarded, and 500µL of buffer RPE was added to the spin column before a 
further centrifuge at full speed for 3 minutes. The spin column was then placed into a 
1.5ml microcentrifuge tube and 40µl of RNase-free water was pipetted directly onto the 
membrane. A final centrifugation for 1 minute at maximum speed was undertaken. This 
final step was repeated with the flow-through being pipetted directly back onto the 
membrane before centrifuge.  
The RNA sample in the collection tube (RNA solution) was quantified (concentration 
and purity) using spectrophotometric analysis (spectrophotometric analysis (Thermo 
Scientific NanoDrop 2000 – Thermo Fisher Scientific Inc.: see Section 2.3.4).  Most 
abundant extracted RNA is ribosomal and messenger RNA. A simple test of integrity is 
to then run 2-5µL of this total RNA on a 1% Agarose Gel. Two of the four (28S and 
18S) subunits of RNA can be demonstrated on the 1% Gel. Any genomic DNA 
contamination would manifest as larger products on the Agarose gel (Figure 3.4). 
8µL was then used in cDNA synthesis and the rest stored at -400C.  
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Figure 3.4: 1% Agarose gel of RNA demonstrating two bands representing 2 
subunits of ribosomal RNA. No large band is seen, confirming no contamination 
by genomic DNA. 
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3.3.4.2. RT-PCR 
RNA underwent two-step reverse transcription PCR. In this process, cDNA is first 
synthesised by rt-PCR from the RNA. This cDNA was then either stored (4°C) or used 
in PCR using primers of choice. 
cDNA synthesis itself has two stages: 
Two mixtures (SOLUTION A) were prepared as below, totalling 10µL: 
RNA 8µL 
Random Hexamer (50ng/µl) 1µl 
dNTP (10mM) 1µL 
 
These two samples were incubated at 65°C for 10 minutes. This is to denature the total 
RNA. The sample is then placed on ice immediately for 2 minutes to reduce RNA 
degradation and premature cDNA synthesis. During this period, solutions as below are 
prepared. 
 + - (Enzyme free) 
5x RT buffer 4µL 4µL 
RNAse inhibitor 
(10units/µl) 
1µl 1 
Reverse Transcriptase 0.25µl - 
RNAse-free water 4.75µL 5µl 
TOTAL 10µl 10µl 
 
All steps are done on ice: Solution A (10µL) was added to each of these above which 
included a negative control. 
Both samples are then incubated for 4 hours at 37°C, before a termination step for 15 
minutes at 70°C. PCR was then undertaken for β-actin using primers spanning 
exon/exon boundaries, to confirm cDNA presence. Subsequently primers were used to 
amplify ADAMTS17 from this cDNA are demonstrated in appendix XII. 
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3.4. RESULTS 
3.4.1. FAMILY 1-3  
3.4.1.1. FAMILY 1 
See Figure 3.5A for pedigree.  
3.4.1.1.1. CLINICAL 
This patient (IV:1) was examined by colleagues in Gießen, Germany (Dr Markus 
Preising and Professor Birgit Lorenz). This male child was born at full term via normal 
vaginal delivery to first cousin parents. He was noted to have reduced vision at 6 
months old. At one year old his binocular vision was recorded as 0.1 LogMAR. He was 
noted to have ectopia pupillae. Pigmentary changes were noted throughout the retina. 
Electroretinogram (ERG) illustrated a reduced amplitude of the combined rod and cone 
specific responses. The amplitude of rod responses was however maintained. Photopic 
cone amplitude was markedly diminished, and remained so, at the next four 
examinations over six years. Whether these changes are stationary or progressive is not 
clear. Most convincingly there was significant micro-cornea (horizontal corneal 
diameter 8.5cm OU). At last appointment (7 years old: 2006) visual acuity was 
LogMAR (1.25LogMAR (right eye)and 1.43 (left eye). Axial length at 3 years of age 
was 23.04mm bilaterally and the patient was emmetropic.  The provisional diagnosis for 
this child was cone-dystrophy of unknown origin associated with EP and microcornea. 
There was no lenticular pathology. 
No one else in the family was affected, in particular both parents (III:1 and III:2). 
3.4.1.2. FAMILY 2 
See Figure 3.5B for pedigree. 
3.4.1.2.1. CLINICAL 
Family 2 are of Pakistani origin. The proband (AII:1) was born in 1981 to parents who 
were first cousins once removed. He was born full term, via normal vaginal delivery. He 
presented at the age of two years with bilateral cataracts. These were extracted and it 
was noted that he had weak zonules. He was also noted to have a significant exoptropia, 
and underwent medial rectus resection and lateral rectus recession in the same year as  
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the cataract surgery. He was found to have an unusual tessellated fundal appearance 
(Figure 3.6), associated with a nystagmus. In 1984, there was concern of neurological 
delay, and he therefore had urine homocystine levels measured which excluded 
homocystinuria. By 1990, his visual acuity was noted to be 1.0 (LogMAR). Paediatric 
electrodiagnostic analysis in 1992 suggested that there was unlikely to be gross retinal 
dysfunction. By 1993, he was noted to have micro-cornea (8mm horizontally 
bilaterally) (Figure 3.7). A pattern ERG was attempted, but the nystagmus prevented a 
detectable response. A full field ERG was undertaken in 2003. Rod specific ERG b-
wave amplitude was 60µV on the right and 45µV on the left; both accompanied by 
latency delays. Maximal response a- and b-wave amplitudes were 135 and 155µV on 
the right and 125 and 140µV on the left.  A-wave latency delays were noted. 30Hz 
flicker was of abnormal implicit time from both eyes, with amplitudes of 15µV 
bilaterally. Photopic single flash ERG demonstrated profound a-wave latency delay 
with additional abnormal b-wave implicit time. Overall, this demonstrated  subnormal 
cone and rod function with profound delays, worse in the former.  Axial lengths were 
26.06mm (in right eye) and 25.86mm (in left eye). His best visual acuity in 2012 was 
0.9 LogMAR (6/48). He had no other medical history, and required no medication. His 
parents were unaffected. 
His brother (AII:2) was born in 1988 at full term by normal vaginal delivery. He 
presented at the age of three years with bilateral ectopia lentis (EL). He was 
hypermetropic with a refractive error of +6.5DS bilaterally. His best visual acuity was 
regarded as 0.78 LogMAR (6/36) bilaterally. Central macula pigmentation was noted at 
this stage. He was registered partially sighted. He was noted over the years of attending 
the eye clinic that he was of Marfanoid appearance. In 1999, he suffered an RD in the 
right eye. His lens was extracted at the time of initial repair of the RD. He underwent 
three operations, which resulted in this eye being left with silicone oil in situ. His retina 
was detached under the oil. He was noted to have unusual peripapillary atrophy in the 
left eye at that stage. In 2006, he suffered a RD in this left eye, and at surgery, the 
vitreoretinal interface was described as unusual.  After two operations, his retina has 
remained attached. He is aphakic, and has aphakic glaucoma. His axial lengths were 
21.7mm (right eye) and 29.5mm (left eye; posterior Staphyloma). He was also noted to 
have microcornea (8mm). Systemic examination revealed arachnodactyly (Figure 3.8C). 
Systemic examination has excluded connective tissue disorders such as MFS. 
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Figure 3.7: Anterior segment photography of AII:1 illustrating microcornea 
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. 
  
Figure 3.8: Clinical features of AII:2. A: Ocular ultrasound demonstrating 
almost total retinal detachment (arrow). B: Left fundal photograph 
demonstrating widespread peripapillary atrophy. C: Arachnodactyly  
D: Microcornea and normal appearing iris 
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Post-contrast computed tomography (CT) of the brain and orbits demonstrated imaging 
features common to both siblings (Figure 3.9 a-f). The sella turcica was expanded with 
displacement of pituitary tissue and infundibulum inferiorly and posteriorly respectively  
within the pituitary fossa. Meckel's caves (location of the Gasserian ganglion of the 
Trigeminal nerves) were also observed to be large and predominantly of cerebrospinal 
fluid (CSF) density. This CSF density was seen to extend to and through foramina 
Ovale (through which the Mandibular nerves exit the skull). The overall appearances 
were suggestive of dural ectasia and herniation similar to that seen in raised CSF 
pressure states (e.g. Idiopathic Intracranial Hypertension) neurocutaneous syndromes, 
(e.g. Neurofibromatosis type I) or connective tissue disorders (such as MFS). 
3.4.1.3. FAMILY 3 
See pedigree (Figure 3.5C) 
3.4.1.3.1. CLINICAL 
The male proband (BII:1) is of Pakistani origin born to first cousin parents. At two 
years of age he was noted to have myopic astigmatism. With correction, there was no 
improvement by the age of six years of age and he was referred for an opinion on 
punctate lens opacities and a myopic tessellated fundus (Figure 3.10). At this time his 
visual acuity was logMAR 0.2 in his right eye and 0.3 in the left. Spherical equivalence 
was noted to be -5DS bilaterally. Microcornea was noted. 
By eight years of age his visual acuity had deteriorated (Right eye 0.4 LogMAR and 
Left eye 0.34 logMAR). His myopia has also increased -7.50 DS (right) and -9.50DS 
(left) (spherical equivalent). Electroretinography revealed cone dysfunction with normal 
rod function.  
A ISCEV[348] ERG aged 13 years showed progression to a cone rod dystrophy. His 
myopic refraction had further progressed to -14DS spherical equivalence bilaterally. He 
was noted to have central cataracts, smooth irides and microcornea (7.5mm horizontal 
bilaterally: Figure 3.10A).  
At the age of 15 years old, he developed a total RD  in the right eye, secondary to a 
giant retinal tear. A year later, he presented with the same condition in his contralateral   
eye. The RD was successfully repaired in each eye.  
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Figure 3.9: Computerised Tomography of AII:1 and AII:2. Post-contrast 
Computed Tomography (CT) of the 2 siblings: panels a,c,e and b,d,f belong to 
each sibling respectively. Axial reconstructions through the orbits (a & b) 
demonstrating aphakic and elongated orbits. In panel (b), there is a posterolateral 
ocular staphyloma (white arrow) and evidence of previous scleral banding and 
silicone oil tamponade (white arrowheads). Sagittal reconstructions through the 
pituitary fossa (c & d) demonstrating enlargement of the fossa which is 
predominantly CSF filled and displacement of the pituitary gland and 
infundibulum inferiorly and posteriorly respectively (white arrows). Coronal 
reconstructions through Meckel's caves and foramina Ovale (e & f) 
demonstrating bilateral CSF filled enlarged Meckel's caves and herniation of this 
through foramina Ovale (white arrowheads). g & h: Axial sections of skull, 
demonstrating no occipital defect. (Thanks to Dr Indran Davagnanam (Dept of 
radiology, Moorfields Eye Hospital) for images and report). 
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Axial lengths were 27.7mm (right) and 29.0mm (left). Magnetic resonance imaging 
(MRI) imaging revealed no occipital defect. No other family members were affected. 
3.4.1.4. GENETIC 
3.4.1.4.1. Family 1  
The proband had an unusual phenotype consisting of microcornea, ectopia pupillae and 
cone dystrophy, which has not previously been described. The pedigree suggested this 
to be inherited in an autosomal recessive manner. With the consanguinity in the family, 
it was more likely that this would be due to autozygosity; thus homozygous mutations.   
The EP in this child was initially considered as an incomplete iris coloboma.  The MRC 
Human Genetics Unit, University of Edinburgh (Dr K. Williamson and Dr D 
Fitzpatrick) were investigating this case using classic trio based exome  sequencing 
(III:1, III:2, IV:1) as part of the UK10K exome sequencing cohort[349]. This was 
undertaken at the Wellcome Trust Sanger Institute (Cambridge, UK) using the Agilent 
SureSelect All Exon 50 mb kit. Excluding variants with a minor allele frequency 
>0.005, they then focussed on homozygous non-synonymous and pathogenic changes. 
In fact there was only one homozygous nonsense mutation. This was c.1067T>A 
[p.L356*] on exon 7 of ADAMTS18, a 23 exon gene on chromosome 16q23.1 covering 
153kb of genomic sequence. This was confirmed with Sanger Sequencing, and found to 
be heterozygous in both parents (Figure 3.11).  No other family members were available 
for investigation. 
3.4.1.4.2. Family 2 
The diagnosis in these two affected brothers was unclear, so investigations were 
undertaken to elucidate the cause of the phenotype. Because of the consanguinity in the 
family, it was assumed that the inheritance would be autosomal recessive. The proband 
(AII:1) was analysed using the Affymetrix Genome Wide Human SNP array 6.0[350]. 
Regions of homozygosity are demonstrated in table 10. 
To help define the causative mutation, DNA from this proband underwent high 
throughput sequencing for 106 genes known to cause retinal dystrophies at St Mary’s 
Hospital, University of Manchester [4].  
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Figure 3.11: Chromatograph demonstrating the ADAMTS18 mutation c.1067T>A 
[p.L356*] in family 1. It is in the heterozygous state in both parents  
(III:1 and III:2). The wild type (WT) is also shown.  
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Chromosome Autozygosity size (mb) 
19:6,059,840-14,742,924 8.683 
20: 1,681,609-9,950,715 8.269 
16: 72,334,370-79,228,734 6.895 
22: 33,056,621-38,877,740 5.821 
22: 44,069,626-46,165,101 5.095 
19: 52,108,930-54,054,786 1.945 
12: 128,059,453-129,656,359 1.597 
20: 60,398,804-61,406,884 1.008 
 
 
 
 
 
 
 
 
 
 
 
  
Table 10: Regions of homozygosity for AII:1 (presumed to be autozygous) 
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The genes screened at the University of Manchester are defined in table 11. 
No pathogenic mutations were discovered. The homozygosity data was therefore 
revisited. In the region on chromosome 16q23.1 one candidate gene stood out; 
ADAMTS18 (Figure 3.12).  
This gene was sequenced in the two affected brothers (AII:1, AII:2),their father (AI:1) 
and 40 control chromosomes from the same ethnic group as the patients. One 
homozygous missense mutation was discovered (c.2159G>C (p.C720S)) (Figure 3.13).  
3.4.1.4.3. Family 3 
Because of the similar phenotype to Family 2, ADAMTS18 was sequenced in DNA from 
the proband (BII:1) and his father (BI:1) using the same methods as described for 
Family 2. One homozygous mutation in exon 13, (c.1952G>A [p.R651Q]). was 
discovered from the proband which was in the heterozygous state in the father (Figure 
3.14).  
All three mutations are predicted to be pathogenic according to in silico analysis 
(SIFT[244], PolyPhen[245], Mutation Taster[351]). The two missense mutations were 
absent from 40 ethnically matched controls chromosomes and are not present in online 
databases (1000 Genomes[248], Exome Variant Server[246], Genbank dbSNP 
library[247]). The amino acid residues affected by the mutations are conserved amongst 
vertebrates.  
3.4.2. FAMILY 4 
See Figure 3.15 for pedigree.  
3.4.2.1. CLINICAL 
This family are of Romanian gypsy origin. The proband (CII:1) was noted to have poor 
vision by the age of 2 years old. He has had developmental delay diagnosed by the age 
of four years old. By the age of 15 years he was seen at Moorfields Eye Hospital and a 
horizontal jerk nystagmus was evident bilaterally. Visual acuity was LogMAR 0.7 (right 
and left) at 50 centimetres. 
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CA4 PROM1 RLBP1 ELOVL4 BBS2 OTX2 
CERKL PRPF3 ROM1 CNGA3 BBS4 DHDDS 
CNGA1 PRPF31 RP2 CNGB3 BBS5 PITPNM3 
CNGB1 PRPF8 RPE65 GNAT2 BBS7 MKS1 
CRB1 PRPH2 RPGR PDE6C GPR98 PRPF6 
CRX RGR SAG RS1 PCDH15 UNC119 
EYS RGS9 SEMA4A FZD4 USH2A  
FSCN2 RHO TOPORS LRP5 CDH23  
GUCA1B KCNV2 TTC8 NDP MYO7A  
IDH3B RIMS1 TULP1 GUCA1A USH1C  
IMPDH1 RPGRIP1 CEP290 TIMP3 USH1G  
KLHL7 UNC119 AIPL1 EFEMP1 FAM161A  
MERTK C1QTNF5 GUCY2D RDH5 C2orf71  
NR2E3 BEST1 LCA5 TEAD1 IMPG2  
NRL ABCA4 LRAT RAX2 PDE6G  
RP1 CHM RD3 CLRN1 SNRNP200  
RP9 BBS9 RDH12 ARL6 RBP3  
PDE6A MKKS SPATA7 BBS1 ZNF513  
PDE6B TRIM32 ADAM9 BBS10 CDHR1  
PRCD DFNB31 CACNA2D4 BBS12 RP1L1  
 
Table 11: Genes screened by next generation sequencing by the  
University of Manchester [4] 
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Figure 3.13: Chromatograph demonstrating the ADAMTS18 mutation 
(c.2159G>C) in affected members of Family 2: II:1 and II:2. It is absent in the 
wild type (WT), and heterozygous in the unaffected father (I:1) 
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Figure 3.14: Chromatograph demonstrating the ADAMTS18 mutation 
(c.1952G>A) in affected family 3. It is absent in wild type (WT) and in the 
heterozygous state in the unaffected father (I:1)    
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Figure 3.15: Pedigree of Family 4  
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Anterior segment examination revealed microcornea bilaterally (horizontal corneal 
diameter 8mm bilaterally at 16 years of age – Figure 3.16A & D) and bilateral EL. Both 
lenses were displaced superotemporally. He had characteristic lens opacities (Figure 
3.16B & E). Fundal examination demonstrated bilateral chorioretinal atrophy. 
Electordiagnostic examination (aged 15 years) revealed a small amplitude cone specific 
ERG with a delay to peak. Rod photoreceptor function was normal. This was interpreted 
as a cone dystrophy. Axial lengths were noted, at 16 years old, to be 26.01mm (right 
eye) and 26.02mm (left eye). He is registered partially sighted. Examination revealed a 
fibrillar vitreous, similar to seen in vitreoretinopathies[117]. Skull imaging revealed an 
occipital bone midline defect above the external protuberance with herniation of brain; 
suggesting an encephaloceole.  
His sister (CII:2) was noted to have EL at a very early age. She has also characteristic 
lens opacities (Figure 3.17). No developmental delay was noted. She had a similar 
fundal appearance to her brother; characteristic chorioretinal, particularly peripapillary 
atrophy. Axial lengths, at 10 years old, were noted to be 29.3 (right eye) and 29.1 (left 
eye), indicating high myopia. Skull imaging revealed an unusual appearance over the 
occipital protuberance which may be consistent with an encephaloceole.  
3.4.2.2. GENETIC 
The very similar phenotype to family 2 led to screening ADAMTS18. This revealed no 
mutations. Therefore, because of the consanguinity in this family, autozygosity mapping 
was arranged for CII:1. DNA was hybridised to the Illumina CytoSNP-12 v2.1. Regions 
of homozygosity are shown in table 12. 
There were numerous regions over 5mb on different chromosomes. Of particular 
interest in the region on chromosome 21 which harbours more than 30 genes, including 
COL18A1. An image of this region from www.ucsc.edu is demonstrated in figure 3.18, 
with COL18A1 in particular gene of interest highlighted.  
The gene COL18A1 is known to cause Knobloch syndrome 1; a condition with 
strikingly similar phenotype to our proband. This gene is currently undergoing 
screening at the UCL Institute of Neurology, and it is expected that a homozygous 
mutation will be harboured within this gene. 
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Figure 3.16: Clinical features of CII:1. A&D: Right & Left anterior segment 
demonstrating featureless iris. B&E: Right and Left characteristic lenticular 
opacities. C&F: Right and Left fundal photograph. G: Fibrillar vitreous  
H: Axial CT demonstrating occipital defect (arrow). 
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Chromosome Nucleotide Size (bases) 
17 21,714,456-55,220,949 33,506,493 
1 223,614,061-241,720,543 18,106,482 
1 4,833,498-14,126,651 9,293,153 
44 9,972,163-18,787,232 8,815,069 
2 138,870,442-158,283,430 19,412,988 
2 99,264,217-107,778,931 8,514,714 
1 156,209,857-165,195,664 8,985,807 
11 57,992,068-77,730,725 19,738,657 
21 31,194,195-48,098,824 16,904,629 
Table 12: Regions of autozygosity greater than 8mb for BII:1 
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3.4.3. FAMILY 5 
See figure 3.19 for pedigree. 
3.4.3.1. CLINICAL 
This is a family of six brothers and two sisters. Four of the brothers have a characteristic 
phenotype of RD and EL during childhood.  
The proband DII:1 presented to Moorfields Eye Hospital by the age of seven years, 
having already lost the vision in the right eye secondary to failed RD surgery with lens 
extraction. At the age of 14 years old, he was noted to have a RD in his left eye, 
premature cataract and EL. The RD was secondary to a giant retinal tear. He was noted 
to have extensive superior circumferential lattice degeneration in this eye. This was 
repaired with pars plana vitrectomy and silicone oil injection. After removal of this 
silicon oil, his retina has remained attached. He is aphakic, with poor vision in the 
functioning left eye. He has also developed aphakic glaucoma. He is noted to have 
microcornea (8mm horizontal diameter) (Figure 3.20A). Although he is reported to be 
having been a high myope as a child, this may have been primarily lenticular, as his 
axial length at age 22 years was 21. 3mm.  
Systemic examination reveals some Marfanoid features, including arachnodactyly 
(Figure 3.20B), large arm span: height (179cm tall with arm span 183.5cm) and an 
arched palate. Beighton hypermobility score[136] was 4/9. However, echocardiography 
features were completely normal, contributing towards an exclusion of clinical MFS 
(personal communication Dr A Child, St George’s Hospital, London). MRI imaging of 
the brain revealed no occipital defect (Figure 3.21). 
DII:2 developed a total RD in the left eye at eight years of age. The surgery to repair 
this failed, and he was left with a phthisical eye. Later that year, he was noted to have 
EL and a total RD in the contralateral (right) eye. This was repaired at Moorfields Eye 
Hospital with a lensectomy, vitrectomy and oil injection. He has also developed aphakic 
and silicone oil associated glaucoma in this eye. He has microcornea (Figure 3.20C) and 
axial length in this functioning right eye of 22.51mm. Systemically, he is noted to have 
Marfanoid features, including arachnodactyly (Figure 3.20D). Cardiovascular 
examination was unremarkable. 
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Figure 3.19: Pedigree of family 5  
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Figure 3.20: Clinical images of Family 5  
A&C: Anterior segment images (A: DII:1, B:DII:2) illustrating microcornea. 
B&C: Arachnodactyly (B: DII:1, D: DII:2). 
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Figure 3.21: Axial MRI of  DII.1 skull, demonstrating no occipital skull defect. 
(Thanks to Dr Indran Davagnanam (Dept of radiology, Moorfields Eye Hospital) 
for images and report). 
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DII:3 was diagnosed with a right RD at the age of four years. At the time bilateral EL 
was also noted and extensive nerve layer myelination. The right eye was repaired with 
pars plana vitrectomy and lensectomy. Later that year the same operation was 
undertaken on his left eye for RD with EL. He had silicone oil injected into both eyes, 
but required further surgery to the left eye at the age of 11 years. He has also developed 
aphakic silicone oil associated glaucoma.  
DIII:4 was diagnosed with significant EL bilaterally at the age of three years. He 
underwent bilateral vitreolensectomies. He was stable until the age of five years, when a 
total RD was noted on the right. In this boy it will be difficult to know if this was a 
primary RD or secondary to the vitrectomy for the lens removal. In view of the family 
history it is likely that he may have developed an RD independently. He required 
silicone oil injection in this eye. A further operation was required at the age of seven 
years to remove emulsified silicone oil from this eye. At most recent visit, his vision 
was LogMAR 1.0 (right) and 0.74 (left).  
3.4.3.2. GENETICS 
DNA was only available from the proband (DII:1), thus limiting the analysis. The other 
affected members are children, and parental consent for investigations was not possible. 
In view of the similar features to family 2 (particularly AII:2) ADAMTS18 was 
sequenced in the proband. This revealed no pathogenic mutations.  
Because of the EL and Marfanoid features, FBN1 was sequenced. One heterozygous 
missense variant was discovered (c.8300A>G (p.N2767S)) (Figure 3.22). 
In parallel to this experiment, DNA from DII:1 was hybridised to the Illumina 
CytoSNP-12 v2.1 and homozygous regions identified. Homozygosity mapping for DII:1 
revealed large regions of autozygosity (Table 13). 
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Chromosome Nucleotide location Size (Mb) 
Total homozygosity 
(55.3Mb) 
5 5: 38463799-58831872 
20.3 
5 5:116069685-127108252 
11.0 
7 7: 4809660-13889107 
9.1 
14 14: 71194774-76774194 
5.6 
19 19: 1192769-3311830 
2.1 
7 
7:155768061- 
157637962 
1.9 
22	   22: 17903914-19135603 
1.2 
9 9:139711726-141044489 
1.3 
18 18: 2122221-3254795 
1.1 
 
Table 13: Regions of homozygosity from D:II:1. 
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Secondary to the homozygosity mapping, two genes were identified of interest within 
these regions; PAPLN and LTBP2. The former is a 25 exon gene covering 37.1kb and 
the latter a 36 exon gene covering 8.6kb, both on 14q:24.  
Sequencing Papilin revealed no pathogenic variants. LTBP2 sequencing revealed one 
homozygous missense single nucleotide variant on exon 3: (c.785C>T (p.Pro262Leu) 
(Figure 3.23).  
Segregation analysis has not been possible in this family.  
These four families share many ocular phenotypes, and yet only two of the families 
have yet had a confirmed genetic cause identified.  The ocular phenotypes of the 
families still under investigation is demonstrated in table 14. 
3.4.4. FAMILY 6 
See Figure 3.24 for pedigree. 
3.4.4.1. CLINICAL 
A 14-year old male proband (EVI:1) of Sri Lankan origin, born of a consanguineous 
marriage, was noted to have elevated intra ocular pressures of 23mmHg and 26mmHg 
in the right and left eyes respectively. He was found to have bilateral lens subluxation, 
with phacodonesis. Best-corrected visual acuity was 6/9. The child was born through a 
breech delivery at full term and had normal developmental milestones, with no hearing 
or developmental problems. He had no abnormal cardiac signs. His hands and feet were 
normal, although his toes were slightly short and his joints were slightly hypermobile. 
His father had been seen previously (see below) 
This child was tall (75th percentile for his age). He had high myopia (-10.0 DS: right 
eye, -12.0 DS left eye), but short axial lengths (21.7mm right eye and 22.0mm left eye), 
suggesting lenticular myopia. His anterior chamber depths were 1.7mm in the right and 
1.3mm in the left. B-scan ultrasonography showed microspherophakia (small spherical 
crystalline lens). The lens thickness (normal: <4mm) was 4.35mm in the right eye and 
4.35mm in the left eye. Gonioscopic examination showed closed angles. After 4 years 
of follow-up, his intraocular pressure was maintained with medication.  
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PHENOTYPE Family 4 Family 3 
Ectopia Lentis ü ü 
Microcornea ü ü 
Childhood cataract ü ü 
Featureless Iris ? ü 
RD/ Vitreoretinopathy ü ü 
Cone dystrophy ? ü 
Myopia 0 ü 
Hypermetropia ü 0 
 
  
Table 14: Ocular phenotypes of affected members in families with unknown genetic 
aetiology. 
ü: Present.; 0: Absent; ?Unknown 
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Figure 3.24: Pedigree of Family 6 
The teenage proband (EVI:1) is indicated with a filled-in square (male). His 
mother (EV:1) is second cousin once removed to his father (EIV:1), and his 
paternal grandparents (EIII:1 and EIII:2) were first cousins. Individual EV:6, who 
is second cousin once removed to EIV:1, also has bilateral ectopia lentis 
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He had been reviewed by a clinical geneticist who ruled out MFS. WMS had been 
diagnosed clinically in his father. It is probable that the proband has WML, with ocular 
features but no brachydactyly or joint stiffness. 
The proband’s father (EV:1) is a patient under the care of Moorfields Eye Hospital. He 
had evidence of EL, both lenses were subluxed infero-temporally at a young age. He 
had no evidence of angle-closure. EV:1 had classical WMS habitus: He has short toes 
and fingers (brachydactyly) (Figure 3.25) with broad feet. 
His height was 172cm (25th centile for his age), and he had no cardiac problems. This 
gentleman was also born of a consanguineous marriage.  The diagnosis of WMS was 
made in Sri Lanka. His second cousin once removed (EV:6) also diagnosed with WMS, 
had bilateral lens subluxation and advanced glaucoma. This gentleman’s eye 
examination at last follow up was LogMAR 0.6(Right eye) and 0.2(Left eye). He had 
been diagnosed and treated at Moorfields Eye Hospital with open angle glaucoma. He 
was myopic with a refractive error  of -12.0DS in the right eye (axial length of 
23.76mm, lens thickness 5.4mm ) and -13.0DS in the left eye (axial length of 23.61mm, 
lens thickness 5.62mm).  
No affected individual in this family suffered from RD. It is interesting that axial 
lengths were not as long as the myopia would have suggested.  
3.4.4.2. GENETICS 
DNA samples from EIV:1 and EVI:1 underwent Sanger sequencing of 65 exons of 
FBN1 revealing no pathogenic variants. Subsequently, ADAMTSL4 was sequenced in 
both samples, which equally did not reveal any mutations. Collaborating with Professor 
Valérie Cormier-Daire (Department of Genetics, Paris Descartes University Hôpital, 
France), ADAMTS10 was screened, as the father had been diagnosed with WMS. No 
pathogenic mutation was discovered in this gene. Three samples (EV:3, EV:6 and 
EIV:1) were hybridised to the Illumina Cyto12 SNP chip to assess for regions of 
homozygosity. 
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Figure 3.25: Hand of FV:1; demonstrating bradydactyly  
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At this juncture, more saliva samples (DNA-Oragene, Genotech, Ontatrio, Canada) 
were collected from EIV:1 and EIV:2 and EV:6 in the post from Sri Lanka, as the 
laboratory stock of DNA had been depleted. DNA was not extractable from the saliva 
sample from EIV:2.  
To our attention came the gene ADAMTS17. Three homozygous mutations in this gene 
were published in WML [226].  Subsequently, we sequenced two samples (EIV:1, 
EIV:1); the proband and his father, which were received by post.  
Exons 1-14, and 16-22 were sequenced and no pathogenic mutations were found. 
However, we were consistently unable to sequence exon 15 in EVI:1; though the 
primers and conditions had been optimised, and successful in control DNA.  This was 
also challenging in EIV:1, and eventually, it was completed. No pathogenic mutations 
in exon 15 were found, and in fact one heterozygous variant (c.A2090G (p.K697R)) 
was found (Figure 3.26). 
This variant was not present on dbSNP[247], Exome Variant server [246] or 1000 
genomes project[248]. There are however at least seven SNPs recorded in the 70bases 
around this one, and a SNP 2 bases downstream (rs200441121) and 2 SNPs upstream 
(TMP_ESP_15_100636611) and rs141443664, three and five bases away respectively. 
This suggests that this may be a polymorphic region. The variant is thought to benign 
according to Polyphen[245]. Nevertheless, it was thought this condition was inherited 
recessively. This variant was thus dismissed. 
At around this time, the results from the homozygosity mapping were available. Using 
Genome Studio (Illumina: 
http://www.illumina.com/software/genomestudio_software.ilmn) the genotypes were 
called and exported to Microsoft Excel. Using an Excel macro formula, homozygous 
calls for SNPs were matched between the three affected individuals to assess which 
regions of homozygosity were shared. By far the largest region was on 15q25 (Figure 
3.27). 
In the region on 15q25, there are over 80 genes. One particular gene stood out: 
ADAMTS17. This posed significant problems, as it was believed that one of the affected 
patients had a heterozygous variant in ADAMTS17 which should not have been possible  
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Figure 3.27: A: Regions of homozygosity shared between FV:3, FV:6 and FIV:1. 
B: Largest region on chromosome 15 magnified: Height of bar indicates the 
amount of homozygosity. 
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in a region of homozygosity. Exon 15 from ADAMTS17 was therefore re-sequenced to 
check the variant again. This was again challenging, but eventually managed. We 
believed that the variant was now homozygous (Figure 3.28), suggesting a sequencing 
error previously. 
At this point it was believed that the previous heterozygous change was inaccurate. 
There was therefore evidence of shared homozygosity including ADAMTS17. All other 
genes in the shared regions were considered, and no candidates were thought to be 
convincing based on a priori knowledge. 
ADAMTS17 was thus the most likely gene causing the phenotype in this family, based 
on 3 families published with a very similar phenotype to EVI:1 (WMS-Like). Having 
screened all the exons in the genomic DNA, we considered whether a deep intronic 
change in ADAMTS17 may be responsible. 
It is thought that deep intronic changes, if affecting splicing, more commonly activate 
cryptic splice sites and in doing so, create a “pseudo exon”[352]. Repetitive sequences, 
such as Alu sequences are found throughout the genome, and may act as potential 
cryptic 3’ splice sites[353]. Numerous examples of this have demonstrated the presence 
of pseudo-exons causing disease phenotype[354, 355]. It is on this theory which led to 
attempts to amplify ADAMTS17 mRNA from leucocytes; to establish if a post 
transcriptional extra exon had been created, or a skipping of an exon; which would not 
have been detectable from genomic DNA. rtPCR was then performed to produce 
cDNA, which was then used for PCR.  
Morales and colleagues [226] had amplified exons 11-13 from leucocytes. Using their 
primers (GACACATCCTGCAAGACCAA and AGGCTTATCGTCAACCAC), 
amplification was possible from control cDNA (Figure 3.29). 
Primers were then designed to cover the whole of the ADAMTS17 gene as described in 
the methods. However, experiments to amplify this gene failed repeatedly. Long range 
PCR with primer 1F (GCTGGAGGGCTTCACTC) and 22R 
(GACTGCGTGTCACGAGTCG) was also attempted.  This also was not successful. 
Concurrently, we had taken a fresh DNA sample from EIV:1 from blood extraction, as 
he was in the UK. 
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Figure 3.29: Amplification of cDNA of Exon 11-13 (ADAMTS17) in control DNA 
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The genetic cause of this phenotype had to be re-considered. This fresh sample along 
with EV:6 underwent exome capture next generation sequencing to determine if an 
alternative gene in the regions of shared homozygosity harboured a pathogenic 
mutation. The data was returned in .bam files and Excel spread sheet. When comparing 
all homozygous variants which were present in in both samples, non-synonymous and 
with a frequency <1% in the 1000 genomes, revealed no genes in the regions of 
homozygosity, and no convincing candidate genes. 
When the exome data for ADAMTS17 was analysed it became apparent that Exon 15 
was not covered in either samples (Figure 3.30), but was covered by the same exome 
experiment on other samples. 
This suggested that Exon 15 was not amplified in either of the affected individuals. 
Using fresh DNA samples from EIV:1, EV:6 and a positive control, exons 14, 15 and 
16 were reamplified with PCR. Exons 14 and 16 were amplified, whilst 15 was not in 
EIV:1 and EV:6 (Figure 3.31). 
This clarified that Exon 15 was not amplified from either of the affected patients. The 
previous sequencing of exon 15, must have been from a mislabelled sample., as this 
saliva sample had come with EIV:2 in the post from Sri Lanka. We were unable to 
extract DNA from the sample labelled EIV:2 to confirm this mislabelling.  
3.5. DISCUSSIONS 
3.5.1. ADAMTS18 
Family 2 was the first family we discovered with an inherited previously undescribed 
phenotype including EL and RD. The affected pair were from a consanguineous family, 
and it was therefore assumed that the causative mutation would be homozygous. In such 
families, the chance of either parent carrying a mutation is not entirely independent. In 
these families, runs of homozygosity secondary to autozygosity are therefore more 
common[340].  In addition, the rarer the phenotype, the more likely that the causative 
mutation is autozygous[340]. Therefore, autozygosity mapping was deemed a prudent 
approach.    
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Figure 3.30: View from Integrative Genomic Viewer (IGV). Results from Next 
generation Exome Sequencing.  ADAMTS17: A: Exon 14. (i) EIV:1 (ii) EV:6.  
B: Exon 16 and 17. (i) EIV:1 (ii) EV:6. C. Exon 15. (i) EIV:1, (ii) EV6  
(iii) Control   
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Figure 3.31: PCR 2% Agarose Gel of ADAMTS17, exon 14, 15 and 16.  
+: Positive control. N: Negative control. Expected amplicon size: Exon 14: 
315bp, Exon 16: 361bp, Exon 15: 331bp. 
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In addition, high throughput sequencing of 106 genes which are known to cause retinal 
dystrophies excluded known mutations. Autozygosity analysis and Sanger sequencing 
demonstrated a causative missense mutation in ADAMTS18. Because of the strikingly 
similar phenotype between Family 2 and 3, ADAMTS18 was investigated in the latter 
family; leading to a discovery of a further pathogenic missense mutation.  Family 1 
were analysed in another unit for novel causes of coloboma by trio-based exome 
sequencing. The proband was found to have a homozygous nonsense mutation in 
ADAMTS18.  
ADAMTS18 (OMIM 607512) is a 23 exon gene on chromosome 16q23.1 covering 
153kb of genomic sequence. It encodes ADAMTS18, one of the 19 ADAM 
metallopeptidase with Thrombospondin type 1 motif proteins.  As previously described, 
they are a family of enzymes with a wide range of biological processes, including cell 
migration, coagulation, angiogenesis and ECM regulation[21].  
ADAMTS18 was first identified and described in 2002, which suggested it to be widely 
distributed within the body[17]. One of the first suggested roles stemmed from the 
findings that the region 16q was frequently deleted in cancer cells 
(http://amba.charite.de/~ksch/cghsuper/index.htm), and ADAMTS18 was then 
demonstrated to be a tumour suppression gene[356, 357]. It is thought that somatic 
methylation of promotor regions of this gene (as a consequence of early tumour genesis) 
leads to silencing, and thus promoting carcinoma in a wide range of tissue. Conversely, 
Wei and colleagues[358] showed that somatic mutations within the gene promoted 
migration, growth and metastasis of melanoma cells. They suggest that mutations are 
mostly found near the C-terminus, altering the substrate specificity of the protease. A 
conclusion to these seemingly contradicting functions has not been reached. However, it 
seems probable that the roles ADAMTS18 may have on modulating the ECM are likely 
to play a part in the impact on tumour biology.    
For ADAMTS proteins, cleavage of the C-terminus is an important post translation step. 
However, for ADAMTS18, thrombin, in vascular endothelial cells, can induce this 
cleavage. It is interesting that this cleaved C-terminus of ADAMTS18 may fragment 
platelets and thus prevent thrombus formation[359, 360] and thus potentially reduce 
carotid artery thrombosis[361]. This demonstrates that the C-terminus of ADAMTS18 
has its own role, independent of the N-terminus protease domain; a unique feature 
amongst ADAMTS proteins.   
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Genome wide association studies have suggested a role for ADAMTS18 in advanced 
age. These include contributing to bone mineral density[362, 363], and tentatively for 
influencing white matter integrity [364]. However, an exact mechanism has yet to be 
suggested for either of these.  
A role in ophthalmic disease was first suggested by Aldahmesh and colleagues in 
2011[1]. They describe an eight year old girl from Saudi Arabia of consanguineous 
parents. This child was reported as having classical Knobloch syndrome. In addition to 
the classical features, this child also was described as having progressive retinal 
degeneration; though ophthalmic phenotype data in this paper is limited. The condition 
in this child was termed Knobloch Syndrome 2 as this was the first to describe a novel 
genetic cause for KNO. Aldahmesh and colleagues demonstrated the orthologue of 
ADAMTS18 to be present in developing lens and retina of the mouse. The role of this 
protein in the development of Knobloch syndrome is unclear.  
3.5.2. KNOBLOCH SYNDROME 
Knobloch Syndrome (OMIM 267750, 608454) (KNO) is a very rare autosomal 
recessively inherited condition. Its prevalence is unknown and has been reported in 63 
individuals representing 23 families to date. It was first described in 1971 in a family in 
whom all those affected had high myopia, vitreoretinal changes, occipital 
encephalocoeles  and RD[168]. The former three have been maintained as cardinal 
features of the syndrome.  Since the initial description, other features have been 
sporadically described. Reported extraocular features include abnormal lymphatic 
vessels in the lung[365], unusual palmar creases[366], neuronal migration defect [367], 
cerebral and cerebellar atrophy[368] duplex kidneys[369], acute lymphoblastic 
leukaemia[370] and epilepsy [371]. Described ocular features include early onset 
cataract, EL, retinal dystrophy[1], fibrillar vitreous condensations[224, 370] retinal 
pigmentary changes with nycloptia, glaucoma, nystagmus and phthisis[372], corneal 
dystrophy[368] and chorioretinal atrophy[224, 370]. It has been suggested that the 
ophthalmic phenotype may itself predict the presence of the syndrome[224]. 
KNO is therefore characterised by high myopia, vitreoretinopathy and occipital defects. 
There are similarities with other vitreoretinopathies. Stickler 1 (OMIM108300), Stickler 
2 (OMIM 604841) and Marshall Syndrome (OMIM 154780) all manifest with axial 
myopia and cataract with a high propensity of RD. Autosomal recessively inherited 
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syndromes such as Walker-Warburg Syndrome[373] and vitreoretinopathies such as 
Stickler IV (OMIM 614134), Stickler V (OMIM 614284), Goldman Favre syndrome 
(allelic with enhanced S-cone syndrome: OMIM 268100) can be particularly 
challenging to differentiate from KNO. The most similar families with autosomal 
recessive vitreoretinopathies are from Switzerland[374] (later mapped to 22q13[375]), 
Italy[376] and of Hispanic origin[377]. The latter two of these reports may well have 
been undiagnosed KNO. 
Homozygous mutations in COL18A1 were first described as causative of KNO in 
2000[378] and further families have since been reported. [367, 370, 379-381]. 
COL18A1 is found on 21q22.3 and spans 108.5kb. The encoded protein COL18A1 is a 
non-fibrillar collagen found in three isoforms, each differing in the N-terminus (Figure 
3.32). Their production depends on two separate promoters. Exon 1 and 2 encode the 
shortest variant, whilst Exon 3 encodes the longer two. The middle length variant is a 
consequence of alternative splicing of exon 3, leading to the removal of the frizzled 
domain (Figure 3.32)[24]. The long isoforms are found to localise in liver, whilst the 
shorter in basement membranes and muscles[382]. Figure 3.33 demonstrates that the 
protein contains 11 non-collagenous domains and 10 triple-helical collagen domains 
and similar in structure to COL15. It is of interest that these two collagens contain 
Thrombospondin regions; similar to members of the TSR superfamily; including 
ADAMTS18.  
As with its distribution, the function of this protein is expansive[24]. Particularly of 
interest is the role of the C-terminus fragment of this protein; endostatin. Endostatin is a 
183 amino acid product of enzymatic cleavage from the N-terminus of COL18A1 by 
cathepsin, elastase and matrix metalloproteinases (MMP) -3, -7, -9, -13, -14 and -
20[383]. It acts via Integrinα5β1 and VEGF membrane receptors to maintain the 
integrity of basement membranes[384], inhibit angiogenesis[385] and inhibit the Wnt/β-
catenin signalling[386]. Of further interest is the role it may play in inhibiting tumour 
growth; to such an extent that is has been used in clinical trials, and indeed been 
approved as a treatment for non-small cell lung cancer[387]. Whether this effect is via a 
similar mechanism to that of the role of ADAMTS18 in tumour biology is unknown, 
and may be worth investigating in view of the proposed similar ocular phenotype of 
mutations in these genes.  
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Figure 3.32: Three isoforms of COL18A1. Adapted from[24] 
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Figure 3.33: ADAMTS18. A: Schematic image of ADAMTS18 demonstrating 
domains. B: Homology modelling of molecular surface of the catalytic domains. 
Front view showing the active site  
Adapted from [16] and [17].  
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A further similarity lies in the fact that, although functional cleavage products are 
reported for many proteins, ADAMTS18 is the only one of its family to manifest this 
phenomenon.  
Within the eye, it is expressed widely, including in various basement membranes, the 
internal wall of Schlemm's canal and trabecular meshwork, epithelial layers of the iris 
and the muscle cells of the ciliary body and iris [388]. With this widespread 
distribution, it is unsurprising that mutations may result in a diverse phenotype 
described above in KNO.  
Although in patients who have had endostatin measured, there are reports of reduced 
levels in KNO[389, 390], normal levels were described in a patient with a splice site 
mutation (IVS1-2A>T)[371]. This suggests that the whole protein may be required for 
ocular development, rather than a specific role of the cleaved C-terminus product.  
KNO is characterised by an occipital defect. It is unclear whether this is a consequence 
of disrupted bone development or is a manifestation of abnormal neuronal cell 
migration, suggested by knockout animals[391]. The lack of a skull defect in the 
knockout mouse[47], do suggest that the former may be more plausible. Although Khan 
and colleagues[224] have suggested that occipital defects are not necessary for the 
diagnosis of KNO; they base this on only four reports, none of whom had had skull 
imaging. It is appropriate to still consider that occipital defects as a cardinal feature of 
the condition. 
The role of COL18A1 causing particular ocular features is worth exploring. Although it 
is present in the lens, it is unclear as to why peri-nuclear cataracts seem to predominate 
(when described)[224]. Why EL is described in KNO is also not clear. This may be as a 
result of basement membrane disruption of the capsule; particularly at the insertion of 
the zonules. This speculation has not been confirmed.  
High myopia is cardinal to the diagnosis of KNO and again the cause of this is 
undetermined. Other collagen genes[392] and other vitreoretinopathies have been 
associated with myopia. However, the role of COL18A1 in myopia is not clearly 
understood. It does not seem to play a role in non-syndromic myopia[393, 394]. It 
seems unlikely to be a consequence of lenticular changes (leading to form deprivation) 
as not all cases of KNO manifest such lenticular changes. Fukai and colleagues suggest 
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that disruption of the vitreoretinal interface is a precursor of myopia in col18-/- 
mice[47]. It has been established that COL18A1 is found in the human ILM[45]. They 
suggest that the ILM, being buffered by vitreous is uniquely vulnerable to loss of 
COL18A1 compared to other basement membranes. The vitreous, consisting mostly of 
collagens II, IX and XI is significantly different to the ECM surrounding other 
basement membranes. The vitreous adheres to the ILM and breakdown of this adhesion 
results in vitreous detachment. Disruption of a major component of the ILM 
(COL18A1) may result in abnormal vitreoretinal adhesions. This theory is certainly 
plausible, and would explain the high prevalence of RD in KNO, but not the high 
myopia. 
In 2004, Menzel and colleagues[379] excluded linkage to COL18A1 in 2 brothers with 
KNO, from non-consanguineous parents. They suggested an unmapped locus causing 
KNO and termed this Knobloch Syndrome 2 (KNO2). Seven years later, Aldahmesh 
and colleagues suggested ADAMTS18 mutations as the cause of KNO2. Interestingly 
the term Knobloch Syndrome 3 was coined for a family in whom linkage suggested the 
region 17q11.2[372]. It was later determined by high density SNP mapping, as opposed 
to using microsatellites as in the original study, that this family actually had a mutation 
in COL18A1[395], discounting the suggestion of KNO3. There therefore only exists 
KNO1 (caused by mutations in COL18A1) and KNO2 (ADAMTS18). The latter has 
however only been described in one patient. Due to a lack of cardinal features; 
particularly an occipital defect, our patients have not been diagnosed with KNO.  
After years of speculation, it appears however that Family 4 are likely to have the 
diagnosis of Knobloch syndrome. Their high myopia, EL, vitreoretinopathy and 
occipital bone defect are consistent with the cardinal features of this condition. In 
addition, both affected patients have microcornea and an early onset retinal dystrophy. 
These features are shared with our two families who had mutations in ADAMTS18.  
However, on homozygosity mapping, it appears that COL18A1 is the likely candidate, 
and DNA from this proband has been submitted for screening of the gene at the UCL 
Institute of Neurology.  
The diagnosis being made in this family has helped the understanding of the proband’s 
(CII:1)) neuro-developmental delay. Epilepsy in KNO was first described in a four year 
old in 2002[371]. Keren and colleagues[367] reported pachygyria  of the frontal lobes 
and agenesis of the septum pellucidum in a patient with KNO. They were the first to 
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describe neurodevelopmental delay in KNO, which they suggest may be associated with 
loss of the medium and long isoforms of COL18A1. Pais an-Ruiz and colleagues[368] 
have also described Knobloch in an Indian family with epilepsy, ataxia and neurological 
decline. Both groups suggest that mutations affecting the C-terminus of the protein are 
more likely to result in neurological manifestations. It is at this end of the protein where 
the TSR domains are found. Other proteins with this domain have been implicated in 
neuronal growth[26], and this important domain may have a role to play in this.  It 
would be of interest to know if a mutation in COL18A1 is found in this family, if it 
affects this end of the protein.  
The exact role that ADAMTS18 may have in this condition or in our expanded 
phenotypic description is unknown. A second patient with a homozygous mutation in 
ADAMTS18 was published in January 2013[22]. This patient was diagnosed with an 
early onset retina dystrophy (EORD).  In particular this patient had no features of KNO, 
which led the authors to suggest that this gene produces multiple effects on the eye. It is 
of interest that our three families with mutations in ADAMTS18 had phenotypic features 
which overlapped with both KNO and EORD (Table 15). This confirms that the 
phenotypes described are likely to be relevant but also poses questions as to the real 
effect of ADAMTS18 on ocular tissue and development. Peluso and colleagues[22] 
attempted to explain this with ADAMTS18 knock-down Medaka fish.  They suggested 
that fish depleted of ADAMTS18 had disrupted central nervous system development. In 
particular the telencephalon, the telencephalic ventricles and the optic tectum in the 
mesencephalon were all affected. This phenotype was rescued by injection of wild type 
human ADAMTS18 RNA, but not with ADAMTS18 RNA containing their missense 
mutation. Interestingly, they demonstrated no ocular phenotype in this knock down 
model. However, using the light induced photoreceptor damage model, reduction of the 
retinal outer segment, and a reduction of rhodopsin-positive retinal areas in the knock 
down fish compared to the wild type after prolonged light exposure was demonstrated. 
Although they demonstrated the expression of ADAMTS18 from human retinal cDNA 
libraries, they did not demonstrate the protein to be present in the outer segments of the 
mouse. The authors suggest that the presence in the RPE would explain a role in 
maintaining the photoreceptor function.  
This paper is the only one demonstrating any functional effect of this protein and gene. 
Our patients all had had photoreceptor dysfunction, which corroborates their findings. 
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However, the expansive phenotypes in our families suggest that there are further 
functions, which are as yet unknown. 
Three patients from two families (AII:1,AII:2 and BII:1) had lenticular changes (early 
cataracts) whilst AII:2 also suffered from EL. The patient described by Aldahmesh and 
colleagues[1] also suffered EL. AII:2 and BII:1 also presumably suffered a 
vitreoretinopathy resulting in early onset RD. These two features are very similar to the 
phenotype of KNO. This may suggest that ADAMTS18 and COL18A1 may play 
collaborative roles in ophthalmic development.  
However, there were other similarities in our patients. All the patients had anterior 
segment anomalies; particularly microcornea.  
Microcornea is a manifestation of ocular dysgenesis with a prevalence of 0.001%[396]. 
It can occur alone, but is usually accompanied by other ocular dysgenesis such as 
anterior microophthalmos, coloboma and cataract[397] [398, 399]. Recently, 
heterozygous mutations in PAX6 [400] and BMP4 [401] have also been described as 
causative in microcornea. Of further interest, Couprey described two families with EP, 
microcornea (and other ocular features similar to Axenfeld Rieger anomaly) with 
diffuse periventricular leukoencephalopathy[402]. These patients all had mutations in 
COL4A1. 
The exact mechanism of microcornea is unclear, but certainly mutations in genes 
involved in ocular development can result in microcornea. It is worth comparing the 
combination of phenotypes shared by AII:2 with the autosomal dominantly inherited 
condition microcornea, rod-cone dystrophy, cataract, and posterior Staphyloma (MRCS) 
(OMIM 193220)[403, 404].  Although some genetic heterogeneity is suggested, 
mutations in VMD2 have been attributed to this and autosomal dominant 
vitreoretinochoroidopathy (ADVIRC)[161]. The region of this gene on 11q12.3 was not 
in any of the regions of homozygosity; reducing the likelihood of a recessive effect of 
this gene.  
The phenotype of our patients and the two published patients with ADAMTS18 
mutations is in table 15. 
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Table 15: Phenotype of all patients published with homozygous mutations in 
ADAMT18. 
 
KNO2:  Knobloch Syndrome 2 
ü:    Present in this affected member 
RD:    Rhegmatogenous Retinal Detachment 
RP phenotype:  Retinitis Pigmentosa phenotype includes attenuated retinal 
vessels, posterior subcapsular cataract, cystoid macular 
oedema 
 
 
 
 
  
 Aldahamesh 
[1] 
(KNO2) 
Family  
1 
Family  
2 
Family 
3 
Peluso 
[22] 
(Retinal 
dystrophy) 
IV:1 AII:1 AII:2 BII:1 
Ectopia Lentis ü   ü   
Fibrillar 
vitreous/ RD 
ü   ü ü  
Occipital Defect ü      
Myopia ü  ü  ü  
Hypermetropia    ü  ü 
Cryptless 
smooth Iris 
ü    ü  
Childhood 
Cataract 
ü  ü ü ü  
Retinal 
Dystrophy 
ü ü ü  ü ü 
Exotropia   ü   ü 
Nystagmus   ü   ü 
RP phenotype      ü 
Ectopia pupillae  ü     
Micro-cornea  ü ü ü ü  
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Three different mutations have been described in our patients with ADAMTS18 
mutations. One (c.2159G>C (p.C720S)) is in exon 14, which encodes a peptidase 
domain. Traditionally it is suggested that the structural role of the ADAMTS proteins, 
which has been assumed to influence the ocular phenotype caused by mutations in the 
ADAMTS genes, depends on their ancillary domains[16]. Our data may suggest a role 
for the protease domains in ocular development. The second mutation (c.1952G>A 
[p.R651Q]) does not encode a particular domain. The third mutation c.1067T>A 
[p.L356*] is a nonsense mutation, and is more than 55 nucleotides from the Exon-Exon 
boundary; it is likely to result in a mRNA transcript which undergoes NMD[268]. The 
phenotypes of those with the first two mutations (which are missense) are more similar 
to the patient with the nonsense mutation; which may suggest a genotype-phenotype 
relationship. This cannot be inferred reliably, as this number of patients is too small. As 
more patients are discovered, this speculation will be further clarified.  
Of interest in family 2 (AII:1 and AII:2)  was the neurological imaging findings which 
were consistent and shared. Dural ectasia is a feature of MFS. It was re-classified as a 
minor criterium in 2010; offering a systemic score of 2 if present[186]. It occurs in up to 
70% of patients with MFS, most commonly affects the lumbo-sacral region and is 
usually asymptomatic[405]. Dural ectasia is a result of the defective fibrillin-1 in the 
connective tissue of the dura mater. Intracranial ectasia are rarely reported in MFS 
alone. AII:1 and AII:2 did not have symptoms from these. These findings may suggest a 
mild connective tissue disorder (MFS was excluded in this family by cardiological 
review) as a result of ADAMTS18 mutations. Alternatively, it may suggest functional 
linkage of this protein with fibrillin-1, as has been suggested with other members of the 
ADAMTS family[279, 406]. However, this finding was not consistently found in the 
affected proband in family 3 and imaging from IV:1 was not available. 
The manifestation of EL, early cataract and EP is particularly interesting in the context 
of the ADAMTS proteins. In this thesis, it has already been shown that recessive 
mutations in ADAMTSL4 and ADAMTS17 can result in these anterior segment 
phenotypes. ELetP has only been demonstrated to be inherited recessively, and to date 
only known to be caused by mutations in ADAMTSL4. IV:1 in this study was found to 
have  EP.  Although the aetiology and molecular genetics of ocular coloboma are 
extensively investigated [407], the aetiology of EP is less well understood[408]. 
Differentiating between them can be challenging, particularly with very displaced pupils 
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in EP; and as both EP and iris coloboma may be bilateral [407]. EP is likely to be a 
result of a dysfunction in ocular development.  
3.5.3. FAMILY 5 
No definitive diagnosis was made for this family, and neither was a causative mutation 
definitely found. We did discover some variants in the proband which are worth 
elaborating. 
The mode of inheritance in this family may be X-linked recessive (with two affected 
boys), or autosomal recessive. In view of the small tribe both parents originate from, 
and probable subsequent endogamy in the pedigree and with only one generation being 
affected, autosomal recessive inheritance was more probable.  
3.5.3.1. FBN1 variant 
The most common genetic cause of EL is thought to be in FBN1. Although this is 
usually inherited in a dominant fashion, homozygous recessive mutations in this gene 
have been described causing recessive MFS[409]. With the marfanoid habitus, FBN1 
was therefore screened. This variant found  (c.8300A>G (p.N2767S ) was heterozygous. 
One must consider, on discovering this mutation whether this was in fact a dominant 
condition caused by a de-novo FBN11 mutation (because of the normal parents) in the 
affected proband. However, to have all four affected children manifest the same de-
novo  pathogenic change is unlikely[342]. 
Next we must consider the functional effects this variant might have. The variant we 
discovered in the proband was heterozygous c.8300A>G (p.N2767S). This variant lies 
within an N-glycosylation domain.  
N-glycosylation is a post translational modification involving addition of complex 
carbohydrates by covalent bonding to the nitrogen atom of an amide group on an amino 
acid (most commonly asparagine)[410]. These sites occur where the sequence Asn-X-
Ser/Thr occurs; with X representing any amino acid other than proline; as this is thought 
to interfere with the ability of the peptide to conform to the appropriate structure[411]  . 
It is believed that these sugar side chains are important for the correct folding of 
proteins, and may be important in protein-protein interactions[412]. 
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This modification is more common in transmembrane or extracellular proteins. The 
process usually commences in the endoplasmic reticulum, subsequently occurring in the 
Golgi apparatus[342]. The role of such modification is dependent on the protein in 
question. In humans, defects affecting glycosylation most commonly result in 
neurological and developmental disorders[410].  
Within FBN1, there is precious little known regarding mutations affecting these 
domains. Lonnqvist and colleagues demonstrated a missense mutation in FBN1 
resulting in an extra N-glycosylation site[413]. They suggest that excessive n-
glycosylation leads to impaired secretion of the protein. The reported case had neonatal 
MFS.  Conversely, in vitro work by Whiteman and Handford [414] suggested that 
certain missense mutations might result in a lack of complex glycosylation which wild 
type fibrillin-1 undergoes, thus leading to an accumulation of this protein in the 
endoplasmic reticulum. The missense mutations both these groups investigated did not 
directly affect N-glycosylation domains; in fact affected cb-EGF domains. It is well 
established that mutations affecting these domains are very common in 
fibrillinopathies[187]. It is therefore unclear whether it is a disruption of the cb-EGF 
domain itself, or the resulting extra N-glycosylation domain in these descriptions which 
leads to disrupted fibrillin-1 molecules. The effect of N-glycosylation on disease is 
therefore controversial. Furthermore, there have been no reports in the literature, or the 
database of over 300 FBN1 mutations at the Sonalee laboratory (St George’s University 
of London) (personal communication), of mutations in these domains causing disease. 
In our patient, the sequence of amino acids creating the affected domain were Asn-Ile-
Ser. In vitro work suggests that substitution of threonine with serine results in reduced 
glycosyl transfer[415], which may suggest reduced such activity at domains with serine 
in the sequence in vivo. Furthermore, there are suggestions that not all N-glycosylation 
sites on fibrillin-1 are normally utilised[416]. One can also consider online prediction 
algorithms (SIFT[244]PolyPhen[245]) which suggest this mutation to be non-
pathogenic. 
Considering all this together, there is compelling evidence that the variant we found in 
FBN1 is not pathogenic. Of course further segregation analysis would help to confirm 
this. 
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3.5.3.2. PAPILIN 
This gene is 25 exons and spans 37.1kb of genomic DNA. The encoded protein is 
papilin. It has been reported as an ECM protein found in basement membranes [417, 
418]. It is thought to have high homology with the ADAMTS proteases and interact 
with them in the ECM. Interestingly, it is believed to play a role in the molecular 
pathways involving fibrillin-1 and ADAMTS10. This seemed therefore a good 
candidate gene to screen. Although it was not found to harbour a mutation, it is certainly 
worth considering as a candidate in the future if it lies in areas of interest in patients 
with disorders of ocular development.  
3.5.3.3. LTBP2 
One homozygous variant was discovered in LTBP2. This gene (OMIM 602091) was 
first characterised in 2009[227] and has been demonstrated to be expressed throughout 
the eye [419]. Unlike other members of its protein family, LTBP2 does not bind to 
latent transforming growth factor, and instead its C-terminus has high affinity for the N 
terminus of fibrillin-1. The many ocular manifestations of mutations in this gene, 
include primary congenital glaucoma[419], and EL with microspherophakia and 
meglocornea (OMIM 251750)[420, 421]. Mutations in this gene have also been recently 
described in Weill-Marchesani 3[422]. The function of this gene and its protein is 
unclear, but its role with fibrillin-1 and ocular disease made it a good candidate gene for 
analysis.  
Only one potential homozygous missense single nucleotide variant ((c.785C>T 
(p.Pro262Leu) was discovered. This variant is a registered SNP (rs143106228). 
However, it is very rare. Out of the 4502 chromosomes sequenced by the Exome 
Sequencing Project[246], the T allele was only described in the heterozygous manner, 
in less than 1% of cases. The minor allele SNV was never described in the homozygous 
state. This was therefore interesting to consider as a pathogenic variant. However, in 
silico analysis of this mutation suggests that it is benign [244, 351] [245] We would like 
to perform segregation analysis on this family to investigate this mutation further.  
In summary, we have not discovered the genetic source of the phenotype in this family. 
There are further candidates we could investigate in the regions of homozygosity. One 
must consider that this has strong phenotypic characteristics of KNO, and neurological 
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imaging would help to confirm this. Although COL18A1 was not within any of the large 
regions of homozygosity, it must be considered that compound heterozygous mutations 
in this gene may be present. There are examples of allelic and locus heterogeneity in 
consanguineous families[423]. Though the proband CII:1 has multiple large regions of 
homozygosity , this family does not report obvious consanguinity. The possibilities of 
non-homozygous mutations therefore must be considered.  
3.5.4. FAMILY 6 
Family 6 presented with EL and a phenotype similar to WMS and WML. WMS was 
first described by Weill[424] and Marchesani[425] with over 200 cases being described 
since. Although no formal diagnostic criteria have been described, characteristic 
features include short stature, brachydactyly, joint stiffness and EL (commonly 
manifested as microspherophakia)[426]. Cardiac malformations have been reported to 
include prolonged QT interval and mitral valve prolapse[427] and pulmonary 
stenosis[426]. These occur very occasionally, with Faivre and colleagues suggesting 
this to occur in only 39% of autosomal recessive cases and 13% of autosomal dominant 
cases[428]. The clinical description of WML by Morales and colleagues[226] described 
cases in which brachydactyly and joint stiffness were excluded. The former seems to 
therefore be crucial in the differentiation of WMS and WML. WMS was defined in the 
classification of genetic skeletal disorders[429]. Although brachydactyly can be 
associated in isolation or with many syndromes[430] there is no definition of which 
type of brachydactyly is seen in WMS. In summary, a ratio of the middle phalanx to the 
length of the palm is most commonly used[430]. On discussion with a clinical geneticist 
(personal communication; Dr Sabha Mansour, St George’s Hospital, London) it was 
believed that this family manifested brachydactyly. With regard to joint stiffness, this is 
a more subjective assessment. Although Beighton score analysis[136] can be 
undertaken for the opposite extreme for joint mobility, it has less utility for stiff joints. 
On discussion with the clinical geneticist regarding EIV:1, it was believed that joint 
stiffness was manifest. No cardiac anomaly was detected, although this is not a 
discriminating factor in WMS or WML. He was therefore diagnosed with WMS, and 
ADAMTS10 was screened on this basis.  
WMS is inherited in an autosomal dominant or recessive pattern[428]. The former 
(OMIM 608328) is thought to be caused by mutations in FBN1 [431, 432], specifically 
mutations affecting heparin binding of the eight-cysteine domain (TB) number 5 
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(TB5)[433]. A genetic basis for autosomal recessive WMS (OMIM 277600) was first 
described by three mutations in ADAMTS10 in three families[280], subsequently 
confirmed in 3 further families with two more mutations[226]. Interestingly, mutations 
in LTBP2 have recently been demonstrated to cause WMS[422]. This latter report also 
described patients with what they termed “Weill-Marchesani Like syndrome” with 
mutations in LTBP2. However none of those patients had any ocular features, which 
were cardinal in the first description of WML [226].  
ADAMTS17 was first described in the seminal paper which highlighted seven of the 
ADAMTS proteins and genes, including ADAMTS18[17]. It is found on 15q26.3 and its 
protein (Figure 3.34) has high homology, particularly the catalytic domains, with 
ADAMTS19. The gene has two isoforms of 22 exons (1095 amino acids) and 16 exons 
(502 amino acids). 
Its role, as with all in this family of proteins is unclear. Morales et al [226] first 
described homozygous mutations in ADAMTS17 in a consanguineous family causing 
EL and short stature. They coined this condition as “Weill-Marchesani-Like syndrome” 
(OMIM 613195) (WML).  Distinguishing this from WMS is challenging.  
The three mutations of ADAMTS17 in three families with WML [226], with 
confirmation of a further mutation in the same gene by the same group in a further 
family[324] are the only convincing mutations causing WML.  
Whether our patients had WMS or WML is unclear.  EIV:1 was initially diagnosed, 
clinically, with WMS, and ADAMTS10 screening was undertaken on this basis. His son, 
EV:1 did not fulfil the systemic features of this condition, and would therefore more 
likely be a candidate to have a ADAMTS17 mutation.  Our genetic analysis has not been 
conclusive. The causative mutation is likely to affect Exon 15 of ADAMTS17. We 
believed that exon 15 was screened and present in EIV:1. However, the presence of the 
heterozygous variant initially was confusing. This was however repeated and this 
variant was not found. On homozygosity mapping the largest region shared between 
father, son and cousin was a 4.9mb region covering chromosome 15q25-26. This 
indicated that a homozygous mutation in this region was most likely. The most likely 
candidate in this region was ADAMTS17.  
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Assuming that no mutation was found in the coding regions of ADAMTS17 we needed 
to consider other possibilities.  
Having assumed that all the exons had been screened, it was considered that an 
alternative, deep intronic change within this gene may be responsible. There are 
numerous examples of such mutations causing ophthalmic disease[434, 435]. Most 
recently, mRNA analysis identified the creation of a pseudoexon in USH2A caused by a 
deep intronic change[355]. It was hoped that a similar explanation would fit in our 
family. 
Although amplifying the region between exons 11-13 using primers described by 
Morales et al[226], doing so for the whole gene proved impossible. However, 
concurrently, exome sequencing had been undertaken. 
The next generation exome sequencing experiment on EIV:1 and EV6 revealed that 
exon 15 on ADAMTS17 was not amplified. This was confirmed by PCR amplification, 
and suggests that this exon deletion is the pathogenic cause of this phenotype. 
Deletion of whole exons is not an unusual process and can be caused by numerous 
pathways. This includes splicing errors and genomic rearrangements. With no splicing 
errors discovered on direct sequencing, it was likely that genomic rearrangements would 
be causative.  
3.5.4.1. GENOMIC REARRANGEMENT 
Exonic deletions may be part of large deletions as a consequence of structural genomic 
rearrangements. Such a process occurs during recombination, where a crossover of 
chromatids from parental DNA occurs. This is characterised by allelic regions of 
homology sharing DNA. However, there are triggers which may result in this process 
not occurring accurately, including increased proximity of chromosomes, cellular stress, 
DNA sequence or structural features and inappropriate repair[436]. The former two are 
certainly important in cancer genetics. It is suggested that as replication and translation 
occur at the same template, any interruption at this junction can lead to “replication 
stress” thus increase the rate of structural abnormalities[437]. Furthermore, as double 
stranded breaks occur at regions of replication, this increases the risk of rearrangements 
at these sites. Certain DNA characteristics are more prone to such breaks. It is thought 
that regions which contain strings of CGG or AT repeats may be more prone to 
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breaks[438]. Also regions of DNA which do not conform to the characteristic “B-DNA 
helical shape” may be more susceptible[439]. Finally there are numerous avenues of 
inappropriate repair. The most common is when non-allelic homologous regions line up 
(Figure 3.35). Areas of repetitive DNA (“segmental duplications” or “low copy 
numbers”) are susceptible to this. These regions are also more likely to slow down the 
replication process, and thus make the segment more prone to structural abnormalities. 
In regions of non-allelic homology, the process of non-allelic homologous 
recombination (NAHR) may occur[342]. This can happen at the intrachromatidal, 
interchromosomal or intrachomosomal level. The former will only produce deletions 
whilst the latter can produce duplications or deletions[440]. This also depends on the 
orientation of the segmental duplications at which point alignments tend to occur[441].  
For there to be homozygous regions downstream to such a structural rearrangement, as 
would be the case in our family, would suggest that the NAHR occurred between 
homologous chromosomes, rather than chromatids[442]. 
The deletion of exon 15 was demonstrated by exome sequencing of ADAMTS17. Sanger 
sequencing of this gene however was inaccurate. The saliva samples which were sent 
from Sri Lanka included a sample of an unaffected individual (EIV:2). These samples 
were likely to have been mislabelled. The presence of the heterozygous variant should 
have alerted us to this. However on repeat sequencing, this SNP was deemed to be 
homozygous. On reflection again of this chromatograph, it is not likely to be 
homozygous. No reverse sequence was available to confirm this. 
This was an expensive error and led to many months of work attempting to amplify 
RNA from leucocytes in search of a deep intronic change causing a pseudo-exon. In 
fact, the causative skipped exon was in front of us.  
This illustrates some of the difficulties of acquiring DNA from remote areas. Although 
delivering swabs/ samples for DNA extraction through the post has been demonstrated 
to be successful[443], small errors such as these are costly.  
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Figure 3.35: Non allelic homologous recombination. Arrows represent Low Copy 
numbers (repeat sequences prone to non-allelic pairing). Blue boxes represent 
genes. The result can be insertion or deletion, as evident in the gametes produced.  
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3.5.4.2. Mutations in ADAMTS17 
There are four mutations in four consanguineous Saudi families. c.2458_2459insG, 
c.1721+1G > A, c.760 C > T[226] and c.652delG[324]. The latter two mutations are in 
Exon 4 and 2 and result in PTC. Interestingly, the first mutation was predicted to 
produce a truncated protein. The splice site mutation abolished the consensus donor 
sequence thus causing a deletion of exon 12. The authors of these papers suggest that 
the catalytic domains would be retained by this latter mutation, but the C terminus 
would be abolished. It is difficult to predict what an unknown mutation in our family 
would result in; however, exon 15 does encode a peptidase domain of ADAMTS17.  
To confirm our finding further of a deletion of exon 15, we could consider techniques 
such as multiplex ligation dependent probe amplification[444] or Comparative Genomic 
Hybridization array technology[445] may be employed to allow characterisation of 
deletions of single and multiple exons.  
In summary, work in this chapter has investigated EL and RD in six families. It has 
been successful in delineating a novel ocular phenotype consisting of microcornea and a 
cone predominant dystrophy, in association with congenital lenticular abnormalities 
(cataracts and EL) and early onset RD. Recessive mutations in ADAMTS18 appear to be 
responsible for this phenotype.  
This work has also provided novel features to Knobloch syndrome, and suggested a 
novel genomic rearrangement in ADAMTS17 as causing WML. It has also made evident 
that the ADAMTS family of proteins have an important part to play in ocular 
development. There are considered to be at least 12 major genes involved in anterior 
segment disorders[446]. This work helps towards suggesting that the ADAMTS 
proteins will be recognised in this group. It is possible that the ADAMTS proteins may 
also be shown to influence photoreceptor development.  
Finally, we have one further family to date with an as yet undiscovered genetic mutation 
causing EL and RD. Our group is continuing to work with this family to establish the 
genetic cause. 
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4. CHAPTER 4: THE GENETIC ASSOCIATIONS AND 
PHENOTYPE OF NON-MENDELIAN 
RHEGMATOGENOUS RETINAL DETACHMENT 
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4.1. INTRODUCTION 
4.1.1. COMPLEX DISEASE GENETICS 
Tradition has dictated that genetic predisposition to disease be termed Mendelian or 
Non-Mendelian. The term Mendelian is reserved for those phenotypes which a single 
genetic locus attributes to its aetiology. This has been the basis of investigations so far 
in this thesis. Non-Mendelian traits are everything else. In reality, this represents a 
spectrum. However, the term “complex” is generally reserved for conditions which are 
influenced by multiple loci as well as the environment. Although DNA variants may be 
individually insufficient to cause complex phenotypes and have small effects; they are 
thought to influence the various factors which in combination contribute to disease 
susceptibility [447]. The genetic components may be dependent on each other’s effects 
(polygenic inheritance), interact with each other (epistasis) or act independent (genetic 
heterogeneity)[448]. Furthermore the environment-gene interactions may influence the 
final phenotype[449]. 
Genetic investigations for multifactorial disease fall broadly into two groups: candidate 
gene studies and genome wide studies. Candidate studies involve prior understanding of 
genetic function and pathogenesis of the trait in question. These have traditionally been 
very expensive and laborious, with very few successes [450]. There have also been 
many un-replicated results[451]. 
Genome wide studies encompass linkage and genome wide association studies.     
Utilising the former can involve subsets of families who may display “near-Mendelian” 
inheritance. In studying these families, it may be possible to perform segregation 
analysis to establish a theoretical genetic model[452]. This model can then be used 
within traditional parametric linkage analysis. Non parametric linkage has been used 
widely with mixed results [453] with some notable successes, such as inflammatory 
bowel disease[454]; occasionally in conjunction with association studies [455] in 
complex diseases.  However regions which are highlighted, may cover in excess of 
10cM, thus requiring further candidate studies to narrow this down.  
In 1996, Risch and Merikangas[456] demonstrated mathematically that the power of 
association analysis for complex conditions was greater than linkage studies. They 
suggested that the future of complex disease analysis lay in large scale association 
studies.  
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4.1.1.1. COMMON DISEASE –COMMON VARIANT 
Theories about the genetic factors involved in complex genetic disorders include the 
“common disease – common variant” hypothesis (CD-CV) [457]. This considers that 
these factors are susceptibility loci, influencing but not determining overall disease risk. 
This hypothesis explains that genetic factors associated with these conditions are 
common (>1%) and many generations old.  
The implications of this are that these factors must have a small impact on the final 
phenotype; otherwise the prevalence of the disease would be equal to that of the genetic 
variants. Secondly, if common factors have a small genetic effect, and common 
disorders show hereditability, then multiple such factors may influence disease 
phenotype. These loci individually have low effect, but in combination and with 
epigenetic effects (e.g. environment) have an additive contribution. 
Investigating for such low impact factors is highly prohibitive with linkage studies. 
Association studies were first suggested as a means of detecting weak genetic factors in 
1996 [456]. Association studies aim to statistically identify alleles associated with a 
certain phenotype.  
Associations may be direct or indirect. Direct association studies are designed such that 
the variants investigated are thought to be causative. This is therefore very powerful, 
and utilises variants in likely candidate genes[458]. This method is however limited in 
that a priori hypotheses are required. Indirect association studies have been more 
successful, and are discussed in section 4.1.6. 
4.1.2. SINGLE NUCLEORTIDE POLYMORPHISM (SNP) 
Association studies are based on the most basic unit of genetic variation: the single 
nucleotide polymorphism (SNP). SNPs are single base pair changes in the DNA 
sequence; and are the most frequent form of genetic variation in the population[248].  
Because of their abundance, they are the preferred markers for such large scale 
population studies. Indeed, they are also the preferred marker for any genome wide 
study; as demonstrated in Chapter 3. The definition of common SNPs has been 
suggested as having minor allele frequencies (MAF) of greater than 0.5% whilst rare are 
sometimes classified as <0.5%[459], though this fine definition is debateable[327].  
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4.1.3. INTERNATIONAL HapMap PROJECT 
The understanding of SNPs increased rapidly with the development of the International 
HapMap project and of rapid massive parallel genotyping. The International HapMap 
Project is a large international collaboration that began in 2002 and sought to determine 
the common patterns of DNA sequence variation in the human genome. It has done this 
by characterising sequence variants, their frequencies and the correlations between them 
in 269 DNA samples from populations with ancestry from parts of Africa, Asia and 
Europe. It therefore provided detailed genotype data in over 1 million SNPs. It was a 
huge and successful collaboration that made all data freely available in the public 
domain [460]. This catalogue of genetic variation has provided a ‘blueprint’ of human 
genetic variation; and in particular SNP locations. Along with the Human Genome 
Project [353] and the SNP Consortium [461], over 10 million DNA variants have been 
identified. With the advent of NGS this has since been augmented by such endeavours 
as the 1000 genomes project[248] and the NHLBI GO Exome Sequencing Project[246]. 
4.1.4. HARDY WEINBERG EQUILIBRIUM 
When investigating variants in population genetics, one of the most important principles 
is estimating genotype frequencies. Genotype frequencies are determined, partly, by 
mating pattern. If one assumes that mating is random, there are no overlapping 
generations, the allele frequency is equal between men and women, the allele 
frequencies do not alter between generations (i.e. no mutations, migration or natural 
selection) and that the population is large enough not to be affected by sampling error 
(ideally an infinite population; but realistically over 500) one can draw the following 
inferences in table 16. 
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 Male gametes 
 Allele A a 
Allele Frequency p q 
Female 
Gametes 
 
A p 
AA 
p2 
Aa 
pq 
a q 
aA 
qp 
aa 
q2 
 
  Table 16: Punnett Square 
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In this table (known as a Punnett square[462]): A and a are the two alleles at a locus. p 
is the frequency of the allele A and q is the frequency of a in the zygotes of any 
generation. 
From this box, one can see that the frequencies of the alleles in the population would be: 
p2 + 2pq + q2 = 1 
This equation was described independently, by G.H Hardy and W Weinberg in 
1908[463] (Hardy-Weinberg Equilibrium; HWE). 
Although the assumptions upon which this equation is based may seem incorrect, the 
HWE is used as a reference model for tracking allele frequencies. These frequencies are 
the same from generation to generation, and will be attained in just on generation (with 
the assumptions in place).  
4.1.4.1. TESTING FOR HARDY WEINBERG EQUILIBRIUM 
When investigating allele frequencies, it is important to deduce whether the observed 
frequencies are significantly deviated from expected (in accordance with HWE). This 
may be calculated with chi-square tests, taking into account the degrees of freedom. 
This would then help determine a threshold p-value (comparing observed to expected 
allele frequencies). This p value is the probability that chance could produce a deviation 
between the observed and expected values. A large value would suggest that chance 
alone could account for the differences seen. A small value would suggest that the 
observed values are not in HWE. The threshold is determined in advance. An example 
for the p value threshold is the Welcome Trust Case Control Consortium (WTCCC) 
GWAS[464] where this was to reject SNPs which had p <5.7x10-7 when assessing for 
HWE. Within such GWAS, deviations from HWE are likely to indicate severe 
genotyping errors[465].  
4.1.5. LINKAGE DISEQUILIBRIUM 
Linkage Disequilibrium (LD) was first coined in 1960 [466]. It refers to the non-random 
association of alleles at two or more loci within populations. Alleles in LD share a 
common ancestor and travel together through generations; this relationship is not eroded 
by recombination. Confusingly, it does not require linkage; thus leading to some authors 
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terming it gametic phase disequilibrium[467]. Famously R. Lewontin (who first coined 
the phrase) “regretted using the term “linkage disequilibrium”.  
LD is most influenced by the recombination rate between two loci and time; measured 
in generations. The frequency of recombination (“r”) between genes depends on 
whether they are present on the same chromosome and the physical distance between 
them. LD is therefore strongly influenced by physical distance[468] and  recombination 
hotspots[469] (whereby nucleotides either side of a hotspot will share little or no LD 
because of recombination at that juncture). It reflects population history, breeding 
patterns, geographic structure, mutation and natural selection.  Older populations tend to 
have shorter conserved segments, as the population would have experienced more 
recombination; leading to lower LD[470]. Finally, rare variants tend to have larger areas 
of LD[464]. These variants are likely to be evolutionarily younger; therefore be less 
likely to have undergone recombination. 
LD can travel long chromosome distances. When tracked across the genome, these 
regions are termed haplotype blocks [471], and are separated by recombination 
hotspots. The characterisation of these haplotype blocks was undertaken by the 
International HapMap project (see Section 4.1.3)[460].  
4.1.5.1. MEASURING LINKAGE DISQEQUILIBRIUM 
The measurement of LD has three components. “D” is used to represent the linkage 
disequilibrium parameter. Simply put, this is the difference in allele frequency in 
chromosomes that underwent recombination, and those which did not. If D=0, this 
represents no recombination. This value, however, is dependent on the individual allele 
frequencies, and therefore is difficult to use across a region or genome. Therefore the 
magnitude of LD is usually demonstrated by a quantity known as D’. 
D’ is a measure which is defined as D/Dmax. This range is -1 to 1, and therefore allows 
comparisons between genomic regions, or populations or even species.  
r2 is often used as an alternative measure of LD. This is another confusing 
nomenclature, as r is used for the frequency of recombination between genes. This is 
directly related to the correlation coefficient in the allelic state between alleles in the 
same gamete. The maximum value of r2 is 1, when there is perfect LD.  
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4.1.6. INDIRECT ASSOCIATION STUDIES and Tag SNPs 
Direct association studies initially had very limited success. Indirect association studies 
take full advantage of the understanding of LD to distinguish associations between 
alleles and phenotypes. Critical to this is the utility of “Tag SNPs”. These are SNPs 
which are selected because of the knowledge of their LD patterns. By genotyping these 
SNPs informs about their tagged SNPs (Figure 4.1). These Tag SNPs are usually chosen 
so that they may have r2>0.8 with common SNPs[472]. Thus these Tag SNPs would be 
able to provide detail on true polymorphisms associated with disease or phenotype thus 
reducing the number of SNPs that need to be tested[473]. This is the principle of 
imputation. Imputation is particularly useful in meta-analysis, where different SNP 
chips may have been utilised in different studies.  
Genome Wide Association Studies (GWAS) utilise this technique by genotyping large 
set of SNPs (>100,000) across the human genome to determine the most common 
genetic variations that have a role in disease or to identify heritable quantitative traits 
[20].  
4.1.6.1. GENOTYPING CHIPS 
The success of the International HapMap and the understanding that emanated 
motivated commercial companies to develop generic “chips” for GWAS analysis. The 
market is dominated by two such companies. Illumina, which uses fibreoptic 
technology, and Affymetrix, which uses DNA probe microarrays. The former chose tag 
SNPs based on reliability for genotyping, whilst the latter concentrate on an even spread 
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Figure 4.1: Indirect association: The tag-SNP (in blue) is genotyped, which 
provides information on those variants in LD with it (in red). Adapted from [20] 
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across the genome. Both companies provide comparable power[474]. The first wave of 
these chips (2005-7) had between 100,000 – 500,000 SNPs. Currently, chips may have 
1,000,000 SNPs; approximately one per 3kb.   
4.1.7. GWAS ISSUE AND STUDY DESIGN 
The typical GWAS has four parts: a) selection of a large number of individuals with the 
disease or trait of interest and, in a binary condition, a suitable comparison group; b) 
DNA isolation, genotyping and quality control; c) statistical tests for associations 
between the SNPs that pass quality control thresholds and the disease/trait; d) 
replication of identified associations in independent population samples or experimental 
examination of functional implications. By far the most common design in published 
GWAS comprises a case-control study with a binary outcome. Other study designs 
include individuals with measured continuous phenotypic variables (e.g. refractive 
error) analysed as a quantitative trait and family based designs such as trios (proband 
and parents) or other pedigrees of related individuals.  It is ideal to recruit case subjects 
and control subjects systematically from the same population of single ancestry as case-
control differences in ancestry (population stratification; see Section 4.1.7.3) can 
confound association test results.   
4.1.7.1. CASE AND CONTROL SELECTION 
This is an important aspect of case-control GWAS. Most successful GWAS involve 
numerous centres, and strict case definition and ensuring the same population is a 
crucial part of successful GWAS[475]. Ideally, control samples should be collected at 
the same institution concurrently; then genotyped at the same time on the same chip; 
this may reduce the batch effect seen in large scale genotyping experiments[476]. 
However, it is more common place to use common control databases. This is useful in 
relatively rare conditions, as the proportion of cases in the control set will be negligible.  
This method was used successfully in the Wellcome Trust Case Control 
Consortium[464]. 
4.1.7.2. SAMPLE SIZE 
Experience has shown that large sample sizes (2,000) are needed to detect common 
genotypic variants likely to have a low relative risk (1.2-2) and to offset the large 
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number of independent SNP association testing [477].  Contemporary genotyping 
platforms have specific advantages and limitations, however most provide a high level 
of genomic coverage estimated to capture between 67-90% of common SNP variation 
in Caucasian ethnicity [478]. After genotyping, extensive data cleaning (quality control) 
is required to detect problems that can result in false negative or false positive findings, 
such as genotyping errors, duplicate samples,  unexpected relatedness among subjects 
and strong deviations from HWE [479]. 
4.1.7.3. POPULATION STRATIFICATION 
One of the most challenging issues to account for is population stratification. This is the 
presence of differences in allele frequencies between populations; particularly evident in 
those of different ancestry. It is caused by non-random mating followed by genetic 
drift[462]. Even small degree of population stratification can result in errors in 
GWAS[480]; because of the large samples sizes required. A famous example suggested 
a significant association with LCT (a gene which has undergone strong selection in 
certain European populations) for height; which was then markedly reduced once 
population ancestry was matched[481]. Careful selection of controls of same ancestry 
can minimise this. Nevertheless, Quality Control methods can be employed to assess for 
this. A common method used is to examine for genome wide identity by state (IBS) and 
identity by descent (IBD: Figure 3.2). IBS represents individuals who have an 
independent copy of a particular allele, whilst those who share IBD have the identical 
copy of the same ancestral allele. Using the genome-wide proportion of alleles shared 
IBS, individuals may be clustered based on their IBS compared to the sample average. 
Using these, a multivariate statistical method can be devised (primary component 
analysis (PCA)) to analyse for stratification. PCA is a method used to generate 
uncorrelated variables (“principal components”) from data containing observations 
across correlated variables. In genotyping data, the observations are individuals and the 
variables are markers, or SNPs[480]. Using this method, it is therefore important to 
remove regions of high LD, to reduce the correlation of the SNPs (variables) as much as 
possible[482]. 
4.1.7.4. ANALYSIS 
Analysing for association studies have used a standard χ2 test for independence on 2 
degrees of freedom (allowing for 3 genotypes at a SNP; two homozygous and a 
227 
 
heterozygous). If one was to presume an inheritance (dominant or recessive); this could 
result in a reduction of the number of genotypes included in the analysis; thus the 
degrees of freedom. If there is a presumption of this kind; a Cochran-Armitage Trend 
Test (CATT) may be used.  
Alternatively logistic regression may be used in case/ control studies. This allows 
predictors to be included in analysis (such as age, gender etc.). This has further utilities 
in that interactions between loci, and environmental effects may be incorporated into the 
model.  
4.1.7.5. MULTIPLE TESTING 
This is an important consideration in GWAS analysis. With a p value set at 0.05, and 
multiple tests being undertaken (SNPs genotyped); a large number of false positives 
would be generated. The expected number of errors (“family wide error rate”) when 
undertaking N tests would be αN (where α= significance level). Therefore a more 
stringent measure of significance is required. The most famous method of addressing 
this is the Bonferroni correction; named after the Italian mathematician, Carlo Emilio 
Bonferroni. This is equivalent to multiplying all p-values by N and applying a threshold 
of α. To achieve an α= 5% if conducting 100,000 independent tests the actual threshold 
for genome wide significance of association is P<5X10-7.  A suggested cut off has been 
suggested as 5x10-8 for modern GWAS[483]. 
Within GWAS this is however complicated by LD: as SNPs are correlated. The 
Bonferroni correction may therefore be overly conservative. Alternatively a permutation 
test may be used. In this method, the genotype data is fixed, and the phenotype data is 
shuffled randomly. This is then analysed again, and the minimum p value is compared 
with the original p value. Repeating this N times, the corrected p value is (R+1)(N+1), 
where R is the number of times that the permutation p value is less than the original p 
value. It is suggested that this method may be more powerful than Bonferroni, when 
SNPs are in LD[484].  
There are challenges of separating the many false positives from the few true positive 
associations. Therefore, putative genetic variants that are identified and reach genome 
wide significance need to be replicated in additional case-control cohorts, preferably of 
larger size, as the best method to verify a true association[485]. Finding a true causal 
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variant however only represents the beginning; genetic association does not imply 
causality but offers a genetic hypothesis of an underlying biological pathway that 
warrants further exploration. 
There are many examples of GWAS proving a success in elucidating the genetic 
architecture of ophthalmic traits and diseases. A few are illustrated below. 
4.1.8. GENOME WIDE ASSOCIATION STUDIES IN OPHTHALMIC 
CONDITIONS 
4.1.8.1. AGE RELATED MACULAR DEGENERATION 
A genetic predisposition to age related macular degeneration (AMD) has been 
suggested for almost thirty years [486] with familial aggregation studies[487 ], twin 
[488] and linkage studies [489] providing most of the evidence. 
Initial investigative techniques focussed on assessing candidate genes which primarily 
comprised those associated with macular dystrophies and similar phenotypes to AMD 
[490]. Over 45 such loci were investigated[491], with most failing to yield replicated 
associations. Linkage studies proved challenging because of the difficulty in recruiting 
large affected families and the late age of onset of the disease. Genome wide linkage 
studies have suggested numerous loci, but only two (on chromosome 10q26 and 1q32) 
have been replicated convincingly. The former of these contains over 70 genes, 
including peroxiredoxin 3 (PRDX3) gene, which encodes a protein with antioxidant 
function. Interestingly chromosome 1q contains the well characterised gene complement 
factor H (CFH).  
The first GWAS success story was the discovery of the association CFH with AMD 
which was independently described in three cohorts [492-494]. A coding variant Y402H 
in exon 9 of CFH was significantly associated with AMD. This finding was replicated 
throughout the world in many ethnic groups. This mutation affects the binding 
properties of CFH, thus resulting in inappropriate complement activation [495]  
The discovery led to investigations of other complement factors in AMD, and the 
understanding of the association with complement factor B and complement component 
C2 [496], further replicated across the world [497-499] adding to the understanding of 
this condition.  
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Previous linkage studies had long established 10q26 as a candidate locus for AMD 
[489]. Age related maculopathy 2 gene (ARMS2 -previously known as LOC387715) 
was subsequently suggested as the candidate locus [500], in particular SNP rs10490924.  
However the pathogenesis of this gene was not clarified. A GWAS undertaken by 
DeWan [501] highlighted an alternative gene in the locus 10q26; high temperature 
requirement A1 (HTRA1), in 96 Oriental patients with neovascular AMD (nAMD). The 
risk SNP rs11200638 (in complete linkage disequilibrium with rs10490924) was found 
to be highly associated with wet AMD. It encodes a heat shock serum protease 
expressed in human retina that  is activated by cellular stress [502, 503]. Meta-analysis 
has suggested that both ARMS2 and HTRA1 may contribute towards AMD 
independently with an augmented combined affect [504] 
Kopplin et al.   [505] completed a GWAS on patients with late AMD in conjunction 
with a family based GWAS. They not only confirmed previously associated risk genes, 
but went further to suggest protective functions of genes MYRIP and SKIV2L. The 
former of these is involved in trafficking melanosomes in the RPE [506] and thus may 
prevent or delay declines in RPE function. SKIV2l is involved in breakdown of RNA, 
and may have a role in autophagy [507]. Variations in SKIV2L have additionally been 
associated with a protective role in polypoidal choroidal vasculopathy [508]. 
Risk factors associated with AMD have additionally been studied in relation to risk 
alleles. It has been shown that smoking and high body mass index (BMI) with at risk 
alleles significantly increase the risk of developing AMD, adding considerations as to 
possible interactions [509]. Further interactions of risk factors with CFH genotypes 
were explored by Seddon and colleagues [510]. They reported a risk profiling system 
which illustrated that established risk factors in combination with genotypes could 
predict progression to advanced AMD independent of demographic factors and ocular 
phenotype. Alternative predictive schemes have followed [511]. In addition, algorithms 
have been suggested for predicting treatment prognoses [512]. Predictions of treatment 
outcomes with modern anti-VEGF agents have been suggested based on genotype 
variations of CFH and HTRA1[513]. These steps toward a personalised risk profile, may 
provide for a more target approach to prevention and management of this condition. 
The influence of the complement system in AMD has now even extended to novel 
treatments, aimed at modulation of this system[514]. The landmark GWAS in AMD 
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have paved the way for almost 50% of the hereditability of this condition now being 
explained. This genetic understanding is unrivalled by any other complex diseases. 
4.1.8.2. GLAUCOMA 
4.1.8.2.1. Primary open angle glaucoma 
The first gene implicated in the pathogenesis of primary open angle glaucoma (POAG) 
was Myocilin (MYOC) [515] where mutations may result in a breakdown of the 
extracellular matrix structure in the trabecullar meshwork. Mutations in this gene are 
responsible for up to 4% of POAG cases [516]. Mutations in optineurin (OPTN)[517] 
and WD Repeat Domain 36 gene (WDR36)[518] have also been shown to be causative. 
However, mutations in these genes have however been shown to be infrequent and can 
explain only a small proportion of the genetic architecture of POAG [519]. 
Nakano [520] et al published the first GWAS in POAG in a Japanese population, with 
meta-analysis revealing 3 associated loci with moderate but not genome wide 
significance. Six polymorphisms were identified: near ZP4 gene, and PLXDC2 gene. 
The functionality of these associated genes and the markers were not discussed or 
replicated and were absent in an independent Indian population [521]. 
Thorleifsson et al [522] conducted a large multiethnic GWAS. They found two SNPs (rs 
4236601, rs1052990) which were in the same linkage disequilibrium block as genes 
CAV1 and CAV2, which encode caveolin 1 and 2. Both these proteins are expressed 
throughout ocular tissue [523 ]. Caveolin 1 is thought to play a regulatory role in the 
function of endothelial nitric oxide synthase and TGFβ signalling, mechanisms that 
have been implicated in the pathogenesis of POAG [524, 525]. The most statistically 
significant variant (rs4236601) however did not have an effect on IOP or central corneal 
thickness.  
Thorleifsson et al found differences in rs4236601 within ethnicities. When compared to 
European populations, this variant was absent in a Japanese cohort but posed a greater 
risk with lower frequency in a Chinese population[526]. Osman and colleagues[527] 
also showed significant association with CAV1 and CAV2, amongst other genes, in a 
GWAS on an Asian cohort. However, these findings were not replicated in a North 
American cohort [523].  
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Burdon and colleagues analysed 590 patients with advanced open angle glaucoma 
[528]. They found two regions of significance, near the TMCO1 gene and the CDKN2B-
AS1 gene both of which were shown to be expressed throughout ocular tissue.CDKN2B 
was shown to be upregulated in response to raised IOP. These genes have been 
suggested to play a role in apoptosis[529], with the link thus with glaucoma. Of further 
interest, CDKN2B was shown previously to be related to optic disc cupping 
[530](section 4.1.9). The particular SNP in that study had a P value = 3.9x10-7, further 
implicating an association of this region with OAG. TMCO1 has subsequently been 
associated with intraocular pressure (section 4.1.9.5), providing further evidence to its 
role in disease aetiology. 
This paper raised further interesting issues. Firstly, they validated the efficacy of using 
extreme phenotypes in GWAS; the variants found in their discovery cohort of severe 
OAG were replicated in cases with less severe disease. Secondly, many of the cases in 
this study were used as a replication in Thorleifsson’s GWAS[522]. Interestingly, 
although in that paper the analysis confirmed a role for CAV1 & CAV2, this was not 
found to be so in this full GWAS with the same cases. This is not a novel situation, and 
highlights some of the challenges of interpreting GWAS and replication data. 
Conversely, this adds further credibility to those associations which are replicated in full 
hypothesis free GWAS.  
More recent GWAS [527, 531] and targeted genotyping [532] have provided further 
evidence for the association with CDKN2B, in numerous ethnicities. This gene has now 
been shown to be significant in multiple independent GWAS in both normal tension 
glaucoma (section 4.1.8.2.2) and POAG. Some have suggested its role is therefore on 
optic nerve susceptibility[520], perhaps via effects on the TGF-beta pathway[531]. 
Certainly its role in glaucoma is now established, and further understanding of its role 
and effect on phenotype is now warranted. 
4.1.8.2.2. Normal tension glaucoma 
Normal tension glaucoma (NTG) is an important subset of primary open angle 
glaucoma, with a high prevalence in Japanese populations [533]. Studies have 
implicated several genes , including optic atrophy 1 [534-536], optineurin [537], p53 
[538] and apolipoprotein E [539, 540]. The mechanism of these genes may involve 
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abnormal regulation of apoptosis [541], but this remains controversial and represent a 
small proportion of NTG patients.  
The first GWAS investigating NTG compared 305 Japanese NTG patients to 355 
controls [114] under the age of 60. The most significant SNP (rs3213787) along with 
the 7 next SNPs they  found lay in the gene for S1 RNA Binding Protein 1 (SRBD1). 
This group established expression of this gene in brain, bone marrow and retinal 
ganglion cells (RGC) of neonatal mice and demonstrated that the at risk allele resulted 
in enhanced SRBD1 expression. Although the function of this gene is unknown, they 
suggest that over expression may result in apoptosis and inhibition of cell growth; 
leading to retinal ganglion cell and optic nerve axon loss. Also rs735860, a SNP of 
genome wide significance, lies within the elongation of long-chain fatty acids family 
member 5 (ELOVL5) gene. This is one of a family of enzymes expressed in mammalian 
retina that involved in long chain polyunsaturated fatty acid synthesis (LCPUFA). 
Alteration in LCPUFA expression implies potential mechanism towards RGC 
apoptosis.  
The same investigators have since replicated the significant SNPs in a separate 
population of NTG and high tension open angle glaucoma (HTG) patients, with a wider 
age range than the original cohort [542]. Although SRBD1 and ELOVL5 are thought to 
be non-IOP related genetic factors, both SNPs (rs3213787 & rs735860) were found to 
be associated with NTG and HTG. There was no difference in the maximum IOP 
between the HTG patients with the at risk alleles, leading to the suggestion that these 
SNPs act independent of IOP. Their findings also implied that these genes are 
associated in late onset open angle glaucoma. Further replication of these results have 
yet to be done. 
More recently, large independent GWAS and meta-analysis on GWAS cohorts[543, 
544] investigating over 1500 NTG patients have suggested the role of CDKN2B in the 
aetiology of Japanese NTG. This gene is highly relevant to high pressure open angle 
glaucoma (see Section 4.1.8.2.1). The importance of this gene on glaucomatous optic 
neuropathy[545] suggests its role is likely to be IOP independent[546]. 
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4.1.8.2.3. Pseudoexfoliation  
Genetic factors contributing towards the development of pseudoexfoliation (PXF) and 
pseudoexfoliation glaucoma (PXG) are established, with a demonstrated increased risk 
to relatives [547]. Multiple modes of inheritance have been postulated [548]. 
Pseudoexfoliation has been associated with an increased production of microfibrillar 
material, such as fibrillin-1, latent transforming growth factor β binding proteins 
(LTBP) and transforming growth factor (TGFβ). It has also been associated with a 
decreased level of clusterin; which may increase abnormal aggregation of microfibrillar 
material. Of these candidates, only polymorphisms encoding for clusterin (CLU) had 
been associated with PXF and PXG [549]. 
Thorleifsson et al [550] performed a GWAS initially on 195 patients with glaucoma. 
They found moderate significance of SNP rs2165241 in this group. However, 
significance was very high in the subgroup of 75 patients with PXG (OR=3.4). This 
SNP was sequenced in additional Swedish and Icelandic cohorts and confirmed to be 
associated with PXG. It is found in an intron of the lysyl oxidase–like protein 1 
(LOXL1) gene. Although no mutations in the LOXL1 gene itself were determined to 
cause PXF, certain sequence variations were found more frequently in cases; suggesting 
an association with this gene. The association of LOXL1 with pseudoexfoliation has 
been replicated numerous times [551-558]. The LOXL1 protein is part of a family of 
enzymes which catalyses deamination of tropoelastin resulting in formation of elastin 
fibres and is essential in homeostasis of elastic and connective tissue [559]. 
Furthermore, it is suggested that PXF material consists of elastin microfibrillar 
components [560]. Functional studies have demonstrated reduced expression of LOXL1 
in ocular tissue of PXF and PXG [561] and specifically in lens capsule of patients with 
PXG [562]. Functional studies  have demonstrated reduced cross linking domains in 
elastin and decreased expression of LOXL2 , an enzyme from the same family and with 
similar activity as LOXL1, in a black American population compared to a white 
population, perhaps increasing susceptibility to glaucomatous optic nerve damage [563].  
Krumbiegel and colleagues [564] performed a GWAS with DNA pooling and 
confirmed the association of the LOXL1 locus. Additionally they highlighted a locus 
within the CNTNAP2 gene on chromosome 7, which did not reach genome wide 
statistical significance. CNTNAP2 encodes contactin-associated protein-like 2 
(CNTNAP2) a neuronal membrane protein[565]. Its function is not yet clear, though it 
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may be involved in potassium channel trafficking [566]. Krumbiegel et al [564] 
demonstrated widespread expression of CNTNAP2 mRNA and protein throughout 
ocular tissue, including retinal ganglion cells and trabecullar endothelial cells, although 
no difference was demonstrable between pseudoexfoliation and control tissue.  
4.1.8.2.4. Primary angle closure glaucoma 
Primary angle closure glaucoma (PACG) is a separate condition aetiologically and 
genetically from the more common POAG[567]. Few studies have investigated a 
genetic predisposition to PACG[568]. Vithana and colleagues[569] performed the only 
GWAS to date on 1854 cases from across Asia, replicated in 1917 cases from Asia and 
UK.  They suggested two novel genes to be associated with PACG. Firstly, PLEKHA7 
on 11p15.1 was demonstrated as significant. PLEKHA7 has a role in paracellular 
permeability. It is distributed widely in the eye, and the authors suggest it may be 
involved in fluidic aspects related to PACG.  
They also suggest an association with COL11A1, a gene which causes the monogenic 
conditions of Marshall (OMIM 154780), and Sticklers type 2 (STL2: OMIM 604841). 
They note the paradox that PACG is normally co-existent with hypermetropia, whilst 
Marshall and STL2 are normally associated with progressive axial myopia. The 
existence of COL11A1 protein in the trabecular meshwork suggests to the authors that 
alterations in this gene may influence numerous sites in eyes with PACG. 
Finally a third locus on 8q was suggested, although no definitive gene could be 
identified.  
It is probable that these associations will help future investigations into PACG, and 
perhaps ocular structural development. 
4.1.8.3. CORNEA 
4.1.8.3.1. Fuchs endothelial dystrophy 
Fuchs corneal endothelial dystrophy (FCED) is thought to occur in 38% of first degree 
relatives of probands [570]. Linkage studies first revealed a missense mutation in 
COL8A2 in a multigenerational affected pedigree [571]. However some controversy 
exists over the reported findings. Additionally, rare autosomal dominant mutations in 
SLC4A11[572] ZEB1 [573]& KCNJ13 [155] have been reported.  
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The first GWAS in FCED was published in 2010[574]. Baratz K.H. et al found 
numerous SNPs within the Transcription Factor 4 (TCF4) locus independently 
associated with FCED. The most strongly associated haplotypes spanned one exon, with 
the impact of the most significant variants increasing with disease severity. The authors 
however were unable to define a variation within the coding region, and suggested that 
a non-coding regulatory region around the encoded protein is important.  
The protein encoded by TCF4 is called E2-2. It is a member of the class I basic helix–
loop–helix (bHLH) transcription factors that are involved in cellular growth and 
differentiation [575]. E2-2 itself, found within the corneal endothelium, may influence 
FCED formation by altering the expression of ZEB1. If variants reduce the expression 
of E2-2, deficient proliferation or migration of endothelial cells may be causative. 
Alternatively enhanced ECM deposition may be causative if variants result in increased 
expression of E2-2.  
This original GWAS was replicated by Li et al [576] in 450 cases with genome wide 
linkage on 64 families with 215 affected members. They confirmed the significance of 
the SNP rs613872 with their former analysis (p=9.33x10-35). Linkage revealed the 
significant region was on chromosome 18 – only 1.5mb from TCF4. Further evidence in 
other ethnicities has followed, with Thalamuthu et al [577] confirming the association 
of TCF4 with FECD in a Chinese population.  
4.1.8.3.2. Keratoconus  
A genetic contribution towards the aetiology of keratoconus (KC) has been established 
for over a decade[578]. All modes of Mendelian inheritance has been suggested [579], 
with various loci suggested. The lack of consensus loci, suggests that the inheritance is 
likely to be complex[580]. Two large GWAS to date have investigated keratoconus. Li 
and colleagues[581] completed a GWAS on 222 Caucasians with keratoconus 
replicating in a further 611 cases, and suggested an association with RAB3GAP1 on 
2q21.3.  This association was most significant, after meta-analysis,and has since been 
replicated[582].This gene is involved in neurotransmitter exocytosis[583], and defects 
in this gene are known to cause Warburg Micro Syndrome[584] (which includes 
microcornea in the ocular phenotype). Simultaneously, this group performed a meta-
analysis with a GWAS performed by Australian colleagues, suggesting the promoter 
region of HGF to be significantly associated with keratoconus[585]. HGF had 
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previously been shown to be associated with myopia[586]. It has also been associated 
with narrow angle closure [568], suggesting that this gene may well play a role in 
structural development of the anterior segment. The encoded protein is also found in the 
cornea, particularly the stroma[587], and the authors suggest that this gene may play a 
role in keratoconus pathogenesis via an inflammatory pathway. 
The different genes suggested in these papers based on data from the same cohort may 
seem conflicting, however, they offer novel pathways in KC. Replication will be crucial 
for validation.  
4.1.8.4. DIABETIC RETINOPATHY 
Diabetic retinopathy (DR) is the leading cause of visual loss in the working ages of the 
developed world[588] There is growing evidence that the genetic contribution towards 
DR is significant[589], with suggestions of the heritability of severe retinopathy being 
between 25-50%.[590]     
Prior to the advent of GWAS, genome wide linkage studies highlighted regions on 
chromosomes 1, 3, 9 and 12. Numerous candidate genes were also investigated (for 
review see Patel et al. [591]).  However, the era of GWAS further illuminated our 
understanding. 
The two largest GWAS of DR in Type 1[592] and Type 2[593] diabetes mellitus (DM) 
investigated 973 and 749 cases respectively.  Grassi and colleagues performed GWAS 
on 2 different platforms on 2 separate cohorts with proliferative diabetic retinopathy 
(PDR) and macular oedema, imputing results to combine the data. They found a 
significant SNP between two genes (AKT3 and ZNF238) on chromosome 1. The former 
of these is known to be activated by insulin-like growth factor and platelet-derived 
growth factor – both of which are activated in PDR[594]. They also analysed 281 
patients with DR without nephropathy, and demonstrated association with an intergenic 
SNP on chromosome 6. Furthermore, they also investigated SNPs tagging Copy 
Number Variants (CNV); and showed an association with CNVR6685.1 on 
chromosome 16. A number of genes involved in transcriptional regulation (CCDC101), 
post-translational protein modification (SULT1A1 & SULT1A2) and apoptosis (NUPR1) 
are in within or in linkage disequilibrium to this region. However, this same group were 
unable to later replicate these findings in another cohort[595]. 
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Huang and colleagues [593] published in the same year on a cohort of 749 Taiwanese 
patients with type 2 diabetes with proliferative and non-proliferative retinopathy. They 
demonstrated regions of interest on chromosomes 1, 5, 10, and 13, mapping to 4 known 
genes. 2 of these genes (ARHGAP22 and PLXDC2) are involved in endothelial cell 
angiogenesis. They also confirmed the results of a previous genome wide linkage study 
associating 1q32 with DR[596], re-iterating the importance of this region. It is 
particularly interesting that neither GWAS investigating the retinopathy in type 1 and 2 
DM found overlapping regions.  
Publications of GWAS into diabetic retinopathy are novel, and more will be on the 
horizon. They are undoubtedly providing insights into the genetic architecture of these 
conditions, and separating them from the genetics of diabetes. It is worth noting, that the 
cohorts in both GWAS had had diabetes for significantly longer than controls. It would 
be prudent to control for this in future studies to ensure findings are related to DR, and 
not age of onset of disease. 
4.1.9. GENOME WIDE ASSOCIATION STUDIES IN OPHTHALMIC 
QUANTITATIVE TRAITS  
Quantitative traits refer to continuous phenotype data (e.g. blood pressure, blood 
glucose, height). When investigating complex diseases, there are many factors which 
may have influential roles (e.g. total cholesterol, total low density lipoproteins, total 
triglycerides and the risk of cardiovascular disease). One way of further understanding 
the complexities of these conditions, is to study these quantitative risk traits (sometimes 
termed “endophenotypes”).  
4.1.9.1. REFRACTIVE ERROR 
Much of the current information on human myopia molecular genetics can be drawn 
from familial studies of high myopia. To date there are at least 16 loci listed on the 
OMIM database (http:// www.ncbi.nlm.nih.gov/omim) (MYP2–MYP17) for non-
syndromic high myopia, common myopia or ocular refraction that are distributed 
among 13 chromosomes. At least seven loci for refractive phenotypes (MYP1, MYP3, 
MYP6, MYP11, MYP12, MYP14 and MYP17) have been successfully replicated in 
independent linkage datasets and identified as being associated with myopia. 
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Most of the biological information derived from these studies has implicated connective 
tissue growth and extra cellular matrix reorganization in the pathogenesis of myopia. 
This group includes genes that encode matrix metalloproteinases (MMP1, MMP2, 
MMP3, and MMP9), growth factors and growth factor receptors (HGF,TGFB1, TGFB2, 
and MET), collagens (COL1A1and COL2A1), and proteoglycans (LUM). (see 
Wojciechowski R[597] for summary) 
GWAS and linkage disequilibrium mapping have for the first time implicated 
mitochondrial and apoptotic pathways in the pathogenesis of myopia[598]. Andrew et 
al. demonstrated an association of refractive error with MFN1, PSARL and SOX2OT, 
while Nakashiki et al. identified a polymorphism (rs577948) at 11q24.1(near BLID) that 
was associated with an elevated risk of pathological myopia (OR = 1.37). MFN1, 
PSARL and BLID are expressed in mitochondria and are involved in mitochondrial-led 
cellular apoptosis[598]. In addition, a further GWAS identified a polymorphism 
(rs9318086) at 13q12.12 significantly associated with an increased risk of high myopia 
in a Han Chinese population (OR=1.64)[599]. This region contains the genes MIPEP 
and C1QTNF9B-AS1. The former is expressed in the retina and is involved in oxidative 
phosphorylation and processing in the inner mitochondrial matrix. Given that the retina 
is the most energy consuming tissue in the eye, these discoveries have led to increasing 
interest in role of the mitochondrial pathway in refractive error [599].   
In a large twin based GWAS of refractive error in a European population, several 
polymorphisms at 15q25 near the RASGRF1 gene were found to be associated with 
ocular refraction[130].  RASGRF1 was shown to be highly expressed in human retina 
and its expression is regulated by muscarinic receptors[600]. This provides another 
intriguing biological mechanism as anti-muscarinic agents can prevent ocular 
elongation in animal myopia models[601] and have been employed to reduce myopia 
progression in human trials [602]. In a companion paper, Solouki et al reported another 
European GWAS with a polymorphism (rs634990) at 15q14 significantly associated 
with refractive error [131]. This polymorphism was found in a putative regulatory 
region near the genes GJD2 and ACTC1, both of which are expressed in the retina. 
GJD2 encodes a neuron-specific protein (connexin36) that is present in photoreceptors, 
amacrine and bipolar cells, and is thought to play an important role in the transmission 
process of the retinal circuitry by enabling intercellular transport of small molecules and 
ions[131]. This novel finding suggests for the first time that modulators of retinal visual 
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signals may have a role in susceptibility to refractive error. More recent reports have 
replicated loci at 15q14 that underscore a risk for high myopia, in particular an 
association with axial length[132]  and a further GWAS for high myopia in a French 
population have refined a risk locus at MYP10 implicating a role for microRNA 
variation in predisposition to high myopia[133].   
There have now been eight GWAS investigating myopia or related endophenotypes. 
Most recently, two very large GWAS have been published which have greatly furthered 
our understanding. The largest GWAS of refractive error (n=45,771) was published in 
early 2013[603]. This group discovered 20 novel loci in a European cohort associated 
with myopia.  These included the strongest association with a SNP in the intron of 
LAMA2. Laminins are structural proteins which are integral to the ECM. They also 
found an association 17kb upstream from ANTXR2; which binds type IV collagen; thus 
further implicating ECM remodelling. Further pathways highlighted were by 
association with RDH5 and KCNQ5. Both play a significant role in the visual cycle. 
They also implicated genes involved in eye growth (PRSS56, BMP4, BMP3, ZBTB38, 
and DLX1). Associations with ZIC2 and ZMAT4 suggested a role retinal ganglion 
outgrowth in development. Finally, the authors suggested a role of genes involved in 
neuronal development, which were not involved in the vision cycle (KCNMA1, 
RBFOX1, LRRC4C, DLG2, TfP2).  Of further interest in this study was the method of 
recruitment. All of the cohort were paid members of 23andMe Inc, and self-reported 
their myopia. This may have resulted in misclassification. However, many of their 
findings were confirmed by the Consortium for Refractive Error and Myopia (CREAM) 
who conducted a meta-analysis on well-defined and phenotyped cohort. They co-
discovered[604] 16 of the 20 novel findings from Kiefer and 23andI cohort. Of the 22 
novel loci discovered by CREAM, 14 were replicated by Kiefer. CREAM not only 
confirmed previous locus [605], but also confirmed roles in ECM remodelling, ion 
channel transportation and eye development[604]. Both these studies illustrate the 
importance in very large sample size in successful GWAS; and Kiefer and colleagues 
even demonstrate the possible dismissal of expensive phenotyping in conditions with 
early onset; such as myopia. It is likely that a combination of both will be required to 
demonstrate further success. Finally, further studies are likely to require incorporating 
measures of environmental exposure into the statistical analysis of GWAS. 
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4.1.9.2. OPTIC DISC PARAMETERS 
Optic disc area and vertical cup: disc (VCDR) are important parameters in the 
development of numerous ophthalmic conditions, including anterior ischaemic optic 
neuropathy, Leber’s hereditary optic neuropathy, and open angle glaucoma. The 
hereditability of optic disc area and VCDR are estimated as 52-58% and 48-80%. 
However, few studies prior to the advent of GWAS in quantitative traits attempted to 
analyse optic disc parameters in the normal population.  
Ramdas et al. [530] investigated 7360 Caucasians (of whom 188 had POAG) from 
Rotterdam. They found three genetic loci associated with optic disc area, and six 
associated with VCDR which persisted when the 188 patients with POAG and the 115 
with myopia were excluded. Their findings were replicated in 4455 Dutch and British 
Caucasians. Three SNPs within one locus (10q21.3-q22.1) were found to be significant 
in both traits, accounting for 2.7% of the variation within optic disc area and 2.2% of 
the VCDR variation. The most significant common related gene to these loci was atonal 
homolog 7 (ATOH7), more so in VCDR. Several genes were found to be associated 
with VCDR and included: CDKN2B (chromosome 9p21); which encodes a cyclin 
dependant kinase, thought to play a role in cell growth regulation [606], SIX1 
(chromosome 14q22-23); which is involved in eye development and linked to 
anophthalmia[607], SCYL1 (chromosome 11q13); which is associated with optic 
atrophy in mice [608], CHEK2 (chromosome 22q12.1); which has no previous 
association with ocular conditions, DCLK1 (chromosome 13q13) and BCAS3 
(chromosome 17q23). Additionally, for optic disc area TGFBR3 on chromosome 1p22 
was shown to interact with ATOH7 influencing VCDR parameters.   
Macgregor and colleagues subsequently performed a GWAS on two Australian twin 
cohorts [609] and confirmed the association with ATOH7. This was further replicated in 
a UK cohort [609].  
Optic disc parameters are known to vary between races [610]. Khor [611] however 
confirmed the association of ATOH7 and TGFBR3 through a further GWAS on 2132 
Indians and 2313 Malays in Singapore. Additionally, they found most significance 
associated with a novel gene CARD10, on Chromosome 22q13.1, which encodes 
Caspase recruitment domain containing protein 10. This protein plays a role in 
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apoptosis via a transcription factor called NfkappaB [612]. This pathway has been 
implicated in other neurodegenerative disorders, such a Alzheimer’s disease [613].  
The most common condition related to optic disc parameters is of course glaucoma. 
Ramdas[614] performed a meta-analysis, investigating SNPs found to be related to 
optic disc parameters in populations of POAG upon whom GWAS have been 
completed. Of particular interest, they confirmed 3 loci associated with optic disc 
parameters also having an association with POAG. These included ATOH7.  
Burdon and colleagues [528] discovered an association between CDKN2B-AS1 gene 
and primary open angle glaucoma providing further evidence to the role of this locus 
9p21 in OAG and optic disc morphology.  
4.1.9.3. CENTRAL CORNEAL THICKNESS 
Central corneal thickness (CCT) is a normally distributed quantitative trait known to be 
associated with ocular hypertension and primary open angle glaucoma [615]. Family 
and twin studies have suggested the hereditability of CCT range between 0.6-0.95 [616] 
however, candidate gene analysis provided limited results. Previous studies have 
focussed on genetic mutations associated with collagen disorders and complex 
conditions: FBN-1 [194], collagen V (Ehlers-Danlos)[617], and PAX-6 (Aniridia)[618] .  
Lu et al published a multi-staged GWAS in CCT [619]. They initially performed 
GWAS on two population groups that individually provided weak associations. Meta-
analysis revealed 4 associated SNPs – on chromosomes 16, 13 and 10. They performed 
replication GWAS on further population cohorts, and two SNPs were most significant. 
These were closest to the gene ZNF469 on chromosome 16q24 and FOXO1 on 
chromosome 13q14.1.  
The authors calculate that FOXO1 may account for 1.2% of the variability of CCT. The 
exact role of FOXO1 is unclear. Within the eye, FOXC1 is a transcription factor 
involved in the development of the anterior segment and involved in anterior segment 
dysgenesis. FOXC1 seems to regulate the expression of FOXO1 [620], thus perhaps 
suggesting a role for the latter in anterior segment formation.  
Mutations in ZNF469 had already been described in a Brittle Cornea Syndrome [621]. 
However, the mutations in this condition are very rare, compared to the SNPs found in 
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the GWAS with a minor allele frequency of 0.44. It has been suggested that Linkage 
Disequilibrium is unlikely between these two variants in this gene. This further suggests 
that although there may be similarity between the roles of these variants, there may also 
be significant differences. 
A further GWAS on a Scottish and three Croatian populations further confirmed the 
association of ZNF469 [622]. Meta-analysis with the previously published GWAS 
confirmed the association of FOXC1. Additionally, three further SNPs reached genome-
wide significance. The first was on chromosome 13q12.11 near the transcription factor 
gene AVGR8 (Autogenous Vein Graft Remodelling associated protein 8). The next SNP 
is on chromosome 15q25.3, the linkage block of which extends into the gene AKAP13. 
The encoded protein is thought to link cell surface receptors and transcription factors 
which may regulate collagen production in the ECM in the gastrointestinal tract via 
FOXF2 [623]; a similar role may be postulated within the cornea. The third SNP on 
9q34.3 is near COL5A1. This is of interest particularly, as it initially appeared 
significant in the first GWAS. Functionally, this is an attractive candidate gene. Not 
only are collagen V present within the cornea [624, 625], but mouse models have shown 
that heterozygote COL5A1  null mouse cornea is 25% thinner with fewer collagen 
fibrils than wild type mice [626]. 
More recently, a large GWAS on Caucasians from throughout Europe confirmed the 
association of ZNF469 and COL5A1 [627]. These genes therefore particularly, appear to 
genuinely play a role in corneal thickness.  
4.1.9.4. CORNEAL CURVATURE 
Hereditary influence for corneal curvature have been estimated between 60-92%. 
Previous investigations focussing on candidate genes [628] and monogenic disorders 
affecting corneal morphology [629]provided limited insight into the complex trait. 
Han and colleagues have recently published the first GWAS into this trait[630]. They 
found significant loci associated with FK506 binding protein rapamycin complex-
associated protein 1 (FRAP1) gene and platelet-derived growth factor receptoralpha 
(PDGFRA) gene. These associations were corroborated in a cohort of Indian adults and 
Chinese children. Both these genes encode enzymes with kinase properties. The former 
has effects on cell growth and proliferation [631], whilst the latter induces intracellular 
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kinase activity via enzymes such as MAP kinase, which are known to influence 
collagen fibres [631]. Indeed the role of PDGFRA in cell growth [632] has implicated it 
in fibrotic diseases of the eye such as proliferative vitreoretinopathy [633]. The 
replication of the data within a young population reassures of the role these genes may 
have in corneal development. The ethnic variety within this cohort suggests that the role 
of these genes may be conserved throughout these populations.  
Mishra et al [525]performed meta-analysis on two GWAS Caucasian cohorts, and 
suggest a further gene, TRIM29. This is shown to be expressed in patients with 
keratoconus[634] and to be associated with CC variation. More relevantly, they 
confirmed the association of PDGFRA in corneal curvature variation[525]. This gene 
has also been demonstrated to be significantly associated with corneal astigmatism in a 
GWAS of over 8000 Asian individuals[635]. This gene in particular has become a very 
likely candidate for the heritability of corneal curvature.  
4.1.9.5. INTRAOCULAR PRESSURE 
The greatest controllable determinant towards the aetiology of glaucoma (IOP) is 
thought to have a hereditability of up to 0.62[636]. Van Koolwijk and colleagues[637] 
performed a GWAS, including 11972 affected Caucasians from 4 cohorts, replicated in 
7482 further patients. They found significant association with GAS7 and TMCO1. The 
former of these is thought to play a role in the outflow of the trabecular meshwork and 
has previously been shown through linkage studies to be associated with POAG[638]. 
TMCO1, as mentioned previously, has been suggested to be associated with 
POAG[528]. Van Koolwijk and colleagues also investigated the effect of the minor 
alleles of these genes on POAG. The minor allele of GAS7, which decreased IOP by 
0.19mmHg, reduced the glaucoma risk (OR = 0.88, 95%CI = 0.78–0.98). That of 
TMCO1, which increased IOP by 0.28mmHg, increased the risk of POAG (OR= 1.31 
(95%CI = 1.12–1.53). The evidence of the importance of these genes in the aetiology of 
IOP and POAG is therefore growing. The major success of GWAS in all disease and 
traits is demonstrated in Figure 4.2. 
  
244 
 
  
Figure 4.2: Published GWAS Reports (2005 – 6/2012)  
Adapted from http://www.genome.gov/gwastudies/ 
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4.1.10. MISSING HERITABILITY 
In spite of the over 12000 loci for over 160 complex disorders and traits being 
discovered, it is estimated that the proportion of the heritability of these is minimal; as 
low as 1.5% in fasting glucose[639], to as high as at least 50% in AMD. Therefore the 
term “missing heritability” has been used for this large majority of the genetic 
architecture which is not understood for many complex diseases.  The theories behind 
this are varied. Firstly, this may be secondarily to a simply inflated estimate of 
heritability[640]. Further considerations are to the fact that most GWAS to date have 
been performed on European Caucasian populations[641]. There is ample evidence that 
allele frequencies [642] and LD patterns[643] differ between different populations. 
With greater genetic variation in those of African descent[478], it is perhaps 
unsurprising that a large proportion is unknown. With a growing number of GWAS 
being undertaken in different populations, this may be addressed in time.  
Secondly, there is growing consensus that structural variants play a role in the genetic 
aetiology of complex conditions. The role that copy number variants, copy number 
polymorphisms, insertions, deletions, and complex rearrangements have in Mendelian 
inheritance has been studied at length; however this remains largely unknown for 
complex conditions[644], though in recent years is growing in prominence[645], 
including eye disease[646]. 
There has also been debate as to whether our understanding of LD is complete[647]. 
Furthermore, incomplete tagging by current genotyping SNPs may result in missing 
causal variants[459]. 
4.1.10.1. RARE VARIANT 
The largest proportion of the missing heritability is thought to lie in an alternative 
concept to the CD-CV theory. The “rare variant” theory suggests that complex diseases 
are the result of a summation of high penetrance, low frequency variants[648]. Low 
frequency alleles are defined as having a minor allele frequency (MAF) between 0.5%-
5%, whilst rare are sometimes classified as <0.5% [459]. The recent exponential human 
population growth, particularly over the last 400 generations, has distorted the principle 
of population genetics, resulting in an abundance of these rare alleles[649]. These 
variants may have significant effect sizes (even three fold increases) without conferring 
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a Mendelian segregation[475]. It is thought that rare variants may well be the missing 
link, and may contribute greater to the inheritance of multifactorial conditions than 
common variants[648]. They are more likely to be directly affecting amino acids. It is 
suggested that they may act in a mildly dominant or dominant-negative affect[648]. 
This concept has been discussed for over a decade, with the role of rare variants in 
High-density lipoprotein (HDL) phenotype being one of the earliest discussions on this 
topic[650]. The most telling examples of these rare variants having a significant role 
came from the findings of rare missense variants in the APC gene contributing 
significantly to the aetiology of non-familial colorectal cancer[651], which accounts for 
30-40% of this condition.  
There are numerous other arguments supporting the role of multiple rare variants. It is 
thought that the relatively recent expansion in population may result in numerous 
functionally important rare variants which may influence phenotype[652]. Secondly, the 
role of numerous rare variants to monogenic diseases[653], suggests that such a process 
is possible for complex diseases.   Thirdly, the identity of multiple functional variants 
associated with quantitative phenotypes[654], suggests that this may well be relevant 
for other clinical phenotypes.  
The effect of and search for rare and common variants in complex diseases is illustrated 
in Figure 4.3. 
The exact role that rare variants have may be acting synergistically with common 
variants to influence a phenotype. Alternatively, they may be acting independently or as 
a subset of rare variants in certain locations influencing the phenotype together. A very 
compelling argument is that a given susceptibility gene may contain numerous 
individual rare variants which have differing effect sizes. These may combine and in 
aggregate contribute a significant population attributable risk[655].  
Rare variants are likely to be “younger” (perhaps 10-20 generations old), more 
population specific and may have higher greater effect sizes than common 
variants[648]. 
A major challenge is where and how to search for these rare variants. An obvious start 
is, as with the HDL and colorectal cancer examples above, to sequence candidate genes. 
This harks back to the days before association studies, which had yielded limited  
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results. The major advantage of having a hypothesis free approach is the novel inroads 
made with such approaches. Nevertheless, genotyping chips have been designed to 
search for variants based in genes which are thought to play an important role in 
specific conditions with some success[656, 657].  
The logical target therefore for a hypothesis free approach would be to investigate the 
exome. It is estimated that there are 180,000 exons in the human genome, encompassing 
23000 genes; approximately 1% of the human genome[658]. It is suggested that 85% of 
mutations with an effect on human disease are in the exome[659]. Taking this further to 
complex conditions specifically, Lehne and colleagues found a significant concentration 
of association signals in exons and genes for diseases genotyped as part of the 
Wellcome Trust Case Control Consortium[660]. This was analysing data of common 
genome wide SNPs, and one might therefore envisage this association may be greater if 
the variants were specifically targeted at exonic variants.  
Investigating for rare exome variants has over the last 3 years undergone an exponential 
growth, with the combination of exome capture and NGS. For Mendelian traits and 
conditions, as mentioned in chapter 3, it has proven very successful[18], including in 
ophthalmic traits[661]. It is undoubtedly true that this method has unrivalled power to 
discover rare exome variants. However, the power gains may be small compared to 
genotyping arrays[662], and the cost are still prohibitive for large scale analysis.  
Although there is much debate as to the utilisation of NGS in complex conditions, and 
probably the future of association studies[663], the design and analysis are 
challenging[664]. A summary is presented in table 17. 
Microarray genotyping may be utilised as an alternative to exome capture NGS. By 
selecting variants from the large scale whole genome and whole exome (such as [246, 
248]) studies, and focussing on those which are predicted to affect protein structure, it is 
possible to select a significant proportion to be included on a genotyping array, which 
are most likely to have a functional effect on almost every gene in the genome. 
Towards investigating the exome on a large scale, in 2011, the two genotyping 
companies released genotyping arrays specifically towards this. These include the 
Illumina HumanExome BeadChip and the Affymetrix Axiom ® Exome genotyping 
array.   
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Rare variant 
genotyping 
Exome Sequencing Array 
Coverage of exomic 
variants 
+++ + 
Throughput + +++ 
Cost per sample +++ ++ 
Ease of analysis + +++ 
Scalability to large 
studies 
+ +++ 
 
  Table 17: Exome sequencing and array based analysis. 
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4.2. AIMS 
The aims of this chapter are three fold. Firstly, it describes and discusses the ocular 
phenotype of 1302 consecutively collected unrelated patients with non-Mendelian RD 
presenting to Moorfields Eye Hospital. Secondly, the cases collected contributed 
towards the first GWAS into RD. This work was based at the MRC Human Genetics 
Unit, University of Edinburgh. This GWAS is presented here. Following on from this 
GWAS, further work is being undertaken to investigate the role of rare exome variants 
in non-Mendelian RD. This chapter describes the initial quality control of data of 
genotyping 2000 samples on the Illumina HumanExome BeadChip.  
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4.3. METHODS  
Consecutive patients presenting with a primary RD to the vitreoretinal department at 
Moorfields Eye Hospital were phenotyped and had blood extraction. For the analysis, two 
racial groups were focussed on; White Caucasians (defined as persons whose both parents 
were are of European descent) and patients who were South Asian (defined as persons 
whose parents were ethnically from India, Pakistan, Bangladesh or Sri Lanka).   These 
races were chosen as it is believed that the numbers of patients from these racial groups 
represent the greatest number of RD cases presenting to Moorfields Eye Hospital. Other 
units in the UK have similar experiences[665]. The intention was to provide comparative 
data, and provide a biobank of DNA for investigations in different racial groups. Patients 
who have had previous retinal surgery or penetrating injury were excluded, as were 
patients who had had complicated cataract surgery (associated with vitreous loss) or any 
cataract surgery within the previous two years. The blood was stored in a freezer in the 
vitreoretinal emergency (VRE) clinic. When appropriate (approximately every month), the 
samples were transferred to the UCL Institute of Ophthalmology (IoO) department of 
Genetics. However, on the 18th February 2011, I was informed that the freezer at the IoO 
in which 236 samples had been stored had had a power failure, which was not noticed for 
at least 48 hours. The samples had all defrosted. On this realisation, all the samples were 
transferred to KBiosciences (now LGC Genomics (Herts, UK)) for permanent storage and 
DNA extraction. We were fortunate that the 48 hours of defrosting had not adversely 
affected the DNA concentrations. Samples were subsequently transferred directly from the 
VRE freezer to LGC Genomics (Herts, UK) for DNA extraction. 
4.3.1. DATA COLLECTED  
Each patient was examined and phenotyped. Patient demographics were collected.  
Demographic data included: age, sex, ethnicity, parental ancestry, Occupation, History of 
ocular trauma and type of trauma and Family history of eye disease. 
4.3.2. PHENOTYPE DATA 
Refractive error and axial length (prior to cataract or retinal surgery) was collected. This 
was achieved (if phakic) by autorefraction (NIDEK) or focimetry through participants’ 
glasses.:   
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Axial length was assessed using the IOL master (Carl Zeiss Meditex, Jena, Germany), if 
the fovea was attached) or Bscan. Previous ophthalmic history, including date of any 
previous ophthalmic surgery or laser treatment. 
Family history of RD: A positive family history was regarded as any first or second degree 
relative affected by RD. 
Snellen Chart visual acuity: This was assessed at 6 meters using a standard Snellen chart. 
Best corrected visual acuity (BCVA) was assessed for individual eyes. 
The anterior segment was assessed and pupils were pharmacologically dilated (G. 
Phenylephrine 2.5% and G. Tropicamide 1%). Fundus examination was performed on both 
eyes, and indirect ophthalmoscopy with indentation was performed. Detailed retinal 
phenotype was assessed.  
4.3.2.1. OCULAR FEATURES 
A myopic refractive error was defined as spherical equivalence (SE) of -1DS or greater, 
and hypermetropic refractive error as greater than +1DS.  
Rhegmatogenous Retinal Detachment was regarded as a full thickness break in the 
neuroretina accompanied by two disc diameters or greater of sub retinal fluid.  
Posterior vitreous detachment (PVD) is regarded as separation of the vitreous from the 
inner limiting membrane of the retina. Although diagnosis can be challenging, the presence 
of a Weiss ring is regarded as indicating a complete PVD[666].  
Trauma was regarded as direct or indirect trauma to the eye resulting in an ophthalmic 
review. 
Proliferative vitreoretinopathy (PVR): this abnormal scarring of the retina was graded 
according to the Retina Society Committee[667]. 
Details collected regarded the phenotype of the RD at presentation: quadrants involved (1-
4), macular involvement, PVR presence and grade, type of break (atrophic holes, tractional 
tears, dialysis, giant tear) – documented by standardised retinal drawing. Characteristics of 
the vitreous were documented:  – attached or detached. If both eyes were affected, this data 
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was collected from both eyes. If unilateral presentation, phenotype of the vitreous and 
retina were collected regarding the contralateral eye – documented by retinal drawing. 
DNA samples were collected and used as part of two genotyping experiments. The first 
was part of the “Scottish Retinal Detachment Genome Wide Association Study”. 
Secondly, 1000 samples were used as part of a novel genotyping analysis investigating 
the Exome; using the Illumina HumanExome BeadChip. 
4.3.3. GENOME WIDE ASSOCIATION STUDY ON 
RHEGMATOGENOUS RETINAL DETACHMENT 
Most of this work was undertaken by my colleagues Dr Veronique Vitart and Mirna 
Kirin, at the MRC Human Genetics unit at the University of Edinburgh. I attended 
where possible, and undertook some analysis, under supervision. In particular, I 
undertook association analysis of significant SNPs between the cases recruited from 
Moorfields Eye Hospital and controls.  
The GWAS was designed in 2-stages. Satagopan and Elston[668] demonstrated that this 
method was a cost effective approach to discovery stage of GWAS. In this method, all 
markers are genotyped in a subset of cases and controls. The most promising markers 
are subsequently genotyped in the remaining individuals. They are then analysed in all 
individuals in stage 2. They illustrate that this method can be very effective compared 
with one step method; and significantly reduce the costs of genotyping.  
The first stage involved genotyping DNA from 912 Scottish RD study which recruited 
all primary RD cases from the six vitreoretinal surgical centres in Scotland during 
October 2007- November 2009[669]. These samples were genotyped using the Illumina 
CNV370v3 Quad genotyping array comparing the genotypic counts with 1,986 ethnicity 
matched Scottish controls that were previously genotyped using the Illumina Hap 300 
and Hap240S in the Scottish Colorectal Cancer Study[670].  This cohort was collected 
between 1996-2009, as part of the population-based study of colorectal cancer in 
Scotland. Although there was an age difference between the RD cases and the SOCCS 
controls (RD mean age(Standard Deviation))=58.9(13.8); SOCCS controls mean 
age(SD)= 50.16(6.1); p<0.001)), and a gender imbalance ((RD(N) cases: 
Male(513):Female(355) = 1.44:1 and SOCCS cases and controls(N): 
Male(1,003):Female(965)= 1.04:1 ; χ2 difference –15.92;p<0.0001)), this group was 
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still deemed a suitable control group; particularly as there was no difference in 
geographical origin between the two groups. Furthermore, the chip used by the controls 
(Illumina Hap300 and Hap240S) which together cover 95% of the SNPs on the Illumina 
CNV370v3, used in the cases. 
After quality control, 299737 SNPs were genotyped on 867 cases and 1953 controls. An 
association analysis was performed on these. The P value was corrected with a 
Bonferroni correction based on 197628 independent SNPs; being 1.27x10-7.  This was 
the first discovery stage.  
In the second discovery stage, 4347 SNPs were taken forward to be genotyped on 748 
cases from the UK (457 of which were recruited at Moorfields Eye Hospital), 252 cases 
from the Radboud University Nijmegan Medical Centre, Netherlands, and 2912 controls 
(2592 from the 1958 birth cohort and 320 from the control candidates of a Dutch 
schizophrenia study). These SNPs consisted of, initially, 4706 SNPs from the first stage 
which reached a significance of p<10-3 and 1275 SNPs tagging (r2>0.8) 18 candidate 
genes (Table 18). These candidate genes had been chosen as potentially biologically 
relevant in RD. 
Quality control resulted in the 4347 SNPs being analysed. Association testing was done 
for each cohort separately, and then re-run in a meta-analysis. The p-value was set at the 
same 1.27x10-7.  
The seven most significant SNPs from this discovery cohort were taken forward for 
replication. These were genotyped on 846 samples collected from Moorfields Eye 
Hospital, 2737 controls from the National Blood Service[464], 120 cases collected from 
the University Clinical Hospital, Zagreb, Croatia and 269 controls which had been 
collected for a colorectal study based on Croatia. The analysis of the Moorfields Eye 
Hospital samples in this stage was undertaken by myself directly under supervision by 
Dr Veronique Vitart and Mirna Kirin in Edinburgh. This was undertaken in 
PLINK[671] by creating PED and MAP files.  
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Candidate 
gene 
Number of selected 
tagging SNPs  
per gene 
(Number successfully  
tested) 
Candidate 
gene 
Number of selected  
tagging SNPs  
per gene  
(Number successfully  
tested) 
COL11A1 34 (14) LAMA1 161 (67) 
COL18A1 58 (29) LAMB1 54 (24) 
COL2A1 54 (21) LAMC1 41 (13) 
COL4A4 62 (42) OPTC 33 (7) 
COL6A1 39 (16) VERSICAN 116 (42) 
COL9A1 89 (45) FBN1 56 (20) 
HAS1 95 (50) FN1 46 (12) 
KCNJ13 16 (4) FZD4 62 (24) 
HAPLN 28 (13) COL11A2 48 (15) 
 
  
Table 18: Genes believed to be biologically relevant to RD, for which tagging 
SNPs were chosen to take forward to stage 2 of the discovery stage.  
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Association was performed, and subsequently, results from both the discovery stages 
and replication stages were combined in a meta-analysis. For this overall meta-analysis, 
the p value was set at the conventional[483] 5x10-8 , corrected for the use of two genetic 
models to 2.5x10-8. A summary of the methodology is in Figure 4.4 
4.3.3.1. PATHWAY ANALYSIS 
A challenge upon highlighting important regions (for example haplotype blocks tagged 
by SNPs) is to identify key genes from within these regions which may be related and 
thus be involved in common pathways. Beyond LD, there are likely to be other related 
genes which contribute to the phenotype. The most used method to highlight these has 
involved using protein function to prioritise genes in regions[672, 673]. Identifying 
shared function can involve using established molecular networks[673] or starting with 
sets of genes with known common functions[672]. Alternatively, functions thought to 
be relevant to the disease or phenotype may be used to identify genes [674]. 
Raychaudhuri and colleagues devised an approach which relied on two key methods: a 
novel statistical strategy which assessed the significance of gene relatedness; and a 
similarity measure based on text in PubMed abstracts to score relatedness of two genes. 
This system was called “Gene Relationships Among Implicated Loci (GRAIL)[675]. 
The system has variable statistical thresholds to consider relatedness; with narrow 
regions having lower thresholds, and large regions higher. In this manner, large regions 
with many genes are prevented from dominating the analysis. They have demonstrated 
that their system was able to link genes which had not till then had established common 
pathways defined, and compared favourably to other established methods. Other groups 
have since successfully utilised GRAIL[676, 677]. 
The first six top ranking SNPs displaying the same direction of effect from the meta-
analysis (thus with low heterogeneity) were selected to be further analysed using 
GRAIL.  
The genes highlighted through GRAIL were then investigated for pathway analyses 
using Ingenuity® Systems (www.ingenuity.com). This software uses regularly updated 
internal databases to identify networks between related genes.  These networks are 
thought to represent important biological functions. The molecules which are entered 
are then added to molecules from the ingenuity database (with a maximum total of 35 
molecules) to create networks.   
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Figure 4.4. Schematic diagram illustrating methodology for GWAS in RD 
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These are then scored based on the number of molecules in the network and the size of 
the network. This score is converted into a statistical p-value; which represents the 
likelihood of the molecules interacting together randomly. This system has been used 
successfully to uncover pathways from GWAS findings[678, 679] and is comparable to 
other pathway analytic systems[680]. 
The parameters used for this analysis were; only direct relationships were used, high 
confidence reliability (experimentally observed) and pathways involved in all diseases, 
biofluids and all possible mutations were included. 
4.3.4. EXOME WIDE ASSOCIATION STUDY ON 
RHEGMATOGENOUS RETINAL DETACHMENT 
Subsequent to the GWAS performed, it was decided to further investigate for the 
missing hereditability of RD. As mentioned, it is believed that rare variants may play a 
significant role in this. Exome rare variants are likely to be particularly significant. 
Although NGS would undoubtedly offer the deepest coverage to investigate for these, 
the limitations both financial and bioinformatic are not insignificant. We therefore 
decided to consider an alternative approach. 
As mentioned in the introduction to this chapter, Illumina and Affymetrix in 2011 had 
released novel genotyping arrays aimed at investigating for variants based within the 
exome. These seemed the perfect tools to enable our investigations. 
4.3.4.1. POWER CALCULATIONS 
Power calculations for GWAS are challenging[681]. Furthermore, calculations for rare 
variants are not well defined. Certain assumptions, upon which most power calculators 
are based, may not be valid in rare variant analysis. For example if utilising collapsing 
methods for allele analysis (see Section 4.6.1.2), the correction for multiple testing used 
in GWAS may be conservative. Nevertheless, no specific calculators are available for 
Exome Wide Association Studies.  
Using the Genetic Power Calculator (http://pngu.mgh.harvard.edu/~purcell/gpc/) we 
explored the number of cases required to provide 80% power at a genome wide type I 
error rate of 1x10-7. Most GWAS have demonstrated a genotypic relative risk (GRR) of 
1.1-1.7 [682]. Assuming for GRR of 1.5, in perfect LD with typed marker (r2=1), 
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MAF=0.1 (rare), disease prevalence of 0.0001 and a multiplicative inheritance model, 
we estimated that 1483 cases would be sufficient to provide 80% power for an type I 
error rate of 1x10-7 (Table 19). 
On this basis we were successfully awarded two grants; The Major Project Grant from 
the Royal College of Surgeons of Edinburgh (2012); and Research Grant from the 
Special Trustees of Moorfields Eye Hospital (2012). I then approached various 
institutions regarding genotyping our cohort of 1996 Caucasians collected from 
Moorfields Eye Hospital (n=999) and as part of the Scottish Retinal Detachment study 
(n=997) with RD on one of the above Exome centred arrays. The Institute of Psychiatry 
at King’s College London offered the most cost effective and timely service for 
genotyping the samples on the Illumina HumanExome BeadChip 12 v1.1. This 
laboratory was also able to provide PLINK files from 5963 samples collected as part of 
the British 1958 birth cohort which would be genotyped on the same array. This cohort 
would be valuable to be used as control data. In addition, our collaborators in Edinburgh 
are part of the team analysing genotype data of samples from the Biobank Generation 
Scotland (http://www.generationscotland.org/). This biobank has over 30000 DNA 
samples to be used as controls in the investigation of complex diseases. Over 10,000 of 
these samples have been genotyped with the Illumina HumanExome BeadChip. Access 
to this dataset would prove a further valuable resource for control data, and would be 
used to match the Scottish cases in the analysis and control for population stratification. 
4.3.4.2. ILLUMINA HUMANEXOME BEADCHIP  
This array was designed and released in December 2011. It is based on exome and 
whole genome sequencing of over 12000 individuals, from a wide range of ethnicities 
(Table 20-21). 
This chip is designed to therefore provide a cost effective method of investigating 
variants which are thought to be functional and which may be causative in complex 
phenotypes and diseases. Its utility has recently been demonstrated in analysis of the 
role of rare variants in cardiovascular disease[683] and type 2 diabetes[684]. 
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Alpha Power 
N cases for 80% 
power 
0.1 1 276 
0.05 1 344 
0.01 1 497 
0.001 0.9999 704 
1e-07 0.9694 1483 
 
 
 
  
Table 19: Power calculation for various type 1 errors for GWAS on above 
parameters: (From http://pngu.mgh.harvard.edu/~purcell/cgi-bin/cc2.html) 
Highlighted is the power calculation described 
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.  
 
Contributor    Enrichment    Major Ethnicity    N        
NHLBI Exome Sequencing 
Project (5 tranches)  
Cardiovascular Traits, Lung 
Traits, Obesity 
European, African 
American  
4260 
Autism (2 tranches) Autism European 1778 
GO T2D (2 tranches) Type 2 diabetes European 1618 
1000 Genomes Project (2 
tranches) 
Random Sample Diverse 1128 
Sweden Schizophrenia 
Study 
Schizophrenia European 525 
SardiNIA Random Sample European 508 
Sanger / CoLaus 
Overweight, Diabetes, 
Fasting Glucose 
European 456 
Cancer Genome Atlas Cancer European 422 
T2D Genes Type 2 diabetes Hispanic 362 
Cancer Cohort Study Cancer Chinese 327 
Pfizer – MGH – Broad 
Type 2 diabetes extremes of 
risk 
European 182 
Lipid Extremes Lipid Extremes European 131 
Int’l HIV Controllers Study HIV Controllers European 121 
SAEC DILI (merged 
w/Autism tranches) 
Augmentin DILI European 117 
I2B2 - Major Depression 
Major Depression, Major 
Depressive Disorder 
European 50 
BMI Extremes BMI Extremes European 46 
Table 20:  Illumina HumanExome BeadChip genetic data source. Adapted from 
http://genome.sph.umich.edu/wiki/Exome_Chip_Design 
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Illumina Assay Design Summary 
SNP Set 
Number of  
  Successful Designs   
Coding Content 243,094 
GWAS Tag SNPs 5,325 
Grid of Common Variants 5,286 
Randomly Selected Synonymous SNPs 4,651 
AIM - African Ancestry 3,241 
AIM - Native American Ancestry 998 
HLA Tags 2,459 
ESP Requests 843 
Fingerprint SNPs 259 
MicroRNA Target Sites 270 
Mitochondrial Variants 246 
Chromosome Y 128 
Indels 181 
 
Table 21: Content of Illumina HumanExome BeadChip.  Adapted from 
http://genome.sph.umich.edu/wiki/Exome_Chip_Design 
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4.4. OCULAR PHENOTYPE OF 1309 CONSECUTIVELY RECRUITED 
PATIENTS 
4.4.1. RESULTS 
Between April 2010 and August 2010, 457 blood samples from white Caucasian 
patients who had suffered a RD were sent to Edinburgh to be analysed in the Scottish 
GWAS into RD.  
Between August 2010 and December 2012, 1309 patients with primary RD were 
collected and phenotyped. It is not possible to accurately assess what proportion of 
primary RD of those seen at Moorfields Eye Hospital that this represents. It is estimated 
that the hospital sees 1000 patients a year with the diagnosis of RD. Our total would 
represent approximately 65.6% of the patients seen with this diagnosis over this period. 
However, the figure of 1000 per year is only a rough estimate, and does not differentiate 
between primary or re detachments. This denominator does not take into account the 
criteria we set for inclusion and exclusion. We therefore reasonably assume that the 
eligible number of patients over this period was significantly less than can be estimated. 
Our proportion is therefore likely to be greater than 65%.   
These included 136 non Caucasians; of which 96 were regarded as from the Indian 
Subcontinent (herein termed “South Asians”), and the rest (n=40) were regarded as 
“Other”. These other races included “Chinese”, “Black”, and “unknown”.  For the 
purpose of analysis, racial differences were analysed between Caucasian and South 
Asians; as the numbers in other groups were too small and heterogeneous. A summary 
of the phenotype demographic and phenotype data is in table 22. 
4.4.1.1. AGE 
The mean age was 57.72 years (SD: 13.26years) (Figure 4.5).  Racial differences were 
seen. The Caucasian population had a mean age of 58.27 years (SD: 13.09). The South 
Asian population had a mean age of 54.49 (SD:  13.9) and were significantly younger 
than the Caucasian patients (P=0.006). 
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 TOTAL CAUCASIAN ASIAN OTHER 
Sex Male 851 756 71 24 
Female 458 417 25 16 
Age 
Groups 
(Years) 
0-9 0 0 0 0 
10-19 4 4 0 0 
20-29 45 33 9 3 
30-39 82 67 7 8 
40-49 186 170 11 5 
50-59 363 318 31 14 
60-69 399 365 31 3 
70-79 156 147 7 2 
80+ 50 49 1 0 
Affected 
Eye 
Right 617 556 49 12 
Left 620 555 46 19 
Both 14 12 0 2 
Lens 
Status 
Phakic 892 814 52 26 
Pseudophakic 310 267 37 6 
Aphakic 7 4 2 1 
 
  
Table 22: Demographic and lens status of patients recruited for RD Study. 
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Figure 4.5: Age distribution (years) of patients recruited 
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4.4.1.2. LATERALITY 
There were an equal proportion of left and right eyes affected (621 and 617 
respectively). There were 14 (1.1%) of eyes which were affected bilaterally. There was 
no significant difference regarding this laterality. Neither was there a difference 
between the races. 
4.4.1.3. GENDER 
There were 442 females and 827 males (1:2.84) affected in the two main ethnic groups. 
This suggests prevalence for men to be affected. Additionally, the proportion of men 
was greater in South Asians (74.0%) than in Caucasians (64.5%) and suggested a 
significant trend (P=0.06). 
4.4.1.4. LENS STATUS 
14 aphakic patients were recruited. Their blood was however not forwarded for DNA 
extraction. 75.3% of Caucasians were phakic, whilst 58.4% of Asians were phakic. This 
was a statistically significant difference (P<0.001). Asian patients were more likely to 
be pseudophakic (or aphakic) than Caucasians. 
4.4.1.5. BREAK TYPE 
The break type was reported in 1247 of affected eyes. The most common type of NSR 
break was a horseshoe tear, followed by a round hole. Other types of NSR breaks are 
documented in the table 23. There was no significant difference between these groups.  
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 Study Eye 
 TOTAL CAUCASIAN SOUTH 
ASIANS 
HST 977 868 75 
Round 214 182 17 
GRT 31 23 2 
Dialysis 25 20 0 
 
  Table 23: Types of neurosensory retina breaks found in the RD cohort.  
HST: Horseshoe Tear. GRT: Giant Retinal Tear 
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4.4.1.6. FAMILY HISTORY 
A positive family history (first or second degree relative) was demonstrated in 171 cases 
(13.2%). This was reported in 149 (12.8%) Caucasian cases, and 19 (19.4%) South 
Asians. There was no significant difference in the rate of family history between the 
ethnic groups. 
4.4.1.7. LATTICE DEGENERATION 
Lattice degeneration was present in 218 patients. This was present in 149 (12.8%) of the 
Caucasian patients, and 19 (19.4%) of the South Asian patients.  
This difference was significant (P=0.003). South Asian patients with RD were more 
likely to have lattice degeneration in the affected eye.  
4.4.1.8. REFRACTIVE ERROR & AXIAL LENGTH 
The mean spherical equivalence for phakic affected right eyes was -4.48DS (SD 4.07). 
The mean axial length in this eye was 25.08mm (SD 1.9).  
The mean spherical equivalence for phakic affected left eye was -4.18DS (SD 3.92). 
The mean axial length in this eye was 25.07 (SD 1.78). There were no significant 
differences with between the eyes. 
Comparisons between races, revealed that South Asians were significantly more myopic 
(mean -6.1DS) compared to Caucasians (-4.2DS) (P=0.032).  Mean axial lengths was 
25.06mm (SD 1.82) in Caucasians and 25.65mm (SD 2.30) in Asians (P=0.014). This 
significance was maintained in phakics (25.03mm (SD 1.80) in Caucasians, 25.85mm 
(SD 2.47) in South Asians: P=0.01)). 
Correlating axial length with spherical equivalence revealed a good correlation; 
increasing axial length being associated with decreasing spherical equivalence (Figure 
4.6).  
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4.4.1.9. MACULA STATUS 
Macular status was recorded for 1016 (86.4%) of Caucasians and 91 (92.9%) of Asians. 
The proportion of patients with macula on or bisecting was 50.51% (Caucasians) and 
44.9% (South Asians). This was not significant.  
4.4.1.10. LOGISTIC REGERESSION 
A logistic regression model was performed to analyse the predictors which would 
determine the different types of NSR breaks.  
For the purpose of these analyses, age was determined as a continuous variable, per 
year. Sex was comparing males vs. females. Axial length was analysed as a continuous 
variable, per mm. Ethnicity was analysed for Caucasians compared to South Asians.  
The interpretation for these is that age is the strongest determinant for the type of break 
seen. Younger patients are more likely to experience a round hole, whilst older patients 
a HST. Furthermore, it appears that ethnicity was also important in the development of 
a HST; with Asians more likely to suffer a HST RD. 
The relationship between race and age is further demonstrated in Figure 4.7. It suggests 
a steeper relationship with age and risk of developing a HST RD for Asians.  
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Round Holes: 
Round Holes: Odds ratio Stand Error P Value 95% CI 
Age 0.93 0.008 <0.0001 0.92 -   0.95 
Gender 1.33 0.28 0.18 0.88-    
2.02 
Axial length 1.01 0.055 0.84 0.91-    1.12 
Family 
History 
0.85 0.25 0.59 0.48-    
1.51 
Ethnicity 0.75 0.29 0.46 0.35-    1.61 
 
Horseshoe tear: 
HST Odds ratio Stand Error P Value 95% CI 
Age 1.06 0.007 <0.0001 1.04-    1.07 
Gender 0.88 0.16 0.45 0.62-  
1.24 
Axial length 1.04 0.049 0.37 0.95-     1.14 
Family 
History 
1.13 0.28 0.61 0.70-    
1.83 
Ethnicity 2.14 0.77 0.035 1.05-    
4.34 
 
Table 24: Results of logistic regression model using different types of NSR breaks as 
outcome.  Highlighted are the statistically significant variables. 
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Figure 4.7: Relationship between race, age and development of a horseshoe tear RD 
Asians 
  Caucasian 
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4.4.2. DISCUSSIONS 
The ocular phenotype of 1309 consecutive patients with primary RD was acquired over 
28 months from the vitreoretinal department of Moorfields Eye Hospital. The majority 
of the patients were Caucasian (89.6%), with 7.3% being Asian and 3.05% being other.  
Differences in phenotype were analysed between the two largest racial groups in this 
cohort; Caucasians and those ethnically South Asian.  
4.4.2.1. AGE 
The peak age for RD is between 60-69[96, 685-687]. The incidence in this age bracket 
has been reported as high as 70 per 100,000 in one 20 year epidemiological study[688]. 
Our data agrees with this (Table 22), across both racial groups. This peak age bracket 
has not been explained adequately. Although the rate of PVD (the invariable pre-cursor 
for most horseshoe tear (HST) RD) is known to increase with age[689] it has been 
suggested to be present in 11% of 60-69 year old, and 46% of 80-89 year old[690]. One 
could infer from this that the incidence of RD should continue to increase. Furthermore, 
the pathological event of RD is likely to occur more frequently in an “incomplete 
PVD”[81]. In a prospective study using modern imaging techniques to diagnose 
incomplete PVD, Shao and colleagues[691] suggest that the prevalence of an 
incomplete PVD is higher in younger age Chinese; with a minimal prevalence occurring 
between 75-80 years. The reason why the peak age for RD is between 60-69 years is 
therefore uncertain. This may suggest that PVD occurring in younger patients (60-69 
years) may present with an abnormal PVD more frequently than those at a later age. 
Alternatively, there may be simply other health factors influencing the number of more 
elderly patients presenting with RD. Indeed, the life expectancy in England in 2010 was 
78.2 years for men and 82.3 years for women[692]. This may influence the rate. 
It has been suggested that there is a bimodal incidence pattern; with a smaller peak 
between 20-29[105, 685, 693, 694]. However, the largest UK epidemiological study 
into this condition did not replicate such a bimodal distribution[687]. Our age spread 
was in keeping with this latter epidemiological study. This suggests that the main 
determinant of RD is likely to be vitreous liquefaction, which increases with age.  
The racial differences in age are novel. This data suggests that South Asians patients 
with RD were younger than Caucasians, particularly in the development of HST. 
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Rosman and colleagues[695] analysed 916 RD cases in Singapore over a 4 year period. 
The mean age for RD (for three Racial groups in the study; Chinese, Malay and Indian) 
was 46.1 years; and this group were the first to postulate that RD may occur at a 
younger age in Asians (their terminology included the three races in their study). 68.1% 
of the 22 Indians in their cohort were aged under 60 years old. 
Few other robust studies have documented a racial difference in RD. Mowatt and 
colleagues[665] investigated the rate in the Midlands in the UK. They demonstrated that 
Indians had a rate of 2-4.6 per 100,000, whilst the incidence in Caucasians  ranged from 
6.3-13.0 per 100,000 in two different towns eight miles apart. The age differences in 
between Indians, Caucasians and Black patients were not described in this study. Wong 
and colleagues[105]also describe a lower incidence amongst Indians (3.9 per 100,000) 
compared with Chinese (11.6 per 100,000). A small study from India described the 
mean age of those with unilateral RD as 38.8 years[696]. No explanation has been given 
to the differences between races.  
4.4.2.2. GENDER 
There were a higher number of men affected by RD (1.85:1). This trend was more 
marked in South Asians (2.84:1) compared to Caucasians (1.81:1), which although did 
not reach statistical significance (P=0.06), does suggest a trend. The reason behind men 
being more prone to RD has often been suggested as trauma[90]. However our cohort 
did not include traumatic RD. The difference is maintained, when excluding for 
trauma[686, 687, 694]. It is possible that the higher rate of myopia seen in men, or the 
earlier extension of the vitreous base seen in men[77, 101] may be significant 
contributing factors. These differences may be more pronounced in Asians.  
4.4.2.3. LENS STATUS 
25.80% of the cohort was pseudophakic. This is in agreement with the largest UK 
epidemiological study; which demonstrated a rate of 21.6%[687]. Other large cohorts 
suggest this rate to range between 10-30%[693, 697]. The rates have decreased since the 
advent of extracapsular and phacoemulsification cataract surgery. There are however 
reports that the proportion of pseudophakia is increasing, in line with the increase in 
cataract extraction over the last two decades[698, 699].  
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It has been suggested that phenomenon may be secondary to higher rates of PVD and 
vitreous collapse after uncomplicated cataract extraction[82, 700]. What is particularly 
interesting is the higher rate of pseudophakia in Asians (P<0.001) which has not been 
previously demonstrated. It is suggested that the age of onset of cataract is younger in 
British Asians compared to Caucasians[701], thus the rate of cataract surgery may be 
greater. However, as a proportion; lens extraction is a more important feature in Asians 
than Caucasians. This may be due to vitreous differences in Asians; making this group 
more susceptible to changes after cataract surgery. This would need further 
investigation to offer any further speculation.  
4.4.2.4. LATTICE DEGENERATION 
Lattice degeneration was present in 16.7% of the cases. This is lower than previous 
historic reports[69]. However, European reports range from 7%- 29%[108, 702]. The 
largest UK study suggested lattice degeneration to be present in 18.7%[97]. Our data is 
therefore consistent with this range.  
The statistically significantly increased rate seen in South Asian patients poses 
interesting results. Rosman et al.[695] suggest that lattice was present in 31.8% of 
Indians with RD (a small cohort of 22 patients). This higher prevalence of lattice 
degeneration may explain the younger age of Asians with RD. It is likely that this data 
has confirmed the suggestion that lattice degeneration is more common in patients with 
RD from this racial group. 
4.4.2.5. REFRACTIVE ERROR AND AXIAL LENGTH 
The myopic error found in phakic patients was not markedly different to previous 
reports[97]. This may be secondary to the urbanised catchment area of Moorfields Eye 
Hospital; urbanisation has been shown to be associated with higher rates of 
myopia[703]. Moreover, it is of interest that Asians appeared to be more myopic than 
Caucasians. Rosman and colleagues[695] did not provide mean refractive error for their 
cohort, but 7 out of 22 (31.8%) were reported as having myopia > -5DS.  
The correlation between axial length and refractive error agrees with epidemiological 
studies investigating this in a similar population[704].  
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Certain features of the cohort did not demonstrate significant differences between the 
two racial groups.  
4.4.2.6. LATERALITY 
It has been suggested that RD occurs more frequently in right eyes [108, 687, 688]. The 
current data did not confirm this, and was consistent between two races.  
4.4.2.7. BREAK TYPE 
The most common type of break was a HST; which is in keeping with previous 
studies[687]. This is due to the combination of traction on the retina; at the tip of the 
horseshoe, increasing the likelihood of liquefied vitreous tracking underneath[34]. The 
only determinants in the logistic regression models were age; round holes appearing in 
younger patients and HST in older. This relationship is well established. 
4.4.2.8. MACULA STATUS 
The proportion of patients presenting with a macula involving RD was similar to UK 
epidemiological studies[97]; suggesting a good access to health care for these patients.     
4.4.2.9. FAMILY HISTORY 
The proportion of patients who admitted a first or second degree relative with RD is 
greater than previous reports, which report rates between 1% - 8.2%[96, 97, 170]. This 
may reflect population differences between the various studies. Alternatively, the direct 
questioning in this dataset may have revealed a true higher rate. There was no difference 
between the races; and is consistent with other complex inherited ocular conditions. 
In summary, much of the data from this cohort agrees with findings from large 
epidemiological studies. Furthermore, differences in the phenotype of the two main 
ethnicities investigated here is novel. It appears that patients from the Indian 
subcontinent, although are suggested to suffer from RD at a lower rate to Caucasians, 
seem to have more severe phenotype if affected. This includes having more severe 
myopia if phakic, greater axial lengths, a greater proportion of lattice degeneration and 
have a younger age of onset for disease. 
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4.5. GENOME WIDE ASSOCIATION STUDY ON 
RHEGMATOGENOUS RETINAL DETACHMENT 
4.5.1. RESULTS 
In total after quality control measures, the case-control analysis included 299,869 SNP 
in 870 cases of RD and 1,968 controls. Case control analysis was performed by the 
group based in Edinburgh using both PLINK and the GENABEL software in R. After 
logistic regression analysis, with the stringent significance rates applied, one SNP 
reached genome wide significance (1.88x10-9); rs10510663 on 3p22.3 (Figure 4.8). This 
SNP was not significantly associated in the second discovery stage in either the 
Moorfields Eye Hospital (p=0.86) or Dutch (p=0.24) samples. After meta-analysis the 
top ranked SNPs and their genes are in table 25. 
This highest ranked SNP was rs12960119, located on 18q11.2 in an intron of SS18. The 
direction of effect was consistent across the three populations. This was true for most 
SNPs with p<10-4. 
Using GRAIL for the six most significant SNPs with the same direction of effect 
revealed gene relatedness shown in table 26. 
4.5.1.1. INGENUITY NETWORK ANALYSIS 
When analysed using IPA (www.ingenuity.com) revealed on highly significant (p=10-
62) network (Figure 4.9). This network showed enrichment for molecules involved in 
DNA replication and cell death. The most significant systems involved were the 
development of the haematological system.  
4.5.1.2. REPLICATION PHASE 
The six most significant SNPs and one further with low heterogeneity across studies 
were taken forward for replication. These SNPs are listed in table 26. These were typed 
in 846 samples from our cohort at Moorfields Eye Hospital, and 120 cases from Croatia. 
This was done by myself in conjunction with colleagues in Edinburgh. 
This is undertaken using PLINK[671]. PED and MAP files were created. Subsequently, 
SNPs of interest were extracted from control database acquired from the 1958 birth 
cohort (provided as BED and BIM files).  
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SNP Minor 
allele 
CHR CEU  
MAF 
OR 
(95%CI) 
Association  
p -value 
Direction GRAIL  
input genes 
Genes in 
LD block 
r2>0.8 
with 
index 
SNP 
rs12960119 G 18 0.075 1.46 
(1.26-1.67) 
1.58E-07 +++ PSMA8, TAF4B, 
SS18  
SS18, 
PSAM8 
rs267738 C 1 0.275 0.79 
(0.71-0.87) 
6.7E-06 --- GOLPH3L, 
CTSK, 
FAM63A, 
SETBD1, CTSS, 
MCL1, CERS2, 
ANXA9, 
PRUNE, ARNT, 
HORMAD1, 
ADAMTSL4, 
ENSA 
CERS2 
rs955943 A 4 0.067 1.54 
(1.27-1.87)  
9.9E-06 +++ LDB2  LDB2 
rs7097067 A 10 0.075 1.65 
(1.32-2.07) 
1.28E-05 -++ PPA1, 
NPFFR1,TYSN
D1,AIMF2, 
SAR1A 
PPA1,NP
FFR1 
rs1074463 A 5 0.092  1.31 
(1.16-1.48)  
1.28E-05 +++ CDH12 CDH12 
rs2045084 G 8 0.425 1.21 
(1.11-1.31) 
1.54E-05 +++ TSTA3 TSTA3 
rs8132771 A 21 0.075  1.43 
(1.21-1.69) 
1.96E-05 +++ TIAM1, SOD1, 
SCAF4 
SOD1, 
SCAF4 
rs11259960 A 15 0.200 1.35 
(1.17-1.54) 
2.36E-05 +-+ HOMER2 HOMER2 
rs2368106 A 2 0.125 1.35 
(1.17-1.54) 
2.58E-05 -++ CW22 CW22,UB
2E3 
rs7234959 A 18 0.083 1.34 
(1.17-1.53) 
2.68E-05 +++ TAF4B,PSMA8, 
SS18 
SS18, 
PSMA8 
rs6070015 A 20 0.067 1.67 
(1.31-2.13) 
2.91E-05 +++ RAE1, SPO11, 
BMP7, RBM38 
BMP7 
rs913444  A 9 0.250 1.22 
(1.11-1.34) 
3.00E-05 +++ TRKB TRKB,AG
TPBP1 
rs4893905  A 2 0.100 1.33 
(1.16-1.52) 
3.32E-05 +++ CW22 CW22,UB
2E3 
rs1477441 A 5 0.124 1.31 
(1.15-1.49) 
4.03E-05 +++ CDH12 CDH12 
rs12193473 G 6 0.375 1.20 
(1.10-1.31) 
4.25E-05 +++ C6orf170 MAN1A,C
6orf170 
rs218843 A 6 0.375 1.20 
(1.10-1.31) 
4.40E-05 +++ C6orf170 MAN1A,C
6orf170 
rs4715056 G 6 0.275 0.81 
(0.73-0.90) 
4.94E-05 +-- GPR115, 
OPN5,CD2AP,
GPR111 
C6orf38 
rs2817896 G 1 0.242 1.24 
(1.12-1.37) 
5.35E-05 -++ EPHB2 EPHB2 
rs10515162 C 5 0.050 0.72 
(0.61-0.85) 
6.48E-05 --- RGNEF RGNEF 
rs11181447 A 12 0.150 1.28 
(1.13-1.45) 
6.68E-05 +++ GLT8D3, YAF2, 
ZCRB1, 
PPHLN1, 
PRICKLE1 
ZCRB1, 
PPHLN1, 
PRICKLE
1 
rs12202993 A 6 0.375 1.20 
(1.10-1.31) 
7.48E-05 +++ C6orf170 MAN1A,C
6orf170 
rs564351 A 6 0.208 0.79 
(0.70-0.89) 
7.49E-05 +-- GPR115, 
OPN5,CD2AP,
GPR111 
OPN5, 
PTCHD4 
rs6035211 C 20 0.117 1.30 
(1.14-1.47) 
8.66E-05 +++ SLC24A3 C20orf79 
SLC24A 3 
 
Table 25. Highest ranking RD association signals in the meta-analysis of the 3 discovery studies. 
Odds ratios with 95% confidence intervals are given with respect to the minor allele for an additive 
model of allelic effect, association p-values, direction of the minor allele effect in Netherlands, 
England, Scotland study (+increasing, - decreasing). Genes potentially underlying each SNP signal as 
identified by GRAIL and genes falling within the higher LD block tagged by the top associated SNP 
(defined as markers in high LD: r2>0.8) 
280 
 
 
SNP Chromosome Genes Gene in LD 
block r2>0.8 
with index SNP 
rs12960119 
 
18 TAF4B, PSMA8, 
SS18 
 
SS18, PSAM8 
rs267738 
 
1 GOLPH3L, CTSK, 
FAM63A,  SETDB1 
CTSS,  MCL1, 
ANXA9, PRUNE, 
ARNT, HORMAD1, 
ADAMTSL4, ENSA 
 
CERS2 
rs955943 
 
4 LDB2 
 
LDB2 
rs1074463 
 
5 CDH12 
 
CDH12 
rs8132771 
 
21 TIAM1, SOD1, 
SFRS15 
 
SOD1, SCAF4 
rs2045084 
 
8 TSTA3 
 
TSTA3 
 
  
Table 26: GRAIL input of most significant SNPs with same direction of effect for 
minor allele 
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All but rs1074463 demonstrated the same direction of effect in the replication analysis 
compared with those in the discovery analysis. The most significant SNPs were 
rs2045084 with p=9x10-4, OR 1.32 (dominant model) an rs267738 with p=7.1x10-3, 
OR=0.83. Of interest, rs12960119 did not replicate in the Moorfields Eye Hospital 
samples. The minor allele (G) effect was in the same direction , however, the frequency 
of the allele in the WTCCC National Blood service (used for the replication) was 
greater (MAF:0.087) compared to the WTCCC 1958BC (MAF: 0.075) (used in the 
discovery cohort).  
4.5.1.3. META-ANALYSIS 
An overall meta-analysis of the seven SNPs analysed on both the discovery and 
replication steps revealed one variant (rs267738) reaching genome-wide significance 
(table 27). 
The significant SNP is in an exon of CERS2 (Ceramide Synthase 2). The minor allele C 
is thought to have an odds ratio of 0.81 (additive model) and 0.78 (dominant model): 
thus it is thought to be protective.  
The effect was consistent amongst all populations; with an excess of the major allele 
homozygous AA. Another SNP (rs267733) demonstrated suggestive significance in the 
discovery meta-analysis (p=5.3x10-5); this is 5’ of CERS2.  
.  
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4.5.2. DISCUSSIONS 
This study was undertaken to investigate the genetic predisposition to non-Mendelian 
RD, the majority of the cases of which were contributed from our collections. The most 
significant SNP (rs267738) was highlighted after meta-analysis of the most significant 7 
SNPs found after the initial two step discovery stage. It is a missense variation 
(c.344A>C [p.Glu115Ala]) in exon 4 of CERS2. The encoded protein is part of the 
ceramide synthetase family. Ceramides are lipid signalling molecules which are an 
intermediate in sphingolipid biosynthesis[705]. Sphingolipids are a class of lipids which 
are involved in signalling pathways[705]. Ceramide itself is thought to play an 
important role in cell proliferation and survival[706]. CERS2 is the most abundant and 
most widely distributed of this family, and has high specificity for fatty acyl-CoA[707]. 
Its precise role is unclear, but it has been suggested that the ceramides have an 
important role to play in most cells, perhaps as a housekeeping gene[707].   
Ceramides have been demonstrated to play a role in apoptosis of RPE cell lines[708, 
709] and mammalian photoreceptors[710]. A precise role in the pathogenesis of RD is 
therefore unclear. Gene identification based on the most significant SNPs highlighted 
21 genes with high relatedness[675]. It is noteworthy that one of these SS18 (the protein 
encoded by SS18; the gene tagged by the most significant SNP in the discovery phase; 
rs12960119) interact with cytoplasmic actin filaments and play a role in the ability of 
cells to bind and react to extracellular matrices[711]. Ablation of it from cultured human 
cells has been demonstrated to result in compromised adhesion to ECM substrates 
(collagen I, IV and fibronectin)[711]. This is thought to be via modulation of 
integrins[712], which are transmembrane glycoproteins involved in this process. A 
further significant gene TSTA3 encodes the enzyme GDP-L-Fucose-synthetase. Many 
adhesion molecules are fucosylated by TSTA3, such as cadherins[713] and 
integrins[714].  Such a cell adhesion role is attractive in RD.  
Of particular interest was the identification of ADAMTSL4 by GRAIL. The methods 
used by GRAIL suggested that it was significantly related to the most significant SNP 
after meta-analysis (rs267738). It must be considered that the relatedness to each SNP is 
very directed by proximity to the marker in question. All the genes highlighted by 
GRAIL as being related to rs267738 are within 500kb from the SNP within CERS2 
(Figure 4.10). It has been suggested that most LD blocks are <500kb and the most gene 
enhancers and repressors are also <500kb[672]. However, many genes within this 
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distance are not included in the list of related genes (Figure 4.10), and the methodology 
of GRAIL has been validated compared to other such gene identifying methods[675]. 
The interactions of these proteins was annotated with IPA (www.ingenuity.com), 
demonstrating a pathway with high reliability (p=10-62).  The most significant known 
pathway involving the relationships in this network was the haematological system. 
However, there are also parts of this network known to be involved in cell-cell adhesion 
and connective tissue development (Figure 4.11). This is an attractive pathway for RD. 
When analysing the role of ADAMTS-Like 4, the connection within the network is 
based its action on TGFβ1. This association has been suggested for numerous members 
of the ADAMTS family, particularly those in which mutations may result in EL 
(ADAMTS10, 17, 18 and ADAMTSL4[16].  TGFβ1 is a member of the TGFβ family of 
multifunctional cytokines which regulate adhesion, differentiation, migration and 
proliferation. Once secreted, it is cleaved into a latency –associated peptide, and latent 
TGFβ1-binding protein http://www.ncbi.nlm.nih.gov/gene/7040). Almost all cells have 
receptors for it and dysregulation of its activity may lead to apoptosis. Of particular 
interest is its potential role in connective tissue regulation. This has been demonstrated 
by work on MFS. It has been suggested that TGFβ interacts with ECM in the presence 
of FBN1 mutation[715]. Furthermore there is an excess of TGFβ activity in humans 
with and mouse models of MFS[716, 717]. It is also been demonstrated that ADAMTS-
Like 6 (of the same protein clad as ADAMTS-Like 4) attenuates the excessive release 
of TGFβ signals it’s associated downstream signal in the mouse model of MFS[718].    
As previously discussed in this thesis, authors have suggested that ADAMTSL4 has a 
role in cell adhesion[719]. This is most likely an assumption based on the TSR domain 
common to the ADAMTS family; which has an important role in ECM anchoring, as 
will be discussed in chapter 5. This role of cell adhesion may therefore be critical to the 
involvement of this pathway in RD. Furthermore, as will be discussed further in chapter 
5, the TSR domains regulate MMP2[720]; which is found in the vitreous[721] and 
modulates, amongst other substrates collagen XI, VII, V IV and fibronectin. Such 
MMPs have been demonstrated to play a role in RD[722]. It is therefore possible that 
ADAMTS-Like 4 has a similar role via its TSR. Furthermore, it is important to note that 
the ADAMTS proteins themselves are members of the MMP family. In addition to their 
role described above, MMPs have a role to play in the development of ocular structures; 
particularly sclera, lens, cornea and trabecular meshwork[723]. 
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Figure 4.11: Molecules (orange) which are involved in cell-cell contact and 
connective tissue pathways. 
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One may speculate that any disruption of these proteins may affect this development 
and result in myopia; thus increasing the risk of RD. As discussed in section 2.5.2, 
ADAMTSL4 may play a role in the development of myopia; either as a consequence of 
early onset EL or as a result of a direct role in ocular development.  
Additionally, Stupka and colleagues[724] demonstrated that the ADAMTS proteins 
(particularly ADAMTS5) played a role in breakdown and modelling of precellular 
versican. As has been discussed earlier, versican is an important component of the 
vitreous, with the monogenic condition of Wagner’s vitreoretinopathy (characterised by 
RD) caused by mutations in Versican. There may be a role for the ADAMTS proteins in 
RD by disrupting the versican of the vitreous in a similar way to the ECM[724]; thereby 
the vitreoretinal adhesions and thus playing a role in RD. Whether this speculation 
would be true for the non-enzymatic ADAMTSL4 is further debatable; but the pathway 
analysis based on the results of this GWAS suggest that this may be an avenue for 
future investigations. 
These findings must be taken with some caution. It must be remembered that 
ADAMTSL4 was one of 13 genes highlighted by GRAIL. Only one gene was in a LD 
block r2 >0.8 (CERS2); not ADAMTSL4. The pathway analysis involves genes not 
directly highlighted by the GWAS or GRAIL (such as UBC); so may only be 
theoretical. Furthermore, no direct relationships were highlighted between the 
molecules inputed from GRAIL. Additionally, the common link in the centre of the 
network is UBC (OMIM 191340). The protein (UBC) is widely expressed and has a 
large range of activities in cell processes, and therefore it may not be surprising that the 
genes from the GRAIL search are connected to it. Therefore, although statistically 
significant, this pathway is a suggestion, and would certainly need more investigations 
to clarify it. 
This study nevertheless was the first to determine a genetic predisposition towards 
complex RD. Although no replicated variant was determined, it does provide a platform 
to further investigate the genetic aetiology to this condition. It will be of interest to 
attempt to replicate the findings in future cohorts. In the first instance, it would be 
valuable to ascertain whether these findings are replicated in the cohort of South Asians 
we have already collected. Our future work would involve larger cohorts, perhaps a 
cohort enriched for disease severity.   
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4.6. EXOME WIDE ASSOCIATION ANALYSIS OF 
RHEGMATOGENOUS RETINAL DETACHMENT 
4.6.1. RESULTS  
The work described below was undertaken by Dr Valentina Cipriani and myself at the 
UCL Institute of Ophthalmology and the UCL Genetics Institute.  
1996 samples were genotyped on the Illumina HumanExome BeadChip at the KCL 
Institute of Psychiatry. The laboratory performed the genotyping on the Illumina 
HumanExome BeadChip 12 v1.1 on our samples, and genotype calling. Genotype 
calling can be challenging on arrays with rare variants.  The type 1 error rate may be 
greater with calling rare SNVs; particularly if the common homozygote is called as the 
heterozygote[725].   
Genotype calling for the Illumina HumanExome BeadChip was done using z-call [726], 
a variant caller  to be used within GenCall in GenomeStudio 
(http://www.illumina.com/software/genomestudio_software.ilmn),  specifically 
designed for rare SNVs. Briefly, this novel genotype calling software determines a 
threshold for common allele homozygosity based on GenCall (or other standard calling 
software). Rare homozygous allele threshold are then estimated though linear regression 
to determine mean and standard deviation of the call intensities of successfully 
genotyped common (MAF >=5%) SNVs. This is then used to determine a z score for 
the whole cohort thus allowing genotype calls to make for even rare alleles.    
Thus they provided two sets of genotype files; with data for 1,996 cases and ,5963 
controls.  
The data was generated using Genome Studio to create a .bsc file. This was converted 
into PLINK files, upon which we undertook quality control. 
Initial inspection of the dataset demonstrated that 12 samples in the PLINK file 
provided on cases data had been duplicated. 12 cases were therefore dropped, leaving 
genotype data on 1984 cases. We also excluded controls which were not labelled as the 
same ethnicity as the cases (White Caucasian). This removed 40 controls, leaving 5923 
controls. 
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Quality control of data must be performed per-individual and per-marker. It is generally 
advisable to perform the former first, as removal of any marker is potentially a lost 
disease association. The impact of this is thought to be greater than the loss of a single 
individual[482]. All analysis was done using PLINK 
(http://pngu.mgh.harvard.edu/purcell/plink/) [671]. 
The first step checked for gender discordance between labelled gender on the sample 
manifest and genotyped results. This would therefore highlight potential sample mix-up 
or plating errors. Genetic gender verification is done by analysing the homozygosity 
rate of markers on the X chromosome. Males have only one X chromosome, and 
therefore cannot be heterozygous for markers on the X chromosome. For males the X 
chromosome homozygosity rate is therefore 1.0. Conversely, females, are expected to 
have a rate <0.2. Thus male samples which are labelled as female would have a higher 
than expected homozygosity rate, and vice versa. The methodology for assessing X 
chromosome homozygosity is therefore to calculate the average rate for all markers on 
this chromosome for an individual, and comparing it to the expected value ( >0.8 for 
males,  <0.2 for females). This process is particularly important if gender will be used 
as a co-variate, but also to ensure sample mix up has not occurred.  
For cases, there were 25 gender mismatches. The records of these patients were re-
checked, leaving 10 individuals with persistent imbalances. They were removed from 
the dataset. This resulted in 1974 cases (M=1234, F=740). The same was done for 
control data and three individuals were removed. This left 5290 control individuals 
(M=3318, F=2602). 
Subsequent steps were aimed at assessing DNA sample quality, as these may have 
considerable impact on genotype accuracy. Genotype failure rate and heterozygosity are 
measures of DNA sample quality. 
We evaluated those individuals in which >2.5% of genotyped SNVs were missing, and 
excluded them (Table 28 and Figure 4.12).  This is a conservative figure compared to 
some large GWAS[464].  This threshold is determined by analysis of the distribution of 
missing genotypes across the whole samples set; and is indicative of the good quality of 
DNA in our cohort. Subsequently, heterozygosity was examined across the whole set. 
This involves assessing the rate of heterozygosity of the variants typed in the 
individuals. This differs amongst populations and genotyping arrays, and therefore is   
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 MAF HETEROZYGOSITY 
Outside 3 Standard 
Deviations from mean 
MISSING RATE: 
>2.5% 
CASES >1% 9 2 
 <1% 0 
CONTROLS >1% 63 0 
 <1% 54 
Table 28: Number of individuals failing heterozygosity and missing genotype 
quality control assessment on Illumina HumanExome BeadChip. 
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Figure 4.12: HETEROZYGOSITY vs PER-SAMPLE CALL RATE for 
VARIANTS CALLED ON ILLUMINA HUMANEXOME BEADCHIP 
 
A & B: Common Variants (MAF>1%) for cases (A) and controls (B) 
C & D: Rare Variants (MAF<1%) for cases (C) and controls (D).  
Tramlines on y-axis represent 3 standard deviations from the mean heterozygosity 
Tramline on x axis  represents 2.5% missing genotype data 
Individuals outside the 3 SD markers and to the right of the 2.5% heterozygosity 
line were excluded 
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unique to each study. Mean heterozygosity across the autosomal SNVs was then 
determined, and the subsequent cluster examined. Heterozygosity is calculated with the 
equation  
(N-O)/N 
N= number of non-missing genotypes, O= Observed number of homozygous genotypes 
for a given individual. 
This rate would vary for common and rare alleles, being greater in the former. This was 
therefore analysed separately for common (MAF>1%) and rare SNVs (MAF</=1%). 
Furthermore, it was done separately on 1984 cases and 5293 controls (Figure 4.12).  
Any individual with heterozygosity values +/- 3 standard deviations from the mean 
were excluded. Excessive heterozygosity may represent contamination, whilst decreased 
heterozygosity; inbreeding.  
There were thus 9 cases (the two cases with high missing rates were also part of those 
which failed heterozygosity control) which were due to be excluded. Two of these were 
already dropped from the gender analysis. Therefore seven cases were excluded. 116 
controls (one case failed both in rare and common variants) were also excluded.  
At this stage of quality control there were therefore 1967 cases (M=1229, F=738) and 
5804 controls (M=3272, F=2532). Further steps in per-individual quality control 
involve assessing for unknown relatedness. Identity by State (IBS) is calculated 
between each pair; based on the mean proportion of alleles shared in common at SNVs 
genotyped. Variants across the genome are used, excluding the HLA regions and SNPs 
with r2>0.2[482]. Duplicates or monozygotic twins would then be denoted as those with 
IBS=1. It is generally regarded therefore that IBD indicates relatedness in a population 
cohort as ours. IBD can then be determined by the genome-wide IBS. It would be 
estimated that IBD shared between first degree relatives would be 0.5, between second 
degree relatives 0.25 and between third degree relatives 0.125.  One of a pair with 
IBD>0.1875 is generally removed[482]. Using rare markers on this chip for this 
analysis is challenging. The Scottish samples had had this analysis already done as part 
of the GWAS (section 4.3.3). This stage of the quality control on the samples collected 
from Moorfields Eye Hospital will be completed in due course.  It is expected that this 
will be low in the cohort, as patients were all asked about family histories of patients  
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with RD, and there were no patients recruited who knew of relatives who had taken part 
in the study  
Finally, analysis for population stratification (ancestral differences) is undertaken. Rare 
variants are likely to be more population specific[648], and thus the issue of population 
stratification must be closely considered. This is undertaken by utilising primary 
component analysis (PCA; as described in section 4.1.7.3). Generally, it is required that 
variants across the genome are used, which may then be compared to HapMap genotype 
data [727] from the different continental origins included in this, to detect large scale 
ancestral differences. For such analysis, it is therefore challenging to use SNVs from the 
Illumina HumanExome BeadChip, which are not genome-wide, are rare and focussed in 
and around the exome. There are no published examples yet available of completing 
this. Ancestral analysis has already been completed for the samples from Scotland as 
part of the GWAS. PCA analysis for stratification will be attempted in the Scottish 
cohort using SNVs from the Illumina HumanExome BeadChip. This may be done for 
SNVs of differing MAF. Outliers will then be estimated. This will be compared to the 
outliers defined using the GWAS chip in this cohort. Such a comparison would then 
offer an indication as to the utility of the Illumina HumanExome BeadChip SNVs in 
population stratification analysis. It would then be used on the Moorfields Eye Hospital 
samples and samples from the 1958 birth cohort controls. This analysis is underway by 
Dr Vitart in the MRC Human Genetics Unit (Edinburgh).  
Subsequently per-marker quality control is undertaken. This was done although the final 
per-sample QC had not been completed. It is expected that the effect of stratification 
and relatedness control will be negligible and that the final figures after the per-marker 
is completed will not be altered significantly. 
4.6.1.1. VARIANT DIFFERENCES BETWEEN CASES AND 
CONTROLS 
On assessing the SNVs between cases and controls, it became apparent that there was 
discordance between the SNVs in cases and the controls. 14 SNVs were present in cases 
alone and 4969 in controls alone, leaving 242,901 SNVs in common.  
We contacted the laboratory at KCL Institute of Psychiatry; who informed us that this 
was due to the fact that the cases and controls were in fact genotyped on different 
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versions of the Illumina HumanExome BeadChip. The controls were genotyped on 
Version 1.0, whilst our cases on the newer version 1.1. There are 4969 SNVs on the 
version 1.0 which are not on the newer version 1.1. A further 21 SNVs failed 
genotyping on controls (14 of which were successfully genotyped on cases). There were 
therefore 242,887 SNVs genotyped in common. 
We had not been aware that different versions of the Illumina HumanExome BeadChip 
were being used in the cases and controls. We therefore were not aware that this 
discordance of SNVs existed, or that it would affect our analysis.   
For assessing SNV quality, it is best practice to complete this in cases and controls 
individually[482]. Therefore, 247849 SNVs underwent quality control in the 5804 
control individuals, and 232901 SNVs underwent this in the 1967 cases. 
Firstly, it is then important to remove SNVs which deviate significantly from HWE. 
However, if there is an association between an SNV and RD, there may be a deviation 
from HWE in cases; and removing these would be undesirable. Therefore it is general 
practice to remove those with HWE deviation in the control cohort; particularly 
population control cohorts such as ours. The threshold for exclusion varies between 
studies, ranging between p=0.001 and 5.7x10-7. For this study we have chosen p=10-6. 
Using this threshold, 662 SNVs were excluded.  
Subsequently, SNVs with high missing rates (unsuccessfully called in a high number of 
individuals) were removed. This is crucial as they may result in false positives, however 
must be balanced with the potential exclusion of disease associated variants. Markers 
with <95% call rate are removed from some studies[728], though this does vary 
between studies. For this study, we elected to remove common and rare SNVs with a 
call rate <97.5% in cases and controls (Figure 4.13). This resulted in 2510 SNVs being 
removed from cases. The total genotyping rate in the remaining case individuals was 
0.9981. 46 SNVs were excluded from controls. The genotyping rate in the remaining 
control individuals was 0.999. 
Further to this, it is important to know the minor allele frequencies of the markers 
genotyped. In GWAS, it is generally suggested that a threshold MAF of 1-2% is 
used[482] for exclusion. This is because of the difficulties in genotyping these SNVs, 
and the challenges of interpreting association analysis demonstrated by these SNVs.  
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However for this study, excluding these SNVs would be unwanted, considering the 
makeup of the Illumina HumanExome BeadChip. Thus this step will not be undertaken; 
rather a description of the variant MAF was done. There were 204188 and 209935 rare 
variants (MAF<1%) genotyped in cases and controls respectively. There were 36203 
and 37206 common variants (MAF>1%) typed on cases and controls respectively.    
After these stages of quality control there remained 1967 cases, 5804 controls, which 
had successful genotype data on 240,391 and 247,141 SNVs respectively. A summary 
of this process is in Figure 4.14. 
Prior to association analysis between cases and controls, it is necessary to merge the 
data files of cases and controls. When successful, association analysis may be 
undertaken.  
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4.6.1.2. EXOME CHIP QC and ASSOCIATION 
Further to Quality Control, association analysis will be undertaken over the next two 
years by our team; led by Dr Veronique Vitart (University of Edinburgh) and Dr 
Valentina Cipriani (UCL Institute of Ophthalmology).  
However there are significant challenges to analysing variants, in which a majority are 
rare SNVs.  
Firstly one must consider the power of studies. The power to detect an association with 
rare SNVs is low[729]. There is a possibility therefore that this study will be under 
powered to elucidate putative variants. 
To combat the issue of power, some authors recommend initially performing individual 
locus analysis on rare variants (however they are acquired); initially to act as an 
additional quality control stage[663]. Subsequently, the most common method of 
increasing the power is to “collapse” variants into a single group, and test their 
collective frequency differences against controls[730] (“burden” of many variants). 
These variants may be collapsed based on numerous criteria, including function, 
location and biological pathways of the genes in which the SNV are found.  
Specific methods of analysing these collapsed variants are numerous. This can be based 
on summary statistics of variant frequencies between cases and controls. An example of 
this is the cohort allelic sums test (CAST)[730]; whereby the frequency of individuals 
carrying one of a group of variants is compared. Alternatively, the combined 
multivariate and collapsing method (CMC)[731] collapses the variants and uses them all 
as one statistic. This method is thought to control type 1 error, and can be used in a 
regression model.  
Collapsing can also be done based on similarities of DNA sequences. This is based on 
the consideration that the nucleotide background of a rare variant can influence the 
phenotype; thus analysing in this manner may assume some form of interaction amongst 
variants[729].  
With regard to using data acquisition focussed on the exome (sequencing or 
genotyping), Price and colleagues first suggested a method based on the CAST 
methods, incorporating predicted functional impact of each SNV[732]. Han and 
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colleagues have subsequently devised methods incorporating the direction of the effect 
of the SNV[733]. Numerous methods have since been devised (for review see[729]).  
In summary, analysing exome data specifically; two methods are employed. This may 
employ counting the number of rare variants across a gene, and then comparing between 
cases and controls[731]. Variants can be weighted (for the purpose of tabulations and 
subsequent analysis) such that a greater score is given to SNV which would be thought 
to have greater functional consequences[663].  Alternatively, methods may be devised 
to assess whether the number of variants which have an effect exceeds the 
expectation[734, 735]. Variants in exome analysis can furthermore be grouped 
according to their likelihood of damage; with splice site, frameshift and nonsense 
mutations being the most pathogenic SNVs.  
A final consideration of analysing rare, coding variants is the replication of findings 
from these experiments. If an association is detected as a result of a burden of numerous 
SNV, it may be necessary to undertake targeted sequencing of the relevant genes 
highlighted from the initial analysis. We have now developed collaborations with units 
across numerous units and countries. These include Guy’s and St Thomas’ Hospitals 
(King’s College London, UK), Addenbrookes Hospital (University of Cambridge, UK), 
Calgary Retina Consultants (University of Calgary, Alberta, Canada) and the 
Department of Ophthalmology at Royal Victoria Eye and Ear Hospital (University of 
Melbourne, Victoria, Australia). Over the next few years, it is hoped that a significant 
cohort will be in place to replicate and extend findings from this work. 
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5. CHAPTER 5: HUMAN OCULAR EXPRESSION AND 
PROTEIN MODELLING OF ADAMTSL4 
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Publications arising from work related to this chapter: 
(i)  Chandra A., Jones M., Cottrill P., Eastlake K., Limb GA., Charteris DG.  
The gene expression and protein distribution of ADAMTSL-4 in human iris, 
choroid and retina.  
British Journal of Ophthalmology 2013 Sep;97(9):1208-12 
 
(ii)  Chandra A , D'Cruz L, Aragon-Martin JA, Charteris DG, Limb GA, Child     
AH, Arno G. 
Focus on molecules: ADAMTSL4.  
Experimental Eye Research. 2012 Nov;104:95-6 
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5.1. INTRODUCTION 
The role of the ADAMTS family of proteins and encoding genes has been discussed at 
length in this thesis. In particular, the role of ADAMTSL4 has been highlighted as 
important in EL and RD. However, the definitive presence of this gene and protein in 
ocular tissue has not been well defined.  
ADAMTSL4 being part of the ADAMTS family of genes is therefore a part of the TSR 
superfamily of genes. This superfamily is characterised by the Thrombospondin Repeat 
domain. 
5.1.1. THROMBOSPONDIN REPEAT DOMAIN 
The TSR domain is an ancient extracellular domain found throughout vertebrate and 
invertebrate proteins[736]. The structure of these domains includes three strands, an 
irregular A strand and 2 regular (B and C) strands with a β structure[737] (Figure 5.1).  
The TSRs are in secreted proteins or in the ECM part of transmembrane proteins. 
Almost 100 proteins contain this extracellular domain, with a wide range of 
functions[738]. The role they play in proteins varies from neuronal axonal outgrowth, 
angiogenesis, tumour progression, activation of TGFβ, wound healing and ECM  
remodelling[26, 737]. The most relevant in the ADAMTS proteins is the role in ECM 
anchoring. A major component of the ECM includes glycosaminoglycans (GAGs). It is 
believed that positive charges across the front face of a TSR domain is crucial for the 
high-affinity binding to GAGs[737].  
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5.1.2. ADAMTS PROTEINS 
The ADAMTS proteins are a family of enzymes. Beyond the TSR domains, they 
frequently contain four other domains; prodomain, metalloprotease domain, disintegrin 
domain and cysteine-rich domains[739]. The former three of these constitute the 
catalytic domain at the N terminus. The latter, along with the TSR domains in 
conjunction with protein specific domains constitute the ancillary domain at their C 
terminus. The ancillary domain is crucial in determining substrate specificity (Figure 
5.2). Excision of the propeptide is an important step post translation. Of interest, some 
ADAMTS proteins ancillary C terminus domains may have independent roles after 
excision. As mentioned in chapter 3 (section 3.5.1) this is the case with a fragment of 
ADAMTS18[361]. 
These proteins play a role in a wide range of biological processes, including cell 
migration, coagulation, angiogenesis and ECM regulation[21]. They have a particular 
role in maturation of procollagen (ADAMTS2, ADAMTS3, ADAMTS14) and von 
Willebrand factor (ADAMTS13). It is suggested that these proteins may cooperate with 
each other to maintain enzymatic function[21].  
5.1.3. ADAMTS-LIKE PROTEINS 
The ADAMTS-Like proteins are products of distinct genes, and are closely related in 
structure to the ADAMTS ancillary proteases, including at least one TSR domain. They 
however lack the catalytic domain, thus do not have enzymatic activity[16]. ADAMTS-
Like 4 and ADAMTS-Like 6 form part of one clade, differing from ADAMTS-Like 1, 
ADAMTS-Like 3 and ADAMTS-Like 7 by lacking immunoglobulin repeat regions.  
The function of these proteins is unclear. Mutations in ADAMTSL2 result in a condition 
known as geleophysic dysplasia[740]. This condition is characterised by high levels of 
TGFβ activity, and has systemic phenotypes similar to WMS[740]. The protein 
ADAMTS-Like 2 binds to latent TGFβ-1 (a fibrillin-1 ligand) and fibrillin-1. EL is a 
common phenotype of mutations in these genes. It has been suggested that some of the 
genes which cause EL may also be involved in the TGFβ pathway[16]. Alternatively, 
ADAMTS-Like proteins may have independent functions in the ECM, but these are not 
yet clear. 
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Figure 5.2: Image of the ADAMTS proteins Aadapted from [21].  
The common stem of each ADAMTS protein is at the top. The specific ancillary  
C-terminus domain of each ADAMTS protein is shown on the right. 
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5.1.3.1. ADAMTSL4 
ADAMTSL4 (A Disintegrin And Metalloproteinase and Thrombospondin Motifs Like 4) 
is one of seven of the ADAMTSL genes and has been discussed at length in this thesis. 
First described in 2003, it was initially termed TSRC1 (Thrombospondin Repeat 
Containing Gene 1)[239]. Buchner [239]suggested that a chromosomal inversion 
involving an ancient ADAMTS gene may have generated two separate genes, 
ADAMTSL4 and ADAM15, a protein containing four of the ADAMTS domains, but 
lacking the TSR domains. This would have to have occurred prior to the separation of 
the mouse and human lineage, as they are closely related in both. 
It has 79% nucleotide sequence identity and 76% amino acid homology with mouse 
TSRC1 and encodes a 1074 amino acid protein; ADAMTS-Like 4. This differs from the 
mouse protein by 38 amino acids; most of which are encoded within the large divergent 
Exon 6.  
ADAMTS-Like 4 contains seven Thrombospondin type 1 repeat domains, six of which 
are clustered towards the C Terminus. Other domains present in the full length protein 
are an ADAMTS spacer 1 domain, a ADAMTS cysteine rich module and a PLAC 
(Protease and Lacunin) domain[279] (Figure 5.3). Like other ADAMTS-Like proteins it 
lacks enzymatic activity, and thus further suggests that it may play a role only in 
maintenance or anchoring the ECM; indeed this proposed function has been discussed 
at length in this thesis. 
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5.2. AIMS OF THIS CHAPTER 
The aims of this chapter are to further understand the ADAMTSL4 gene and protein.  
Firstly, already in this thesis it has been demonstrated that ADAMTSL4 has an important 
role to play in EL, and potentially in RD. Although the encoded protein, ADAMTS-
Like 4 is known to be extracellular [741], and is distributed widely throughout the 
body[2], its distribution within ocular tissue is not clear. It is not yet known to be 
causative or associated with any extraocular phenotype, yet papers describing the 
expression of the gene and protein, either did not investigate [2] or provide no evidence 
for [239] ocular expression and distribution. We therefore aimed to investigate the 
mRNA expression and protein distribution patterns of ADAMTSL4 in human ocular 
tissue. 
For this project, I was privileged to work in the laboratory of Professor Astrid Limb 
(ORBIT, UCL Institute of Ophthalmology), and supported by her team. 
Secondly, although the primary structure of ADAMTS-Like 4 is established ,the further 
secondary and tertiary structures are unknown. Protein structure is best defined by 
formal protein crystallography[742]. The crystalline structures of ADAMTS-1[743], 
ADAMTS-4, ADAMTS-5[744] and part of the non-catalytic region (residues 287-685) 
of ADAMTS13[745] have been described. However, none of the crystalline structures 
of the other ADAMTS or any of the ADAMTS-Like proteins have been deposited onto 
the Protein Data Bank (PDB: http://www.rcsb.org/pdb/home/home.do)[746]. An 
alternative to crystallography is comparative or homology modelling. This has been 
proven to be very accurate method of protein structure prediction[747].  We therefore 
planned to model the protein structure of ADAMTS-Like 4 using this methodology.  
For this endeavour, I was fortunate to work with Dr Leon D’Cruz (St George’s 
University of London), who was instrumental in this process. 
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5.3. METHODS 
5.3.1. EXPRESSION OF ADAMTSL4 IN OCULAR TISSUE 
Acquisition of human tissue adhered to the tenets of the declaration of Helsinki. 
Following approval of the local research ethics committee, eyes with consent for 
research were obtained from Moorﬁelds Hospital Eye Bank. 
5.3.1.1. PREPARATION OF OCULAR TISSUE 
Ocular tissue was acquired within 24-48 hours post-mortem. Three eyes underwent 
preparation for immunostaining. Tissues from five eyes were isolated to provide RNA 
and protein for experimental studies.  
Instruments were sterilised with sodium hypochlorite (diluted 1 in 10) followed by 
several washes with sterile phosphate buffered saline (PBS). Gentle dissection was 
required to allow isolation of lens, retina, choroid and iris, from the eye cup. The eye 
was dissected (Figure 5.4) and iris was isolated from the anterior chamber. The vitreous 
was then removed. Retina was dissected off with sterile PBS. Choroid was then 
isolated.  
The three different ocular tissues were then subjected to various biochemical treatments 
to either extract RNA or protein from the disrupted cells as described below.  
5.3.1.2. RNA EXTRACTION 
Tissue was disrupted and the lysate homogenised in Buffer RLT Plus (Qiagen, UK). 
This lysate was then centrifuged for 3 minutes at maximum speed. The supernatant was 
then removed by pipetting. This was then transferred to a gDNA Eliminator spin 
column placed in a 2ml collection tube and centrifuged for 30s (at ≥8000 x g (≥10,000 
rpm). The flow through was saved and 350µl of 70% ethanol was added, and mixed 
well by pipetting. Up to 700µl of the sample, including any precipitate, was transferred 
to an RNeasy spin column placed in a 2ml collection tube, which was centrifuged for 15 
s at ≥8000 x g. The flow-through was then discarded. 700µl of Buffer RW1 was added 
to the RNeasy Mini spin column (in a 2 ml collection tube) and centrifuged for 15 s at 
≥8000 x g. The flow-through was again discarded. This was repeated with 500µl Buffer 
RPE with the same centrifuge settings and the flow-through discarded. 500µl Buffer  
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Figure 5.4: Preparation and isolation of ocular tissue post-mortem.  
A and B: Dissection of human eye. C: Isolation of choroid and iris.  
D: Removal of vitreous 
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RPE was added to the RNeasy spin column and a further centrifuge for 2 min at ≥8000 
x g (≥10,000 rpm) was undertaken. The membrane of the RNeasy spin column was then 
dried by one further centrifuge for 1min. 30–50µl of  RNase-free water was added 
directly to the spin column membrane and a final centrifuge for 1 min at ≥8000 x g was 
undertaken to elute the RNA. DNase (RNase-Free DNase Set, Qiagen, 79254) treatment 
was applied during RNA isolation to eliminate any genomic DNA contamination of the 
RNA isolated. This involved 8µl RNA being treated with 1µl of DNAse and 1µl of 
DNAse buffer at 370C for 30 minutes. This reaction was stopped with 1µL stop solution 
and incubated for 10 minutes at 650C.  
The concentration of RNA was determined using a spectrophotometer (Nanodrop-1000, 
Thermoscientific) (see section 2.3.4). RNA was then stored at -80 degrees and thawed 
on ice before use for RT- PCR. 
5.3.1.3. RT-PCR 
RNA (1µg) was transcribed into cDNA using AMV Reverse Transcriptase (Roche). The 
reaction was performed in a ﬁnal volume of 20 µl consisting of 5 mM MgCl2, 1 mM 
dNTP, 1 U/µl RNase inhibitor, 0.8 U/µl AMV reverse transcriptase and 80 ng/µl oligo 
dT-15 primers. The mixture was incubated for 10 min at 250C, 60 min at 420C, 5 min at 
990C and 5 min at 40C in a thermal cycler (Eppendorf, http://www.eppendorf.co.uk). 
The cDNA was then either used immediately for PCR reactions or stored at -200C. 
The cDNA (5 µl) was used for PCR reactions to amplify ADAMTSL4 using the High 
Fidelity PCR kit (Roche). The ampliﬁcation was performed in a ﬁnal reaction volume of 
25µl consisting of 1.5 mM MgCl 2 , 0.2 mM dNTP, 2.5 U Expand HiFi Taq DNA 
polymerase, 0.4 mM primers in 50 mM KCL (Primers: 
GCGGCAACAGGTGGCTGTGT and GCCTGGGGCCCTGTGAGAGA), 10 mM 
Tris/HCl, pH 8.0. The primers were predicted to produce a product of 470base pair 
(Figure 5.5). The mixture was incubated at 940C for 2 min followed by 30 cycles under 
the following conditions: 940C for 30 s, 570C for 30 s, 720C for 30s and 1 cycle of 720C 
for 5 min. Products were run on 1% agarose gel containing 1 in 15,000 dilution of 
GelRed (Biotium). GAPDH primers (CCAGTGCAAAGAGCCCAAAC and 
GCACGGACACTCACAATGTTC) were used as an internal control. 
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5.3.1.4. PROTEIN EXTRACTION 
Eye tissues (iris, retina and choroid) were cut with a scalpel on slide in PBS. The tissue 
was resuspended in 100 µl of ice cold Radio Immuno Precipitation Assay (RIPA) buffer 
containing protease inhibitors as indicated below. This buffer was used to isolate both 
nuclear and cytoplasmic proteins. A homogenous suspension was ensured by vigourous 
pippeting and vortexing. The mixture was placed on ice for 5 minutes to allow the cells 
to swell and lyse. After then centrifuging for 5 minutes at 8-10,000 rpm to pellet any 
debris, the supernatant was extracted. This contains proteins of interest and can be 
collected and stored at -200C. In this manner protein was extracted from 3 choroidal 
tissues, 2 iris tissues and 3 retinal tissues.  
5.3.1.4.1. Preparation of RIPA buffer with protease inhibitors 
RIPA lysis buffer was prepared just before use. The following were added:  
- Protease Inhibitor Cocktail (Sigma) P-8340 (stored at -200C). A concentration of 
10µl / ml of buffer was used.  
- 0.5M DTT (dithiothreitol) (1 µl/ml of buffer (1/1000)) to a final concentration of 
0.5mM.   
- 0.5M PMSF (Phenyl Methyl Sulfonyl Fluoride) was added (2 µl/ml of buffer 
(1/500) to a final concentration of 1mM was added.  
- 0.6 M Sodium Orthovanadate- Na3 VO4 (Phosphatase inhibitor, stored at -20) : 5 
µl/ ml (1/200) to a final concentration of 3mM 
This was kept on ice till tissues were prepared as above.  
5.3.1.5. PROTEIN CONCENTRATION ESTIMATION 
Using the Biorad DC Protein Assay Protocol (Bio-Rad, Hemel Hempstead, U.K. 
www.biorad.com), based on the Bradford assay, protein concentrations were determined 
The Bradford Assay is based on the dye Coomassie-blue G-250. This is a hydrophobic dye 
which binds to hydrophobic protein molecules. It exists in two forms, red and blue. When 
the red form binds to the arginine residues in proteins it absorbs maximally at 595nm, and 
the blue form of the dye becomes more stable. The absorbance at 595nm is proportional to 
the protein concentration, which can therefore be quantified. 
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The method involved the following steps: 
First a standard curve was made by preparing 3-5 dilutions of a protein standard  
containing from 0.2 mg/ml to about 1.5 mg/ml protein.  Samples were diluted (1/10 and 
1/20). 5 µl of standards and samples were pipetted into a clean, dry microtiter plate. 25 
µl of reagent A was placed into each well, followed by 200 µl of reagent B. The plate 
was mixed for 5 seconds. The samples were incubated at room temperature for 5-15 
minutes. 
The entire sample and standard were placed into cuvettes. A control level was measured 
using control samples, and the samples were then measured using a spectrophotometer.  
5.3.1.6. WESTERN BLOT ANALYSIS 
Western blot analysis was performed using the NuPAGE electrophoresis gel system 
(Invitrogen, UK). Running buffers were prepared initially. MES SDS running buffer 
were diluted to 1X (commercially available as 20X). 500 µl of antioxidant was added to 
200ml of running buffer. The loading buffer was warmed so as to dissolve the salts.  
Finally a reducing agent (containing Dithiothreitol) was prepared (used to break 
disulphide bonds and resolve proteins secondary and tertiary structures). 
Proteins samples were prepared such that the volume was 19.5µl at the same 
concentrations. Thus the lowest concentration in a batch of samples was used as a 
reference.  
The 30µl loading samples consisted of 3µL of reducing agent, 7.5µL of loading buffer 
and 19.5µl protein sample. 
Loading sample was warmed for 10 minutes at 700C to denature the proteins further and 
ensure only the primary structures were present. After centrifuging for 10seconds, the 
samples were loaded into premade NuPAGE electrophoresis gel (Life Technologies, 
Paisley, Scotland,http://www.invitrogen.com) for Western blot analysis. A 10%Bis-Tris 
Gel was used in conjunction with MOPS SDS running buffer (NP0001, Invitrogen, 
UK). This was used as the protein size we expected was 140kDa. Protein samples were 
loaded into 15 well gels. These were then fitted into the XCell SureLockTM Mini-Cell 
mini vertical electrophoresis system (Invitrogen, UK). After closure of the chamber, 
running buffer with antioxidant was added, and the gel was run at 200V for 50 minutes.  
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Whilst the gel ran, transfer buffer was prepared (400mL of 1 in 20 dilution with 60mL 
of 15% methanol). Transfer membranes (Polyvinylidene Fluoride (PVDF) – Hybond-P 
# RPN303F, Amersham, Little Chalfont, U.K. http://www.gelifesciences.com) were 
soaked in methanol for 2 minutes, proceeded by washing in distilled water before being 
transferred to the transfer buffer. The transfer was then carried out at 35V for 90 
minutes.  
Membranes were blocked in Tris Buffered Saline with 0.1% Tween-20, 5% skimmed 
milk and 3% FBS at 370C for 1 h. Primary antibodies Anti-ADAMTSL4 (HPA006279; 
Rabbit; 1 in 100, Sigma Life Sciences, USA. http://www.sigma-aldrich.com) and β-
actin (1:5000; monoclonal; Sigma)) were diluted in blocking buffer. Membranes were 
incubated overnight at 40C with the primary antibodies, before incubation with a 
secondary antibody conjugated with Horseradish peroxidase (1:10,000, Jackson 
Laboratories http://www.jacksonimmuno.com) for 1 h at room temperature. On removal 
of the secondary antibody, the membrane was washed again over an hour with TBS 
with 0.1% Tween 20, and Blots were visualised by chemiluminescence using ECL 
advanced detection reagent (GE Healthcare http://www.gelifesciences.com). 
5.3.1.7. IMMUNOFLUORESCENCE STAINING OF TISSUE 
Whole eyes were ﬁxed in 4% Paraformaldehyde for 10 min and cryoprotected with 30% 
sucrose. After imbedding tissue in Optimum Cutting Temperature compound (OCT; 
TissueTek MSDS), cryostat sections were prepared (Figure 5.6). Sections were prepared 
of approximately 15µm thick, and placed on Superfrost Plus Slides. Blocking agent was 
prepared in advance (0.5% in PBS, microwaved for 10s and shaken further till uniform 
cloudy appearance was present). Slides were blocked for 1 hour in this Blocking 
Solution. Primary antibodies were diluted in the blocking reagent and incubated with 
the cells overnight at 40C in a humidified chamber. The primary antibody used was 
Anti-ADAMTSL4 (HPA006279; Rabbit; 1 in 100, Sigma Life Sciences, USA. 
http://www.sigma-aldrich.com). In parallel, an incubation with only secondary antibody 
was included to control for background staining of this antibody. Speciﬁc binding of 
primary antibodies was detected using secondary antibody; donkey anti-IgG labelled 
with Alexa Fluor 448 or 668 (Molecular Probes, Invitrogen) reacting with Rabbit; (the 
species in which the primary antibody was raised) for 1 hour at room temperature in the 
dark.  
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Figure 5.6: Cryostat preparation of eye fixed in Optimum Cutting Temperature 
compound. Anterior segment structures (lens) visible 
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Slides were then washed with Tris Buffered Saline (TBS), before incubating with DAPI 
(Sigma) to visualise cell nuclei and mounted using Vectashield (Vector Laboratories, 
U.S.A. http://www.vectorlabs.com). Fluorescent images were recorded using confocal 
microscopy (Leica TCS SP2 AOBS, Leica, Germany http://www.leica-
microsystems.com) using a 40x oil objective. Images were analysed using the Leica 
Confocal software.  
Corresponding sections to those fluorescently labelled were also stained with 
haematoxylin and eosin to further illustrate morphology, using the following protocol: 
The slides were immersed in isoparaffinic hydrocarbon (Safeclear) for 10 minutes, 5 
minutes and 1 minute. They were then immersed in alcohol at 100% for 1 minute then 
alcohol 70% for a further 1 minute. This was followed by washing in running water to 
remove any residual alcohol They were stained in Gill’s 3 haematoxylin for 5 minutes, 
washed in running tap water for 2 minutes, differentiated in acid alcohol for 8 seconds, 
placed in lithium carbonate 1% for 1 minute, then washed in running tap water for 1 
minute. Following this they were counterstained in eosin (1%, made up in tap water) for 
3 minutes then washed in running tap water for 30 seconds. The slides were then 
immersed in 90% alcohol for 30 seconds, then 4 changes of absolute alcohol for 2 
minutes each, then immersed in isoparaffinic hydrocarbon for 5 minutes, 2 minutes and 
1 minute. The slides were drained briefly on a tissue, then the sections were mounted in 
Safeclear mountant and covered with a coverslip.  
5.3.2. PROTEIN MODELLING 
The most definite methods of understanding the structure of a protein is crystallography, 
mostly via X-ray, Nuclear magnetic resonance (NMR) spectroscopy or 3 dimensional 
electron microscopy. There are over 70,000 proteins and peptides with such structures 
now deposited on the PDB[748]. However, this is laborious and expensive. Although ab 
initio protein modelling is undertaken, the prediction of many proteins by comparative 
modelling is considered more accurate[747]. It involves predicting the structure of an 
unknown protein (target) based on homology to known structures (template).  
Successful protein model building requires four basic steps. Firstly, a template must be 
identified. This template should have an experimentally determined 3D structure. For it 
to act as a template, it should show significant amino acid sequence similarity 
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(homology) with the candidate protein sequence. Homology refers to both sequence 
identity and residue properties (such as hydrophobicity). The predictive modelling is 
then grounded on the assumption that residues will conform to a similar structure in two 
different proteins or domains based on a similar linear amino acid sequence. The three 
dimensional structure of proteins in a same family can be more conserved than their 
linear sequence[749]. Therefore, if there is sequence similarity, some structural 
similarity may be assumed[747]. Specifically, it is generally accepted within the 
structural community that within a stretch of at least 80 amino acids, 30% sequence 
homology is the minimum needed prior to modelling an unknown protein sequence by 
comparative modelling[19]. Choosing the template can be based on amino acid 
sequence-sequence homology[750]. Alternatively, the selection can be more iterative, 
and involve not only amino acid sequence, but also evolutionary history, residue 
characteristics, and domain and protein family function[751]. Other factors such as the 
function of the template and the target, and the quality of the templates crystallography 
structure should be considered. Frequently, proteins are divided into domains which 
may have homology or evolutionary relationships with domains on templates. We used 
Protein BLAST (blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins) and 
CLUSTAL[752] to generate templates.  
Subsequently, the target and template sequence are aligned. In doing so, statistical 
analysis can be undertaken to evaluate the homology. There are various methods of 
model building which are equally accurate if used optimally. We used MODELLER[6], 
which is based on restraining the predicted structure based on distances and angles of 
residues in the template protein. Further constraints based on molecular mechanics of 
bonds are also superimposed. A major advantage of this method is that constraints or 
restraints from numerous sources may complement those of the homology driven 
restraints. This may add accuracy to and improve the quality of the model, particularly 
in more challenging modelling cases.  
Models then need to be evaluated, and there are a variety of programs which may do 
this. They assess if the model has the correct fold. This is primarily reliant on sequence 
homology, as the greater the homology (particularly over 30%), the greater the chance 
of structural similarity. Evaluation also assesses the environment of predicted domains. 
For example calcium binding domains may undergo conformational structural changes 
when bound to calcium. If modelled on similar domains without calcium bound, the 
320 
 
model is likely to be inaccurate. Finally, bond stereochemistry (e.g. bond length, 
torsional bond angle, side chain torsion angles) are evaluated in the model. These were 
done with a programme called PROCHECK[753]. This compares every bond structure, 
particularly angle and distance, to a database of all bonds (Ramachandran plot[754]). To 
assess the feasibility of the model based on amino acid charges and ionic repulsions, the 
software CHARMM (Chemistry at HARvard Macromolecular Mechanics)[755] was 
used. Adjustments to the model structure in conjunction via both programs, before the 
final structure is created.  
5.4. RESULTS  
5.4.1. GENE EXPRESSION AND PROTEIN DISTRIBUTION 
5.4.1.1. GENE EXPRESSION OF ADAMTSL4 IN OCULAR TISSUE 
Amplification of cDNA derived from iris, choroid and retina, using primers targeted at 
ADAMTSL4, gave a product of 470bp (consistent with that expected from the designed 
primers). The product was observed in both choroidal and iris tissue, but was absent 
from retinal tissue (Figure 5.7A). Band quantification using ImageJ software [756], 
revealed a significant difference (P<0.01) in product band intensity between choroidal 
and retina tissue (Figure 5.7B). These findings suggest that mRNA expression of 
ADAMTSL4 is abundant within the choroid but absent within the retina. 
5.4.1.2. PROTEIN EXPRESSION OF ADAMTS-LIKE 4 IN OCULAR 
TISSUE 
Western blot analysis of choroidal, retinal and iris extracts using ADAMTS-Like 4 
antibody, revealed a product of 140kDa from choroid and iris tissue, which was absent 
from retina (Figure 5.8A). This product has previously been suggested to be the major 
species of this protein within ocular tissue [406]. Quantification of band intensity 
showed the greatest abundance in the choroid but absent from the retina (Figure 5.8B). 
Although not a significant difference (P=0.06), this trend was consistent with the RNA 
expression work.  
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Figure 5.7:  GENE EXPRESSION OF ADAMTSL4 IN OCULAR TISSUE 
 
Figure 5.7A: Expression of ADAMTSL4 and GAPDH (control) mRNA from 
ocular tissue of four donors. A product of 600bp for GAPDH was obtained 
from all samples, but the 470bp product for ADAMTSL4 was obtained only in 
iris and choroid and is absent from neural retina. 
 
Figure 5.7B: Quantification of ADAMTSL4 expression in choroid, retina and 
iris. The above bands were analysed by Image J and showed a statistically 
significant (P<0.01) [indicated by *] difference between the choroid and 
retina. 
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Figure 5.8: ADAMTS-LIKE 4 PROTEIN EXPRESSION IN OCULAR TISSUE 
 
Figure 5.8a: Western blot illustrating a product of 140kDa within choroid and 
iris. This is thought to be the size of the major species of ADAMTS-Like 4.  
A product of 42kDa, consistent with β-Actin, was seen in all three tissues 
(choroid, iris and retina).  
 
Figure 5.8b: Quantification of western blot band intensity from choroid, iris and 
retina. This suggests ADAMTS-Like 4 expression to be greatest in choroid, 
intermediate in iris, and least within retina. 
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5.4.1.3. LOCALIZATION OF ADAMTS-LIKE 4 PROTEIN IN OCULAR 
TISSUE 
Immunofluorescence (IF) staining demonstrated that ADAMTS-Like 4 is widespread 
within the eye. It is clearly evident within the ocular anterior segment, particularly in the 
ciliary body and processes (Figure 5.9a). Ocular posterior segment investigations 
suggest that ADAMTS-Like 4 localises within the choroid, RPE and the retinal outer 
segments (Figure 5.9b). Control ocular tissue without primary antibody did not stain 
(Figure 5.9c). These results corroborate the findings from the protein and mRNA 
expression work.  
5.4.2. PROTEIN MODELLING 
To fit with the required 30% sequence homology, two different templates were used. 
Firstly, the structure of the Exosite-Containing Fragment Of Human ADAMTS13 
(Protein Database ID = 3GHM), showed between 29-60% homology to the specific 
regions of the ADAMTS-Like 4 molecule. 
Subsequently, the Thrombospondin homologous region was aligned to another 
template; the Thrombospondin-1 TSR Domains 2 And 3 (Protein Data Base ID : 
3R6B)[757].  This template showed approximately 33%-57% sequence homology to 
specific areas of the ADAMTS-Like 4. 
The regions of strong homology are therefore non-contiguous. Figure 5.10 shows the 
regions where amino acid sequence homology to known structures in the PDB databank 
is found.  The best homologies are to the protein 3GHM, which is the Crystal Structure 
Of The Exosite-Containing Fragment Of Human ADAMTS13[745].  However, 
sequence homologies to other structures are also found in other parts of the protein as 
described in the legend.  
Although sequence homologies are found to the above proteins (Figure 5.10), they bear 
no relationship to the family of proteins to which ADAMTS-Like 4 belongs.   
 
 
324 
 
  
Figure 5.9: LOCALISATION OF ADAMTS-LIKE 4 PROTEIN IN OCULAR 
TISSUES 
 
Figure 5.9a: Immunofluorescence of anterior segment tissues illustrating 
expression within ciliary body and processes. CB: Ciliary Body. 
 
Figure 5.9b: Immunofluorescence of ADAMTS-Like 4 within ocular posterior 
segment illustrating presence within choroid and retinal pigment epithelium.  
 
Figure 5.9c: Immunohistochemistry of control ocular tissue (without primary 
antibody). Bar: 50µm 
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Figure 5.10: Schematic diagram demonstrating sequence homology to other 
known structure. 3GHM: Protein database ID (PDID) for ADAMTS13 
(http://www.rcsb.org/pdb/explore/explore.do?structureId=3GHM).  
3T8Q: PDID Crystal Structure Of Mandelate racemase muconate lactonizing 
enzyme Family Protein From Hoeflea Phototrophica (a marine aerobic 
alphaproteobacterium[12].  
3IZ3: CryoEm Structure Of Cytoplasmic Polyhedrosis Virus[13].  
3FTC: Structural Model For The Large Subunit Of The Mammalian 
Mitochondrial Ribosome[15]).  
3TQR: Structure of the Phosphoribosylglycinamide Formyltransferase (Purn) In 
Complex with CHES from Coxiella Burnetii 
(http://www.rcsb.org/pdb/explore/explore.do?structureId=3TQR)) 
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Thus, modelling such areas based on these proteins as a template is technically possible; 
however the interpretation of the results subsequently would be open to debate.  Whilst 
sequence normally determines the nature of the protein fold, one should also take into 
account the family of proteins that it is being compared with.  Large areas of the protein 
encompassing the mutation prone areas[2, 7, 10, 27, 30], such as the mutations 
described in chapter 2, have no sequence homology to any proteins in the database; 
these are represented by the broken line areas. Furthermore, there would be no empirical 
evidence to show that those areas would fold or adopt structures as the purely 
mathematical/theoretical methods predict. These areas in principle could be also 
assigned structural coordinates using ab initio theoretical modelling procedures 
The areas modelled are illustrated in Figure 5.11. 
5.5. DISCUSSION 
5.5.1. GENE EXPRESSION AND PROTEIN DISTRIBUTION 
Whilst completing this project investigating the distribution and expression of 
ADAMTSL4, a publication emerged investigating a similar expression profile and 
relationship with fibrillin-1[406]. It was of great interest, and provided valuable 
comparisons.  
The described work in this chapter has shown, by both western blot and IF analysis, that 
ADAMTS-Like 4 is expressed in choroid and iris, but is absent from retina. This 
finding is in slight contrast to the protein expression pattern suggested by Gabriel and 
colleagues, whose immunohistochemical (IHC) staining showed a broad distribution of 
ADAMTS-Like 4 in many ocular tissues including the ciliary body, sclera, cornea, and 
retina, and associated with both cells and fibrillar ECM [406]. This difference, where 
retinal localisation was not found by IF, is most probably due to either the use of 
different antibody in this study, or to the method (IF)  possibly being more specific than 
IHC (used by Gabriel et al[758]), leading to a limited protein distribution being 
detected. Confocal microscopy with high resolution imaging does provide better image 
qualities than is possible from chromatic immunohistochemistry. The major 
disadvantage of IF is the stability of the images is shorter, therefore providing no long 
term record, as it is available through IHC. The findings of a lack of protein expression 
in the retina are also supported by a lack of mRNA expression in the retina, which was 
not undertaken by Gabriel and colleagues[758]. 
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This does provide further evidence, as it is recognised that mRNA levels are correlated 
with protein expression levels[759]. 
We could not demonstrate ADAMTS-Like 4 presence in the retina by western blot as 
was achieved by Gabriel et al., however, although their pure retina sample did 
demonstrate clear bands, another sample of mixed vitreous and retinal tissue did not, 
possibly suggesting sample variation. It is therefore arguable that, contrary to the 
previous findings, this gene is not expressed in the retina. The work in this chapter did 
not attempt to quantify values, and the PCR bands cannot therefore reflect the intensity 
of IF.  
Considering the shared phenotype caused by mutations in ADAMTSL4 and FBN1, it is a 
reasonable hypothesis that an interaction exists between fibrillin-1 and certain 
ADAMTS proteins in which mutations cause EL. The identification of a very similar 
ocular phenotype within WMS with FBN1 and ADAMTS10 and ADAMTS17 (OMIM 
607511) mutations [225] first suggested an interaction between the proteins. It has been 
postulated that ADAMTS10 not only co-localises with fibrillin-1, but also participates 
in microfibril biosynthesis [281]. Certain domains of fibrillin-1 were thought to interact 
specifically with certain ADAMTS-Like proteins [432]. Furthermore, ADAMTS-Like 6 
was first shown to promote fibrillin-1 matrix assembly [760] and one isoform 
(ADAMTS-Like 6β) even improves fibrillin-1 microfibril assembly in a mouse model 
of MFS [718]. ADAMTS-Like 4 and ADAMTS-Like 6 being closely homologous, it is 
therefore possible that a similar interaction between ADAMTS-Like 4 and fibrillin-1 
exists. In support of this, Gabriel and colleagues have demonstrated co-localisation of 
ADAMTS-Like 4 and fibrillin-1 in cultured fibroblasts [406]. They also suggest that 
ADAMTS-Like 4 may play a role in formation or maintenance of fibrillin-1.  
This chapter demonstrated expression of ADAMTSL4 and its protein within human iris 
and choroidal tissue but not in retinal tissue. Although fibrillin-1 has been demonstrated 
throughout various ocular tissues [193, 761, 762], the retina has not convincingly been 
shown to be a fibrillin-1 containing structure.  In view of suggested co-localisation of 
fibrillin-1 and ADAMTS-Like 4 [406], this would be in line with the present finding of 
an absence of the latter in the retina. In contrast, fibrillin-1 has been shown to be present 
in the iris and choroid [193], and these  results suggest that ADAMTS-Like 4 is also 
present within these tissues. Although it was not possible to isolate ciliary body and 
zonules for western blot analysis, our IF results do confirm the presence of ADAMTS-
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Like 4 within the ciliary body. It is however of interest to consider Cain and colleagues’ 
work [763]. They dissected microfibrils from various tissues, including human zonules, 
and used mass spectrometry to investigate the protein constituents beyond fibrillin-1. 
They discovered, in addition to fibrillin-1 and MAGP-1, that there were collagens II and 
IV, α- and β-crystallins, annexin V, TIMP-3 and histones. They however did not 
determine ADAMT-Like 4. This work was published before the identification of the 
role of ADAMTSL4 mutations in EL[2]. It would be of interest if this were repeated, in 
light of our current understanding. 
The relative abundance in the choroid is of great interest. It is well documented that 
fibrillin microfibrils are constituents of arterial walls[764], and although the same level 
of evidence is limited for ocular vasculature[193], it is probable that a similarly high 
expression is found in choroidal vasculature.  The highly vascular component of the 
choroid may thus also be the host to ADAMTS-Like 4.  It would be interesting to know 
if this choroidal expression is affected in view of the axial myopia demonstrated in 
those with ADAMTSL4 mutations in chapter 2 of this thesis. Certainly, choroidal 
thickness is inversely related to axial length and may contribute towards myopic 
degeneration [765].  
Finally, the present IF results suggest ADAMTS-Like 4 expression within human RPE, 
which has also been shown to express fibrillin-1[193]. It has been suggested that 
ablation of the RPE leads to arrested ocular development[766]. Mutations in genes 
expressed in the RPE, such as VMD2[161][767], and MFRP [768],  have been shown to 
affect eye development and axial length. The mechanism behind this phenomenon is 
unclear. A similar role may be played with regard to ADAMTS-Like 4, its RPE 
localization, and increased axial length in patients with mutations in its gene. This 
would need to be confirmed.  
It is probable that ADAMTS-Like 4 has additional roles to its suggested effects on the 
structure and function of ciliary zonules. Indeed, the possible pleiotropy of ADAMTS-
Like 4 has been suggested by the GWAS pathway (section 4.5.2) and the patient 
described in section 2.4.5[301]. Furthermore, there have been reports investigating the 
expression of this protein in ocular tissue, beyond the work on cDNA libraries done by 
initial investigators[2]. Schwenk and colleagues[769] investigated plasma and serum 
protein profiles of patients with Metabolic Syndrome using an antibody array based 
approach. They demonstrated higher levels in both serum and plasma of ADAMTS-
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Like 4 in patients with high HDL cholesterol and low triacylglycerol and suggested that 
it may be utilized as a clinical biomarker. Juric and colleagues demonstrated differential 
expression of ADAMTSL4 in different subgroups of Acute lymphoblastic leukaemia 
patients[719]. They suggested that the cell adhesion modulation role of ADAMTS-Like 
4 may lead it, amongst others, to be a candidate gene likely to play a role in certain 
leukemogenesis. The implications of these two papers need yet to be understood fully.     
As previously described, the other ADAMTS genes associated with similar ocular 
phenotypes (ADAMTS10[225], ADAMTS17 [226] and ADAMTS18 [1]) (Table 9) all 
contain Thrombospondin repeat (TSR) regions and a protease and lacunin (PLAC) 
domain[21]. The role of the TSR domain in cell adhesion has been discussed. 
Additionally, mutations in ADAMTSL4 affecting the PLAC domain have been reported 
by our group in IEL [7], which may suggest that it too may have a role to play in this 
function. .  
In summary, the present observations have confirmed the gene and protein expression 
of ADAMTS-Like 4 in the human iris and choroid, but could not demonstrate 
expression in the retina. Taking these findings together with published expression 
patterns of fibrillin-1; it may be possible to suggest that ADAMTS-Like 4 and fibrillin-1 
be closely related functionally. Closer inspection of other ocular and non-ocular tissue 
known to manifest fibrillin-1 may further elucidate the relationship between these two 
proteins in pathological conditions associated with mutations in these genes.  
5.5.2. PROTEIN STRUCTURE 
Comparative or homology modelling is a highly accurate method of structure 
prediction[747]. We undertook this using known structures available on PDB, and then 
used MODELLER[6] to undertake homology modelling. The model was then evaluated 
using PROCHECK[753] and CHARMM[755].  
The protein modelling was limited by incomplete sequence homology. The closest 
protein with crystalline structures was ADAMTS13. This protein’s structure itself has 
not been completely described[745]. We were however able to model the TSR domain. 
In our modelling, this was based on high sequence homology with Thrombospondin 1, 
TSR domains 2 and 3[757]. As described previously, this domain may play an 
important role in adhesion of the ECM.  
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When considering the TSR domains, it is of interest, to discuss the role of B3GALTL in 
Peter’s Plus anomaly, an autosomal recessive condition characterised by developmental 
defects of the brain, skeletal system and the anterior segment of the eye (OMIM  
261540)[770].  The cause of Peter’s Plus anomaly has been suggested to be secondary 
to mutations in B3GALTL[770]. The encoded protein beta1,3-glucosyltransferase 
(B3GALTL) is thought to act to join a glucose (Glc) moiety to O-linked fucose (Fuc) 
forming a glucose-β1,3-fucose disaccharide [771]. This has been shown to specifically 
occur in Thrombospondin Type 1 Repeats (TSR1)[25]. The list of proteins with this 
domain includes, amongst others, Thrombospondin 1, ADAMTS-Like 1 and 
ADAMTS13. The region of this interaction is shown in the Figure 5.12. 
Although this particular motif is not found in the ADAMTS-Like 4 protein sequence, 
there is high homology within the domains encoding the TSR domains (Figure 5.13) 
between ADAMTS-Like 4 and the template protein 3R6B. 
However, no complete homology was found for these motifs. It is possible therefore 
that 3 dimensional structure of the TSR region of ADAMTS-Like 4 is different to those 
TSR regions which are crucial to the function of B3GALTL. It is unlikely that the same 
interaction is involved in ADAMTS-Like 4, and the mechanism of disease development 
different. However, the role of TSR domain in developmental disorders of the anterior 
segment of the eye bears considering, in view of the disease manifestation of mutations 
in ADAMTSL4 and B3GALTL. 
Other suggested roles of the TSR domain include regulating matrix metalloproteinase 2 
(MMP2)[720]. The substrates of MMP2 include Gelatin, collagen IV, V, VII, XI and 
fibronectin. This and other MMPs have been demonstrated in the vitreous[721] and 
subretinal fluid[772], and may play a role in the development of RD[722].  To 
understand the  role of TSR proteins, including ADAMTS-Like 4, in the development 
of RD, it  would be important to identify the presence of this protein and the expression 
of the gene in the vitreous of eyes affected by this condition. Our model of the TSR in 
ADAMTS-Like 4 may help the understanding of this domain in the future. 
 
 
 
332 
 
  
Figure 5.12: The thrombospondin type 1 repeat (TSR). (Adapted from Heinonen et 
al [25]). This demonstrates the secondary structural elements, showing the three 
antiparallel strands as horizontal rectangles (A, B, and C). The loop between 
strands A and B contains the sequence motif, indicated by the amino acids inside 
the vertical rectangle, to which the Glc-Fuc disaccharide is attached. Glc = glucose; 
Fuc = fucose. 
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Figure 15.13 The TSR residue of ADAMTS-Like 4 and 3R6B.  
Between the two sequences is the highlighted homology (17/36: 47.2%) 
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We modelled the ADAMTS-spacer domain. This domain, which is adjacent to a 
cysteine rich domain (CRD), is part of the “ancillary domain” of all ADAMTS 
proteins[21]. Within the ADAMTS proteases, this CRD-spacer domain is an ECM 
binding domain[773]. This may have a crucially similar role within ADAMTS-Like 4. 
Although the limitations of comparison modelling are noted[774], there are numerous 
examples of applications of results from predictive modelling. These have included 
designing mutants to examine hypothesis of the function of a protein[775], modelling 
substrate specificity[776] and protein-protein interactions[777]. Although we were 
unable to model domains affected by mutations in the gene, we have been able to 
provide some information on crucial structures of the protein. These would provide 
avenues for future understandings of the function and interactions of ADAMTS-Like 4.   
  
335 
 
6. CHAPTER 6: GENERAL DISCUSSIONS & FUTURE 
WORK 
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This work aimed at understanding further the genetic predispositions towards 
Rhegmatogenous Retinal Detachments (RD) and Ectopia Lentis (EL). They have been 
known to be associated conditions for many years, but rarely studied in parallel. There 
have been significant challenges faced in this process, collaborations forged and much 
learned and added to the understanding of these conditions. 
6.1. CHALLENGES 
As with any study, there were administrative and logistic challenges. Gaining ethical 
approval for the multiple stages of the research was a novel undertaking, and the 
experiences will continue to help in my research career. Ethical approval was acquired 
for four separate projects.  
The daily commitment of recruiting patients from the vitreoretinal clinics and 
emergency service and advertising the project proved successful eventually. Choosing 
the DNA extracting facility and arranging the administration between the research unit 
and KBioscience took many months to establish. It was forced by the inadvertent failure 
of a freezer in the UCL Institute of Ophthalmology; where 236 blood samples had 
defrosted. Fortunately, this had not impacted the DNA quality. Samples from then were 
transferred directly from the vitreoretinal service at Moorfields Eye Hospital to 
KBiosciences. 
During the PhD, I was fortunate to be working in five different units on these projects. 
These were at Moorfields Eye Hospital vitreoretinal research unit; MRC Human 
Genetics Unit, University of Edinburgh; Sonalee Laboratory, St George’s University of 
London; Department of Genetics (Professor Andrew Webster’s laboratory) and the 
Division of Ocular Biology and Therapeutics (ORBIT; Professor Astrid Limb’s 
laboratory), both of UCL Institute of Ophthalmology. The challenges of combining 
these five units, both geographically and logistically were not insignificant. However, as 
a consequence, I was privileged to work with different scientists, technicians, 
statisticians and supervisors. I also learned many different techniques.  
Writing grant applications is an important skill in academic medicine. I practiced the art 
of this during my PhD. I was fortunate to be a co-investigator on a successful grant 
(Fight For Sight; Grant Number 1982) and ultimately a principle investigator on a 
further successful grant from the Royal College of Surgeons of Edinburgh (Major 
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Project grant) to fund the Illumina HumanExome BeadChip genotyping. These skills 
will continue to improve, and I hope to grow to be more successful in such ventures in 
my career. 
Successful research also depends on successful collaborations. With regard to the 
genetic predispositions of complex conditions large such networks are crucial. I have 
personally forged such collaborations with the MRC Human Genetics Unit (University 
of Edinburgh, UK), Department of Ophthalmology at Guy’s and St Thomas’ Hospitals 
(King’s College London, UK), Department of Ophthalmology at Addenbrookes 
Hospital (University of Cambridge, UK), Calgary Retina Consultants (University of 
Calgary, Alberta, Canada) and the Department of Ophthalmology at Royal Victoria Eye 
and Ear Hospital (University of Melbourne, Victoria, Australia).   With regard to the 
Mendelian work in this thesis, collaborations have been established with Department of 
Ophthalmology, Ninewells Hospital Dundee; Department of Clinical Genetics, Guy’s 
and St Thomas’ Hospital London; Department of Clinical Genetics, St George’s 
Hospital London; Dept. of Ophthalmology, Justus-Liebig-University, Giessen, 
Germany; and the Department of Genetics, Alfaisal University Riyadh, Saudi Arabia. 
Developing these relationships has been of great professional satisfaction, and I hope 
that these collaborations will continue to foster successful research. 
6.2. SUCCESSES 
The understanding of the ADAMTS proteins has been extended by this work. 
ADAMTSL4 was first described ten years ago; in 2003. In 2009, the role of this protein 
in EL was first described, and since then the importance of this gene has been greatly 
expanded by this work. We have suggested that some of the ocular phenotypes, 
particularly corneal features, caused by mutations in this gene are very similar to those 
with FBN1 mutations.  It has been suggested[758] that ADAMTS-Like 4 co-localises 
with fibrillin-1 and thus is likely to act to augment the role of this protein. To some 
extent, the gene expression and protein distribution work in this thesis has provided 
further evidence for such a co-localisation. However, it must be considered that it is 
possible that co-localisation does not necessarily equate to co-function. Further work in 
this thesis does suggest that there may be independent roles for ADAMTS-Like 4; in 
view of the younger age of onset, and subsequent higher myopia compared to those with 
FBN1 mutations. These two features may be related to each other. On the other hand 
these may be manifestations of the fact that this gene plays an important role in ocular 
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development. We demonstrated its expression within the RPE, and other proteins 
present in this tissue are known to affect ocular development and axial length. It would 
be valid to establish whether a disruption of the ERG or EOG is evident in patients with 
ADAMTSL4 mutations. This is work that our group is considering undertaking in the 
future.  
The potential pleiotropic effect of this gene has not been discussed prior to this thesis. 
We first demonstrate a potential role for mutations in this gene causing defects in the 
cranial sutures. Whether this is secondary to a role in microfibril development or an 
independent role remains to be proved. The genome wide association study undertaken 
as part of this work has been the first to suggest that proteins involved in cell adhesion 
may play a role in the molecular pathway leading to RD. Among these genes was 
ADAMTSL4. This is a fascinating connection between EL and RD and would need 
further confirmation. When the data from the Illumina HumanExome BeadChip is ready 
for analysis, it will be useful to investigate if variants, both common and rare in this 
gene are significant. If it is replicated; it would be of interest to establish whether the 
role of this protein in these two separate phenotypes is common. The axial myopia seen 
in those with ADAMTSL4 mutations must be remembered and considered when 
discussing RD. 
Alternatively, it is more likely that ADAMTS-Like 4 may have an important function in 
cell adhesion; particularly involving the ECM. This may play a role in the ciliary 
zonules for EL, and at the vitreoretinal junction for RD. With regard to such a role, 
further expression and protein localisation work of ADAMTSL4 in these structures 
would be invaluable. Although this work demonstrated no ADAMTS-Like 4 in the 
inner retina; it would still be worth investigating the vitreoretinal junction; particularly 
the internal limiting membrane. The cell adhesive function is as yet undefined, but if 
true, is likely to involve the TSR domain of the protein. The modelling work of this 
domain done as part of this thesis may thus prove useful in further understanding this 
function.  
It would be important to understand extra-ocular effects of ADAMTS-Like 4. As work 
in this thesis has demonstrated, the majority of probands labelled as “isolated ectopia 
lentis” caused by FBN1 mutations would have their diagnosis altered to Marfan 
syndrome with the new Ghent criteria.  With the suggested co-localisation of 
ADAMTS-Like 4 with fibrillin-1 and cooperative role in extracellular microfibril 
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deposition, it would be pertinent to understand if ADAMTS-Like 4 has a role to play in 
other tissues which are affected by abnormal microfibrils. It is as yet unknown whether 
patients with ADAMTSL4 mutations have abnormal cardiovascular and skeletal features, 
as those with FBN1 mutations often do. Although it is assumed that this is not the case; 
confirming this is crucial for these patients, and our understanding of the protein. Our 
group is currently investigating cardiovascular parameters in our cohort. Beyond this; 
examining gene and protein expression in cardiac and skeletal tissue would also be 
enlightening.  
The role of other ADAMTS proteins has been additionally extended in this work. 
Mutations in ADAMTS17 have been demonstrated in four WML families to date. We 
have demonstrated a novel exon deletion lesion; which may have interesting 
implications. The challenges in the investigations of this gene have provided lessons. 
The expense of mislabelling and possible contamination cannot be overstated, as with 
the work invested in this family. More work is yet to be done to further evaluate this 
gene and confirm its role in other families.  
Furthermore, we have delineated a novel ocular phenotype; characterised by micro-
cornea, cone dystrophy, and a propensity for RD, early onset cataracts and EL. The 
phenotype has been demonstrated in this thesis to be caused by recessive mutations in 
ADAMTS18. The exact role of the protein in ocular development is unknown, but the 
wide range of disruptions caused does suggest that this protein has an effect on global 
ocular development. Further understanding this will take many formats. Establishing 
localisation and expression of this gene, as was done for ADAMTSL4 would be useful; 
as would comparing it to other genes which manifest similar phenotypes. This would 
include members of the ADAMTS family, but also COL18A1, which shares many 
phenotypic features with our cohort. In particular, it would be valuable to understand 
the role ADAMTS18 may play in the zonules, lens, photoreceptors, RPE and at the 
vitreoretinal interface. COL18 is known to localise at the ILM, and comparing this with 
ADAMTS18 would help demonstrate if a relationship exists. The features of RD and 
EL may indicate a structural role of ADAMTS18; as with other proteins which tend to 
cause these phenotypes. The phenotypic heterogeneity of those with mutations in 
ADAMTS18 does suggest that other epigenetic and environmental factors may be at 
play.   
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Traditional theories of the ADAMTS proteins suggest an enzymatic role; however it is 
possible that certain members have a predominantly structural function. This can be 
more easily envisaged for the ADAMTS-Like family; which lack the enzymatic 
domain. The work in this thesis has started to suggest that the function of certain 
members of these proteins is very different to these traditional beliefs. As with 
ADAMTS-Like 4, the role of the TSR domain in other members of this family would be 
particularly interesting. It would be valuable to evaluate the role that variants within 
these genes may have in complex non-Mendelian RD.  
There are common phenotypic features of those with mutations in the ADAMTS genes 
investigated in this thesis. Firstly anterior segment pathology was common; micro-
cornea and lenticular abnormalities.  Reis and colleagues[446] postulated that there are 
12 major genes which cause anterior segment dysgenesis (ASD). It is thought that there 
is inter- and intra- familial heterogeneity in the phenotypes caused; similar to our 
families. Furthermore, many of the causative genes are considered to share common 
downstream pathways. It will be useful to add the ADAMTS family to this list, and 
investigate for relationships with the established ASD genes. Understanding the role in 
ocular development could involve investigations in foetal ocular tissue; firstly for gene 
expression.  Comparisons to genes involved in global ocular development (e.g. OTX2, 
SOX2, STRA6, HCCS, BMP4, SMOC1, GDF6, VSX2, RAX, SHH, SIX6 and PAX6) 
would also provide interesting insight. 
Axial myopia is a further phenotype shared. There are over 20 loci allocated to non-
syndromic myopia to date. The aetiologies behind these may be secondary to the early 
lenticular abnormalities; or direct impact on axial length development. No studies 
investigating complex myopia have highlighted any of the ADAMTS genes.  
Further genes are still to be discovered in familial RD and EL. With regard to EL, we 
have at least one family with isolated EL and three affected brothers in whom no 
causative gene has been found. The work in this thesis also suggest a recessive mutation 
causing RD and EL is yet to be found. This family shares phenotype features with 
Knobloch syndrome (though missing the crucial occipital defect), and with our families 
with ADAMTS18 mutations. Having excluded numerous candidate genes, and having 
suggestive regions of autozygosity, our group is continuing to investigate this family. 
The first step in this process will involve acquiring samples from other family members; 
affected and unaffected, to clarify the variants found.   
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The GWAS on RD has illuminated a potential associated gene. The biological impact of 
CERS2 is yet to be fully understood, but does provide avenues of further research. It is a 
widely expressed gene, and understanding the role at the vitreoretinal junction is 
challenging. Replication in further cohorts is crucial, and our group is continuing to 
recruit patients from our own institution, and the numerous institutions with whom 
collaborations have been made. Prior to this, it will be useful to understand the impact 
of rare exonic variants when the results of the genotyping using the Illumina 
HumanExome BeadChip are fully analysed. The quality control of SNVs demonstrated 
numerous challenges. The realities of using cohorts collected at different times in 
different centres and comparing with controls separately collected and genotyped are 
common to all working in GWAS. Successful GWAS have mastered these challenges. 
The work done will lay a platform for analysis of the common SNVs from the Illumina 
HumanExome BeadChip. Further steps in quality control are required, prior to 
association analysis over the next year. It is likely that many positive findings will be 
highlighted from this first stage of analysis and the large replication cohort will be 
critical. Our team is continuing to expand the work in this field.  
Further work will need to be done to try and delineate if there is any interplay in the 
genetic aetiology of myopia and RD. Although the genetics of complex myopia has 
progressed rapidly in the last 5 years, there is still much to be understood. Meta-
analyses of the large GWAS into myopia to date, are now underway. These studies have 
been made possible by multinational collaborations, and comprehending the genetics of 
RD will also involve such groups; which we have now instigated. Alternate approaches 
may involve “un-phenotyped” cohorts who self-report a history of RD. This perhaps 
surprising methodology has proved successful for myopia[603] and may provide a 
rapid, cheaper method of increasing the power required. Comparing cohorts of myopia 
and RD may eventually help delineate different pathological mechanisms involved in 
these two related conditions. 
Carefully phenotyping patients in our cohorts will however continue to hold value. 
Determinants such as axial length will prove useful as a covariate in future analysis to 
help with the question of myopia. Furthermore, although the genetic aetiology of lattice 
degeneration[114] and proliferative vitreoretinopathy [778, 779] is under debate, our 
cohorts will be able to contribute significantly towards the understanding of these 
conditions.  
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Finally, the genetic determinants of RD and EL in Mendelian and non-Mendelian 
inheritance must be taken in the context of the racial origin of those studied. There are 
many examples of Mendelian mutations aggregating in certain ethnic groups. In 
complex conditions, the issue of population stratification is critical and has been made 
previously. Work in this thesis has demonstrated that there are phenotypic differences 
between Caucasians and South Asians with multifactorial RD. This further underlines 
the value of phenotyping large cohorts. Not only are the phenotypic features novel, but 
they also suggest that different genetic determinants and interactions may be involved in 
alternate ethnicities. Confirming findings such as CERS2 in our cohort from South Asia 
will be the first step in this process. Furthermore, those from South Asia may prove to 
be a valuable cohort to investigate some of the features shown to be more common; 
such as lattice degeneration.  
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7. CHAPTER 7: CONCLUSIONS 
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The work in this thesis has investigated the genetic predisposition of two closely related 
ocular phenotypes; rhegmatogenous retinal detachment and ectopia lentis. Using 
numerous techniques, much has been demonstrated in this field. Although genetic 
investigations still are divided into “Mendelian and non-Mendelian“, and the techniques 
used in this thesis are further testament to this division, there is a natural convergence, 
with the common currency being genetic variation. Unifying groups and methodologies 
to investigate such conditions with similar and related phenotypes will provide an 
exciting future in genetics. With the advent of next generation technologies, this future 
may not be so distant. Although costs are reducing, currently this and the bio-informatic 
support systems still offer some challenges. As John Hardy, professor of neuroscience 
at UCL Institute of Neurology, said in 2010 at a round table debate “I am reminded of 
the great Warren Zevon song ‘Lawyers, Guns and Money’. (We need) Samples, Kit and 
money”.  
As with any scientific endeavour, it seems that in answering some questions, this thesis 
has created many more. These fields are uniquely placed in their relative novelty, and 
being part of the groups investigating them will provide great interest for my academic 
career ahead.  
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9. CHAPTER 9: APPENDICES 
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9.1.  APPENDIX I: QUESTIONNAIRE TO MEMBERS OF THE 
MARFAN TRUST (UK) 
 
IF YOU HAVE MARFAN SYNDROME, PLEASE DO COMPLETE THIS FORM 
WHETHER OR NOT YOU HAVE HAD AN EYE PROBLEM 
Retinal detachment is the most serious complication of Marfan Syndrome. However, it 
is unclear how frequently this condition affects those with this condition. We hope to 
clarify this and the nature of when it occurs with your help. Please take a few minutes to 
complete the questionnaire and return it in the enclosed envelope. All information will 
be confidential. 
 
Name___________________________________________  Date of Birth_________ 
Address_________________________________________ 
Home Tel Number ________________________________ Mobile number________ 
1. Do you have Marfan Syndrome (MFS)?  YES   NO 
2. Have you ever had a retinal detachment?  
YES          (go to question 3)   NO    (go to question 8) 
3. Which eye was affected? Tick all that apply 
Right              Left    Date of any surgery (s): __________ 
     Type of surgery: “buckle”  
        “gas” 
        “oil” 
       Don’t know 
Did you have the lens removed at the SAME time? YES  NO  
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4. Is there anyone in your family who has had a retinal detachment? 
  YES:   HOW ARE THEY RELATED? _______ 
  DO THEY HAVE MFS? YES:    NO:  
  NO:     
5. In which hospital did you have your eye surgery? (Hospital name and address) 
_____________________________________________________________________ 
____________________________________________________________________ 
6. What was the name of the consultant in charge of your care? 
Operation 1: _______________ 
Operation 2: _______________ 
Operation 3: _______________ 
Don’t know  
7. Would you give us permission to contact your surgeon to get further information 
about your surgery?   
YES  NO       (go to question 8) 
  If Yes: Please sign below: 
I give my permission for Mr Aman Chandra to contact my consultant ophthalmologist 
to discuss my medical history. 
  SIGNED:  
  FULL NAME: 
  DATE: 
8. Have you had dislocated lenses (“ectopia lentis”)? 
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YES          (go to question 9) 
NO   (END OF QUESTIONNAIRE) 
9. Which eye was affected? 
  RIGHT:    LEFT 
Have you had surgery for this?   
YES:   DATE: ________ 
NO: 
Have you had surgery for this?   
YES:   DATE: ________ 
NO: 
10. In which hospital did you have any surgery? 
___________________________________________________ 
11. What was the name of the consultant in charge of your care? 
_____________________________________________________ 
12. Would you give us permission to contact your surgeon to get further information 
about your surgery?   
YES:     NO: 
If Yes: Please sign below: 
 
I give my permission for Mr Aman Chandra to contact my consultant ophthalmologist 
to discuss my medical history. 
SIGNED:  _______________________ 
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FULL NAME: _______________________ 
DATE:  ________________________ 
Thank you very much for your help.  
If you have any questions about this questionnaire, please contact  
Mr Aman Chandra 
Vitreoretinal Department 
Moorfields Eye Hospital 
City Road 
London EC1V2PD 
 
 
 
PLEASE RETURN IN THE SAE ENCLOSED. 
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9.2.  APPENDIX II: REVISED GHENT CRITERIA (2010) FOR 
DIAGNOSIS OF MARFAN SYNDROME AND RELATED 
CONDITIONS 
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9.3.  APPENDIX III: BEIGHTON SCORE 
 
The Beighton score is a simple system to quantify joint laxity and hypermobility. It uses 
a simple 9 point system, where the higher the score the higher the laxity. The threshold 
for joint laxity in a young adult is ranges from 4-6.  
Joint Finding Points 
left little (fifth) finger passive dorsiflexion beyond 90° 1 
  passive dorsiflexion <= 90° 0 
right little (fifth) finger passive dorsiflexion beyond 90° 1 
  passive dorsiflexion <= 90° 0 
left thumb passive dorsiflexion to the flexor aspect of the 
forearm 
1 
  cannot passively dorsiflex thumb to flexor 
aspect of the forearm 
0 
right thumb passive dorsiflexion to the flexor aspect of the 
forearm 
1 
  cannot passively dorsiflex thumb to flexor 
aspect of the forearm 
0 
left elbow hyperextends beyond 10° 1 
  extends <= 10  0 
right elbow hyperextends beyond 10° 1 
  extends <= 10  0 
left knee hyperextends beyond 10° 1 
  extends <= 10  0 
right knee hyperextends beyond 10° 1 
  extends <= 10  0 
forward flexion of trunk with 
knees full extended 
palms and hands can rest flat on the floor 1 
  palms and hands cannot rest flat on the floor  
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9.4. APPENDIX IV: PRIMERS, AMPLIMER SIZE AND ANNEALING 
TEMPERATURES FOR ADAMTSL4 
N
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Ex1 
GAGGTTGCCTGGAGAGAGC 
  
  
CACCCCAACAGGTGTCTTTC 
ADAMTSL4 Ex1F 
53
4 
57  
  
Ex2 
  
ADAMTSL4 Ex2R 
Ex3 
CCAGATGCCTGCGTAGTTTT 
  
  
GGAGATGAAAGGGTGGCA 
ADAMTSL4 Ex3F 
43
3 
 57 
  
Ex4 
  
ADAMTSL4 Ex4R 
Ex5 
TTGGTCTACATGGACACTCTGG ADAMTSL4 Ex5F 
49
5 
57  
CTCCCCTTTCCTTCATGCTA ADAMTSL4 Ex5R 
Ex6 
TCAGAGGGCTTGTCTTTGGT ADAMTSL4 Ex6(A)F 
57
4 
57  
ACCGAAGGAAAAGGATCAGG ADAMTSL4 Ex6(A)R 
CTACGGCATCACCCCAGA ADAMTSL4 Ex6(B)F 
51
5 
57  
TGCCCTGAGGTGGTCAGAT ADAMTSL4 Ex6(B)R 
Ex7 
TTGGCATCTGACCACCTCA ADAMTSL4 Ex7AF 
62
6 
57  
ATGAAGCGGATGGTAACCTG ADAMTSL4 Ex7R 
Ex8 
GAATGATGCACCCACCTC ADAMTSL4 Ex8F 
41
5 
57  
GTATGCATATGGGGGCATGT ADAMTSL4 Ex8R 
Ex9 
GGCACAAAAAGCAGGGTAGT ADAMTSL4 Ex9F 
45
1 
57  
CCCTCTCAGCTTCCTCACTC ADAMTSL4 Ex9R 
Ex10 
CTCGTGGAAGGAGTGAGGAA ADAMTSL4 Ex10F 
48
4 
57  
TGGGTTTTCCTCCTGAAAGA ADAMTSL4 Ex10R 
Ex11 
CTGTGGTTGTCAAGATGGGA ADAMTSL4 Ex11F 
46
0 
57  
ATGCAGAGTGTCCCACTCGT ADAMTSL4 Ex11R 
Ex12 
TTCACCTCCTCCAATCCTTG ADAMTSL4 Ex12F 
46
8 
57  
TAGAGCCCAAGCTCAGTGGT ADAMTSL4 Ex12R 
Ex13 
GAGACATCACAGTGCGTTCC ADAMTSL4 Ex13F 
44
2 
57  
TTTCTTGCTGCCTACCGAAT ADAMTSL4 Ex13R 
     
Ex14 CAGCCCCACACATCTCATC ADAMTSL4 Ex14F 
31
9 
57  
421 
 
GTTGTTCACCTGTGCCCAT ADAMTSL4 Ex14R 
Ex15 
CCACGAAGCCATGTGACTG ADAMTSL4 Ex15F 
46
2 
57  
GCCCCTCATGGAAGTTGTT ADAMTSL4 Ex15R 
Ex16 
AAGTGAGAACAACTTCCATGAGG ADAMTSL4 Ex16F 
56
8 
57  
CGTCCCCAGTTTGGATACAC ADAMTSL4 Ex16R 
Ex17 
CACTTGGGGTGCTCTCTGTC ADAMTSL4 Ex17F 
35
5 
57  
GCTTGGCTGGGCTTATTCT ADAMTSL4 Ex17R 
Ex18 
CCAAGCGTTACCACTGTCCT ADAMTSL4 Ex18F 
40
8 
57  
TCCCACTGGTCCTTTCTCAT ADAMTSL4 Ex18R 
Ex19 
CTCTCCCCAATCCCCAATAC ADAMTSL4 Ex19F 
50
9 
57  
AGTCCCAAAAGCACACCTGA ADAMTSL4 Ex19R 
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9.5. APPENDIX V: PCR MIX FOR ADAMTSL4 AMPLIFICATION 
 
 
 
Constituent Volume Concentration 
PCR buffer 2µl 10x 
MgCl2 1.2µl 25mM 
dNTP 2µl 2mM 
Taq polymerase 0.1µl 5U/µl 
H2O 11.3µl  
Forward Primer 0.4µl 10mM 
Reverse Primer 0.4µl 10mM 
DMSO  1.6µl 8% 
DNA 1µl 50ng/µl 
 
MgCl2:  Magnesium Chloride 
dNTP: Deoxyribonucleotide triphosphate 
H20:  Water 
DMSO: Dimethyl sulfoxide 
 
  
423 
 
9.6. APPENDIX VI: PRIMERS FOR FBN1 PCR AND SEQUENCING 
 
1-FN GCAAGAGGCGGCGGGAG 
1-RP GAAACTTGGGAGACCCACA 
2-FN TCTGCCAGGATTCATCTTGC 
2-RN CAACACAACAAAAGAAGGAC 
3-FN TCGTGTTCCAAATCCATGTG 
3-RN TGGGTATAACCACATAAAATAAT 
4-FN AACTCCTGTGAGCTGTTGC 
4-RN GCTGTGTCCCAGGTAATCG 
5-FP TTTCAGGTAAAGCGTCTCAG 
5-RP CCGGGTACCAGCATGTCTT 
6-FN TCTGCATGATGGTTCCTGC 
6-RN CCAGAGCAAATAAGATTAATCC 
7-FP TTCTGCAATGAATTTCATATGAG 
7-RP CTACACCCCCCAACTGCAA 
8-FN ACTGACGAATGGTTTTATATTG 
8-RN TACACAAACCATGCATGCTG 
9-FN GTTACAAGTATTATCTCAGCG 
9-RN GCTGGGATGGGATATTCTG 
10-FN CAGCTGTTGTGTTTTGTTTTG 
10-RN ATGTTAACTTGAACAATGCAAG 
11-FN ACTGATGAAAGATACCATAGTT 
11-RN AGGAACAGAATTACAACAGAC 
12-FN AGAATTATGAGGTATTGCTATG 
12-RN CAGTTAGCATATATGTCCCAC 
13-FP CTCCCCCAAATAAAGCTATTTC 
13-RP TTGAAACTGCAATGGAAGGAG 
14-FN TCAGGTCATAAGAAAATGTATG 
14-RN GGAGGAGAAAAGGCACGTG 
424 
 
15-FN TGTCACTTCATTTTTAATAAGTG 
15-RN GTGACAGAGGCTGAACCTC 
16-FN CTCATCTGTTTGAAGTGACAG 
16-RN GGTGGCAGAAGGCTGGC 
17-FN GATCTACCTGTTCTGCAAAC 
17-RN GTAAATTTTGAAAGGAATCCTTA 
18-FP TAGCTCCTAAGGTCATTACATT 
18-RP ATTATGCAGGCAATGTTTCAG 
19-FN AAAGTTTGGGCCCTTTTTAAG 
19-RN ATAGCAAAGTACACAGTATAAG 
20-FN CCCAGACTAGATTTTAGCAG 
20-RN TTAAGTATAACAACATTGATAAAC 
21-FN GTGTATGTTTGAATTTTTATATAG 
21-RN CTCATGTGAGCCTAGATAAATG 
22-FN CTACTTCATGCTCCAGGTC 
22-RN CTGTTCCGTTTTGTAGTTCTC 
23-FN GTTTTATGAACTTACCAGGTTC 
23-RN ACCGAAGCTAAGTGCTCAG 
24-FN CAGCAAATTATTATGTGTGCAG 
24-RN ATCAAGTAGAGTGCTGAGATC 
25-FN CAAGAACTTCCAACCTTCATG 
25-RN TTAAAGGACGTCCCCTCTC 
26-FN AATTAAGGCTGTCCTGAGAC 
26-RN CATGGAATCCTTCTCTTTCTG 
27-FP GCCCCCACCTTTAACATGG 
27-RN GAAAGTCTTTGCTCCTTAC 
28-FP GCCAAAGTTGGAAGCTTATGT 
28-RP ATAACATAACATAACATAAAATAAAG 
29-FN CAGACATCCAAACCATATCAG 
29-RN GAACCTACTGAGAGATTCAAC 
425 
 
30-FN AATAGTCTTATGCTAGTAGGC 
30-RN ACAGTGCTTATGACTAACAAG 
31-FN GTACTCAATGATATCAAATAGC 
31-RN ACCAATCTCTTAACTACTTAATA 
32-FN CCAAAAGACATTTGTGCTGAG 
32-RN GTGTAATCTATGCAGTCCTTG 
33-FN GGTTTTAAATACCACCCTTTC 
33-RN CTGGCTTCTCTGACTAGTG 
34-FN CGAGGAAGAGTAACGTGTG 
34-RN TCAAGCCCAGCAAGGCTC 
35-FP GTTAAGTTTTTGCTTTTTCTCC 
35-RP GACACCAGGGAGCTGATTTT 
  36-FN GAGATAACTCCACTACTCAC 
36-RN AATACACAGTATGCTTGCTTC 
37-FN GTAGAAAGATTCTGCCTGATG 
37-RN GAACTGGCTGGAGTTGAAAT 
38-FN AAACTTTAGATTCAAAACAACTC 
38-RN TCAAGTTGTGTGTGCTTTAAG 
39-FN ATTTACAATGCTAAAGGAATGC 
39-RP TTCTTGATATCTGCAAGACCTT 
40-FN AAATGTGAAGTTTTCATATTCAC 
40-RN CATGCATTACTGAGAAAAGCT 
41-FN GCTTGTTGAGTATCCACTTAG 
41-RN GCTTCCTTCGCTAAGACTG 
42-FP TCCGGTCCCACCTTTGTTTA 
42-RP AAACCAGAAAGTTCTGACAATG 
43-FP TGTCACTCATGAATGACTACT 
43-RN CTCTTTTCTGGATATGATAAAG 
44-FN CTGTTCTCCTTCAAATTCAGT 
44-RN GTAGGCATGTCCAGCCTG 
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45-FN GAGCTAGGATTACTCCTGAG 
45-RP TGAAGCTTTCAACAGCATATG 
46-FN AAGTTCTCAGCCTATGGATG 
46-RN TGGTTCACTAGAGATGATGC 
47-FN GACATCTTTGGAATATATTAAAG 
47-RP CCAGGTCTTTCTAAGTCCTGT 
48-FP AACCTCTTCCTTATTTTTCCC 
48-RP CCTCATTTGCTACAACTGATA 
49-FN TGATGTCTCCATCGTGTTTG 
49-RP GACCACCACAAATAAACATGC 
50-FP GGACTCAGTAGGAAAGCAAC 
50-RP CCAGTCTGCACCCTGCAT 
51-FP AGCTTGTAATGAATTGCTATTG 
51-RP GAAGCAGATTGAGAATACTGA 
52-FP GATTAAACACTGAAATGATCATAA 
52-RP AATTTGTAAAGTTCCTATGGAAG 
53-FN CTCAATTCATCATGTTTTGGAC 
53-RN CCATCAGGCCTAGATGATC 
54-FN CTTTGTTGCTGTCCATGATC 
54-RN CTCACAGATAAAGCTTCCTG 
55-FN GCAGATATATGCATTTTCTTTG 
55-RN GTCCACTGTCACTTCTGATG 
56-FN TGGTCAGATGACTCTTCTTG 
56-RN GTGTGGAGGCTGAGGTTAG 
57-FN ATTTCCTGACATCCCCTTTG 
57-RN CAAATAAATAGATTCCCTGTAAG 
58-FII GTTGTCAATTTTATGATATATTTCT 
58-RII ATTTCCACTTGAGGATAAGCC 
59-FN GCGTGTACACATCATTTTTAG 
59-RN ATGTGTCAGGAGCTAGGTG 
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60-FN ATCCTGTTTTGTTGGCTGAC 
60-RN GAATCGCTACAATCCATGTAG 
61-FN GTATGTGTGAGCACACCTG 
61-RN CTCCACAAGGATTCACCAG 
62-FN AGAGATGTTGAGTTGGCATC 
62-RN TAGGACCTGATAGCCATGC 
63-FN CAAGTGGCCAGATCCAATG 
63-RN GGTTCTCCTCTGCTAGGAC 
64-FP TACCTTGTCTTCCCATTCTAA 
64-RH AGGAGACATCAGGAGAAACTA 
65a-FP GCTAAGTGGCATATGTACATT 
65a-RP GCTGATCCCTTCCTTTTGG 
65b-FP AGATACTTGATCGAATCTGGA 
65b-RP GTTCTACCTATCTATATTTGTTT 
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9.7. APPENDIX VII. PCR MIX FOR FBN1. 
dNTP: Deoxyribonucleotide triphosphate, MgCl2: Magnesium Chloride, Taq: Taq 
Polymerase, F; Forward Primer, R: Reverse Primer, FV: Final Volume 
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9.8.  APPENDIX VIII: PRIMERS USED TO AMPLIFY AND 
SEQUENCE ADAMTS18 
 
EXON PRIMERS (F and R) Amplicon 
(bp) 
1-2 CCCTCCCTCAGAGCTGGA 
GGGAAGGAAGGGTCAAAGTG 
803 
3 ATTTGGAATTGTGGGCTCTG 
GAGTTGGCTGGAAGAGCATT 
425 
4 TTAGCTCCTGTGCCCACAT 
AGGGTAGCCCCATTTTGACT 
460 
5 GGATTGGTGGTGTGTTGGTT 
ACCTGCTATTCAACCCATGC 
355 
6 TGATTCCCCCTAAGGTTTTG 
ATTCTGAACGGCAGACTGAA 
455 
7 TTCAGCATTCTCATCTCTGTG 
GGGCTATCCATCATCCATAGAA 
256 
8 AAATCATCATCATGTATCTGTGTGTG 
CAACGGTTAGAGGAACACCAA 
197 
9 AATGGGTTCACAAAGCAGGA 
GGAGCACAATTCTGTCATCA 
203 
10 CAGAAGTGTGTTGTCGTAAATGG 
CTTCTGTTAGGGACACAGACACA 
247 
11 TTTATTGTATATCACCATTAACAGCA 
GCATTCACCCTAAGGTCACAA 
186 
12 CTGTTACTGTGCAGGTGTTGG 
GCGTGTTACAGGCTGAAGGT 
250 
13 CACTGTGGCAGTGCTCATCT 360 
433 
 
GGTCTGGGGAGTGAAAGGTA 
14 TTTTGACAATCCTATCATTTTTCC 
TCTCTCACACCACTGTTCACG 
240 
15 GAGGGATTTGAACCCCAAGT 
AACCACATTTGGCGTGACTC 
334 
16 CATGTCGGGCCATTTCTAGT 
GGAGTTCTGGCTCAAATTGC 
360 
17 TCCTGGGAAAGCTTTAAGTCA 
AGACGCCTGGAGTGAAAGAA 
338 
18 CAATGCTGGTAAATCAGAAGC 
CACAGTGAGCTTTCATCATCTCA 
255 
19 CATGGCTTCCATAGGTGGTT 
TAAACTGCCAAGAGCCCAGT 
355 
20 TTTTTAATGTGGCTACTGAAACC 
CAGCCTCCCCAGTAGATCAG 
341 
21 ATTTCATGTGGATGGTGCAA 
GTTTGCAGAACGCCTCATTT 
339 
22 GGGAATTCCTTCTGTTTGATG 
GCTGCACTACTAACAAAGTAGCC 
256 
23 AGACACCCTAGCCAACATGC 
CAAAGGCAGCTGGTCTCTCT 
190 
 
  
434 
 
9.9.  APPENDIX IX: PRIMERS USED TO AMPLIFY AND 
SEQUENCE PAPILIN 
 
EXON Primer Sequence (F and R) Amplicon 
(bp) 
2 CTGTGGGCCATAGGGAGAGA 
CTGACATCGCCCCTTTCCTG 
261 
3 TCCTTGATGGGTAGGGGAGG 
CCCCTGCTCCTGCTTTAACA 
265 
4-5 GAGAGTCCCGCAGAAGTTGG 
ACTGTGGCATCAACGTAGGT 
697 
6 ACCCATGCTTTCCTGTTGCT 
AAGCTCATGGCAGCTACCTG 
328 
7 CCTGATGTGGCCATGATGC 
GACAGGCAAGGAAGGGACAG 
242 
8-9 AGGGTTAGGTCCTAGGCAGG 
ACTTGTCCATCTCCCCAGGA 
683 
10 GAACGCGCTTGGTGAATGTT 
TGGGCCTCATCATGGGTAGA 
224 
11 TGTGAGTGAGGGCAGAAACC 
CTCGGTTTCCACAGCAGAGA 
379 
12-13 CTAGCTGTCCGAACTGGCG 
GGACATGCTTGCTGGGTTTG 
650 
14-15 CAGTGGGGTAGAAGCCAGTG 
ATTCCTGAGCTCTGCACACC 
785 
16-17 ACCATGGGGAGCCTCAGAG 
GGAAGGTCTTTGGTCCTGGG 
762 
18 GGATGGAGGGTGCAGCTTTA 609 
435 
 
TAGCTCCAACTGGCATGCTC 
19 GCTTAGGGTGGTTCTGGTCC 
TGTCACACACACCTGTCAGG 
276 
20-21 AGACTCACTGTTGCCCTTGG 
AGCAGACGTTCCCCTCCTTA 
661 
22 AGAGGTGCCCATGGGAGTAG 
CAGGACTGGCCATGACCATG 
316 
23-24 CTTGTGTTCCCTCCCTGACC 
GGTGACAGTGACATCCCTGG 
519 
25 TGTCTCCCAGACCTCCAGAG 
CAGGGTGAGCCAGGATTCAA 
337 
26 GGCAGGTGAGAATTTTCAGCA 
TAACTCCCTTTGCCAGCCAG 
340 
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9.10. APPENDIX X: PRIMERS USED TO AMPLIFY AND 
SEQUENCE LTBP2 [203] 
 
EXON Primer Sequence (F and R) Amplicon 
(bp) 
1a GCCGACCACAAAGCTCTTC 
GAGTGCTTCTCCGGGTCTG 
434 
 
1b TGCAGCCAAGGTGTACAGTC 
CCCCTCTGTACCCTCCAAAC 
342 
 
2 TGCAGCCAAGGTGTACAGTC 
GCGGAGTGTCTGCTACTGGT 
286 
 
3 AGAGTGGCTTCCTGCTTGAG 
CTTCACCAAACGGTCCAAAG 
476 
 
4 GCAGCCAGAGAGCATTTTTC 
AACTCAGCCCCTCTGTGAGA 
403 
 
5 AATGCCCTTGAGATGAATGC 
CTGGCTCTCTGGCCATCTAC 
349 
 
6 GCCTGTTTCTCTGTGGTGGT 
CAGCTTCCCTATCCCTGTCA 
386 
 
7 TGGTGGATACCCTTCAGAGG 
GAGGAGGAGAAGGGCAGACT 
441 
 
8 AATGTGGGGAGTGAGCTCTG 
AAGGCAGGTCTGGGAAGTCT 
351 
 
9 AGGTGGGCTGAGAGGAGTCT 
TAGTCCCCTGGAATCAGCAG 
415 
 
10 CGGGCACTTGGTCATCTCCT 
GTGATCAGGTCTGGGGAAAA 
262 
 
11 GCTCCAAACTTCCCAACTGA 444 
437 
 
GGTTGGGATAAGCACGTGAG  
12 TCACGTGCTTATCCCAACCT 
AGGGACCCAGGATTAACACC 
447 
 
13 CAGAGGAGCCAAAAGTGACC 
TCCTTCTCACCCTCCTCTGA 
206 
 
14 GTCTGAGCACCAGGGAAGAG 
GAGGGACCCTGTGTTCTTTG 
370 
 
15 CACCCTGCCATAACCTCTGT 
TGCTTGGACCTTCTGCTTCT 
271 
 
16 GGCTGACTTTATGGCTTCCA 
CAGGCTGGAGTTCTGGTCTC 
457 
 
17 ATCCTTTGTCCTTGGCCTCT 
GAATGTCACTGAGGGGATGG 
406 
 
18 AGGGACAAGGATTTGCTGTG 
ACCTCTTTCCCTTTCCGTGT 
287 
 
19 CCCTGGCCTCATAACTGAGA 
GGATGTGTTGGGTCAGTGTG 
350 
 
20 CTGCAGAGTCCCACACAGAA 
TATTCTGTCCCCTTCCACCA 
202 
 
21 TCCCCAAGTTCAGAGTGAGG 
AGCTTGTGAGCGACTCTTGG 
466 
 
22-23 GGAGACTTCCCCCTTGACTC 
GCTGGCTTCCCATGCTCCTG 
475 
 
24 GCCCAGAGGAAGCTACACAG 
GAGCTAAGGACCAGGCAGTG 
273 
 
25 GGAAATCGTCCTGACCTTGA 
TGAAAAGCAGCCTCTCAACC 
492 
 
438 
 
26 GTGCATGCGTGTGAGAGAGT 
CAGGACCAGTTGAGGAGGAG 
298 
 
27 AAGGCCTAGCCTGCTTCTTT 
CCTGTAGCTCCTGGTTTTGC 
447 
 
28-29 CCTTAGAGGGTCATGAACAGACA 
CCCACTCAGGTGAAGGAGTT 
489 
 
30 CCCTCATACTGCCTCTCACC 
TCCTGGGGACAATCTCTGAC 
356 
 
31-32 TGATAGGCAAACACCCTTCC 
CCTGCAGGGTATCCCCTTTG 
499 
 
33 CAGAGGGTACCAGTCCTTGC 
CTAGCAGGTGGAGGAGATGG 
455 
 
34 AGTCTGGACACAGCCCTCAG 
TCTTCCAGCCTTCCTGAGTT 
279 
35 CTTGGGCATGGTATGAGCTT 
AACCTCTGGCCTGATGTCAC 
450 
 
 
 
  
439 
 
9.11. APPENDIX XI: PRIMERS USED TO AMPLIFY AND 
SEQUENCE ADAMTS17 
 
EXON Pimers Sequence (F and R) Amplicon (bp) 
1 TCCGCAGCGCTAATTACTTT 
ACCCGATTCCCGTACTCC 
353 
2 CTGACGCGTCTCCTCTCTCC 
TGCCTATAGAGGGTACCGAAGG 
579 
3 CAAATCACAGCAAGGTGGTC 
TTCTCACTCATGTGGCTTCAGT 
359 
4 CTGACCACTCTCTCGGGC 
ACCCAGCGTCTTCCTCACT 
383 
5 TTTCTGTGTCCCAAGTTCCC 
AGAGAGTGACGGAGACTGGC 
290 
6 GCCTCCACCTTAACGTCCTT 
GTGGCCCAAGGTCTGATTT 
362 
7 TTGCAGGATGACTACTTGAGG 
GCTTGTTTGAGGACAGCTCC 
237 
8 TTGATTGTGCATGACGTTGA 
CAGATGCAGCAAAGGCATAG 
314 
9 AAGACTTGATTTACCTTAGCATGG 
TTCTCCACTTCACACTTGCTG 
329 
10 GGAGGTGCCCTCTTCTCAGT 
GTGCTGAGTGTGAATGCCC 
361 
11 ATTTGAAACAGTGGTTGGGC 
TGTTTCAGGGGCTCCTAAGT 
304 
12 TGGCAGCACGGCATTTT 
CTTCTAATGCTCAGCGGGAG 
342 
13 CCCTTCCTCTCCTCCCC 
CTGGGTTGGTTTGGGAAAG 
369 
14 CTTCCTCAGGGTTTCCCTCT 
CCTGAGACCTCTGCTCTACCC 
315 
15 TATGCTGCACCTCATGGAAA 
TCCACTACCATCTAGCCCTTAAA 
331 
16 CTGTGGAAGGGAGACCTCTG 361 
440 
 
GAGGTCCCAGGCAGAAGTAA 
17 AAAGAGCTGGTTACCCCTCA 
ATGTCTCACACTCTGCGTGC 
370 
18 GCACCCAAACATGCTTTCAT 
GCATAGAGCAGTACTGTGGCA 
331 
19 AGGGCAGCAATTCCAGGAT 
CAACTTCAAGCTGACCTGGG 
415 
20 GCACCTGGCACATTGGA 
GCCTAGTTACGCTGGGACTG 
357 
21 CCTGGGCATGACACACAGT 
TGTCAGCCTTATGTGACAAGTGA 565 
22 AGTGCAAAGGGTTGACGTGT 
CCAAGTCCACGCTCATGTT 
429 
 
 
  
441 
 
9.12. APPENDIX XII: PRIMERS USED TO AMPLIFY ADAMTS17 
cDNA 
 
Primers Expected amplicon size (bp) 
Ex 1F:   
CTGCCTCCGCTCGTCCTG 
Ex3R:   
AGCTGAATGAGGCCAACCAG 
449 
Ex2F:   
GAGCTGTGCTTCTACTCGGG 
Ex10R:  
GGTGCTGACTTTTGACTTGAGG 
972 
Ex10F: 
AGATGACCTTGAAAACTTCCTCA 
Ex16R: 
GTCTTTGAGAGCTGTCCCCC 
850 
Ex15F: 
AAGGGCGACTTCAGCCAC 
Ex20R: 
GCAGAGCACTGTGACCACTC 
698 
Ex19F: 
ATCTGGGAGGCGTCTGAGT 
Ex22R: 
GACTGCGTGTCACGAGTTCG 
528 
 
 
 
 
 
 
